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Abstract 
 
Background: There is increasing recognition of the need for service development for 
patients in the advanced stages of neurological conditions. This study explores the 
palliative care needs of people with advanced amyotrophic lateral sclerosis, multiple 
sclerosis, Parkinson’s disease and related disorders, and assesses the impact of a new 
specialist palliative care service (SPCS)   
 
Methods:. A mixed methods approach was adopted:  
 
• a qualitative needs assessment using in-depth interviews with patients and their 
family carers  and focus groups  of professionals involved in the care of this 
population. 
• a quantitative pilot-explorative randomized and controlled trial (RCT) to assess 
the impact of a new SPCS designed to meet the palliative care needs of the study 
population – using a waiting list  methodology comparing the immediate 
provision of SPCS with  standard care . 
 
Results: 
 
• Qualitative study: 22 patients, 21 family carers and 11 professionals participated 
to the needs assessment. The content analysis showed a high prevalence of 
problems. Professionals confirmed the high burden of problems, were positive 
about the creation of a new SPCS and their knowledge of specific palliative care 
topics seemed lacking.  
• Quantitative study: 50 patients, with 45 carers, participated in the explorative 
RCT. The comparison between the groups (FT-ST) after 16 weeks revealed 
significant improvement for the SPCS group for  quality of life and in four  
physical symptoms - pain, breathlessness, sleep disturbance and intestinal 
symptoms  
 
Conclusions: This research confirms the high prevalence of physical symptoms, 
psychosocial issues and spiritual themes for people severely affected by advanced 
neurodegenerative disorders and that these can be helped  by specialist palliative care. 
The input of a SPCS caused a significant improvement of the individual quality of life 
of the patients and improved symptom control for pain, breathlessness, quality of sleep 
and intestinal symptoms compared to standard best care alone.  
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General summary 
 
Background: Patients severely affected by progressive neurodegenerative conditions 
experience a high burden of physical symptoms as well as psychosocial and spiritual 
unmet needs. The family carers are exposed to an increasing burden of care as the 
patients’ disability progresses. There is increasing recognition of the need for service 
development for patients in the advanced stages of neurological conditions, but little 
evidence of the efficacy of Specialist Palliative Care Services (SPCS) to meet the 
palliative care outcomes (PCO) in this population and how this can best be provided to 
address them. 
This study explores the palliative care needs of people in advanced stages of 
amyotrophic lateral sclerosis, multiple sclerosis, Parkinson’s disease and related 
disorders, assesses the impact of a new specialist palliative care service  on  the care of 
patients and, on the basis of findings, recommends options for a more tailored palliative 
care service provision for this population. 
 
Methods: The overall methodology adopted followed a validated framework for the 
design and the evaluation of complex services to improve health. A mixed methods 
approach was adopted to address the research question:  
1) a qualitative needs assessment using (*) in-depth interviews with patients and their 
family carers to explore the unmet needs and to capture the strategies adopted to 
overcome the problems and (*) focus groups to collect the experience of the 
professionals involved in the care of this population. 
2) a quantitative pilot-explorative randomized and controlled trial (RCT) to assess the 
impact of a new SPCS designed to meet the palliative care needs of the study 
population. The RCT adopted the waiting list methodology that compared the effects of 
the SPCS on group of patients immediately receiving the service (FT) with a control 
group receiving standard care (ST) that received the care after a period of 16 weeks. 
 
Analysis: for the qualitative study a thematic content analysis aimed at finding the main 
groups of unaddressed needs was performed and the results were used to identify some 
PCO to be assessed in the following phase. For the quantitative study descriptive 
statistics were used to analyze the sample and groups comparison statistics plus a 
clinical judgement of significant impact were adopted to find differences between the 
groups for the trial outcomes.  
 
Results: 1) Qualitative study: 22 patients, 21 family carers and 11 professionals 
participated to the needs assessment. There was a   high prevalence of physical 
problems -movement impairment and oral-swallowing problems affected 100% of the 
interviewed patients, painful conditions and respiratory troubles 81%, intestinal 
symptoms 70%, urinary and sleep disorders 60%; the presence of psychological issues - 
anxiety, depression, abandonment and coping issues were reported by 70-100% of the 
participants; social isolation (100%); spiritual themes like difficulties to find a meaning 
in the experience of the disease and ambivalence related to faith, religiousness and 
spiritual support (50-88%). The existing services did not provide adequate home care 
support, were not equally distributed among the different diagnostic groups and did  not  
help in  end of life decisions. Professionals confirmed the high burden of problems 
faced by the neurological patients, were positive about the creation of a new SPCS and 
reported their difficulties to provide care outside the hospital when patients are too ill to 
be transported. Knowledge of specific palliative care topics, like symptomatic therapies 
for the advanced stages, seemed lacking.  
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2) Quantitative study: 50 patients, with 45 carers, participated to the explorative RCT. 
They were randomized 25 in the FT and 25 in the ST groups. At baseline no differences 
on demographics, diagnostic groups and trial outcomes were found between the groups. 
The comparison between the groups (FT-ST) after 16 weeks revealed that the FT 
patients had a statistical (p<0.01) and clinical (>20%) significant improvement in 
individual Quality of Life and in four physical symptoms - pain, breathlessness, sleep 
disturbance and intestinal symptoms; clinically relevant advantage (>20%) for the social 
isolation of the patients; moderate clinical advantage (11-20%) for the urinary and the 
oral symptoms; one spiritual theme “finding a meaning in the experience of the disease” 
and the satisfaction about the received services for both patients and carers were found 
in the FT versus the ST. For all the other analyzed variables no differences appeared 
between the groups, though for some psychological issues the trend seemed favouring 
the patients who did not receive the SPCS. The caregivers’ burden of care was reduced 
very little in the FT versus the ST, but the variation is too small to be clinically or 
statistically significant (5%).  
 
Conclusions: this original research provides an in-depth perception of the palliative 
care unmet needs of people severely affected by advanced neurodegenerative disorders. 
It confirms the high prevalence of physical symptoms, psychosocial issues and spiritual 
themes that can be helped  by specialist palliative care. There has been a lack of 
adequate services available for this population in Turin city and its province.  
This  is the first study to assess the impact of a SPCS on the palliative outcomes of 
patients severely affected by different neurodegenerative conditions and in their family 
carers. These are novel data from a population for which data exploring the impact of 
SPCS are still lacking and they show that the input of a SPCS caused a significant 
improvement of the individual QoL of the patients and improved  symptom control for 
pain, breathlessness, quality of sleep and intestinal symptoms compared to standard best 
care alone. The findings of this research can be relevant for the developing clinical 
services for these patients. The adopted  methodology was a feasible and reliable 
method to be followed for the design, development evaluation of new SPCS for patients 
with disease other than cancer. 
Chapter 1. Introduction 
 
1. Introduction  
1.1  Presentation 
 
The research was stimulated by the increased awareness of the need to look at the 
provision of palliative care for people with diseases other than cancer (NCHSPCS 2003, 
Addington-Hall, J. M. and Higginson 2001). FARO (Foundation for Assistance and 
Research in Oncology) is a charity of Turin, Italy, providing a multidisciplinary home 
palliative care service since 1989. In 2001 a 14 beds hospice opened, and  both the 
home care service and the hospice facility where dedicated exclusively to people 
severely affected by cancer. FARO celebrated in 2009 its first 20 years of home care 
assistance during which the service took care for of more than 11.000 patients and their 
families. The multidisciplinary service consists of physicians expert in palliative 
medicine, trained nurses, psychologists, physiotherapists, a spiritual assistant and a 
group of volunteers. In 2006 the FARO administration board felt that other services, 
specifically dedicated to non cancer patients, should be developed.  Following 
attendance at international seminar the role of palliative care in neurological disease was 
raised. This led to consideration of a new service for this patient group. 
 
However there was little known of the needs and problems of this patient group in Italy 
and before a service was developed a fuller assessment was needed.  Moreover it was 
felt that any service development should be fully evaluated before wider dissemination, 
to ensure it was acceptable to patients, families and staff, feasible, effective and cost 
effective. 
 
These reasons led to a contact with my actual supervisor, Dr David Oliver, a world 
known expert in palliative care and neurological diseases, chair of the Task Force for 
Neurology of the  European Association for Palliative Care (EAPC) and editor of the 
firsts published books on these subjects (Oliver, Borasio and Walsh 2006, Voltz et al. 
2004).  
A research project was set up with the double purpose of the development, assessment 
and evaluation of a new SPCS provided for FARO in Turin and a PhD research at the 
University of Kent. The present thesis collects both the service development process 
matched to the research framework and its methods and results. 
1.2 The research question 
 
The research question of this thesis is composed by two parts:  
• What are the palliative care needs of people severely affected by 
neurodegenerative conditions? 
and  
• How can a Specialist Palliative Care Service (SPCS) best meet their unmet 
needs?  
1.3 The research outcomes 
 
1. answer to the research question  
2. alongside the development of a new SPCS for patients severely affected by 
ALS/MND, MS, PD and related disorders in Turin, assess and evaluate the 
impact of this service on some important Palliative Care Outcomes. 
Chapter 1. Introduction 
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1.4 General methodology 
 
The general scheme adopted for the development and evaluation of the new SPCS for 
patients severely affected by ALS/MND, MS, PD and related disorders was the MRC 
framework for design and evaluation of complex interventions to improve health. 
 
Figure 1: the MRC framework phases (Campbell et al. 2000) 
 
A mixed methods methodology was chosen to answer the research question matching 
the studies with the different phases of the framework: 
A literature review in the preclinical (fig.1) phase produced the evidence of  the need 
for this research project by providing existing data on: 
• prevalence and description of symptoms and psychosocial and spiritual issues 
for the different diagnostic groups 
• how different health and social support systems impact on patients and their 
families quality of life. 
 The results of the literature review allowed to generate the choice of the methods of the 
research project (theory, fig.1) through: 
 
1. The demonstration of how much the subjective reports from the patients and 
carers stories (qualitative data) can educate a forthcoming new care team 
about the fields in which their professional skills are to be strengthened. 
This induced the choice of a qualitative approach to explore the needs of 
patients and families with advanced ALS/MND, MS, PD and related 
disorders in order to better organize the following intervention on the real 
told experience of the potential participants (modelling – phase 1, fig.1). 
In this qualitative study, named Neu-Needs, in-depth interviews with 
patients and their family carers and focus groups with professionals involved 
in the participants’ care, were used. The study aim was to:  
• explore the lived experience of the diseases, 
• the problems faced by patients and their families, 
• the coping strategies adopted, 
• the level of satisfaction about the various available services 
• and the congruence of the problems aroused in the interviews and 
focus groups with the previous published experiences. 
Chapter 1. Introduction 
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2. A quantitative study (explorative trial- phase 2, fig.1) was chosen to 
evaluate the impact of a SPCS on some important Palliative Care Outcomes 
(PCO), most of which came out from the content analysis of the previous 
qualitative study.  
This choice was induced by the clear feeling of the potential benefits that the 
skills of a SPCS could provide to this population, but, on the other hand, the 
absence of strong evidence of efficacy due to the lack of randomized 
controlled trials in this fields particularly in such an heterogeneous group of 
neurological patients. 
The quantitative study, named Ne-Pal from the initials of neurology and 
palliative care, was an explorative randomized controlled study adopting the 
immediate referral to the 
service (fast-track_FT) versus a 16-week wait (standard best practice_ST) 
methodology (Higginson, I. J. et al. 2008). Group comparison between FT 
and ST at baseline (T0) and after 16 weeks (T1) allowed to highlight which 
changes in the measured outcomes could presumably be due to the SPCS 
intervention, in other words to see if and where a SPCS made the difference 
on PCO versus a control group. 
 Main outcome measures were: 
• Quality of life of patients 
• Burden of care on family carers 
Secondary outcomes were: 
• Symptom load 
• Psychosocial and spiritual issues 
• Service satisfaction  
• Feasibility of RCT in this population (Compliance, recruitment, 
completeness of follow-up, impact on survival) 
Chapter 2. Background: Literature Review 
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2. Background: Literature Review 
Palliative care services have been involved in the care of people with neurological 
disease since the early days of St Christopher’s Hospice, which opened in 1967. In a 
letter in 1990 Dame Cicely Saunders, the founder of modern palliative care, wrote to Dr 
Mary Eleanor Toms that they had been caring for patients in terminal stages of Motor 
Neurone Disease since the opening of the hospice, and that their first patient was 
admitted in 1967 (Clark 2002, p. 322). Recently the interface between neurology, 
rehabilitation and palliative care has been explored and a framework indicating each 
specialty peculiar tasks and their overlapping fields of intervention has been published 
(Turner-Stokes, Sykes and Silber 2007, Turner-Stokes et al. 2007). 
The present thesis explore the relation existing between palliative care and neurology by 
means of: 
• a literature review 
• a qualitative needs assessment 
• a quantitative evaluation of a new SPCS for neurological patients   
The first part of the thesis presents the results of the literature review aimed at exploring 
the existing evidences of specific themes of interest for this research project.  
The literature review findings will be displayed in this order: 
• Literature search methodology 
• Definitions of palliative care and of specific concepts related to this topic 
• Introduction to the involvement of palliative care for non cancer patients 
• Palliative care in neurology. 
• Introduction to the neurodegenerative disorders considered in this thesis 
• The human needs, the palliative care needs and the palliative care unmet needs 
in neurology 
2.1 Literature search methodology 
 
The literature review was performed by searching the following electronic databases: 
Medline (Ovid, PubMed), Embase (Ovid), Cinhals, Psychinfo (Ovid), the Cochrane 
library. 
 
The terms that were searched were: 
1. General palliative care terms: Palliative care, Specialist Palliative Care, 
Terminal care, Terminally ill, Hospice, End of life, Death, Dying. 
2. Disease related terms: Neurolog$, Amyotrophic Lateral Sclerosis, Motor 
Neurone Disease, Parkinson$, Multiple Sclerosis, Multiple System Atrophy, 
Progressive Supranuclear Palsy. 
3. Outcome measures: Outcomes, Symptoms, Place of Care, Place of Death, 
Quality of Life, Caregivers, Carers, Needs Assessment, Service Evaluation. 
 
Terms listed in the point 1 were combined using the Boolean term “OR”, the same for 
the ones at point 2 and 3. The results of these 3 combination were then combined among 
each others using the term “AND”. 
The resulted papers where then scrutinized by reading the titles and then the abstracts. 
This procedure was performed in June 2006 and repeated in September 2007, October 
2009 and January 2010. 
Hand search of the reference list of the collected papers and of specific books was then 
implemented during the whole period of the research. Electronic sources added extra 
Chapter 2. Background: Literature Review 
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hits as well as posters and other abstracts collected during participations to conferences 
on palliative care and neurology. 
Overall 837 references were retrieved and catalogued into an electronic reference 
manager software (Endnote 9). Of these papers about 200 were then printed in full text, 
while for the remaining only the abstracts were analyzed. 
2.2 Definitions of Palliative Care 
 
The general definition of palliative care usually adopted is the following, from the 
World Health Organization: 
 
WHO Definition of Palliative Care (W.H.O. 2002) 
 
Palliative care is an approach that improves the quality of life of patients and their 
families facing the problem associated with life-threatening illness, through the 
prevention and relief of suffering by means of early identification and impeccable 
assessment and treatment of pain and other problems, physical, psychosocial and 
spiritual.  
 
 Palliative care: 
• provides relief from pain and other distressing symptoms; 
• affirms life and regards dying as a normal process; 
• intends neither to hasten or postpone death; 
• integrates the psychological and spiritual aspects of patient care; 
• offers a support system to help patients live as actively as possible until death; 
• offers a support system to help the family cope during the patients illness and in 
their own bereavement; 
• uses a team approach to address the needs of patients and their families, 
including bereavement counselling, if indicated; 
• will enhance quality of life, and may also positively influence the course of 
illness; 
• is applicable early in the course of illness, in conjunction with other therapies 
that are intended to prolong life, such as chemotherapy or radiation therapy, and 
includes those investigations needed to better understand and manage distressing 
clinical complications. 
 
Palliative care therefore is a complex concept with the aim of promoting both physical 
and psychosocial well-being. It is vital and integral part of all clinical practise, whatever 
the illness or the stage of the illness progression. The key principles underpinning 
palliative care which should be practised by all health professionals in primary care, 
hospital and other settings comprise: 
o Focus on Quality of Life 
o Whole person approach taking into account the person’s past life 
experience and current situation 
o Care which encompasses both the person with life-threatening disease 
and those individuals who matter to that person 
o Respect for patient autonomy and choice (preferred place of care, access 
to specialist palliative care) 
o Emphasis on open and sensitive communication, extending this to 
patients, informal carers and professional colleagues 
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Other definitions that can help to practically explore the palliative care field are the 
following: 
 
1. Palliative care is (NICE 2004) 
 
The active holistic care of patients with advanced progressive illness. 
Management of pain and other symptoms and provision of psychological, 
social and spiritual support is paramount. The goal of palliative care is 
achievement of the best quality of life for patients and their families. Many 
aspects of palliative care are also applicable earlier in the course of the 
illness in conjunction with other treatments.  
 
2. End of life care (DH-UK 2008) 
 
      End of life (EoL) care has been defined as the care that: 
 
Helps all those with advanced, progressive, incurable illness to live as well 
as possible until they die. It enables the supportive and palliative care 
needs of both patient and family to be identified and met throughout the 
last phase of life and into bereavement. It includes management of pain 
and other symptoms and provision of psychological, social, spiritual and 
practical support. 
 
3. Supportive care (NCPC 2006) 
 
Supportive care helps the patient and their family to cope with their condition 
and treatment of it – from pre-diagnosis, through the process of diagnosis and 
treatment, to cure, continuing illness or death and into bereavement. It helps 
the patient to maximise the benefits of treatment and to live as well as 
possible with the effects of the disease. It is given equal priority alongside 
diagnosis and treatment.  
 
Supportive care should be fully integrated with diagnosis and treatment. It 
encompasses: 
• Self help and support 
• User involvement 
• Information giving 
• Psychological support 
• Symptom control 
• Social support 
• Rehabilitation 
• Complementary therapies 
• Spiritual support 
• End of life and bereavement care 
 
The practice of palliative care will vary from area to area and there are profound 
differences across both Europe and the world in the way these principles have 
developed.  Overall the developments have been: 
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Palliative medicine 
 
Palliative Medicine is the medical speciality which concerns itself with the 
appropriate 
medical care of patients with progressive disease (Mathew et al. 2003). 
Palliative medicine has specialty status in just two European countries: Ireland and 
the UK. In five countries it is considered as a sub-specialty, for which a second 
certification is required: Poland, Romania, Slovakia and Germany and, recently, 
France. Some 10 other countries have started the process of certification for 
palliative medicine  (Centeno et al. 2007) .  
When palliative medicine became a specialty in the UK the Association of Palliative 
Medicine provided the definition (NCHSPCS 1995): 
 
Palliative medicine is the appropriate medical care of patients with advanced and 
progressive disease for whom the focus of care is the quality of life and in whom 
the prognosis is limited (though sometimes may be several years). Palliative 
medicine includes consideration of the family’s needs before and after the 
patient’s death. 
 
Palliative interventions are non-curative treatments given by specialists in 
disciplines other than specialist palliative care aimed at controlling symptoms and 
improving patient’s QoL (e.g. palliative radiotherapy, chemotherapy, surgical 
procedures and anaesthetic techniques for pain relief). 
 
Specialist Palliative Care Services: are those services with palliative care as their 
core  speciality. These services are needed by a significant minority of people whose 
deaths are anticipated, and may be provided directly through specialist services, or 
indirectly through advice to a patient’s present professional advisers or carers. These 
services provide physical, psychological, social and spiritual support and involve 
professionals with a broad range of skills including medical and nursing, social 
work, pastoral\spiritual care physiotherapy, occupational therapy, pharmacy and 
related specialties (Addington-Hall, J. M. and Higginson 2001 p.7, Mathew et al. 
2003). 
 
2.3 Specialist Palliative Care Services 
 
The evidence for benefit from SPCS is sparse and limited by methodological 
shortcomings. In a recent review Zimmerman et al. found a small number (22) of 
randomized controlled studies on the SPCS impact on quality of life, satisfaction with 
care or cost effectiveness. Significant benefit from intervention was found in 4 of 13 
studies assessing QoL and 1 of 14 assessing symptoms. A higher impact was shown in 
those studies whose primary outcome was family satisfaction with care. Also cost 
effectiveness is shown in 1 study out of 7.Authors found out limitations in 
randomization techniques, problems with recruitment, attrition and adherence 
(Zimmermann et al. 2008)  
This is in contrast with Higginson’s and Foley’s opinion that conversely states that 
palliative care is a necessity, no longer a luxury, there’s evidence of benefits and cost 
effectiveness, even though the argument that palliative care should be given because it 
Chapter 2. Background: Literature Review 
 18 
 
is cheaper is highly dangerous. Palliative care has to be provided in the most effective 
and efficient way(Higginson, I. and Foley 2009)  
New evidence of palliative care efficacy in cancer patients have recently been published 
by Bakitas et al. Result of their RCT on SPCS versus standard care, measuring QoL, 
symptoms, mood and service utilization, show  significant  improvement from SPCS on 
QoL and depression, while symptoms and service utilization were not different in the 2 
groups (Bakitas et al. 2009). 
Improving awareness of the needs of patients dying from disorders other than cancer 
should lead to an increase in referrals to specialist palliative care services (Edmonds 
2004) 
Palliative care is no longer a luxury, but can now be defined as a necessity. Probably it 
is not as cheap as it was believed in the past, but certainly it has to be provided in the 
most efficient and effective ways (Higginson, I. and Foley 2009). 
 
2.4 Palliative care for non cancer patients 
 
2.4.1 Introduction 
 
Every person with advanced, progressive and incurable illness should receive palliative 
care appropriate to their assessed needs (NCHSPCS 2003).  
Meeting the palliative care needs of non-cancer patients presents a number of difficult 
and largely unresolved challenges including prognostic uncertainties, funding issues, 
boundary disputes between professionals and between services and a lack of relevant 
expertise. 
In an era of increasing emphasis on evidence based health care, the lack of evidence in 
this area is striking (Addington-Hall, J. M. and Higginson 2001 p.8). 
We know, from  a study in  1963, that dying patients affected by non malignant 
conditions are less likely to have physical symptoms controlled than the ones with a 
diagnosis of cancer (Hinton 1963). 
Cicely Saunders, founder of St. Christopher’s Hospice and pioneer of modern palliative 
care, wrote that “terminal care should not only be part of oncology but geriatric 
medicine, neurology, general practice and throughout medicine”(Saunders and Baines 
1983, in Addington-Hall, J. M. and Higginson 2001). 
The rapid growth of specialist palliative care has led to improved care for the minority 
in direct receipt of these services and, as palliative care principles have permeated into 
the mainstream of cancer care, for the majority who do not receive these services. 
However, most people do not die from cancer. People who die from other diseases may 
also need improved symptom control, better nursing care, and more open 
communication about death and dying. Little is known about the needs of people who 
die from non-malignant diseases, the adequacy of existing services, or, indeed, the 
effectiveness of specialist palliative care for these patients. Better information is needed 
if palliative care services for non cancer patients are to develop in an appropriate and 
cost-effective way. In particular, the question of which non cancer patients might 
benefit from specialist palliative care needs to be addressed in order to target funding 
and services (Addington-Hall, J., Fakhoury and McCarthy 1998)  
Patients who have palliative care needs can be grouped in several ways, by diagnosis, 
by symptoms or problems experienced or by type of service received. Each year on a 
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population of 1.000.000 in western countries, there are  about 11.000 deaths  25% are 
caused by cancer and of these we know that around 65% will require specialist 
palliative care. A higher proportion (63%) die from non malignant conditions. Only 
some people with these conditions will require specialist palliative care, but it is still 
unknown how many (Higginson, I. 1997a). An Australian group studied needs of 
palliative care by estimating the size of potential palliative care population. They made 
three potential  estimates to describe the characteristics of people eligible to receive 
palliative care in Western Australia. The Minimal Estimate included ten conditions that 
are clear indicators that palliative care is likely to be of benefit to patients. Deaths from 
these ten conditions constituted exactly 50% of all deaths. Slightly more than half of 
these were due to malignancies. Five other conditions (heart failure, renal failure, 
COPD, Alzheimer’s disease and liver failure) represented sizeable proportions of this 
estimate. Much smaller proportions (less than 2%) of the deaths were due to the 
remaining four conditions (motor neurone disease, Parkinson’s disease, HIV/AIDS and 
Huntington’s disease). The authors concluded that palliative care should be available to 
patients dying of these conditions and these findings are supported both by the literature 
and among workers in the field (Rosenwax et al. 2005). An estimate based on symptom 
load of people who died of non malignant diseases suggested an increase of 79%  in the 
expected caseload  if a SPCS was fully available for non cancer patients. The authors 
stated that, based on these criteria, 16.8% of people dying for progressive non malignant 
conditions would require specialist palliative care (Addington-Hall, J., Fakhoury and 
McCarthy 1998). 
A strong body of opinion argues that the skills and philosophies of palliative care 
should be extended to all care settings. The role of specialist in palliative medicine is to 
offer what has been learnt about palliation of malignant disease to those caring for 
patients with progressive, incurable, non-malignant conditions and to share and 
exchange best practise (O'Brien, T., Welsh and Dunn 1998). 
Specialist Palliative Care Services (SPCS) are involved in the care of terminally ill 
cancer patients. 
Strong evidence suggests that primary conventional care alone is inadequate for patients 
with advanced cancer. In a review is indicated that in hospital, hospice and community 
settings a multi-professional approach with specialist input is beneficial. SPCS improve 
satisfaction of both the patient with advanced cancer and their family or carers. Such 
teams are more able to  identify and deal with patient and family needs, and to provide 
access to other services. There’s also evidence of improved pain control and symptom 
management as result of the specialist approach. SPCS can effect cost by reducing the 
number of hospital inpatient days and time spent in out-of-home services (Hearn and 
Higginson 1998). 
Non cancer patients seem to have lower chances to choose to die at home and to get 
access to home care, if it is true that cancer patients in higher socioeconomic groups 
were both more likely to die at home and to access home care (Grande, Addington-Hall 
and Todd 1998). 
2.4.2 Palliative Care Needs 
 
Prognosis is the medical answer to one of the most important need of people affected by 
life threatening conditions. Answer questions like “How long have I got?”  or “What 
will it happen?” are among the most difficult tasks faced by health care professionals. 
Illness trajectories may be of help (Lunney et al. 2003, Lynn et al. 1996), but since 
diseases affect individuals in different ways, prognosis is often difficult to estimate. 
Because it seems that patients with specific diseases and their carers often have 
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common pattern of experiences, symptoms and needs as the illness progresses, the 
notion of diseases trajectories can help decision making and care planning that can be 
translated into improvements in outcomes for patients and their families (Murray et al. 
2005). Even though prognostic models that attempt to estimate survival of  less than 6 
months have generally poor discrimination, reflecting the unpredictable nature of most 
non-malignant diseases, a number of generic and disease specific predictors are 
available for clinicians to identify older, non-cancer patients with palliative care needs. 
Simple, well validated prognostic models that provide clinicians with objective 
measures of palliative status are needed (Coventry et al. 2005). 
Prognostic indicators for many progressive conditions have been published and are used 
in different countries to identify those patients requiring hospice care (The National 
Hospice 1996, Stuart 1999, Gold Standards Framework 2006, Grbich et al. 2005). The 
surprising question “Would I be surprised if this patient died within the next year?” can 
be a useful prompt for discussion and care planning with the patient. Collaboration 
between specialties to evolve effective symptom management and models of care for 
the increasing number of people living and dying with advanced progressive diseases 
and well-structured, coordinated and adequately resourced delivery of health and social 
care can be an effective response to most of this population needs (Kite, Suzanne and 
Hicks 2005). 
Many symptoms experienced by cancer and non-cancer patients are similar: cancer 
patients’ symptoms may be more severe, but those of non-cancer patients tend to be 
more prolonged (O'Brien, T., Welsh and Dunn 1998, Addington-Hall, J., Altmann and 
McCarthy 1998). A review of the literature looking at the palliative care unmet needs of 
non-cancer patients (Luddington et al. 2001) found that symptom control was 
unsatisfactory in patients affected by chronic obstructive pulmonary disease (COPD) 
where it was defined as comparable if not more distressing than what reported by in 
lung cancer patients (Skilbeck, J. et al. 1998) and were likely to endure a long 
symptomatic course with two third of patients becoming severely disabled in the last 
year of life. Pain was as prevalent as in cancer in last year of life, but more frequent in 
last week of life and breathlessness was more frequent in non cancer than in cancer both 
in last year and last week of life (Addington-Hall, J., Altmann and McCarthy 1998). 
Breathlessness was defined as the most distressing symptoms at the end of life by both 
patients and their carers (Hockley, Dunlop and Davies 1988, Law 1997). Some 
professionals tend to see these patients’ need as less urgent due to the lengthy course of 
the diseases and nurses assume that patients with non cancer diagnosis are less likely to 
suffer from pain (Kurti and O'Dowd 1995). 
Difficulties in coping with the deterioration of health status, decrease of independence, 
social isolation and family burden, limited resources available and difficulties in the 
access to community services, depression, acceptance of poor prognosis and concerns 
about the future are main findings in a research aimed at better understanding the unmet 
needs of people severely affected by chronic conditions (Fitzsimons et al. 2007). The 
authors put in evidence also the difficulties of talking openly with patients and families 
about the palliative nature of the treatments.   
Psychosocial and emotional distress are described in several studies (Luddington et al. 
2001, Hinton 1963, Hockley, Dunlop and Davies 1988). Striving for independence is a 
common need faced by patients affected by life limiting conditions (Cotterell 2008).  
2.4.3 Specialist Palliative Care 
 
The increased attention of the palliative care movement towards the care of non cancer 
patients is introducing the conviction that palliative care should be available to all on 
Chapter 2. Background: Literature Review 
 21 
 
the basis of need, not diagnosis (Addington-Hall, J. 1998, Addington-Hall, J. M. and 
Higginson 2001). Criteria for referral to specialist palliative care are usually advanced 
progressive disease, focus of care changed from curative to palliative, and limited 
prognosis. Appropriate reasons for referrals include symptom management, 
psychosocial issues of the patient or families and terminal care (Edmonds 2004). 
Now the difficult is to determine which kind of service provision can better fit the needs 
of people severely affected by diagnosis other than cancer. Some authors suggest that 
specialist palliative care skills are perceived to be transferable to patients with non 
cancer diagnoses (Kite, S., Jones and Tookman 1999), and that clinicians and patient 
groups caring for patients with advanced non malignant disease have to work together 
with specialist palliative care services and with health commissioners to develop, fund 
and evaluate appropriate, cost-effective services which meet patient and family needs 
for symptom control and psychosocial support (Addington-Hall, J., Fakhoury and 
McCarthy 1998), but there is debate regarding how patient care is best delivered, 
because some authors fear that current models of specialist palliative care may not be 
the most appropriate for addressing the complex problems experienced by the many 
patients with a non-cancer diagnosis. They suggest that care should be structured around 
patient problems, viewing specialist palliative care as a service for those with complex 
end of life symptoms or problems (Field and Addington-Hall 1999, Skilbeck, J. K. and 
Payne 2005). If comprehensive palliative care is to be extended to non malignant 
diseases, existing models of care provision will need modification (Skilbeck, J. K. and 
Payne 2005). Models of care are to be adapted to the fluctuating nature of symptoms 
and a combined approach, with sharing of skills between disciplines, is required. There 
is also a concern of not eroding service provision for cancer patients (Traue and Ross 
2005). 
There is strong evidence that adding a multi-professional support team can provide a 
higher quality of care than conventional care alone. Specialist palliative home care 
services demonstrated their ability to keep patients at home for longer than when such 
services did not exist. They also resulted in lower costs for the health system and better 
symptom control for the patients. These studies included cancer and non-cancer 
patients. However there is little evaluation of new services for patients with progressive 
non-malignant conditions (Higginson, I. 1997a, p214-215, Higginson, I 1993). Further 
criticism has been raised when the impact of different models of specialist palliative 
care on patients quality of life was evaluated. Main concerns were about the lack of high 
scientific evidence of impact due to a lack of  prospective RCT’s, use of inappropriate 
outcome measurement tools and effectiveness of measures of quality of life to reflect 
the values of palliative care (Salisbury et al. 1999, Zimmermann et al. 2008). Research 
that evaluates the effect of general and specialist palliative care on psychosocial 
outcomes in non-cancer patients and their carers is needed (Coventry et al. 2005), as 
there is a need for randomized studies to evaluate different types of service 
configuration and delivery related to specific outcomes (Higginson, I. J. et al. 2003). It 
is imperative to listen to the experiences of patients and carers as a basis for developing 
interventions and guidelines for services (Seymour et al. 2003).  
Professional specialists working in disciplines other than palliative care tend to be 
satisfied about the involvement of specialist palliative care in non cancer: an example is 
represented by the consultant physicians in south-east Wales that expressed a general 
enthusiasm for SPCS to be made available to patients other than cancer. The most 
appropriate form of service according to their point of view, is a system shared care and 
responsibility, and this was seen as a means of addressing concerns regarding the lack 
of disease specific expertise within the palliative care team (Dharmasena and Forbes 
2001). However there is a need, for those palliative care  professionals traditionally 
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evolved from oncology, to receive training in order to respond to the challenges of the 
different needs expressed by these patients and some concern about the limited 
understanding of non-malignant disease process, prognostic factors, appropriate 
medications (Fisher 2006, Wallwork 2000).  
2.4.4 Facts and figures 
 
The Gold Standards Framework agency, in its prognostic indicators paper (Gold 
Standards Framework 2006), indicates how just 25% of deaths in a developed country 
are due to cancer, a higher proportion is caused by organ failure (33%) and frailty or 
dementia (33%), and sudden death (9%). It has been suggested that there are different 
illness trajectories experienced by people at the and of life depending on their diagnosis, 
and these may be shown diagrammatically:  
 
 
From the analysis of the number of potential non cancer patients requiring palliative 
care and of their end of life trajectories it should be possible to estimate the increase 
work load of SPCS. It had previously been estimated that an increase of at least 79% in 
caseload would be expected if specialist palliative care services were made fully 
available to noncancer patients (Addington-Hall, J., Fakhoury and McCarthy 1998). 
Figure 2: Illnesses trajectories at the end of life (Lunney et al. 2003) 
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It is now a key principle in guidance on the commissioning of palliative care services 
for adults in United Kingdom  that ”It is the right of every person with a life threatening 
illness to receive appropriate palliative care wherever they are”. (Addington-Hall, J. M. 
and Higginson 2001, p.7).  In the same chapter the authors stated that in UK 96,7% of 
in-patient hospice and 96,3% of community palliative care services were used by cancer 
patients, despite the fact that 75% of death are caused by non-malignant conditions. 
Provision of palliative care services for patients with diagnosis other than cancer is both 
inequitable and inadequate and there is ample evidence that terminally ill patients with 
non-malignant diseases require palliative care (Addington-Hall, J., Fakhoury and 
McCarthy 1998, Wallwork 2000). Uptake of SPCS is significantly lower in people with 
non cancer diagnosis and in families with lower incomes. This is seen as an unmet need 
by their caregivers (Currow, David C. et al. 2008, Currow, D. C., Abernethy and 
Fazekas 2004).  In a retrospective review of a service appears how in spite of 29% of 
referrals to the hospital palliative care team were for non-cancer patients, only 9% of the 
home care and 4% of hospice inpatient admissions were for patients with diagnosis 
other than cancer (Kite, S., Jones and Tookman 1999). A structured documentary 
review of the Health Improvement Plans 1999-2003 (HImPs) reveals that among the 
health authorities that have made strategic plans for palliative care, the vast majority are 
for people affected by cancer. Especially for non-cancer patients specialist palliative 
care is perceived as an “optional extra” rather than an integral and essential part of the 
overall supportive care strategy (Seymour, Clark and Marples 2002). 
More recently, in the report for the years 2006-2007 the National Council for Palliative 
Care published the National Survey of Patient Activity Data for Specialist Palliative Care 
Services. Overall 7.2% patients cared for a SPCS in the UK had a diagnosis other than 
cancer. The range of percentages of non-cancer patients in the different units ranged from 
0% to 38%. A total of 28 units (20% of responding units) had over 10% non-cancer patients 
while 9 units only saw  cancer patients (National Council for Palliative Care 2007). 
 
In U.S.A. the situation is different: the National Hospice Organisation fact sheet for 
spring 1999 states that in 1995, 60% of hospice patients had cancer and 40% other 
diagnosis (Addington-Hall, J. M. and Higginson 2001, p. 8). Later  figures reveal 
further change in this proportion as the National Hospice and Palliative Care 
Organization published in 2008 the “Hospice Care in America” which reported figures 
of palliative care assistance about the year 2007: of 2,400,000 deaths in USA in that 
year, 930,000 (38.8%) were under the care of a hospice programme. The median length 
of stay in a hospice was 20 days and the average length of service was 67.4 days. The 
primary diagnosis of these patients was cancer for 41.3%, and 58.7%  had a non cancer 
diagnosis:  heart diseases (11.8%), unspecified debility (11.2%), dementia (10.1%), 
lung disease (7.8%) and ALS\MND (2.3%) were the most frequent (NHPCO 2008).  
 
 
2.4.5 The Italian situation 
 
Palliative care is now well integrated in the health and social systems in most developed 
countries. In Italy a rapid growth of new hospices has happened in last ten years, but 
still most of them provide care for cancer patients only. Palliative care for non cancer 
patients has been advocated by many official statements and it is now part of the new 
Italian law on palliative care released by the Italian parliament in March 2010. Regional 
health systems already incorporated these principles for  a long time. The Piedmont 
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Regional Health Commission produced guidelines on palliative care provision in 2002 
stating that hospice care is indicated when patients are affected by progressive disease, 
in advanced stages, with a poor prognosis, for which no therapies aimed at the cure or 
stabilization are possible or appropriate. Neurodegenerative conditions are clearly 
included within these criteria, but often patients severely affected by these illness still 
do not have access to specialist palliative care in Italy.  
Patients severely affected by these disorders are usually cared for by the neurologists 
who diagnosed their diseases, by rehabilitation specialist teams that help with disability 
problems and by primary care, involving general practitioners and district nurses. When 
the disease is in advanced stage patients are often homebound and lose contact with the 
hospital specialist teams. If complications occur, and the primary medicine team can not 
help, patients are taken to the local hospital passing through the A&E department and 
are seen by doctors and nurses who may not have had any previous contact with them. 
If they survive the hospital admission they are then discharged at home where they stay 
until next complication. Specific care facilities do not exist and many patients whose 
family member cannot cope with their disability and needs, are admitted to care homes 
where often die. 
 
The role and use of advance directives have not been clarified by Italian politicians as 
yet. Patients are thus not allowed to decide for their future therapeutic options if they 
lose their mental capacity or consciousness. If a patient with ALS/MND arrives at the 
A&E unconscious from an episode of acute respiratory insufficiency, it is the 
resuscitation specialist who may decide on the use of invasive ventilation, and maybe 
tracheostomy. If the patient previously stated that he did not want that option, and 
families testify that, it is the doctor who will decide and he has to take the decision on 
the patient’s best interest. This often results in an unwanted tracheostomy.  
 
It is  uncertain if there is a role for a specialist palliative care service (SPCS) in the care 
of these people and of their families and the literature seems to indicate that the services 
have a role as, there is a high prevalence of uncontrolled symptoms, unresolved 
psychosocial and spiritual issues. The SPCS may provide comprehensive care of both 
patients and families, care in the preferred place of care and help to stay in the preferred 
place to die, which usually is home, in Italy. A home based palliative care team can 
achieve better level of care than primary care alone, reducing the number of unwanted 
hospital admissions, and, consequently, the risk of undesired invasive therapeutic 
interventions.  
 
SPCS are often involved in the care of people with cancer, facing death and dying and 
are able to provide better information for patients and families and better chance to plan 
the care. If a hospice inpatient facility is available respite can be offered to support  the 
home care assistance and this respite is very much appreciated by lay carers and often 
by patients because they are concerned of the workload that they cause to their 
familiars. However  admission is often feared by those carers who are used to provide a 
personal high quality assistance to their loved ones, as they have concerns as to whether 
the same care can be provided in the  different setting and are often sceptical about this 
possibility. Families involved in the care of people severely affected by 
neurodegenerative disorders may require support, perhaps greater than in cancer, mostly 
due to the longer end of life trajectories and the progressive continual losses and 
adaptations that they have to face but this care has not been available in Italy. 
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Specialist palliative care teams often  have an ambiguous approach to the care of 
patients with a diagnosis other than cancer. Their competence can be helpful in 
symptom control, psychosocial and spiritual care and end of life care, but they  may 
express concern about difficulties in foreseeing prognosis and lack of competence about 
the unknown challenges related to the management of this group of patients. Some 
hospices opened their services to ALS/MND patients, but later expressed concern about 
the care they had been asked to provide as  they felt unprepared when had to manage 
respiratory machines or when assistance last much longer than their usual cancer 
patients. 
 
Italian neurologists, from their part, recognised the need to incorporate palliative care in 
their professional knowledge. Recognising the importance of previously international 
statements published for the American Academy of Neurologists about the duty of 
neurologists to provide palliative and end of life care to their patients facing threatening 
life conditions (AAN 1996, AAN 1998) they started new education courses in their 
annual meetings or through residential modules for neurologists involved in the care of 
people affected by long term conditions. Within the Italian Society of Neurologists 
(SIN) a group of study for bioethics started 20 years ago and in 2000 changed its name 
in Group of Study for Bioethics and Palliative Care in Neurology (Defanti 2000). The 
declared aims of this group are to enhance the bioethics reflection on the issues arising 
in the care for people affected by neurological disorders, promote good research in this 
field and improve the education of neurologists in palliative care. A document about the 
equity of provision of palliative care for neurological patients, analysing the bioethical 
principle of distributive justice, will be published in next months. This approach  shows 
that neurologists are trying to establish connections with palliative care  and this 
collaboration should be encouraged and strengthened..  
 
2.5 Palliative Care in Neurology 
 
2.5.1 Introduction 
 
Since St Christopher’s Hospice was opened  in 1967 and the new era of palliative care 
started the involvement in the care of people with neurological disease has increased.   
Dame Cicely Saunders, founder of St. Christopher’s Hospice and pioneer of modern 
palliative care, wrote in 1981: 
 
 “Our Lady’s Hospice in Dublin (1879) and St Joseph’s Hospice in London 
(1905) both included patients with long-term illness in their wards and St 
Christopher’s Hospice (1967) followed this tradition and opened with at least 
10% of its ward beds for patients with advanced neurological illnesses. The need 
of patients with motor neuron disease continues and their care has been 
integrate into the life of the Hospice” (Saunders, Walsh and Smith 1981). 
The links between palliative care and neurology were established early in the 
development of the hospice, but later as hospices were established the main area of care 
was for patients with cancer. 
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An appreciation of the role of palliative care in neurological conditions was expressed 
in 1996 in  a document published by the American Academy of Neurologists which 
suggested that neurologists have to understand, learn and apply the principles of 
palliative care because many patients affected by neurological disorders die after long 
illness and the neurologist is often the principal or the only consulting physician (AAN 
1996). In the 1999 the AAN published the results of a survey that highlighted a gap 
between established legal, medical and ethical guidelines for the care of severely ill 
neurological patients and the practice and beliefs of many American neurologists 
(Carver et al. 1999). A position statement defined the official position of the American 
neurologists about the assisted suicide and euthanasia, in which the AAN strongly 
refused these practices, but evidenced the importance of palliative care as an option 
aimed at relieve sufferance of patients dying of neurological conditions (AAN 1998). In 
1999  the AAN published the first evidence-based review on ALS/MND where 
guidelines and recommendations were provided for the different stages of the disease, 
with a focus on palliative and terminal care (Miller et al. 1999). These practise 
parameters  have been recently reviewed and authors conclude that no controlled studies 
examined the treatment of pain, dyspnoea, hospice care and recommended design of 
controlled trials of terminal symptom management, advanced directives, hospice and 
spiritual care (Miller et al. 2009). A Cochrane systematic review studying 
multidisciplinary care for ALS/MND patients did not find any high quality study on this 
topic and concluded that further research is needed into appropriate study designs; 
outcome measurement; caregiver needs; and the evaluation of optimal settings, type, 
intensity or frequency and cost-effectiveness of care in the ALS/MND population. 
The authors suggested that future research should focus on observational designs to 
assess care and outcomes in 'real-life' settings (Ng, Khan and Mathers 2009).  
 
The interface between neurology, rehabilitation and palliative care should be explored 
to provide long-term support for ALS/MND and for other progressive neurological 
conditions (Turner-Stokes, Sykes and Silber 2007). These findings must be read 
knowing that ALS/MND is the neurological disease in which the highest palliative care 
involvement has been obtained and were most publications have been made (Oliver, 
Borasio and Walsh 2006), but this disease is by no means the only neurological 
condition requiring palliative care (Borasio and Voltz 2005).  
 
2.5.2 Neurological conditions for which palliative care can have a 
role 
 
Neurodegenerative conditions are progressive and incurable conditions that ultimately 
lead to a state of total functional incapacitation and death. These conditions are 
"terminal" and, therefore, should be managed with a palliative care approach (Low et al. 
2003).  
Neurologists recognise their need of education and knowledge about end of life care as 
one of the major barrier to providing care for patients and families at the end of life 
(Foley and Carver 2001). One concrete initiative to overcome this difficulty was the 
publication of a specialist book titled “Palliative care in Neurology” (Voltz et al. 2004), 
specifically aimed at improving the knowledge of neurologists wishing to providing 
excellent care for neurological patients through the final stage of their disease. This 
book is also a precious source of information for those palliative care teams who are 
interested in being involved in the care of neurological patients not knowing many 
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aspects of the natural history, end of life trajectories, symptoms and other psychosocial, 
spiritual and ethical issues of the neurological disorders. From the table of contents of 
this publication it is possible to see how many different neurological conditions exist for 
which death is attended as an expected outcome and for which a palliative intervention 
can be adopted:  
• Stroke 
• Demyelinating disease (such as multiple sclerosis) 
• Neurological neoplasms 
• Movement disorders (such as Parkinson’s disease and related disorders) 
• Dementias 
• Infectious diseases 
• Diseases of motor nerves (typically ALS/MND) 
• Muscular dystrophies 
• Epilepsy 
• Pediatric neurological disorders. 
In addiction specific neurological conditions, usually resulting from complications of 
neurological diseases, can be of interest for palliative care: Persistent Vegetative State, 
Quadriplegia and Paraplegia and the Locked-in Syndrome. Common symptoms in these 
disorders are described and treatment options provided. Ethical issues, like the difficult 
decisions at the end of life, are explored and the last chapters focus on the other general 
aspects of the palliative care (psycho-social, spiritual and cultural) and on the need for 
palliative care education for neurologists. 
The disorders listed above can therefore be considered as the ones towards which SPCS 
should orient their interest when designing new services or when extending pre-existing 
ones to people affected by neurological conditions. 
Some disorders, like the stroke or dementias, have high prevalence rate and represent 
some of the most frequent cause of death in western countries. If all the people dying 
for these causes had to be cared for by a SPCS this would have a dramatic impact on the 
workload. Furthermore most of these patients die in hospital (stroke) (Hamann, Rogers 
and Addington-Hall 2004) or in nursing homes (dementia) (Volicer 2004) settings 
where palliative care is not usually provided by SPCS.  
As previously reported ALS/MND is the neurological disorders for which most 
evidence of the involvement of palliative care and specifically of SPCS is reported. 
Other disorders like multiple sclerosis have received little attention from palliative care, 
generally patients were considered as chronically ill, with progressive disability, high 
symptom burden, but not people affected by a life limiting condition for whom 
palliative care could play a role. A change in this position has started since evidences 
that MS patients have an increased suicide rate and that up to 5% of them die from 
euthanasia or physician assisted suicide in those countries were these procedure are 
legal (Van der Wal and Onwuteaka-Philipsen 1996) and when epidemiological studies 
evidenced the reduction in the life span of these patients (Bronnum-Hansen et al. 2005, 
Bronnum-Hansen et al. 2006). To date MS is the only neurodegenerative condition for 
whom a specific SPCS was designed, assessed and its outcomes evaluated with a phase 
2 Randomized and Controlled Trial (Higginson, I. J. et al. 2008). 
Movement disorders represent another group of neurological conditions that respect the 
criteria of incurability, relentless progression and shortened life expectancy. In this case 
the number of affected patients is very high, 25 fold more than ALS/MND, and some 
authors described the different phases of the illness trajectories including a palliative 
care stage where the specific drugs lose their efficacy and the focus of care is just on 
comfort and symptom control (Bunting-Perry 2006). 
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Overall, until now, many studies explored the unmet needs of patients experiencing the 
advanced stages of neurological conditions (Chahine, Malik and Davis 2008, 
Kristjanson, Aoun and Oldham 2006), as well as the satisfaction or dissatisfaction of the 
received services (Kristjanson, Aoun and Yates 2006). Literature reviews have 
described and compared the physical unmet needs of these patients (Saleem, Leigh and 
Higginson 2007, Higginson, I. J. et al. 2006a, Lee et al. 2007). There is a common 
feeling that the palliative care skills of the SPCS could have a positive impact on these 
unmet needs. What is lacking yet is the evidence that SPCS can make the difference on 
these outcomes in this population. A Canadian group reviewed the literature exploring 
the issue of palliative care in neurology and discussed the existing evidence base. The 
author conclude that current literature reflects primarily expert opinion and describes a 
growing interest in the early introduction of palliative principles into neurological care. 
Early initiation of palliative interventions has the potential to improve quality of life, 
enhance symptom management and assist in advance care planning. Further data is 
required to determine whether this shift in philosophy has a positive impact on patient 
care (Gofton, Jog and Schulz 2009). Another systematic literature review evidenced the 
need to explore more fully the challenges put forward by diseases other than cancer, 
such as  neurological illnesses and heart disease suggesting  that the impact of SPCS has 
not yet been studied extensively above all in these diagnosis (Zimmermann et al. 2008).  
Recently a care pathway for meeting the palliative care needs of people living with 
neurological conditions has been published. The pathway was designed to support 
timely referrals and coordination of care through a patient's illness journey 
incorporating the provision of palliative and end-of-life care (Brown and Sutton 2009). 
This novel option offers the opportunity to test the referral requirements and should 
facilitate the interaction among neurology, palliative care and rehabilitation. 
 
In Italy the Study Group of Bioethics and Palliative Care in Neurology of the Italian 
Neurological Society has published papers focused on the palliative care themes related 
to neurology and the problems faced by the people dying for neurological diseases. One 
describes how the neurological patients die, highlighting the mechanisms of death 
related to most neurodegenerative conditions (Defanti 2005), the clinical and ethical 
appropriateness of sedation in palliative neurological treatments (Bonito et al. 2005), 
the role of advance directives in neurological patients (Bonito 2005), the 
discontinuation of life support measures in patients in a permanent vegetative state 
(Bonito et al. 2002) and other ethical issues regarding neurology and palliative care 
(Defanti et al. 2007, Gasparini et al. 2006, Gasparini et al. 2004). However there are no 
published experiences of SPCS discussing the involvement in neurological care in the 
literature. It would seem that neurologists recognised the need to start interaction and 
relationships with palliative care whereas the palliative care experts did not seem so 
interested in being involved in the care of people dying for neurological diseases.  
 
From this evidence we can conclude that: 
• further studies aimed at better interpret the palliative care needs of patients (and 
their families) severely affected by neurodegenerative conditions are required 
• many people affected by these disorders die without receiving palliative care 
• SPCS are to be involved in the terminal stages of the diseases, although their 
role and the impact on the palliative care needs of this population is still unclear 
 
For all these reasons some of the neurodegenerative conditions that literature and 
previous experience associated to palliative care will be introduced and common 
features as well as peculiar characteristics will be described.  
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2.5.3 Neurodegenerative disorders considered in this research 
 
After having introduced the potential role of palliative care in neurology and having 
discussed the previously published experiences a brief description of the 
neurodegenerative conditions that are considered in this research project is now 
presented. 
The three groups of neurological conditions involved are : 
• Amyotrophic Lateral Sclerosis, also called Motor Neurone Disease 
• Multiple Sclerosis  
• Movement Disorders represented by the Parkinson’s Disease and by the so 
called Atypical Parkinsonian Syndromes or Parkinson’s Plus Syndromes 
(Multiple System Atrophy and Progressive Supranuclear Palsy) 
 
These neurological disorders, though being very different for many physiopathological 
aspects, share some common features:  
• All are considered neurodegenerative progressive disorders (Voltz et al. 2004) 
• None of these conditions is considered to be curable (Elman et al. 2007) 
• Some symptoms are common to these conditions and can be approached in 
similar ways (Saleem, Leigh and Higginson 2007) 
• All are considered life limiting conditions, even though presenting very different 
trajectories (Millul et al. 2005, Bronnum-Hansen et al. 2006, Muller et al. 2001) 
• National and international directives have suggested a role for palliative care in 
the management of these diseases (DH-UK 2005, AAN-EHS 1996) 
Taken together these conditions are not rare reaching an overall prevalence of 
374/100.000 (Doyle et al. 2004).   
2.5.4 Amyotrophic Lateral Sclerosis or Motor Neurone Disease (ALS/ 
MND) 
 
Motor Neurone Disease (MND) is a term covering a wide range of diseases involving 
the motor neurone cells. Amyotrophic Lateral Sclerosis (ALS) is one form of these 
disorders, but usually they are used as synonymous, even though in USA it is generally 
called ALS (and also Lou Gherig’s disease, from the name of a famous baseball player 
who died of it) and in the United Kingdom and other Commonwealth countries it is 
known as MND (Shaw, C. 2006). For the purpose of this thesis the term ALS\MND will 
be adopted to describe this condition. 
 
2.5.4.1  Epidemiology of ALS/MND 
 
ALS/MND is a relatively rare neurodegenerative condition of unknown aetiology 
(Rowland and Shneider 2001),with an incidence in Europe, Middle East and North 
America of about 1.4-2,5 new cases each 100.000 inhabitants per year and prevalence 
rates 2.7- 4.3 points higher (Brooks 1996). Age and gender specific incidence rates, 
published by the European registers, show that the incidence of ALS increases after the 
age of 40 years, reaching a peak in the late sixties or early seventies, followed by a rapid 
decline (Logroscino et al. 2008). In Italy the Ministerial Committee for diagnosis, care 
and assistance of patients with ALS report an incidence of 2-2.5/100.000 
inhabitants/year, a prevalence of 6-8\100.000, with a slight male dominance 1.2 – 1.3:1, 
a mean age onset of 63 years and a mean duration of the disease of 2.5 years (Bendotti 
et al. 2005). 90% of ALS  are sporadic, but a 10% are familiar form with autosomic 
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dominant inherited disease, being passed down through the generations, often linked to 
a gene mutation on the chromosome 21, the copper\zinc superoxide dismutase (SOD1) 
(Siddique et al. 1991, Rosen 1993). 
Diagnosis is generally based on the El Escorial Criteria –EEC- (Brooks 1994, 
Chaudhuri et al. 1995) even though rigid application of the EEC excludes at least 40% 
of ALS patients from enrolment in clinical trials at presentation, and up to 10% of 
patients at the time of death (Traynor et al. 2000, Logroscino et al. 2008). 
 
2.5.4.2 Natural History of ALS/MND 
 
ALS\MND is characterized by onset of symptoms and signs of degeneration of 
primarily upper and lower motor neurons, leading to progressive weakness of bulbar, 
limb, thoracic and abdominal muscles exiting into rapidly progressive paralysis and 
respiratory failure. (Rowland and Shneider 2001, Andersen, P. M. et al. 2005). 
ALS\MND cause significant disability early and relentlessly progresses so that most 
patients lose the ability to walk, feed and toilet themselves, speak and swallow (Shaw, 
C. 2006). Cognitive functions tend to be spared by the disease, even though signs of 
fronto-temporal dementia (FTD) have been reported up to 15% of patients (Neary and 
Snowden 1996, Neary, Snowden and Mann 2000), although higher rates are reported, 
up to 65% of cognitive dysfunction (Barson et al. 2000, Strong et al. 2003, Lomen-
Hoerth et al. 2003). Typical patterns of impairment relate to alterations in mental 
flexibility, verbal and nonverbal fluency, abstract reasoning and memory, for both 
verbal and visual material (Strong et al. 2003, Abrahams et al. 2004) with selective 
cognitive impairment in the form of verbal fluency deficit accompanied by emotional 
lability and depressive symptomology (Abrahams, Leigh and Goldstein 2005). 
 
The clinical features can be considered in relation to neurological regions or levels: 
bulbar, cervical, and lumbar. Bulbar-onset patients present with slurring of speech 
(dysarthria), difficulty swallowing (dysphagia), or both. Bulbar involvement can be 
lower motor neuron (bulbar palsy), upper motor neuron (pseudobulbar palsy), or both. 
Bulbar palsy is associated with upper and lower facial  weakness and poverty of palatal 
movement with wasting, weakness, and fasciculation of the tongue. 
• Pseudobulbar palsy is characterised by emotional lability (also known as 
pathological laughing or crying), brisk jaw jerk, and dysarthria. 
• Cervical-onset amyotrophic lateral sclerosis presents with upper-limb 
symptoms, either bilateral or unilateral. Proximal weakness can present as 
difficulty with tasks associated with shoulder abduction and distal weakness can 
manifest with impairment of activities requiring pincer grip. Upper limb signs 
might also be upper motor neuron, lower motor neuron, or both. The arm can be 
strikingly wasted with profuse fasciculation and brisk reflexes. 
• Lumbar onset patients present with weakness of the legs, often with a mixed 
picture of wasting and spasticity 
• Progressive muscular atrophy may present with weakness of the arms or legs, 
and the features are of lower motor neurone lesion only, at least initially. The 
prognosis is longer – often 5 to 10 years  
Bulbar onset patients tend to be older, are more likely to be female, have a shorter 
period of time between symptoms onset and diagnosis and a shorter life span if 
compared with limb onset patients (Iwasaki et al. 2002). 
Older ALS patients survive for shorter times. A tendency for older women to suffer 
bulbar-onset of ALS is well known (Iwasaki et al. 2002, Chaudri, Kinnear and Jefferson 
2003). 
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Negative prognostic indicators included site of disease onset, older age and progression 
rate of respiratory, bulbar and lower limb symptoms (Hoffman 2008). Eventually, 
ALS\MND results in total dependence for meeting all basic needs, and often the focus is 
palliative care (Mitsumoto and Rabkin 2007). The disease is usually fatal in 2-4 years 
(Ringel et al. 1993, Borasio and Voltz 1997) although there are variation in life spam 
amongst individuals (Shaw, P. J. 1999). The median time from onset until death has 
been found to be 23 to 48 months in various series with 5-years survival rates ranging 
from 9% to 40%, whereas 10-year survival rates are 8% to 16% (Simmons 2005) and 
patients usually die of respiratory failure (Neudert et al. 2001b, Borasio and Voltz 
1997).  
No known definitive treatment or cure exists for ALS.  The only medication which  may 
extend lifespan is riluzole (Rilutek), approved by the Federal Drug Administration 
(FDA) in 1995 and has been to slow down the deterioration associated with ALS. 
Riluzole acts to inhibit glutamine release, inactivating sodium channels or interfering 
with neurotransmitter actions, thus slowing neuronal damage and retarding disease 
progression (Hoffman 2008). 
A population based outcome study in Ireland concluded that Riluzole reduced the 
mortality rate by 23% and 15% at 6 and 12 months, respectively, and prolonged median 
survival by 4.2 months (Traynor, Alexander and Corr 2003, Simmons 2005).  
 
2.5.4.3 The Palliative Care Approach 
 
ALS/MND is the first neurological condition to which a specific book exploring the 
palliative approach has been dedicated. The main thesis of this publication is that being 
this neurological condition progressive, incurable, and leading to death in some months-
few years, palliative care should be involved in all the stages of the disease. The authors 
suggest that a multidisciplinary approach of care should start from the beginnings, with 
a proper disclosure of the diagnosis and continue through all the stages of the disease 
until the death of the patient and the bereavement counselling to the family. The aim of 
palliative care in ALS/MND is, for the authors of this book, to maximize quality of life 
of patients and families by relieving symptoms, providing emotional, psychological and 
spiritual support as needed, removing obstacles to a peaceful death, and supporting the 
family in bereavement (Oliver, Borasio and Walsh 2006). The palliative care 
involvement, therefore, should neither be restricted to pure symptomatic treatment nor 
to the terminal stages of the disease (Borasio, Voltz and Miller 2001). 
 
In 1999 the American Academy of Neurology published an evidence based review 
about the care of the patient with ALS\MND. Clinical questions addressed in treatment 
recommendations were breaking the news, symptom management, nutrition 
management, respiratory management and palliative care. In the research 
recommendations section for palliative care they list (Miller et al. 1999): 
1. Study symptom prevalence and quality of life in the terminal phase of ALS.  
2. Test the effectiveness of current treatments for palliative care.  
3. Develop new therapeutic approaches for terminal ALS symptoms.  
4. Study the effect of hospice care on quality of life for patients with ALS and families.  
5. Compare hospice home care with hospice inpatient care.  
6. Study the role and impact of advance directives on the dying process.  
7. Include palliative care of the dying patient in medical education.  
8. Examine the psychological impact of ALS on caregivers and health care providers.  
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Acknowledging the importance of these recommendations 6 years later another working 
group underlined the need for guidelines specifically for end-of-life care in patients with 
ALS (Mitsumoto et al. 2005). Authors stated that little evidence was available in the 
published literature that identifies optimal management approaches for caring for the 
dying patient with ALS. In this review other issues are added to the previous indicated 
in the AAN Practical Parameters study: attention to caregivers, psychosocial and 
spiritual aspect of care, access to and cost of the care and quality of life. 
 
Palliative care options are included in another review by the European Task Force on 
diagnosis and management of  ALS/MND (Andersen, P. M. et al. 2005). These authors 
recommend that a palliative care approach should be incorporated into the care plan for 
patients and carers from the time of diagnosis. Early referral to a specialist palliative 
care team is often appropriate. Palliative care based in the community or through 
hospice contacts (e.g. home care teams) can proceed in partnership with clinic-based 
neurological multidisciplinary care. Clinical guidelines for symptom control are also 
suggested, confirming the common approach to symptoms like chronic pain and 
terminal breathlessness with the use of opioids. 
 
2.5.4.4 Specialist Palliative Care Provision 
 
Patients affected by ASL/MND have been cared for by specialist palliative care service 
since the opening of the first modern Hospice: St Christopher’s in London in 1967 by 
Dame Cicely Saunders (Saunders, Walsh and Smith 1981). 
 
Studies aimed at evaluating the quality of care and the adherence to the 
recommendations provided in the guidelines discussed in the previous subchapter 
conclude that patients affected by ALS/MND (and their families) are more likely to 
receive better care if they are cared for in specialized clinics, also called tertiary clinics, 
dedicated to the care of this illness (Chio et al. 2006, Chio et al. 2004b, Bradley et al. 
2004, Miller et al. 2000). Reports from databases of patients cared for by neurological 
ALS/MND tertiary clinics show that between 36-64% of the patients used hospice 
facilities (Albert et al. 1999b, Mandler et al. 2001). 
Oliver showed how the specialist palliative care involvement in the care of ALS/MND 
patients in UK and Ireland varies from unit to unit. Many hospices are involved only in 
the terminal stages o the disease or in providing respite care and later terminal care. 
There is a need to develop collaborative relationships with other disciplines and services 
so to provide more co-ordinated care, in response to and involving patients and their 
families in the decision of care (Oliver and Webb 2000). These results were confirmed 
by a European survey among the members of the European ALS Study Group on 
standards of palliative care in the clinical management of patients with ALS and their 
families. Authors conclude that, although great efforts are made by the centres to offer 
the best possible palliative care to ALS patients, discrepancies in the type of care 
offered are evident and might be resolved by adopting common standards (Borasio et al. 
2001). 
 
The impact of SPCS on the palliative care outcomes has been described indirectly in 
seminal papers discussing the role of the hospice care for this population (O'Brien, T., 
Kelly and Saunders 1992, Hicks and Corcoran 1993) and has then been reinforced by 
international multicentre studies analyzing the quality of death and the effectiveness of 
palliative measures in Germany and in the UK (Neudert et al. 2001a). These studies 
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report the usefulness of the palliative intervention, but were all retrospective and 
without a control group. 
 
Home care received by patients with ALS/MND was described as inadequate and too 
late to relieve the burden placed on family caregivers (Krivickas, Shockley and 
Mitsumoto 1997), but recently another study reported that the need for coordinated 
home care nursing is essential in meeting the patient’s multisystem and emotional needs 
(Hoffman 2008). 
 
In Italy the specialist palliative care involvement in ALS/MND is sparse and anecdotic. 
Italian Neurologists, adopting the international recommendations of the AAN, where 
the first to start an approach towards the palliative care and a specific committees was 
created inside the Italian Neurological Society to study the clinical and ethical issues 
binding neurology and palliative care (Defanti 2000). 
  
In conclusion the literature strongly advocates the involvement of specialist palliative 
care in ALS/MND, neurologists recognise the role of palliative care in many aspects of 
the care of these patients, some experiences of SPCS are described, but prospective 
randomized controlled studies evaluating the impact of specialist palliative care on the 
PCO are still lacking, even though several areas of ALS patient care would benefit from 
controlled studies to establish an evidence base for treatment decisions (Borasio et al. 
2001). 
2.5.5 Multiple Sclerosis 
 
2.5.5.1 Definition 
 
Multiple sclerosis (MS) is a chronic recurrent inflammatory disorder of the central 
nervous system (CNS). The disease results in injury to the myelin sheaths, the 
oligodendrocytes and, to a lesser extent, the axons and nerve cells themselves. The 
cause of MS is unknown although immune mediated mechanisms are almost certainly 
involved, either primarily or secondarily, and many authors favour a primary 
autoimmune basis for MS. MS is characterized pathologically by patches of 
demyelination that are found multifocally within the CNS white matter. Grey matter is 
relatively spared, as are the nerve axons although recent reports have highlighted the 
importance of axonal injury (Goodin et al. 2002). 
 
2.5.5.2 Epidemiology 
 
Women are affected more often than men. The disease typically becomes clinically 
apparent between the ages of 20 and 40 years, although, it can begin either earlier or 
later in life.  
o Prevalence of the disease depends on the geographic area being more frequent in 
countries close to the poles and less in equatorial areas. Prevalence rates in 
Canada, Europe, and the United States (US) range from 100-200 cases per 
100,000 population according to the American Academy of Neurologists  and 
the total estimated prevalence rate of MS in Europe, for the past three decades, is 
83 per 100 000 with higher rates in northern countries. Prevalence rates are 
higher for women for all countries considered with a female:male ratio around 
2.0.  The highest prevalence rates have been estimated for the age group 35–
64 years for both sexes and for all countries (Goodin et al. 2002). 
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o The estimated European mean annual MS incidence rate is 4.3 cases per 100 000 
(Pugliatti et al. 2006). 
o Despite the wealth of epidemiological data on MS, comparing epidemiological 
indices among European countries is a hard task and often leads only to 
approximate estimates. This represents a major methodological concern when 
evaluating the MS burden in Europe and when implementing specific cost-of-
illness studies (Pugliatti et al. 2006). 
o 80% of patients present with relapsing/remitting disease and, typically, the 
illness passes through phases of relapse with full recovery, relapse with 
persistent deficit, and secondary progression. In about a quarter of patients, 
multiple sclerosis never affects activities of daily living; conversely, up to 15% 
become severely disabled within a short time. Episodes happen at random 
intervals, but initially average about one per year, decreasing steadily thereafter. 
In 20% of patients, the disease is progressive from onset, hence termed primary 
progressive—affecting the spinal cord and, less frequently, the optic nerve, 
cerebrum, or cerebellum (Compston and Coles 2002)  
o The neurology services in the United Kingdom estimate that there are 85.000 
people with MS at any time, of whom around 10% have primary progressive 
MS, and 40% have secondary progressive MS (Higginson, I. J. et al. 2006b, 
Multiple Sclerosis 2003). 
o 10% of patients with MS would be expected to have an EDSS of 8 or above at 
any one time (Weinshenker et al. 1991). EDSS (Kurtzke 1983) is a disability 
scale 0 to 10 with higher scores indicating worse disability. A value of 8 
indicates  a patient essentially restricted to bed or chair or perambulated in 
wheelchair, but may be out of bed itself much of the day; retains many self-care 
functions; generally has effective use of arms. On average patients spend 2 or 3 
years in this stage and are considered in advanced stage of the disease 
(Compston and Coles 2002). 
 
2.5.5.3 Clinical forms of MS 
 
Four clinical evolution of the disease have been described (Lublin and Reingold 1996): 
 
• Relapsing / Remitting (RRMS) 
This form  accounts for approximately 85-90% of MS cases at onset (Goodin et 
al. 2002). The disease takes the form of relapses or attacks interspersed with 
periods of remission. This is because the CNS can often compensate for areas of 
damage by repairing myelin or by re-routing messages around the problem area. 
In a remission, symptoms that were disabling during a relapse can virtually 
disappear. Occasionally there is some residual damage after a relapse, leading to 
incremental levels of disability. Exacerbations may be triggered by viral and 
bacterial infection but not by vaccination or immunisation. Exposure to heat and 
high humidity may amplify symptoms (Uhtoff’s phenomena) as may strenuous 
exercise and menstruation. Pregnancy protects against exacerbation but the risk 
of relapse is increased following delivery (Lorenzi and Ford 2002). The 
treatment for acute relapses is to treat any underlying infection before giving a 
course of oral steroids. Steroids have been shown to influence the rate of 
neurological recovery but not the ultimate degree of recovery. For those with 
relapsing disease who meet the criteria set by the Association of British 
Neurologists, disease-modifying therapies (DMT) can be prescribed (Goodin et 
al. 2002). 
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• Secondary Progressive (SPMS) 
About 75% of people whose disease pattern begins with relapsing/remitting 
symptoms go on to develop secondary progressive disease. This heralds a 
gradual increase in disability irrespective of the presence of continuing relapses. 
For 50% of people this change occurs within the first ten years of diagnosis. This 
‘transition’ can be quite gradual and may only be recognised in retrospect, as the 
awaited remission never happens. For others progression can be quite marked, 
and the loss of the improved quality of life previously experienced in remissions 
can be profound. This transitional period can be emotionally and physically 
difficult, as people fear the disease has ‘finally caught up with them’ and often 
worry for the future (Lublin and Reingold 1996). 
 
• Primary Progressive (PPMS) 
About 10% of people have this chronic condition from onset. Symptoms 
gradually worsen over the years, without relapse or remission. This form of MS 
is not amenable to the disease-modifying treatments that have received so much 
media coverage (Multiple Sclerosis 2003). 
 
 
• Progressive/Relapsing MS (PRMS) 
 
This form begins with a progressive course although these patients experience 
occasional attacks, which are superimposed upon their steadily progressive 
disease course (Goodin et al. 2002). 
 
2.5.5.4 Mortality and end of life 
 
Despite being considered a chronic condition causing disability, but not death, we know 
that overall mortality is three times higher, and life expectancy 10 years less among 
people with MS than general population (Bronnum-Hansen, Koch-Henriksen and 
Stenager 2004). The suicidal risk is double respect general population(Bronnum-Hansen 
et al. 2005). General cause of death reported in the Danish MS register are 
cardiovascular and respiratory diseases, infections, suicide and fatal accidents. Risk of 
death from cancer in MS seems lower than general population, (Bronnum-Hansen et al. 
2006).  
Severe MS disability, as measured by an EDSS of 7.5 or higher is a major risk factor for 
death with case fatality ratio for this group of patients approaching 4 times the rate for 
controls (Sadovnick et al. 1991). 
 
2.5.5.5 Specialist Palliative Care needs and involvement 
 
The evidence of symptoms and other unmet needs that can be faced by SPCS for people 
with MS was reported by many authors. 
From these papers it results that in MS six symptoms affect more than 50% of patients: 
problems using legs, problems using arms, fatigue/lack of energy, spasms, pain, and 
feeling sleepy. Many symptoms in people severely affected by MS are as highly 
prevalent and severe as those experienced by patients with advanced cancer. Increased 
disability is associated with increased severity for some symptoms (Higginson, I. J. et 
al. 2006a). 
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Neurologic bladder, sexual dysfunction, swallowing and speech impairment, cognitive 
decline and psychiatric complications can worsen the clinical picture of these people, 
and symptomatic relief and counselling of patients with MS have a strong impact on 
quality of life (Ben-Zacharia and Lublin 2001).  
Qualitative research provided evidence of disbelief and devastation, losses and forced 
life choices, tracking down services and information, and sadness and relief. Authors 
conclude that given the duration, range of symptoms and distress often associated with 
MS the research raise the important question of the role of palliative services in 
supporting the person with MS and the family (Wollin, Yates and Kristjanson 2006). 
Similar findings related to the difficulties to cope with the losses and changes, as well as 
the discomfort in having to fight to obtain everything, above all to track down the 
services were reported in other studies (Edmonds et al. 2007b, Edmonds et al. 2007a, 
Edmonds 2006). Probably due to the long trajectory of the disease MS patients are more 
likely to live alone, without caregivers, compared  with people severely affected by 
other neurological disorders (Kristjanson, Aoun and Oldham 2006). 
MS is the only neurodegenerative disorder for which the involvement of palliative care 
has been evaluated with a RCT. The results show that the involvement with the 
palliative care service appeared to positively affect nausea and problems sleeping to 
some degree, with the effect strongest after initial contact with the clinical service. It 
also seemed to have a positive impact on informal carer wellbeing. User satisfaction 
with the service was high among MS patients, carers and especially other health care 
professionals. Available time, symptom management, end of life decision making and 
liaison appear to be important components of the service. 
Involvement with the palliative care service did not shorten life in patients severely 
affected by MS. Findings suggest that short term interventions from specialist palliative 
care may be beneficial for some patients. The authors conclude that whilst there were 
merits to the model of service delivery evaluated in their study, further work is required 
to determine the most appropriate model(s) of service delivery to best meet patients’ 
and carers’ needs, building on existing expertise in neurology, rehabilitation and 
palliative care. (Edmonds et al. 2006). 
2.5.6 Movement disorders 
 
Movement disorders are a group of neurodegenerative conditions represented by the 
Parkinson’s disease and by the atypical parkinsonian syndromes. 
For the purpose of this thesis movement disorders will be presented as a common group 
formed by Parkinson’s disease and the atypical parkinsonisms (multiple system atrophy 
and progressive supranuclear palsy). This group will be represented with the 
abbreviation PDs. 
In the following paragraph an introduction to the movement disorders considered in this 
research is provided. 
 
2.5.6.1 Parkinson’s disease 
 
Parkinson’s disease (PD) is the second most common neurodegenerative disorder after 
Alzheimer’s disease and its prevalence is increasing with the populations aging 
(Kristjanson, Aoun and Oldham 2006, Lanoix 2009).  
PD is a progressive, degenerative disorder of the nervous system characterized by 
asymmetric onset of bradykinesia and rigidity (Hudson, Toye and Kristjanson 2006). It 
causes substantial morbidity and may result in a shortened life (O'Brien, T. 2002) 
Tremor is present in approximately 75% of cases,  and muscle weakness and postural 
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instability are also characteristic. The disease can present differently in individuals, its 
progression is variable and the degree of disability can fluctuate over the course of a 
day. Depression is a common complication (Stein and Read 1997). 
 
Although PD is not thought to directly cause death, it does shorten the lifespan and 
people in the later stages of the disease may have symptoms that exacerbate other fatal 
illnesses. If the uncertainty of the disease is considered a barrier to effective palliation, 
some authors see it, rather, as another reason for neurologists to be more involved in the 
care of PD patients (Liao and Arnold 2007). People with PD face a variety of losses in 
body image, mobility, social role and independence (Abudi et al. 1997). 
 
2.5.6.1.1 Epidemiology 
 
The prevalence of PD in industrialised countries is generally estimated at 0.3% of the 
entire population and about 1% in people over 60 years of age. PD clearly is an age-
related disease: it is rare before age 50 years and the prevalence increases with age up to 
4% in the highest age groups. It is unclear if there is a higher frequency of PD in males, 
as studies have not confirmed this  (de Lau and Breteler 2006). An  overall prevalence 
in a general population can be estimated at 160/100.000 inhabitants (Doyle et al. 2004) 
even though this raw data is strongly influenced by the age classes of that population. 
 
Reported standardised incidence rates of PD are 8–18 per 100 000 person-years and 
increase of the incidence is seen after age 60 years (de Lau and Breteler 2006). 
Prognosis, mortality and causes of death will be discussed together with the atypical 
syndromes. 
 
2.5.6.1.2 Mortality and causes of death 
 
In one of the first papers about the natural history of PD Hoehn & Yahr found an excess 
mortality in PD patients over the age matched normal population of about threefold and 
concluded that “The state of parkinsonism severely limits life expectancy”(Hoehn and 
Yahr 1967). In the post Levodopa era have found reduced excess mortality but mortality 
ratios were still between 1.5 and 2.5 and average life expectancy has been extended 
from 7.5 to 11 years though with wide variations depending on the response to the 
drug.(Shaw, K. M., Lees and Stern 1980). The mean survival for idiopathic PD ranges 
from 9 to 15 years, age of onset seems to be the best predictor of death within ten years 
(MacMahon 1999, Hely et al. 1999). 
  
The course of the disease, when there is a good compliance and response to Levodopa, 
is characterized by 5 good years. After 10 years patients experience several drug 
changes and became progressively disabled, with or without mental problems. Often 
these events determinate that patients leave their home and are admitted to long term 
facilities where mortality increase rapidly (Clough and Blockley 2004). 
There is little data on the usual cause of death of PD patients. Pneumonia is the leading 
cause of death in Parkinson’s disease followed by cardiovascular events, stroke and 
cancer in most surveys. Parkinsonism is also indicated as cause of death up to 38% of 
patients. (Poewe 2006). Causes of death among PD patients were identified from death 
certificates and compared to a population-based control group of 4,491 individuals. 
Mortality was greater in male PD patients (41%) compared to females (28 %) and age, 
disability scores (Hoehn & Yahr stage) at baseline were greater in the PD patients who 
had died during follow-up compared to survivors. More PD patients (20%) died from 
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pneumonia than controls (9%) while more controls (23 %) had died from coronary heart 
disease compared to patients with PD (13%) (Beyer et al. 2001).  
Cognitive decline as well as older age at onset have been identified as predictors of 
decreased survival in several studies and is a substantial contributor to the death of a 
large number of people. Dementia is a clear marker of poor prognosis and 25-40% of 
patient eventually develop dementia (Jellinger et al. 2002, Buter et al. 2008, de Lau and 
Breteler 2006) while up to 78% in advanced stages have cognitive impairment 
(Bunting-Perry 2006, Weintraub and Stern 2005) 
The symptoms of PD may also exacerbate other illnesses that can be fatal, such as 
pneumonia and cardiovascular disease.(MacMahon 1999) 
 
2.5.6.1.3 Common symptoms  
 
Analysing the motor complications of PD the most frequent and typical are 
hypokinesis/akynesis that usually respond well to the L-Dopa therapy, but when it loses 
its efficacy they evolve towards stiffness and freezing episodes. Dyskinesias and 
dystonia are caused by the dopaminergic drugs and appear in the advanced stages, when 
the therapeutic interval between the positive effect and the side effects becomes too 
limited or totally absent. In this situation motor symptoms are fluctuant and the patients 
alternate episode of freezing in which are completely blocked, with episodes of 
dyskinesias when they cannot control their movements (Elman et al. 2007). Dyskinesias 
can cause weight loss and increase frailty. Excessive dyskinesias can cause death from 
exhaustion. PD in latest stage will cause immobility(Clough and Blockley 2004).  
 
Non motor symptoms are various and often not recognized and undertreated. Studies 
have reported a prevalence of pain in an estimated 40-85% of people with PD; more 
than 20% of patients experience more than one pain at the time and this symptom could 
be PD related or not. Overall,  analgesic use was low (Ford 1998, Lee et al. 2006c). 
Speech, swallowing, sleep, bladder and bowel functions are often impaired (Sandyk 
1986). Speech problems may be accompanied by swallowing difficulties and hence 
weight loss. Dysphagia and cough may indicate inhalation problems which lead to chest 
infections. Immobilization, falls, chest and urinary infections, and exhaustion weight 
loss may lead to death (Hely et al. 1999, Hudson, Toye and Kristjanson 2006). 
 
As mentioned before one of the trigger conditions that indicate a short life span in PD 
are the cognitive dysfunctions, leading to dementia, or psychiatric complications like 
the psychosis induced by the dopaminergic drugs (Elman et al. 2007). Other psychiatric 
complications are anxiety and depression that can affect up to 40% of the patients and 
that in 50% re not recognized by the neurologists (Shulman et al. 2002)  
 
 
2.5.6.2 Parkinsonisms (PD atypical forms or PD plus syndromes) 
 
Parkinsonisms, PD atypical forms, PD plus syndromes are all synonymous terms to 
identify movement disorders that share common features with the typical PD, but 
present other peculiar features that make these syndromes recognizable and different 
from PD. One common characteristic of the atypical parkinsonisms is the low response 
to the L-Dopa and to the other dopminergic drugs, which represent the mainstream of 
the pharmacological therapy for the extra-pyramidal movement disorders. When the 
disease progress, palliative needs successively increase (Sjostrom, Holmberg and Strang 
2002). 
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Parkinsonisms that not respond to L-dopa carries a much worst prognosis (Clough and 
Blockley 2004). Progressive Supranuclear Palsy (PSP) and Multiple System 
Atrophy(MSA) are the atypical PD forms that reflect the most well developed 
knowledge base (Sano 2006) and therefore are the most reported in literature. 
 
2.5.6.2.1 Multiple system atrophy 
 
Multiple system atrophy (MSA) is a degenerative disorder of the central and autonomic 
nervous system. According to seminal researches MSA presents an unremitting 
downward course with life expectancy of 5-8 years (Quinn 1989). Other authors report a 
longer  median survival, around 9 years from the first symptom to death (Wenning et al. 
1994).The disease affects slightly more male than females with a ratio of 1.3/1(Bower et 
al. 1997). Usually there’s earlier onset falls associated to bulbar symptoms. 
Hallucinations and dementia tend not to be specific features (Clough and Blockley 
2004). Recent epidemiological surveys reported a prevalence rate of 4.4/100,000 and an 
incidence rate of 3/100,000/year (Wenning, Geser and Poewe 2005). Italians data report 
a prevalence of 17-29/100.000 for the population older than 55, but with most 
prevalence concentrated between 60-79 (81% of the cases), whereas in the 55-59 and 
>80 groups the prevalence rate is respectively of 9.8% and 8.7% (Chio, Magnani and 
Schiffer 1998, Morgante et al. 1992, Schrag, Ben-Shlomo and Quinn 1999, Vanacore et 
al. 2001). Like PD people affected by MSA presents the typical extrapyramidal 
symptoms (bradikinesia, tremors and rigidity), complicated by other  physical 
symptoms. In particular the patients experience  motor impairment (100%) 
accompanied by cerebellar signs and non motor symptoms like authonomic signs, as 
erectile dysphunction in males, bladder disturbance and postural hyphotension (82-
100%). Other common problems are constipation (57%), dysphagia (30%) and 
respiratory troubles (42%) that can lead to the death of the patients (Colosimo and 
Pezzella 2002). 
 
2.5.6.2.2 Progressive supranuclear palsy 
 
Progressive supranuclear palsy (PSP) or Steele-Richardson-Olszewski syndrome is a 
neurodegenerative disease of middle and late age often mistaken for PD. Again early 
onset falls, absence of response to dopaminergics characterized this condition. Particular 
features are severe ocular movement disorders starting with impaired voluntary vertical 
eye gaze and slow saccadic eye movements. The annual incidence of the disease is 5.3 
new cases per 100.000 person years and the prevalence of the disease is estimated 
between 1.39 per 100 000 population in the US and 4.9 per 100 000 in UK. It is likely 
that these figures are not precise with a considerable under-estimate, as many patients 
with PSP are not diagnosed and die with other diagnoses. The incidence of PSP 
increases with age (1.7 at 50–59 years, 14.7 at 80–99 years). Males are affected more 
commonly than females (Rehman 2000, Schrag, Ben-Shlomo and Quinn 1999). For 
PSP Median survival time from symptoms onset is 5.6 years (Bower et al. 1997, Litvan 
et al. 1996). At the present no curative therapies exist for this condition and the therapy 
is only symptomatic (Rehman 2000). The commonest clinical feature is represented by 
mobility problems associated to visual symptoms that are often severely disabling. 
Complications of accidental falls, swallowing problems and respiratory infections are 
the main causes of death (Nath et al. 2003). Other common symptoms are constipation, 
bladder problems, depression, and muscular stiffness – spasms (Saleem, Leigh and 
Higginson 2007).  
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2.5.6.2.3 Movement disorders common palliative care issues 
 
The Parkinson’s-plus syndromes, multi-system atrophy and progressive supra nuclear 
palsy, which are relatively rare conditions, are included in those 6% of UK hospice 
patients having non-malignant diseases (Morris and Gonsalkorale 2004). 
Both MSA and PSP share common palliative care problems with PD (Clough and 
Blockley 2004) and are often misdiagnosed as PD (Schrag, Ben-Shlomo and Quinn 
1999). The treatment is similar for all these conditions and focuses on controlling 
symptoms and on increasing or maintaining quality of life. In this regard, the situation is 
very similar to the multiprofessional and multidisciplinary team approach used in 
palliative care (Doyle et al. 2004). Some patients respond to levodopa or dopamine 
agonists such as apomorphine, although to a lesser degree than Parkinson patients 
(Sjostrom, Holmberg and Strang 2002). Atypical parkinsonian syndromes considered as 
a whole present an average survival time from diagnosis of 9,8 years (Thomas and 
MacMahon 2004a).  
 
The relevance of aspiration pneumonia as a contributor to the increased mortality in 
Parkinson’s disease and in the atypical syndromes is also suggested by a post-mortem 
study showing a tight correlation between the onset of clinically relevant dysphagia and 
survival time across a group of 77 postmortem confirmed cases of different 
degenerative parkinsonian disorders including PD, MSA, PSP. Survival time after onset 
of complaint of dysphagia is similar in PD, MSA and PSP: 15-24 months, and latency to 
a complaint of dysphagia is highly correlated with total survival time in all disorders 
(Muller et al. 2001). 
 
2.5.6.3 Specialist Palliative Care involvement 
 
Very few experiences of a direct involvement of SPCS in the care of PDs patients were 
found in the literature.  
For the vast majority of those who work in palliative care, the only contact with PDs is 
when it is incidental to a cancer diagnosis (Morris and Gonsalkorale 2004). 
A theoretical model of care have been proposed starting from a classification of the 
clinical stages of the diseases:  Four disease stages for PD patients have been identified: 
diagnosis, maintenance, complex and palliative. The palliative stage  has a mean 
duration of 2.2 ± 2.2 years for PD, and 1.5 ± 1.2 for atypical (Thomas and MacMahon 
2004a, Thomas and MacMahon 2004b). This wide range of time spent in the last stage 
of the disease, which can be up to 4.4 years for PD and up to 2.7 years for the atypical 
syndromes, shows how difficult is to predict the prognosis in PDs even in very 
advanced stages. This is one of the  reasons for which SPCS have been so little involved 
in the care of these patients. Bunting Perry proposes a model describing the trajectory of 
PD related to the increase of physical disability and the linear relationship existing 
between the loss of efficacy of treatments aimed at prolonging the patients’ life and the 
increase of the palliative care needs. Hospice care is proposed as terminal care in the 
very advanced stages extended to the bereavement care for the family after the patients’ 
death. 
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Figure 3: PD trajectory and Palliative Care involvement (Bunting-Perry 2006) 
 
 
The palliative stage of PDs is characterized for having the aim of relieving symptoms 
and distress in patients and carers, morbidity relief and maintenance of dignity and 
remaining functions despite the advanced disease. The role of a SPCS should be to 
provide advice on administration of medications, progressive dopaminergic withdrawal, 
analgesia, sedation, control of urinary symptoms, skin care and psychosocial care. The 
outcomes should be absence of distress, symptoms controlled and maintenance of 
dignity (Thomas and MacMahon 2004a).  
 
Patients may experience several episodes of physical and cognitive decline to the 
disease or co morbidity. In this stage the SPCS should take an active role. Advance 
directives, symptoms control and life prolonging strategies (e.g. PEG) should be 
discussed and put in act if patients and families wish. A further discussion should focus 
on the possibility of withholding or withdrawing treatment at the end of life (Bunting-
Perry 2006). 
 
In a survey in Oregon family caregivers of deceased  PDs and ALS/MND patients were 
asked about symptoms, treatment preferences, health care usage and psychosocial 
experiences during the last month of life. Authors conclude that, in the views of 
caregivers, suffering associated to ALS/MND is no more severe than suffering 
associated to PDs, and both groups have unmet palliative care needs in the last month of 
life. PDs patients had significantly shorter hospice care than ALS/MND patients (Goy, 
Carter and Ganzini 2008). 
At the author’s knowledge, to date, no evaluation of the impact of SPCS for PDs has 
been published. 
2.5.7 Neurodegenerative conditions summary 
 
In the previous chapters evidence from the published literature were reported describing 
the clinical and epidemiologic main characteristics of ALS/MND, MS and PDs , the 
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common illnesses trajectories, causes of death, main palliative care issues and, where 
existing, previous experiences of the involvement of specialist palliative care. 
In summary we can conclude that all these disorders share common features such as the 
relentless progression, the incurability, the high level of physical dependency in the 
advanced stages, the high prevalence of physical symptoms, the psychosocial and 
spiritual unmet issues. All these disease cause a significant reduction of the patients’ 
lifespan even though this is more evident for ALS/MND and for the atypical 
parkinsonian syndromes rather than in MS or PD. 
Little, no evidence exist about the impact of specialist palliative care on the common 
palliative care outcomes experienced by this population. 
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2.6 Patients’ needs at the end of life  
 
This section of the thesis follows the description of the neurodegenerative conditions 
and explore the concept of the human needs. The proposed pathway starts from a 
theoretical concept of human needs, translate it to the hospice setting exploring the 
needs of people in the advanced stages of life threatening conditions and then apply 
these concepts to the neurodegenerative conditions explored in this research. 
2.6.1 Maslow's concepts of the human needs 
 
Human needs have been  described in Maslow’s theory of human motivation (Maslow, 
A. H. 1943). He stated that human needs arrange themselves in hierarchies of pre-
potency. This is to say that the appearance of one need usually rests on the prior 
satisfaction of another, more pre-potent need. 
His theory is often represented in a pyramidal shape:  
 
 
 
 
 
 
Figure 4: Human needs adapted from (Maslow, A. H. 1943) 
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At the base of the pyramid the group of needs with the highest hierarchical position are 
placed:  
• Physiological needs are the most pre-potent of all needs. If these needs are not 
satisfied the organism is dominated by these, and all the others may become 
simply non-existent or be pushed into the backgrounds. 
• The safety needs follow in order of importance. They can however emerge when 
physiological needs are relatively satisfied. This group of needs seems related to 
the infancy and childhood where they are more pronounced and clearly 
expressed. The author describes this phenomenon justified for the fact that 
adults tend to inhibit reactions to potential threatens due to social habits, 
whereas children react in a total fashion if they feel they are endangered.  The 
need of protection is generally satisfied in well developed countries where 
citizens are no longer threatened by wild animals, extremes temperatures or 
assault and murder. 
• The love and belonging needs emerge when and if the 2 previous are relatively 
satisfied. People feel keenly, as never before, the absence of friends, or a loved 
one, a wife or children. In our society the thwarting of these needs is commonly 
at the base of maladjustments and more severe psychopathology. 
• The esteem needs is the desire for a stable, firmly based, high evaluation of 
themselves, for self-respect, or self-esteem and reflects the respect obtained from 
the others. Satisfaction of these needs leads to self-confidence, worth, strength, 
capability feeling of being useful to the world, but thwarting of these needs 
produce feelings of inferiority, weakness and helplessness. These can be the 
base for neurosis. 
• The self-actualization needs are on the top of the pyramid, meaning that can be 
achieved only if all the previous are at least partially satisfied.. When these 
needs are satisfied we may claim that a person is fully satisfied and realized. 
They rely on the specific individual vocation of each person. It can be 
exemplified by the sentence “ What a man can be, he must be”. A musician must 
write music, a poet must write, a painter must paint and so on. It is the tendency 
to become everything that one is capable of becoming (Maslow, A 1970). 
 
The relationship among these categories of needs is certainly hierarchical, but this does 
not mean that a basic need must be satisfied 100% to let the following need to come out. 
So most people have these needs satisfied in different proportions. The fundamental 
meaning of this approach, that will be discussed and applied in this thesis, is to describe 
the palliative care needs of participants, looking at the relationship between these  
unsatisfied needs and the priorities of people with advanced neurological disease. 
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2.6.2 Patient needs and the role of palliative care 
 
The hierarchical concept of needs proposed by Maslow has been widely used in 
business and social sciences, but it appears only sparsely in the palliative care literature. 
Zalensky and Raspa applied this model to the hospice and palliative care settings 
finding high similarity with the Cicely Saunders’s concept of “total pain” affecting 
physical, psychological, social and spiritual components of persons at the end of their 
lives (Clark 1999). 
 
 
 
 
 
Self-actualization: 
personal journey & growth in illness. 
Connection to “Other”, peace, transcendence, 
closure, generativity 
Esteem: 
Respect for past and present (infinite) value 
of the person 
Love & belonging: 
Love for patient is re-affirmed by 
family/caregivers despite illness 
Safety: 
Both physical and emotional 
Free of fears about death and dying 
(choking to death, pain etc.) 
Physiological: 
Biological needs, pain & symptom control, 
restoring ability to meet basic life needs 
(breathing, eating, toileting) 
Figure 5: Maslow’s hierarchy adapted to hospice and palliative care. The 
figure diagrams the dependence on lower needs; the apex of the pyramid 
suggests that higher needs are less frequently realized. 
Adapted from: (Zalenski and Raspa 2006) 
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This adaptation leads to imagine that if physical symptoms are not controlled, e.g. a 
person is in physical pain or experience severe breathlessness, probably emotional, 
spiritual and social issues will be a minor concern for him or her. But if impeccable 
symptom control has been  achieved, as suggested in  the WHO definition of palliative 
care (W.H.O. 2002), and probably even if this result is obtain in a lower extent than 
impeccable, other needs will emerge and are to be somehow fulfilled in order to reach 
the top of the pyramid where self-actualization is located. We know how the loss of 
many capabilities experienced by people severely affected by long term conditions can 
affect esteem and love and belongings too (Edmonds et al. 2007b, DH Longterm 
Conditions NSF 2005).  
It is however true that different needs can have different impact on one’s personal 
quality of life as it is shown in many published experiences (Chio et al. 2004a, Fegg et 
al. 2005, Kaub-Wittemer et al. 2003, Neudert, Wasner and Borasio 2004). Palliative 
care needs were explored in patients, lay carers, multi-professional palliative care 
providers and managerial skate holders in Northern Ireland and the main areas of needs 
identified were social and psychological support; financial concerns, needs for choice 
and information. Furthermore participants highlighted the inequity of provision of 
palliative care for patients with cancer and non cancer diseases.(McIlfatrick 2007) 
2.6.3 Palliative care needs and neurodegenerative disorders 
 
Palliative care needs (PCN) can be represented by the unsolved problems faced by 
people severely affected by advanced incurable diseases and by their families. This 
concept is strictly related to the definitions of palliative care (W.H.O. 2002), where 
describing what palliative care is the various needs are used to define the specific 
concept. PCN are listed as the components of the “total pain” (Richmond 2005) and 
included in the concept of palliative care outcomes, those outcomes that are to be 
obtained to improve the PCN(Higginson, I. J. 1997b). 
PCN can be classified in: 
• Patient needs 
o Physical: uncontrolled symptoms, physical limitations due to disability, 
need for special device to overcome movement limitations, 
communication impairment, tubes for artificial nutrition or hydration, 
aids to help breathing like non invasive ventilation, or invasive 
ventilation, etc.(Addington-Hall, J. et al. 1995, Addington-Hall, J. M. 
and Higginson 2001, Albert et al. 2001, Albert et al. 2009, Archibald et 
al. 1994, Borasio and Oliver 2006, Borgsteede et al. 2009, Chahine, 
Malik and Davis 2008, Colosimo and Pezzella 2002, Cornish and 
Mattison 2000, Kristjanson, Aoun and Oldham 2006, Kubler et al. 2005, 
Lee et al. 2007, Lisak 2001, Maloni 2000, Miller et al. 2009, Miller et al. 
1999, Mitsumoto et al. 2005, Moulin 1989, Moulin 1998, Rabkin et al. 
2005, Rehman 2000, Rehman 2001, Saleem, Leigh and Higginson 2007, 
MSCCPG 1998)  
o Psychological: emotional, anxiety and depression, coping with disease 
and losses, information and communication, abandon, fears (Bolmsjo 
2001, Boston, Towers and Barnard 2001). 
o Spiritual: the meaning of the diseases, relation with faith and spirituality, 
fear of the death and of the dying process, sense of guilt (Taylor and Herr 
2004, Lambert 2006). 
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o Social: isolation, economical concerns, loss of job, change in familiar 
and social roles (Adelman et al. 2004, Aoun and Kristjanson 2004, Chio 
et al. 2005, Clarke, D. M. et al. 2005, Gallagher, D. and Monroe 2006, 
Goldstein et al. 1998, Kaub-Wittemer et al. 2003, Love et al. 2005, 
Edmonds et al. 2007a, Hudson, Toye and Kristjanson 2006, Spliethoff-
Kamminga et al. 2003, Cotterell 2008) 
o Choices: place of care, place of death, advance care planning (Albert et 
al. 1999a, Albert et al. 1999b, Bolmsjo and Hermern 2003, Wollin, 
Yates and Kristjanson 2006, Cotterell 2008, McCluskey 2007) 
• Families needs 
o Support: practical help, education, financial and working adaptation, 
social network, the importance of family atmosphere, help for the 
children and other weak family components etc (Caap-Ahlgren and 
Dehlin 2002, Seymour et al. 2003). 
o Psychological: coping with losses and preparation for the death of the 
beloved, prevention of complicated-pathological bereavement and 
survival after the death of the patient (Dawson and Kristjanson 2003, 
Hughes et al. 2005, Oliver and Gallagher 1998). 
o Spiritual: similar to the patients’ ones. 
2.6.4  Summary of the patients’ needs 
 
In conclusion of this chapter on the palliative care needs faced by patients severely 
affected by neurodegenerative conditions and their caregivers, it results that a big 
amount of research was performed and published providing strong evidence about the 
presence of these unmet needs. 
All subgroups of needs categorised by Maslow’s approach adapted to palliative care, as 
well as Cicely Saunders’s components of total pain are represented in this population. 
SPCS aim at meeting the palliative unmet needs of their users, therefore when such 
services are to be evaluated the domains to be chosen for the assessment must come 
from these categories of human needs applied to the advanced stages of the diseases 
towards the end of life. 
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3. The Qualitative Needs Assessment 
3.1 Introduction 
 
After having reviewed the literature about the needs of people severely affected by 
neurodegenerative conditions a qualitative needs assessment of these needs, in patients 
and their informal carers living in Turin area, was performed. The point of view of the 
professional carers was also explored. 
 
This approach is part of the MRC framework (Campbell et al. 2000), as shown in 
Figure 3.1, as the modelling stage (phase 1) of the framework. This, in turn,  influences 
the theory (preclinical phase) and as well because it helps in the strategic design of the 
project  and can predict major confounders. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6:  the modelling phase, phase 1 of the MRC 
 
As previously shown in the literature review of the palliative care un-met needs of 
people severely affected by neurodegenerative conditions it is now evident that many 
physical, psychological, spiritual and social issues are not met by the available service 
for the care and the assistance of this population. These problems can be related to the 
pathophysiology and the evolution of the diseases (physical needs), emotional and 
relational aspects (psychological needs), transcendence, faith and meaning of the 
experience (spiritual needs), integration in the social network, quality of the received 
care (social needs). 
Most of the previously published research is specifically diagnosis related and provides 
information about different stages of the diseases. Outcomes measured by the rarer 
quantitative studies focus on specific variables like symptoms or social issues, but never 
on the full comprehensive of the load of various problems experienced by this 
heterogeneous group of  patients and their families. Recommendations from the 
published literature suggest that improving awareness of the needs of patients dying 
Needs assessment 
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from disorders other than cancer should lead to an increase in referrals to specialist 
palliative care services (Edmonds 2004) 
3.2 Aims of the qualitative study 
 
The purpose of this project was an accurate evaluation of these unmet needs in people 
severely affected by ALS/MND, MS, PD and related disorders living in Turin city and 
metropolitan area in order to model a new specific SPCS aimed at providing help for 
their needs. 
Specific aims were: 
• explore the lived experience of the diseases told by the directly 
involved protagonists 
• highlight the problems faced by patients and their families ordered 
and weighted by participants 
• analyze the coping strategies adopted 
• explore the level of satisfaction about the available services and the 
participants views about the new palliative care service 
• compare the congruence of the problems aroused in the interviews 
with the previous published experiences. 
• collect data from professionals directly involved in the care of these 
people, their impressions about the quality of the provided care and 
their point of view towards the forthcoming palliative care service 
 
For this reasons the need to proceed to an in-depth assessment of the potential future 
user of the service was felt as urgent. Surveys exploring these needs in sample of 
patients with the same diagnosis (Kristjanson, Aoun and Oldham 2006) revealed how in 
order to better satisfy the needs tailored service were required. The prevalence of 
physical problems has been published (Saleem, Leigh and Higginson 2007) and the 
unique and overlapping aspects of each of these disorders discussed with an emphasis 
upon the clinical management of symptoms. The authors concluded that effective end-
of-life palliative care depends upon an understanding of the clinical aspects of each of 
these disorders (Elman et al. 2007).  
 
The option to proceed with a survey using questionnaires was excluded because no 
specific tools validated for such an heterogeneous group of diseases was available (for 
both patients and carers) and, above all, because quantitative methods could not 
substitute the big amount of data that can be collected by meeting  face to face with so 
highly physically impaired participants and observing their living environment. The 
meeting with patients, families and professional carers to explore the experience of the 
disease and allowing them to rank their needs and the impact of the existing service 
allowed the development of the qualitative study. 
3.3 Methodology of the qualitative study 
 
The qualitative study (NeuNeeds: the unmet needs of people severely affected by 
neurodegenerative conditions) is composed by 2 parts: 
 
1) In depth, face to face interviews with patients (and their main carers, if available). 
a) Patients, specifically adults severely affected by either ALS/MND, MS, PD or 
related disorders, with mental capacity to give a consent permission to the study 
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participation, resident in the area covered by FARO domiciliary home care 
service (in order to be potentially involved in the future new SPCS). 
b) Their lay carers, usually a familiar, sometimes a paid carer. If the patient did not 
have any carer or preferred to be interviewed alone this was allowed.  
2) Focus groups with professionals (involved in their care). 
a) Professional carers directly involved in the patients’ care: usually neurologists, 
but also rehabilitation specialists, physiotherapist and speech and language 
therapists. Nurses and general practitioners were to be involved, but ultimately 
their focus groups did not take place for organizational problems. 
3.3.1 The in-depth interviews 
 
3.3.1.1 Methods 
 
Interviews were conducted at patients home, if possible, to enable participants to be in 
their own environment reducing the stress induced by being in an external setting. Other 
settings were accepted only if the patient had been admitted to the hospital or other 
facility and was keen to be interviewed in that location (it was not considered acceptable 
to ask participants so highly disabled to leave their house just to be interviewed). Two 
researchers led the interviews in order to both control the technical equipment and 
dedicate time and attention to the interviewees. Each interview was video and audio 
taped and field notes were taken. This was due to the high communication impairment 
of most of the patients. In the same video screen the pair formed by the patient and his 
or her main carer were filmed. Video recordings allowed to catch the non verbal 
expression of the severely compromised patients, sometimes their face mimic was the 
only sign to confirm or deny what was told by their carer.  
Participants were previously informed by the professional who made the referral 
(usually the neurologist or  rehabilitation specialist) about the aims of the research. 
Professionals were asked to identify patients and their main lay carer, usually a family 
member. Before the beginning of the interview the study protocol was provided to the 
participants and a consent form was delivered. As most patients were so disabled to be 
unable to sign the written form, a verbal or a clear consent was audio and video 
recorded. A specific informative form for the patients’ general practitioner was given to 
the family asking them to give it to their doctor at the first occasion. 
The in depth interview began with a brief summary of the research aims and participants 
were informed that this assessment was aimed to help the development of a new service 
that was not available at that time and that might or might not be offered to them 
(depending mostly on their will and in part on the future evolution of the research 
project). This was done not to create unreal illusions and, on the other hand, to avoid 
that participants felt forced to receive the forthcoming service. 
When the scene had been set up researchers asked the patients, if able to communicate 
verbally or using Augmentative Communication Aids (e.g. a voice amplifiers) or 
Alternative Communication Aids (alphabet and picture boards, computer keyboards or 
eye gaze computer systems) and the carer (if present) to describe their experience of 
disease speaking freely of the themes that they felt more important. Methodologically 
this possibility offers the advantage to receive information from both the patient and the 
carer, but also to see the interaction between them. It permits to see what happens when 
one participant talks about the problems lived by the other one (eg a carer describing the 
physical symptoms of the patient, or the patient talking about the burden of care 
experienced by his or her familiar). A limit can be that some issues will not be raised 
not to hurt their loved one and for this reason some carer added some piece of 
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information at the end of the interview talking with one researcher while the other was 
staying with the patient. Two patients e-mailed, after the interview extra comments that 
they could not say during the interview or that did not want to share with their carer. 
The researchers just hinted the main area of interest of the research: physical, 
psychological, spiritual and social aspects including comments on the service available 
and experienced. It was then reinforced the fact that it was up to them to cover all these 
aspects or just focus on one or two. Also the order in which they were to talk about their 
problems was free. 
Participants were informed that all data were going to be managed for research purpose 
only, that were going to be treated anonymously, and that the content of the interview 
was not communicated to their professional carers. 
Participants were informed that they could stop the interview at any time, if they felt 
this was too much a burden for them, and that could withdraw their consent to the use of 
the data even at the end of the interviews if they felt that the content could be not 
acceptable or not adequate. 
If some important piece of information about the care programme, serious physical 
uncontrolled symptom or therapeutic options emerged from the interviews the 
researchers offered to get in touch with the professional carers who referred the patient 
to inform them about these issues. 
 
3.3.1.2 Patients’ referrals 
 
Patients referrals were made by neurologists and other professionals involved in their 
care. Participants were identified from neurological ambulatories for the specific 
diseases in Molinette Hospital (Turin), neurological department, and in S. Luigi 
Gonzaga Hospital  (Orbassano). The former host an ALS/MND regional centre (a 
tertiary clinic), an MS ambulatory, and a PD clinic (regional centre for movement 
disorders and recruitment and selection for Deep Brain Stimulation). The latter host the 
regional MS centre, a general neurological ward and a respiratory unit where patients 
affected by respiratory impairment are referred for breathing problems. 
 
3.3.1.3 Inclusion criteria for the patients 
 
• Diagnosis of one of the following neurodegenerative conditions: 
• ALS/MND 
• MS  
• PD or atypical syndromes (Multi System Atrophy MSA, Progressive 
Supranuclear Palsy PSP). 
 
• State of severe advanced disease. Conditions were considered severe if: 
 
o They met the criteria of the specific clinical indicators of 
advanced disease presented in the Gold Standards Framework 
prognostic guidance for the specific diagnosis (Gold Standards 
Framework 2006) 
o The neurologists or other professionals directly involved in their 
care stated that they had serious palliative care needs (Higginson, 
I. 1997a,pag 220) or were presumed them to be in their last year 
or months of life. 
o Disability scales were considered only to help professionals to 
better understand the target of our population. For ALS/MND we 
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suggested to refer patients with ALSFSR-R ≤ 24(Cedarbaum et 
al. 1999), for MS EDSS ≥ 8,5 (Higginson, I. J. et al. 2006c)and 
for movement disorders a H&Y score ≥4(Bunting-Perry 2006). 
• Absence of a cognitive impairment at a level not permitting to give the consent 
to the interview and / or to let their opinion to came out during the interview. 
• Consent to the interview  
• Resident in the territory covered by FARO SPCS 
 
3.3.1.4 Exclusion criteria for the patients 
 
• Diagnosis other than those listed 
• Severe cognitive impairment 
• Unable to express their views even with communication aids 
• Unable to give consent 
•  Resident outside of the territory covered by FARO SPCS 
 
3.3.1.5 Sampling  
 
The first criteria for sampling was heterogeneity of the sample, which means that the 
three groups of different diagnosis (ALS/MND, MS and PD-related disorders) had to be 
represented. 
The second criteria was that different clinical conditions, but all in the advanced stages, 
were to be represented in the sample, so research team could collect data from a variety 
of different clinical conditions. 
The theoretical sampling  method (Coyne 1997)  was used - the sampling decision was 
based on the analysis of the data progressively acquired in the interviews and, therefore, 
is not established “a priori” but is developed in the course of a study. 
To achieve this result a first pool of 10 potential interviewees representative of all 
conditions and with different clinical features was selected. They were interviewed and 
data were collected and analyzed. Afterwards other interviews were added until 
saturation of the themes was achieved.  
3.3.2 The focus groups 
 
Focus groups were aimed at exploring the professionals’ point of view about the unmet 
needs of this population, their opinions about the existing services and suggestions for 
the SPCS in development. 
A secondary expected outcome was to see interaction among them and find out 
differences in opinions and strategies of care. 
Finally this was a chance to start the creation of a network with them foreseeing the 
importance of a future collaboration when their patients were to be referred to the 
service. 
 
3.3.2.1 Participants 
 
Participants were required to be professionals caring for patients with the characteristics 
listed for the interviews. It was planned to be a multi-professional and multidisciplinary 
recruitment. Professionals working in clinics specifically dedicated to the care of 
ALS/MND, MS, PD and related disorders as well as primary medicine doctors and 
nurses, were invited. 
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3.3.2.2 Methods  
 
Events were video and audio taped and fields notes were taken. 
Focus groups were to happen in professionals’ place of work in order to obtain a good 
participation and consent a relaxed environment. Two researchers were present during 
the events, again with the tasks of caring at the technical equipment, lead the groups and 
take the notes. 
 
Participants were asked to introduce themselves, their role and position in their job, 
their professional experience with patients severely affected by neurodegenerative 
conditions. Interviewers introduced the focus group presenting the research project, 
declaring the interest for the participants contribute and listing the main area of interest: 
physical, psychological, spiritual and social issues experienced by their patients, their 
professional opinion on how these patients were managed, their level of satisfaction 
about the offered care and suggestions about the development of the new SPCS. 
Rules for the event were previously stated by the researchers: participants had to 
provide a written consent to the participation (were provided with the study protocol 
and a consent form to be signed). No judgements or professionally inadequate 
comments were accepted. Professional secret was established on the content of the 
focus group. Data was to be used for scientific purpose only and treated anonymously. 
 
3.3.2.3 Sampling 
 
The same methodological approach adopted for the interviews was used. Professionals 
had to represent all the diagnostic categories listed in the patients’ inclusion criteria 
section. They also had to work in clinics or ambulatory specialized for the care of the 
selected diseases in one of  the two main hospital of Turin’s metropolitan area 
(Molinette hospital and San Luigi Gonzaga). Focus group were supposed to be 
multidisciplinary and involving professionals working in primary home care also. 
 
 
 
3.3.3 Data analysis 
 
After each event (interview or focus group) a transcript verbatim of the audio content 
was performed by the main researcher (S.V.). Video was used to add information about 
non verbal communication, to explore facial expressions of those patients with 
communication impairment and to identify the professionals who participated at the 
focus groups. Transcript verbatim was in the original Italian language and the events 
were not transcribed in English as suggested by Strauss and Corbin (Strauss and Corbin 
1998, p 285). Data extract from the text coded in the different categories were 
subsequently translated in English and are presented in the result section of the 
qualitative study of this thesis. 
The methodological approach adopted was a qualitative analysis of the data. The  
transcripts verbatim were read and re-read and significant themes drawn from the data 
(microanalysis) (Miles and Huberman 1994). 
Interviews and focus groups themes were coded independently by two researchers and 
then summarized in one document with the researchers’ agreement.  
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An open coding of these main themes was performed by the 2 researchers (S.V. and 
G.G.) on each interview transcript verbatim. 
Computer based software (Microsoft WORD and Microsoft Excel) were used to code 
the transcriptions. 
The analysis of the data was based on the content analysis (Mayring 2000, Mostyn 
1985). The methodology of the content analysis is described below: 
• First step: the results were grouped into 5 categories of needs: physical, 
psychological, social, spiritual and issues about services satisfaction. These 
categories had been previously obtained from the literature search and mirror the 
various components of the “total pain”, described by Dame Cicely Saunders 
(Clark 1999), (Clark 1999), and  also reflecting the adaptation of the human 
needs described by Maslow (Maslow, A. H. 1943) and adopted by  hospice care 
generally (Zalenski and Raspa 2006). 
• Second step: The main researcher (S.V.)  performed an axial coding (Strauss and 
Corbin 1998) of these preliminary needs in order to reduce the large number of 
emerging problems into the predetermined 5 categories. 
• Third step: a comparative analysis of the needs among the 22 interviews was 
made by calculating the prevalence of the different needs within the 5 different 
categories. This has enabled the themes to be quantified  (how many times a 
particular theme was mentioned by all participants during the same interview, or 
how many times particular needs arise from different interviews) (Strauss and 
Corbin 1998). 
• Inter-coder reliability (Mayring 2000, Strauss and Corbin 1998) was established 
involving a third independent researcher who did not participate at the 
interviews, nor at the focus groups. 
o The second and the third researchers (G.G. and C.R.) performed a further 
axial coding on 5 randomly chosen interviews and the results were 
matched with the original 5 interviews that were axial coded by the main 
researcher. A congruence of 50% of the overall axial codes was 
considered adequate. Tables with results of the coding process were 
made. Diagrams were drawn to show results, which were then matched 
by the main researcher (S.V.) in order to see the degree of concurrence.  
The content analysis of the results produced a quantification of the different needs 
which were reported by participants. These data were used to identify a number of 
domains to be assessed as trial outcomes in the following part of the project (see the 
explorative randomized trial in section). 
Apart from this procedure, which can reflect a quantitative attempt to evaluate 
qualitative data, a further analysis was conducted on the emerged themes: citations 
extracted by the transcript verbatim were used to better understand the qualities of the 
different reported needs. 
These could reflect: 
• The inner properties of the uncontrolled symptoms, (e.g. the intensity of pain or 
its characteristics, the effectiveness of therapeutic strategies, the adherence of 
participants to the prescriptions). 
•  The meaning of the psychosocial or spiritual issues (e.g. the individual impact 
of feeling abandoned or socially isolated, the coping strategies related to the 
disability, the impact of the care giving tasks on the carers’ personal quality of 
life, the relevance of the spiritual distress on participants) 
• The perception about of the available services (e.g. if the degree of satisfaction 
of the participants about the services was influenced by personal aspects such as 
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the attitude of the carers towards them, or depending by general organizational 
issues like the presence or the absence of needed services). 
The aim of this further analysis of the data was to understand the meaning of the 
various reported needs and then use the results to model the forthcoming service (e.g. 
by providing education to the personnel of the SPCS on specific aspects of the care that 
participants reported as lacking and important, or creating a network of professionals 
working in different settings aimed at providing a more effective and comprehensive 
set of services). 
3.4 Ethics 
 
The study was approved by the Ethics Committees (EC) of the two hospitals involved in 
patients recruitment. The approval documents were then mailed to the University of 
Kent Ethics Committee, as this study is  part of a PhD programme at this University. 
Participants’ consent was obtained in the forms described in the previous paragraphs: a 
written consent by the lay carers, professionals and by those patients able to sign. 
Verbal or non verbal assent for patients was acceptable for people who were unable to 
sign. 
Data were treated anonymously and conserved safely by the main researcher.  
Video and audio registrations were made only to better interpret the contents of the 
event and to create a precise transcript verbatim. 
In case of severe suffering during the interviews (both caused by the disease e.g. a 
physical symptom or induced by the interview itself, e.g. an emotional distress) 
researchers were bound to stop the interview and help the participant through 
professional intervention (researchers are physicians and nurses experienced in 
palliative care) offering a quick referral to their professional main carer (usually the 
ones who referred the patient for the study). 
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3.5 Results of the qualitative study 
3.5.1 Introduction 
 
In this section results of the Neuneeds qualitative assessment will be presented. Results 
will be divided in two different sections: 
• the interviews to patients and lay carers 
• the focus groups with professionals 
 
Data collection started on the 14th of May 2007 with the first interview and terminated 
on the 27th of August 2007 with the last focus group. 
3.5.2 The interviews to patients and lay carers 
 
3.5.2.1 Sample description 
 
22 in-depth interviews were conducted with people severely affected by ALS\MND, 
MS, PD and atypical syndromes (PDs). Informal carers were also interviewed with 
patients in order to better understand patients needs when affected by communication 
impairment and, also, to explore the needs affecting them as caregivers. 
Overall participants’ and informal carers’ characteristics are reported in tab 3.1 
 
 
interviews n=22 
Patient’s 
gender M=18 (82%) F=4 (18%) 
Patient’s 
age mean=61,5 range (39-80) 
 
Main carer Wife=16 Husband=3 Daughter=1 Mother=1 None=1 
Place of 
interviews home=20 hospital=1 Nursing home=1 
Paid carers n=13 (59%)  
Diagnosis ALS\MND n=9 MS n=7 PD n=5 MSA n=1 
Disability 
level 
ALSFRS-R*  
mean=11,3  
range= 3-23 
EDSS**    
mean=9  
range=8-9,5 
H&Y***    
mean=4,5 
range=4-5 
Tab 3.1: overall participants characteristics 
• ALSFRS-R (Cedarbaum et al. 1999) relates to ASL/MND 
•  **EDSS (Kurtzke 1983) relates to MS 
• ***H&Y (Hoehn and Yahr 1967) relates to PDs 
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 3.5.2.2 Description of disease specific groups 
 
Because of the different diagnostic subgroups a further description of the sample within 
the 3 selected diagnostic groups is provided. 
Subgroups were composed by ALS/MND patients, MS patients, and PDs patients. 
Within the ALS/MND subgroup 
• 5 patients were using non invasive ventilation (NIV), 3 of them for more than 
14 hours per day, one for about 8 hours per day and one for 2 hours per day.  
• 3 patients were tracheostomized and requiring or receiving invasive ventilation 
(IV) 24 hours per day 
• One patient was not using mechanical ventilation, even though it had been 
prescribed, because he could not tolerate the mask. This patient used low flow 
of oxygen during the night hours 
• 5 had to be fed by PEG 
• All interviews were conducted at patients home, all patients were cared for by a 
family carer and all but one had also one or more paid carers to help in the 
home assistance 
Within the MS sub group 
• 2 patient were in NIV during the night 
• 3 patients used aspirators for bronchial secretions and coughing machines for 
weak cough 
• 4 had to be fed by PEG 
• All interviews were conducted at patients home, all patients all but one were 
cared for by a family carer and 3 had one or more paid carers to help in the 
home assistance. 
Within the PDs group 
• None was using mechanical ventilation or other respiratory aids 
• One patient had a PEG that was used to vehicle continuous infusion of L-
DOPA 
• One patient was in Deep Brain Stimulation 
• Two patients were not interviewed in their home: one because was admitted in 
hospital for symptom control, one had recently been admitted in a nursing 
home for respite. 
• All patients were cared for by a family carer and one had also a paid carer 
 
The common features of the sample were that all patients had been defined as severely 
affected by their neurodegenerative condition, no curative option was possible and the 
level of disability was very high (Kollewe et al. 2008, Higginson, I. J. et al. 2006c, 
Thomas and MacMahon 2004a). For these reasons all were defined as being in a 
palliative stage. 
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3.5.2.3 Data analysis of the interviews 
 
3.5.2.3.1  Inter-rater reliability 
 
The inter-rater reliability analyzed matching the coding process of 5 (22.7%) events 
randomly chosen among the 22 interviews showed a good overlapping among the 3 
independent researchers involved in the analysis of the data. This was probably due to 
the clear exposition of the themes by the participants. 
In the tab 3.2 results of the inter-rater reliability test are presented. 
 
 
   
Analysed Domains Matching among the 3 reserchers (%) 
PHYSICAL  72 
PSYCOLOGICAL   54 
SOCIAL  72 
SPIRITUAL  87.5 
SERVICES  76.2 
Overall Matching 72.34 
 
Table 3.2: Inter-rater reliability test among the 3 researchers expressed in percentage of 
matching of coded domains 
 
 
 
 
An overall of 72.3 % of codes where coincident among the 3 independent researcher on 
5 randomly chosen interviews. This result means that matching the codes found out 
independently by the 3 involved researchers in the 5 randomly chosen interviews in 
72.3% they were coincident, meaning that the qualitative data had been categorised in 
the same code. 
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3.5.2.3.2 The content analysis of the physical needs 
 
A content analysis (Mostyn 1985, Mayring 2000) of the needs that emerged from the 
interview is now presented. 
In chart 3.1 the physical need that came out from the 22 interviews are shown: 
 
Physical Needs
18
10
18
21
9
14
4
10
13
16
22
14
10
13
0 5 10 15 20 25
Breathlessness and respiratory troubles
NIV - IV
Pain, spasms, cramps
Sw allow ing troubles, choking for food-saliva aspiration  and nutritional
issues
PEG
Speech impairment
Communicators
Drooling, dribbling, secretions, troubles w ith saliva.dry mouth
Urinary troubles
Bow el troubles
Movement impairment, tremors, falls, rigidity
Sleep disturbance, anxiety, depression, fears, agitation.
Bed sores and skin troubles
Fever, fatigue, visual loss and other symptoms
n= 22 (100%)
 
 
Chart 3.1: the physical needs 
6 participants talked about EoL decision to be influenced by physical issues 
NIV= Non Invasive Ventilation 
IV= Invasive Ventilation 
PEG= Percutaneous Endoscopic Gastrostomy 
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In table 3.3 the physical needs are reported in percentage also with further details. 
 
PHYSICAL NEEDS Quotes in the 22 interviews Percentage 
Breathlessness and respiratory 
troubles* 18 81.8% 
Pain, spasms, cramps 18 81.8% 
Swallowing troubles, choking for 
food-saliva aspiration  and 
nutritional issues** 
21 95.5% 
Speech impairment*** 14 63.6% 
Drooling, dribbling, secretions, 
troubles with saliva, dry mouth 10 45.4% 
Urinary troubles 13 59% 
Bowel troubles 16 72.7% 
Movement impairment, tremors, 
falls, rigidity 22 100% 
Sleep disturbance, anxiety, 
depression, fears, agitation. 14 63.6% 
Bed sores and skin troubles 10 45.5% 
Fever, fatigue, visual loss and 
other symptoms 13 59% 
*NIV= Non Invasive Ventilation \ IV= Invasive Ventilation or oxygen supply were 
used in 10 patients (45,4%) 
**PEG= Percutaneous Endoscopic Gastrostomy. 9 patients (40,9%) had a PEG placed 
*** Alphanumerical tables and\or Electronic Communicators were used by 4 patients 
(18%) 
table 3.3: the physical needs 
footnote: in 6 interviews participants talked about End of Life decision to be influenced 
by physical issues 
 
 
3.5.2.3.3 The physical needs detailed analysis 
 
In this section data used to create the various categories of needs emerged from the 
interviews will be shown 
 
Participants will be identified with the following categories:  
• Diagnostic groups: ALS, MS, PD 
• Participants’ role: P=patient, C=carer, I=interviewer 
• Numbers are used to identify participants 
Examples: 
• PPD2: in this case is a patient (first P), with a movement disorder (PD) and is 
the number 2 of the diagnostic group. 
• CALS5: carer (C) of an ALS patient, number 5 of his or her diagnostic group 
Age, and time from the diagnosis and further comments are also displayed when the 
information is available and useful for the purpose of the analysis. 
Not all the data is presented in this section, just those significant citations that led the 
investigators to the conclusions presented in the discussion section. 
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3.5.2.3.3.1  Movement impairment 
 
Movement impairments and related symptoms (rigidity, tremors and falls) were 
reported by all participants 22/22 (100%). 
As expected from the high degree of disability of the sample, in all interviews the 
impact of limitation in movements and the symptoms related to this impairment were 
discussed by patients and carers. It was often the first physical need reported by 
participants when prompted to talk about their suffering. 
 
Patients still able to walk underlined the difficulties met in reduced ambulation, 
fluctuation of symptoms and progression of the disability (Oliver and Borasio 2004, 
Clough and Blockley 2004, MacLeod 2004, Saleem, Leigh and Higginson 2007): 
 
PPD1(male, 80 years,  PD diagnosed 9 years ago and CPD1, his wife) 
I= how does he move at home?  
C= with a walking stick. We have a wheelchair to go out. We had a walker 
(walking aid) but we returned it because it wasn’t of help.(…) another problem 
is his muscular rigidity. (…) 
I= did he have muscular rigidity at the masticator muscles? P=I had, now it’s 
slightly improved. 
 
Movement impairment caused insecurity, loss of control and dependence (Edmonds et 
al. 2007b, Bunting-Perry 2006): 
 
PPD2 (male 70 years old, diagnosed 6 years ago, CPD2 his wife) 
P=I went close to an object that I wanted to grab and when I was at the right 
distance… I went through. (…) 
C=In the night he got up, lost his equilibrium and.. fell down 
P=(…) I feel I am blocked.  
C= his legs get blocked. 
P= once  I felt it happening. I felt like it advised me, then it happened but I was 
prepared for it.  
I= did you have enough time to swallow your rescue drug before you got 
blocked? 
P= yes, but the effect arrived later. Now it happens so quickly that I’m aware of 
it when things are already done. 
C= sometimes he stands and at once can’t walk. (…) and falls down. 
P= this is scaring. I fell several times. Last July I climbed those 3 steps of that 
stepladder and then I was abruptly blocked. I fell down. I had such a bad back 
pain! 
 
When the disability evolution is progressive linear falls and consequent complications 
can be seen as the trigger for physical dependence (Hammerbeck and Garret 2006): 
  
PALS3(male, 60, on a wheelchair, severely dyspnoeic, diagnosed 5 years ago, 
CALS3, his wife) 
C= in these 5 years he progressively lost the capability to walk. Before he 
needed a crutch, then 2 and now the wheelchair.  
P= yes, because 2 years ago I fell down and fractured a small bone of the pelvis. 
I had not to move for 90 days, but since then I stopped walking. 
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Sometimes disability can create different views within the family. Some carer can think 
that their loved one is responsible for not fighting against the disease, not collaborate 
with his therapists (Bolmsjo and Hermeren 2001, Sjostrom, Holmberg and Strang 
2002). 
 
PMSA1 (MALE 73, diagnosed 4 years ago. Bedridden, CMSA1 his wife and D 
his daughter) 
I= do you think he cannot walk because he lost his muscular strength or for 
other reasons? 
D= one component is that he didn’t want to collaborate with the 
physiotherapists. (….) we went to meet him, when he was admitted to the 
rehabilitation clinic, we invited him to go to the physio sessions, but he didn’t 
push his wheelchair. not because he couldn’t, because he did not want to. 
C= but our GP and our neurologist say this his not his fault, it’s due to the 
disease. 
 
And there are chronic situation where it seems that complications like falls have been 
accepted by patients and carers as normal occurrence in their life:  
 
PPD4 (Woman, age59 Diagnosed 33 years ago, in deep brain stimulation-DBS- 
since 1999, totally aphonic, CPD4 her husband) 
The patient talks about the good improvement obtained with the DBS, because 
before she was stuck in the wheel chair, dribbling saliva and dysarthric. She 
partially recovered in motor symptoms, but never recovered her voice nor the 
balance: 
P= (….), but I fall down. 
C= every day she falls down.  
P= but they advised me before the operation that I was going to fall. 
(…) 
P= now I don’t have objects falling from my hands anymore, as it happened 
before the operation…. Now I fall with objects in my hands! 
 
Immobility caused distress and required continuous presence of carers at the patient’s 
bed side, the burden of care increased with the functional impairment (Oliver 2004, 
Hecht et al. 2003) 
 
PALS1 (man, age 48 , bedridden, quadriplegic, totally aphonic, tracheostomized, 
CALS1 his wife) 
C= another physical trouble is that he wants to change his position or move 
from the bed to the wheelchair, but there’s not always someone available for it. 
 
Symptoms related to the movement impairment were also reported as very distressing: 
In some case the motor symptoms can cause physical pain (Lee et al. 2006c): 
 
PPD5 (woman in her 70es, diagnosed 18 years ago, wheelchair bound, many a 
finalistic movements, spasms and tremors, CPD5 her husband) 
C= tremors are bad because she suffers a lot, but she doesn’t risk to fall down 
being blocked. When she has movements she’s better because she can walk. But 
it’s more dangerous because of the risk to fall down.  
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Stiffness sometimes is not controlled even with innovative invasive strategies and can 
impact on the quality of care and on the burden of the carers (Higginson, I. J. et al. 
2006a, Ben-Zacharia and Lublin 2001): 
 
PMS7 (man aged 69, diagnosed 25 years ago. Wheelchair- bed  bound, 
anharthric, CMS7 his wife) 
C= we had  botulinum injections against stiffness. (…) It was 2004 and the 
neurologist suggested it. They did it in the inner part of the tights.  
I= were those the most rigid muscles? 
C= yes. Now if I want to bend his legs I have to call my son. I can’t do it by 
myself.  In the beginning it looked if it worked, I was able to open easily his legs. 
Neurologists said it was more helpful for me than for him, because it makes 
easier to wash him. We repeated it 3 times, after the doctor said it couldn’t be 
repeated anymore.  
 
 
Movement disorders can be very distressful for both patients and carers and cause 
confusion about the meaning of the experience. Drugs can be efficient but sometimes 
side effects force professionals to consider their withdrawal or the medication may lose 
its efficacy (Calne and Kumar 2003, Clough and Blockley 2004). 
 
PPD3 (man in his 70, diagnosed 27 years ago. Cognitive impairment, admitted 
in a nursing home for respite, CPD3 his wife) 
C= my husband had very awful crisis, where he started trembling and shaking, 
he had foam to his mouth… he looked as he was in his last minutes…he fell 
down frequently, hit his back, but luckily had never fractured his bones. This 
events lasted for about 20-30 minutes, than they passed without any intervention.  
(….) 
C= about 10 years ago they prescribed apomorphine injections. I injected it 
when he was blocked. He was taking his drugs around the clock and this one if 
needed. It worked well, but one day the neurologist told me to stop it because it 
could harm him. 
 
Rigidity or flaccidity can be present in the same patients in different times, depending 
by external factors or medical complications (Metz, Patten and McGowan 1999, Maloni 
2000, Lisak 2001) 
 
PMS3 (Male, age 46, blind because of MS, EDSS 9,5 quadriplegic, almost 
unable to speak. Fed by PEG, CMS3 his wife) 
C=(…) Usually he is very rigid and has clonus. But with the fever he was flaccid 
and soft.  
 
Subjective distress is caused also by dyskinesias due to the drugs needed to avoid the 
freezing phases(Clough and Blockley 2004, Chase, Engber and Mouradian 1994, Lee et 
al. 2007) 
 
PPD2 (male 70 years old. Diagnosed 6 years ago.) 
 I walk very badly. Once I walked better. My hip is aching.  
I don’t have many tremors. I’ve never had. I have these dyskinesias. It’s a 
continuous movement, I don’t have rest. But not tremors. (…) I can’t stop all my 
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limbs from moving continuously. I dance and can’t control it. It’s very hard to 
enter in the car. 
 
3.5.2.3.3.2  Dyspnoea and respiratory troubles 
 
These symptoms were reported in (81,2%) and were particularly prevalent in 
ALS\MND patients with respiratory impairment (Saleem, Leigh and Higginson 2007). 
 
 In the following comments it results, even  though NIV can improve these symptoms, 
this solution can cause other forms of distress and cannot arrest the progression of the 
symptom (Lyall and Gelinas 2006) 
 
PALS4 (male, 61, quadriplegic, diagnosed 3 years ago, on a wheelchair, 
cachectic, severely dyspnoeic in NIV) 
P= (I feel) great weakness in my legs, tiredness, I can’t climb the stairs 
anymore, and above all, shortness of breath ( he says this with a very low voice, 
sustaining his head with one arm..) 
C= breathlessness debilitated him a lot. He couldn’t walk because of it more 
than because of muscle impairment. (…) and this cause great fatigue (…) 
C= in the night he use NIV by mask. Now he also use it many hours during the 
day.  
P= the mask is a problem. 
C= it tears his skin. Now he’s got this pressure sore on his nose. It happened 15 
days ago.  
Now we have another mask… our lung specialist provided it. But this machine is 
very sensitive and the alarm starts each time air flows outside the mask. In the 
night you get crazy for it! 
 
 
Dyspnoea is present in  patients with diagnosis other than ALS/MND too, as shown in 
this example of shortness of breath episodes for this MS patient (Higginson, I. J. et al. 
2006a): 
 
PMS1 (Male 53 years old, diagnosed of MS 18 years ago, quadriplegic, using 
NIV in the night, CMS1 his wife): 
 P=I’ve got troubles with breathing. They started 3 years ago and I’m using a 
ventilator to sleep, since then”(...) “I had apnoeas. I spent 3 minutes without 
breathing.(…) I just couldn’t breath, I looked at my wife, but I could do 
nothing,(..) without breathing. (…) Now, with the mask I can sleep. Before I 
couldn’t sleep. I had many apnoeas and sudden awakenings. I had to get used to 
it, because it’s not comfortable to sleep with this mask: on summer it is worst, 
it’s hot and you sweat a lot; on winter it flows cold air. But at least now I can 
sleep. 
C= Before using the mask we had to run twice to the A&E in the night because 
he couldn’t breath 
 
And in movement disorders (Lee et al. 2007) as well as shown below 
 
PPD5 (woman in her 70s, diagnosed 18 years ago, wheelchair bound, many a 
finalistic movements, spasms and tremors, CPPD5 her husband). 
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P= this is a very bad disease, because when I’m feeling well… suddenly it starts 
shaking, trembling (she’s trembling while saying this) and it doesn’t stop. (….)… 
I feel something clenching my throat.  
I= do you mean shortness of breath? 
P= yes. 
 
 
Respiratory symptoms can be triggered by the frequent and recurrent respiratory tract 
infections. These events represent a frequent cause of death in neurodegenerative 
disorders and are among the criteria proposed to be admitted to hospice care (Clough 
and Blockley 2004, The-Gold-Standards-Framework 2008, Bronnum-Hansen, Koch-
Henriksen and Stenager 2004). The following experience about these issues is  reported: 
 
PMS3 (Male, age 46, blind because of MS, EDSS 9,5 quadriplegic, almost 
unable to speak. Fed by PEG, CMS3 his wife) 
C=In 2003 he had an aspiration pneumonia. Before that I had to spoon feed him 
because he couldn’t use his hands anymore. But then things went worst and he 
started choking when he had to swallow both solids or liquids.  One day he went 
in coma and was admitted to the hospital where diagnosed this aspiration 
pneumonia.  
Since then he’s fed by PEG. 
 
3.5.2.3.3.3  Pain 
 
Pain syndromes, painful muscular spasms or cramps appeared in 18 interviews (81,3%). 
Some participants reported pain syndromes spontaneously (Lee et al. 2006c, Thomas 
and MacMahon 2004b): 
 
PPD5 (woman in her 70es, diagnosed 18 years ago, wheelchair bound, 
experiencing dyskinesia, muscular spasms and tremors, CPD5 her husband) 
P= I have pain.(…) my goodness it’s so painful!  
C= yes, when she trembles so much (….) she doesn’t take any pain killer, when 
tremble stops she’s quickly better. 
 
Pain is a common sequel of complication of the disease, like fractures following falls 
(Lee et al. 2006c, Calne and Kumar 2003)  
 
PMSA1 (man, age73,diagnosed 4 years ago. Bedridden, unable to communicate) 
C= he has pain. His femur fracture was complicated. The orthopaedic surgeon 
said he was going to be in pain for all his life. He seemed to want d him to be in 
pain for a long time, as it would have meant a long survival. 
With tramadol he’s pain is relieved. Without it his legs are retracted and a long 
and hard string appears at the back of his thighs. We tried to leave him without 
the drug, but the pain and contractures reappeared 
 
Pain is not immediately recognised by the participants as a problem related to the 
disease. It take some time to think and report the symptom which is present even though 
often not directly caused by the neurodegenerative condition (Maloni 2000, Higginson, 
I. J. et al. 2006a): 
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PMS4 (woman, age 69, diagnosed 42 years ago. She lives alone, cared for by 
paid carers, spends alone most of the day and the night) 
P= I don’t have pain. No, what am I saying? I have leg pain, a lot. But I think 
they’re age related or due to rheumatisms or arthrosis (…) I don’t have cramps, 
but spasms and inexhaustible clonus at my right leg. 
 
In the following citation the first answer is negative about pain, then the patient quickly 
realise that she is experiencing pain, even though not directly caused by the disease, but 
by the immobility and the device used to be moved (Borasio and Oliver 2006) 
 
PALS7, (woman, age 60, diagnosed 12 years ago, quadriplegic) 
I= are you in pain? 
P= no, well yes, my shoulder, but it depends on positions. (…) I also have a 
chronic inflammation at this shoulder. Than it gets jammed in the slinging of the 
hoist. So using it 3-4 times a day… it hurts. 
 
 
Pain often was reported as skeletal or muscular and often not treated by physicians who 
fear complications (O'Brien, T. 1993b): 
 
PALS6 (male, 50, diagnosed 13 years ago, tracheostomized, bedridden – 
wheelchair, quadriplegic, aphonic. Communicates with a board giving short 
anwers) 
I= are you in pain 
P= yes, postural.  
I= what if you change position, does it improve? 
P= yes 
I= do you take pain killers? 
P= no 
C= I talked to the doctor, but he said no. 
P= cannabis? ….. 
I= does PHT help for postural pain? 
P= no. 
 
Pain can often have neuropathic features in MS (Maloni 2000, Metz, Patten and 
McGowan 1999) 
 
PMS3 (male 46 years old, blind because of MS, EDSS 9,5 quadriplegic, CMS3 
his wife) 
C= he has spasms and muscular clonus. He’s taking baclofen and dantrolene 
sodium. We put it in PEG. (…) if he doesn’t take it his stiffness increase a lot. 
C= in the night he wakes up and wants to be turned around, or asks me to 
stretch his limbs. 
C= he has pain. Above all trigeminal pain. He was successfully taking 
gabapentin, but now they changed it because he should pay for it (the drug is 
reimbursed by the Italian NHS for chronic pain caused by cancer only). So 
they’re giving him Carbamazepine, but doses are too low yet. 
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In movement disorders pain was seen as well 
 
PPD1 (male 80 years old PD diagnosed 9 years ago) 
C= he had spasms from the base of the neck to the face. They’re planning a 
MNR for it.  
P= it was very painful! 
 I= now is it gone? 
 P= yesterday evening again. But they’re doing intravenous infusion for it.  
C= and drops too. Alprazolam 12-15 drops, but after 4-5 hours it comes back 
again. 
 
3.5.2.3.3.4  Swallowing troubles 
 
Choking when taking food or liquids, saliva aspiration and nutritional issues were 
reported in 21/22 (95.5%) interviews. 9 patients were receiving feeding and hydration 
via a PEG. 
 
Swallowing troubles in general have a very bad impact on the carers, forcing them to 
spend a great deal of time with the patient and changing their habits in food preparation. 
Often episodes of food aspiration led to aspiration pneumonia with hospitalization. The 
presence of these problems has been identified as indicators for referral to palliative 
care (Brown and Sutton 2009)  
 
PMS3 (Male, age 46, blind, EDSS 9.5 quadriplegic, CMS3 his wife) 
C= we can’t leave him alone. Today is a good day for him, but often he has 
sudden worsening and requires constant attendance. For instance he can’t 
swallow saliva, so frequently he chokes and we have to aspirate his mouth (…) 
One day he went in coma and was admitted to the hospital where diagnosed this 
aspiration pneumonia.  
Since then he’s fed by PEG. 
 
Swallowing difficulties can worsen suddenly causing great concern and, eventually 
respiratory tract infections  
 
PMS7 (Male, 69, diagnosed 25 years ago. Wheelchair bound, anarthric) CSM3 
his wife. 
C=(…) swallowing troubles began. It was  years since he had these problems, 
but at that time he couldn’t swallow at all. He put food in his mouth and spit it 
out.(…) We waited until the spring of 2004 where he was even worst. He had an 
appointment in the nutrition clinic for the end of August, but I asked them to 
anticipate it otherwise he wasn’t going to survive so far. We had been informed 
about PEG for a long time. They admitted him to place it and during this 
hospitalization he got a Pseudomonas aeruginosa pneumonia with fever, 
secretions, breathlessness. We were persuaded that he wasn’t going to come 
back home. Well he came back with a PEG 
 
Increased salivation or swallowing difficulties can impact adversely on patient’s quality 
of life and cause important changes in other function too, such as communication, loss 
of pleasure in eating The fears and changes may lead to the discussion and acceptance 
of end of life decisions (Miller et al. 1999, Hardiman 2000, Heffernan et al. 2006) The 
decision to accept a tracheostomy is well described in the following citation: 
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PALS7 (woman, 60 years old, diagnosed 12 years ago, quadriplegic, dysharthric, 
dyspnoeic, NIV 24\24 by nasal mask that consent her to talk, CALS7 her 
husband) 
C= salivation is increasing. Salivation is increasing a lot. 
I= swallowing? 
P= as well.. in this period there’s an acceleration (…) 
I= what about feeding? 
P= I eat everything blended. Since two month I have to do like that. But it’s 
tiring, so I can’t eat as much as I’d like to. It starts a tachycardia and I feel 
shattered. So I introduced snacks but certainly I eat less than I used to. 
I= anyone told about PEG? 
C= a long time ago they talked us about it.  
P= let me say.. according to a medical indication I required a tracheostomy last 
year. But because I can speak they wanted me to decide about it trying to 
preserve my best quality of life.  Now I’m speaking badly and having troubles in 
feeding, so if they‘ll do PEG and Tracheo in one time… (…) but it’s a recent 
issue because until one month ago it was better. 
 
Another experience in a recently diagnosed ALS/MND patient whose relatives were 
struggling to realize the various losses that had developed over a few months.  
 
PALS9 (male, 77 diagnosed 8 months ago, DALS9, his daughter and CALS9 his 
wife) 
I= how long does he have the PEG? 
D= since March. They placed it because he lost a lot of weight, he didn’t eat 
anymore. 
C= now he eats very little. He eats something each meal, but very little.  
P= it’s due to a lack of appetite. 
I= doesn’t it go the wrong way? 
C= yes, swallowing is difficult. He’s having jelly water. Water goes the wrong 
way.  
P= jelly water also requires some time to be swallowed…. 
 
Movement disorders often cause troubles in swallowing as reported below by the 
elderly husband of this PD patient  (Saleem, Leigh and Higginson 2007) 
 
PPD5 (woman in her 70s, diagnosed 18 years ago, wheelchair bound, many a 
finalistic movements, spasms and tremor, CPD5 her  husband) 
C= swallowing is another trouble. I have to whirl everything I cook for her. But 
she complains that everything has the same flavour (…) she’s still eating by her 
self, but it happens that I have to spoon feed her. The bad aspect of this disease 
is that it changes quickly.  
 
 
3.5.2.3.3.5  Speech related problems 
 
Communication problems, with intensity from mild to severe with total impairment and 
loss of speech, were detected in 14/22 interviews. Four patients were using aids to 
communicate: 2 used alphanumerical boards read by the caregiver, one used both a 
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board and an electronical device and one a computer with electronic computerized 
software.  
 
The ALS tracheostomized patients had lost their capability to speak and all needed 
electronic devices to improve their communication. They reported this need as probably 
the most impacting their actual quality of life (QoL): 
 
PALS2 (male 39, tracheostomized, quadriplegic, diagnosed 14 years ago, totally 
aphonic and cognitively not impaired, and CALS2 his wife) 
C= a big discomfort is the impossibility to speak. We use this tab that we saw on 
the Discovery Channel. It’s quicker than the other communicators and 
electronic devices that we had the chance to use. The only device that really 
helps and works is MY TOBII package. But it cost 21.000 euros. 
Anyway, communication troubles are one of the worst aspects of this disease.  
 
In another experience of a patient in similar clinical conditions the wife clearly states 
that communication using alphanumerical tabs is difficult and the results affected by the 
ability of the carer to use it. This ultimately causes a restriction in social activity (Scott 
and McPhee 2006) because friends or other visitors cannot communicate with the 
patient if an educated carer is not present and help facilitate communication: 
 
PALS1 (male 48 years old, bedridden quadriplegic, totally aphonic, 
tracheostomized. He communicates using an alpha-numerical table, and CALS1 
his wife) 
C= (…) now we use this table. We learnt it because we had to. They told him to 
look at the letters and that we had to look where he was looking at.  We use this 
instead of other communicators because this is quicker. The paid carer and I 
were able to communicate quickly. If others come, we must act as an 
intermediate.  
 
 
In other groups of patients loss of speech develops more gradually but this always seem 
to led to a negative impact on relationships and QoL: 
 
PMSA1 (man, age 73, diagnosed 4 years ago. Bedridden and severely dysarthric, 
CMSA1 his wife) 
C= He lost his speech one month ago. Since then it is really difficult to 
communicate with him. Today he has fever and it is totally impossible to know 
how he feels. 
 
 
Few patients with mild- moderate communication impairment wanted to discuss their 
feelings about it and the connection with other losses 
 
PALS9 (male, 77 diagnosed 8 months ago) 
P= when friends come home to visit me I can’t use the mask because it prevents 
me from speaking. So I can’t speak and if I speak a little more than I get 
breathlessness.  
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Or 
 
PPD4 (Woman, age 59 Diagnosed 33 years ago. In deep brain stimulation since 
1999, totally aphonic had a good recover of motor functions, but no 
improvement of the voice that is barely perceivable), CPD4 her husband: 
C= she’s aphonic. That’s not due to her throat (…) it’s because of the brain 
damage.  
P= it’s a long a time ago since I’m like this. I tried speech and language therapy 
but… (it didn’t work at all) 
 C= there are periods, during the day, that her voice is a bit better and other 
that you can’t even hear it.  
 
 
3.5.2.3.3.6  Oral symptoms 
 
Mouth symptoms like dry mouth or drooling and issues related to difficulties in 
managing secretions were reported in 10/22 interviews. 
 
It was often referred as a disabling condition and participants were not very satisfied 
about the effectiveness of medications. Sometimes it was difficult to distinguish 
between drooling and the upper respiratory tracts secretions, but both had a bad impact 
on daily management of the patient: 
 
PALS8 (male in his 70, diagnosed 9 years ago wheelchair bound, totally 
anarthric, fed via PEG, cognitively not impaired, communicates via alpha 
numerical table) CALS8 his wife: 
C= he has drooling of saliva, but only during the day. It’s not a problem in the 
night. he’s taking amitriptyline, 10 drops in the morning and 2 in the evening. 
Usually he doesn’t have big amounts of saliva a part for when he laughs or 
when he has to use a lot his facial expressions.  
P= I have a bad sensation in my mouth, like thick secretions.  
 
This MS patient’s mother was very confused about the therapy and used an aggressive 
approach, like stimulating his vomit with the aspirator, to clear dribbling of saliva and 
respiratory secretion. During the interview one episode was caught on video and the 
patient looked as if he was really suffering during this procedure. They did not  appear 
to be well informed about the palliative remedies to tackle this symptom and her GP had 
not been helpful with the prescriptions: 
 
  
PMS5 (male, 49 years old, diagnosed 24 years ago. EDSS 9,5. patient unable to 
communicate) CMS5 his mother: 
C= he  has this bad drooling. I must stimulate his cough with the aspirator. Now 
he’s breathing well, but it’s not always like that. Often he has rattle with thick 
secretions. So I have to stimulate his cough and vomit. But after he feels better. 
He’s not taking drugs for drooling because there aren’t any. A neurologist 
suggested me atropine but my GP didn’t want to prescribe it because he thinks 
it’s dangerous for his heart . So he gave us an homeopathic preparation of this 
drug. 
(…..) I heard that this antidepressant (amitriptyline) can be useful for drooling, 
but how can you give an antidepressant to a person in his condition? 
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This carer instead followed the neurologist’s prescription, but decided to stop the drug 
because it did not provide the expected result (without asking the doctor for other drugs 
or change in dosage) 
 
PMS7 (Male, 69, diagnosed 25 years ago. Wheelchair bound, anarthric, 
cognitively slightly impaired) CMS7 his wife 
I= Is drooling a problem? 
C= yes, since a long time. I aspirate it. In 2005 the neurologist prescribed him 
amitriptyline. He took 5-7 drop twice a day but it wasn’t helpful, so we stopped 
it. 
 
Other patients reported unsatisfactory treatment of these symptoms and talked about the 
bad impact on their QoL due to the side effects of the drugs: 
 
 
PALS7, (woman 60 years old, diagnosed 12 years ago, quadriplegic, dysharthric, 
dyspnoeic, NIV 24\24 by nasal mask)  
P= (…) also salivation is increasing. Salivation is increasing a lot.(…) 
I= did you use drugs to dry secretions? 
P= yes, I took amitriptiline, but 2 drops were enough to asleep me for the whole 
afternoon. A neurologist suggested me to try with an antiparkinson drug 
(Bornaprina) that should work in low doses. I tried it for two days, but last night 
it caused me a bradycardia. So I stopped it. 
However all these drugs cause saliva to become more sticky. I heard about 
botulinum injections that reduce salivation for 3-4 months. But doctors don’t 
concur on it.  
Now we have the aspirator at home. 
 
This patient wanted to say these words using the alphanumerical table clearly trying to 
make humour about the symptom. His wife, who works and does not spend the day with 
him, is not keen on medication for the symptom, meanwhile the patient’s mother, who 
spends the day with the patient and has to aspirate him often, is of a different opinion. 
 
PALS2 (male 39, tracheostomized, quadriplegic, diagnosed 14 years ago, totally 
aphonic and cognitively not impaired) and CALS2 his wife: 
P= a big physical problem is that I dribble down like a slowcoach or a camel.  
C= they prescribed him amitriptyline but I’m not happy being antidepressant. 
He takes 5 drops a day and doesn’t work. 
This is a disagreement between us. I think that saliva is normal and it’s a side 
effect of the disease. He and his mother claim that it decreased with the drops. 
 
3.5.2.3.3.7  Urinary troubles 
 
13 patients out of 22 (59%) had some form of bladder dysfunction.  
Those could be both incontinence or storage impairment (MacLeod 2004). Devices such 
as incontinence pads, internal or external catheters were widely used. ALS patients tend 
to be less likely to suffer these  issues, but one patient reported this problem: 
 
Incontinence can be overcome using external catheters that are effective in males, even 
though not always well accepted. In the following   
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PMS1 (male, age 53, diagnosis of MS 18 years ago, quadriplegic, using NIV in 
the night, CMS1 his wife): 
P= I’ve been  using an external catheter since 3 years. My wife changes it for 
me. 
I= have you ever had retention problems? 
P= no!  
C= (..)He has bladder problems in storing urine. 
P= I use the catheter only during the day, in the night my wife puts me on a pad. 
 
Another MS patient has the opposite problem and his wife had to learn how to do 
extemporary catheterizations during the day. 
 
PMS2 (male, age 43, quadriplegic, can only move his neck, totally dependent in 
ADL), CMS2 his wife. 
C=He needs to be catheterised twice a day because he could not pass urine. I do 
that. In the morning before going to work and in the evening. Now he doesn’t 
urinate a lot since he has swallowing difficulties and drinks very little . 
 
In movement disorders urinary problems can be related to motor symptoms. In this case 
the patient focus his answer to the improvement experienced after prostatic surgery, but 
his wife highlights how when the patient is in freezing or when in the night he is out of 
the drug effect urinary problems appear.  
 
PPD2 (male, age 70, fluctuating motor symptoms with freezing episodes 
alternate to severe dyskinesias) CPD2 his wife 
I= do you have urinary problems? 
P= I was operated at my prostate and recovered well. Before I had to use a 
catheter for 5 months and was it terrible(…) now, if I can reach the toilet is quiet 
ok  if I can hit the centre of the loo (speaking respectfully!). 
C= when he is blocked he needs a container to urinate because he can not reach 
the toilet. No, he cannot do it when he is blocked. 
P= yes, and this is due to the neurological progression of this disease and the 
limitation of the drugs’ efficacy. Once I could do it, now it cost me a lot. 
 
Recurrent urinary tract infections affected some participants: 
 
PPD1 (male, age 80, cognitively slow but able to understand and severely 
disabled in his movements. During the interview was admitted in the 
neurological ward for symptom control) CPD1 his wife. 
C= he use incontinence pads in the night because of his incontinence. He’s been 
using it for two years.(…) during the day he wears the pads, but can control 
urine.  Sometimes he has urinary tract infections. We had to come to the hospital 
because he had urinary retention due to his prostate. 
I= does sometimes hurts when you have to urinate? 
P= yes, it does. 
C= this is one of the reasons why we are here in the ward. He was a bit blocked 
for his prostate. 
I= did they apply a catheter? 
C= yes, for 10 days. But it is not just the prostate, it is also due to his muscular 
blocks that prevents him from watering well, it is for his stiffness.  
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In this MS patient a complicated urinary tract infection nearly caused death. Fever made 
him unconscious or barely intelligible. His wife testifies how challenging was to obtain 
a diagnosis and a correct treatment after they had been told by the A&E of the local 
hospital that he was dying and nothing could be done. 
 
PMS3 (male, age 46, blind, quadriplegic, muscular spasticity, fed by PEG), 
CMS3 his wife. 
C= now he has a catheter life. Before I did 2 catheterization per day. But this 
caused infections in the urinary tract. Now we do periodic Uri analysis with 
cultures and our GP prescribes antibiotics. Some months ago he had a sepsis 
and almost died because of it. I never saw him so bad. (…) When he has fever 
it’s impossible to understand what he wants or says. We spent horrific days 
when he was in fever ad I called the emergency, they sent an ambulance and we 
arrived at the A&E. A doctor saw my husband and told me that he was dying, 
they could not do anything for him and that the hospital was not appropriate for 
him. I did not know what to do, where to go. We went back home and I called the 
GP begging him to come home and visit him. He came but then told me that if at 
the a patient so ill was not to stay at home so prescribed an immediate 
admission for the hospital, he called the ambulance and we were taken back to 
the A&E. as soon as we arrived the same doctor asked me what I was doing 
there again! They told they were not going to do any investigation or treatments 
and just put him in a dark room at the end of the ward. Luckily a nephew of mine 
is a physician working in a private clinic and he interested himself in our case.  
After 40 days we brought him to the private clinic. Fortunately there they found 
out that he had nephrolitiasis with perinephric abscess. They put a double J 
catheter in his ureter and placed the catheter life. 
 
3.5.2.3.3.8  Bowel troubles 
 
17 out of 22 (72.7%) patients reported intestinal problems. 
 
Constipation was the most frequent problem and it was present in all the diagnostic 
groups: 
 
PMS4( 71 years old woman diagnosis 42 years ago. Paraplegic, wheel chair 
bound, lives alone helped by paid carers) 
P = bowels… that’s a problem. Because I eat very little, I tend to swallow dry 
food, I don’t move and above all, I don’t have the chance to go to the toilet by 
myself…. Nurses have to do rectal explorations twice a week. That is scheduled 
on Monday and Thursday. The problem is when I feel a stimulus on Tuesday… I 
have to pay other people to help me.  
 
Constipation is a typical symptom in PD and often is complicated by the specific 
treatments. 
 
PPD5 (woman age 78, cared for by her husband -CPD5- at home) 
C = her bowel doesn’t work at all. She’s constipated. Now she taking Tamarine 
jam. It works quiet well, but not perfect. 
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Another situation, in this case is an ALS patient where intestinal symptoms are not 
correctly managed as suggested by the “stepped care approach to care” whereby patients 
receive dietary advice first, with oral laxatives prescribed later if necessary (Thomas 
and MacMahon 2004b)  
    
CALS5 is the wife of PALS5, a totally dependent gentleman wheelchair bound 
and severely dyspnoeic 
C= he’s styptic. We do enemas to him, the small ones… 2-3 per day. If a cork 
happens I have  to do 5. 
  
Another trouble is loss of control of the sphincters, above all in MS patients: 
 
PMS2 (male, age 43, quadriplegic, can only move his neck, totally dependent in 
ADL), CMS2 his wife. 
P= I use jellified water. (…) it’s very useful. It helps me for the bowel also. 
C= (…) but I have to help him manually to evacuate the bowels.  
 
Or 
 
CMS6 wife of PMS6 a 53 years old gentleman EDSS 9, fed by PEG, almost 
totally dependent in the ADL 
C= he has his pad on for the whole day. He lost his stimuli so he does everything 
in it. We have to change it in the night as well, we have to put the alarm clock. 
For instance last night I forgot to change it and when this morning the home 
assistants came to wash him he was soaked in the excrements.  
 
3.5.2.3.3.9  Sleep disturbance 
 
14\22 (64%) interviews highlighted how patients are disturbed during the night and this 
was usually be due to physical problems, anxiety, fears, depression, agitation or other 
psychiatric symptoms. 
 
Some referred that nights were disturbed for physical problems (Saleem, Leigh and 
Higginson 2007) 
 
PALS9 (male, age 77, diagnosed 8 months ago, in NIV, CALS9 his wife) 
I= do you sleep well? 
C= he wakes up 2-3 times per night to urinate. He needs a person who removes 
his mask and replace it afterwards, he can’t do it by himself.  
P= I take lorazepam to sleep. 
 
When very high disability limit almost any movement physical problems like gastro 
oesophageal reflux induced by enteral nutrition via PEG can impact on the quality of 
sleep  
 
PMS5 (male, 49 years old, diagnosed 24 years ago. EDSS 9,5, CMS5 his 
mother) 
C=in the night he has to sleep almost seated because of reflux. He had food in 
his mouth, it happened 2-3 times per week. 
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Sleep quality can be altered for the loss of control of the tongue and risk of suffocation 
(Borasio, Voltz and Miller 2001) 
  
PALS7, (woman 60 years old, diagnosed 12 years ago, quadriplegic, dysarthric, 
dyspnoeic, NIV 24 hours a day)  
P= when I’m in bed I feel like my tongue slipping behind and I fear about 
choking. For this reason I sleep in a semi seated position.  
 
Non motor symptoms can be mirrored by night disturbances in movement disorders 
(Chen, Trombetta and Fernandez 2008) 
 
PPD2 (male 70 years old. Diagnosed 6 years ago. 
C= since December 2006 his conditions are worst. He can’t sleep in the night. 
Drugs aren’t working anymore, even if they changed it(…)  
C= he arrived home from the hospital and couldn’t sleep anymore. They quit all 
his drugs because of glaucoma. He just didn’t sleep at all(…) he had 
hallucinations. 
P= yes, I saw things like a tank with a stick inside and it looked to me like a 
person. (…) or tiles that began to fly… 
 
 
Participants reported they couldn’t sleep well because of psychological sufferance and 
often sedative drugs had to be taken in order to allow them to have a proper rest (Oliver 
1998, Mitsumoto et al. 2005). 
 
PALS7, (woman 60 years old, diagnosed 12 years ago, quadriplegic, dysarthric, 
dyspnoeic, NIV 24/24)  
P= I use a benzodiazepine to control anxiety (alprazolam) and an 
antidepressant. (Elopram). It’s been some years ago since I started those drugs. 
I can’t say if they work or not. I’ve always been a positive person, but in times of 
troubles they are of help.  
 
 
And this can impact on their carers quality of sleep, particularly if the patient is 
tracheostomized requiring continuous attention even in the night hours (Mockford, 
Jenkinson and Fitzpatrick 2006). 
 
PALS6 ( male,age 50, diagnosed 13 years ago, tracheostomized, bedridden – 
wheelchair, quadriplegic, aphonic) 
C=  He takes his drops of anxiolytic to  sleeps. He has frequent awakenings, he 
doesn’t sleep continuously. He wakes up because he has to be aspirated and turn 
in the bed. Some night are quiet, others are not. I sleep in the double bed with 
him so I feel when he needs me 
I= so neither of you sleep. 
C= no. and it seems funny, but if I’m relaxed he doesn’t sleep, while when he’s 
calm I can’t sleep 
 
Even though the role of benzodiazepines and other hypnotic have been questioned in 
palliative care (Hirst and Sloan 2002) sometimes they can have a positive impact on 
patients and their families quality of sleep as shown by the following two citations 
 
Chapter 3. The Qualitative Needs Assessment 
 76 
 
PALS2 (male, age 39, tracheostomized, quadriplegic, diagnosed 14 years ago, 
totally aphonic) 
C= to sleep he needs 20-25 drops of lorazepam. Compared to the early years it’s 
better. Before it was a tragedy 
 
One patient refused to take drugs, even if he could take advantage from it, because he 
feared the impact of it on his conditions. 
 
PALS1 (male 48 years old, bedridden quadriplegic, totally aphonic, 
tracheostomized.) 
I= do you sleep well?  
C= well, not so well…  
I= do you take drugs to sleep?  
C= no, no. all these substances act on the nervous system…  
 
3.5.2.3.3.10  Skin troubles 
 
In almost half of the interviews (10/22, 45.5%) skin troubles were reported 
  
Bed sores in patients with very limited movements. Patients with movement disorders 
are subjected to these problems above all when they are admitted in hospital facilities 
where they are more exposed to medical complications (Clough and Blockley 2004): 
 
 
CPD3 is the wife of PPD3 a gentleman in his 70, diagnosed 27 years ago. 
Cognitive impairment, Wheelchair bound, living in a long term facility)  
C= last year he was admitted to a clinic and after few days the nurses told me 
that they had to leave him in bed because he was troublesome, always moving, 
too demanding. They said that he refused physiotherapy, that he didn’t want to 
leave the bed. So I asked the doctor and he told me he was taking a drug that our 
neurologist suspended months before because it blocked his legs. I said him to 
stop it, but he refused. So I took my husband back home.  
It caused him a bad pressure sore at his back. It has not healed yet. It was due to 
both the facts that they left him in bed and to the drug they gave him 
 
Skin irritation due to devices needed for reasons other than pressure. In the following 
case it was a device used to control incontinence to cause skin ulcerations 
 
PMS5 (male, 49 years old, diagnosed 24 years ago. EDSS 9,5. patient unable to 
communicate), CMS5 his mother 
C= he use the urocondom for incontinence. His carer changes it every morning. 
Unfortunately it sometimes cause pressure sores on his penis. 
 
In ALS/MND also skin problems can occur and again immobility and co morbidity are 
common cause. 
 
CALS8, wife of PALS8 (male in his 70, diagnosed 9 years ago wheelchair 
bound, totally anarthric) 
C= he has a mycosis under his armpits and this cause itching. He suffer of 
psoriasis too (…)  he had bedsores at his back. It was due to a diarrhoea 
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syndrome that he had on spring. I cured it with creams. Now I still put it because 
his skin remained very sensitive. 
 
Irritations and painful sores are commonly related to the use of the masks for non 
invasive ventilation as testified by many participants, here an example: 
 
PALS7 woman 60 years old, diagnosed 12 years ago, quadriplegic, dysharthric, 
dyspnoeic, NIV 24/24 by nasal mask 
I= any nasal problem? 
P= yes, I had pressure sores inside, but now the body adapted and it made a 
corn. I also had rhinitis problems and I couldn’t assuage it. So an 
otorhinolaryngologist came and gave me a local therapy. It worked for 1 year, 
but now it’s starting again, 
 
4.5.2.3.3.11  Other symptoms 
 
Other disturbing symptoms, such as fever, visual loss, fatigue, were reported as severe 
in 13/22 interviews (59%): 
 
Most frequent were recurrent fever  and visual loss: 
 
CPD4 is the husband of PPD5 (woman in her 70es, diagnosed 18 years ago, 
wheelchair bound, many a finalistic movements, spasms and tremors) 
C= fever is common with her. Not long ago she had fever. We went to the 
hospital and they diagnosed a bronchitis. She had 38.5°C. I didn’t understand 
why, but she was trembling the whole day. Then we measured her temperature 
and there it was.(…) She’s almost blind. One eye isn’t working at all, at the 
other she has a bad cataract.  
 
CMS6 if the wife of PMS6 (man 53, diagnosed 16 years ago wheelchair bound, 
moves with many difficulties his upper limbs) 
C= he’s almost completely blind because of MS. He can’t read nor watch TV. 
He likes music, so he puts on his I-pod. 
 
  
Visual problems can be side effects of the therapy as comes out in the following 
interview of a PD patient who had to be operated in emergency for an acute glaucoma 
due to L-Dopa. 
 
PPD2 (male 70 years old. Diagnosed 6 years ago), CPD2 his wife 
P= they had to operate my eye. They did an iridectomy old style. They said it 
wasn’t enough just change the crystalline lens.  
C= he was taking Madopar. On the evening of the 6th of December 2004 he 
began complaining of a headache. During the night it got worst and in the next 
morning his eye lost sight. 
I= do you remember which eye? 
P= the right one, my head felt like if it was blowing out. 
C= so we went to the hospital (…) and they treated him with laser but he was 
not recovering his sight. So they decided to admit him and gave us the diagnosis 
of acute glaucoma.  
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P= eye pressure was 70! (…) I read on the drug leaflet that Madopar could 
cause acute glaucoma, the worst of all 
 
3.5.2.3.3.12 End of life themes  
 
These issues arose in the interviews while participants were talking about physical 
symptoms, including comments: 
 
CALS1 is the wife of  PALS1 a gentleman 48 years old, bedridden quadriplegic, 
totally aphonic, tracheostomized) 
 C= he wasn’t eating anymore. He weighed 35 Kgs because he had swallowing 
problems so he wasn’t eating nor drinking enough. We went to the hospital 
because he was not breathing anymore. He was using NIV by mask, but he 
didn’t care about it. When doctor advised him that a PEG was needed he did not 
consent to it. He was determinate to end his life.   
But when the respiratory arrest occurred and we ran to the hospital, everything 
changed. He was admitted to the emergency department where he had his PEG 
and the tracheostomy. Since that moment a new life has started. 
 I= did you make that choice? 
 P= yes! 
 
PALS5 (male in his 70ies, quadriplegic, aphonic, on a wheelchair. he tries to 
communicate using a computer keyboard. Very slow. He is a retired doctor), 
CALS5 is his wife 
C= he’s firmly contrary to tracheostomy. He prepared a living will stating this. 
P= (writes) show them the will. (then, addressing to the interviewer who 
previously discussed the issue of withdrawing treatments) I agree with your 
position that withdrawing invasive ventilation is not euthanasia.  
 
CALS8 is the wife of PALS8 (man in his 70s, diagnosed 9 years ago wheelchair 
bound, totally anarthric, fed via PEG, cognitively not impaired, communicates 
via alpha numerical table) 
C= PEG was placed 3 years ago. (….) one day, it was Saturday, he had a 
persistent cough. He was already using a thickener for the water because he had 
problems with swallowing. (….) he refused to go to the hospital because he 
feared that they’ll put him a tracheostomy. (…) in the evening I was very scared 
because of the incoming night. We called our sons to convince him to go to the 
hospital but he didn’t consent to it. (…) 
 
PMS4 ( female, 69 years old, diagnosed 42 years ago. She lives alone, cared for 
by paid carers, spends alone most of the day and the night. EDSS =8 wheelchair 
bound) 
P=My respiratory tests were totally unsatisfactory, but I refused mechanical 
ventilators. I’ve had enough, I lived my life. 
 
3.5.2.3.3.13 Summary 
 
From the content analysis of the physical problems raised by the participants of the 
interviews eleven groups of symptoms were identified: Movement problems, 
breathlessness and respiratory troubles, pain, swallowing issues, speech related 
Chapter 3. The Qualitative Needs Assessment 
 79 
 
problems, oral symptoms,  urinary problems, bowel troubles, sleep disturbance, skin 
troubles and other symptoms. 
Although some symptoms were more present in specific conditions, like respiratory 
problems in ALS/MND or urinary troubles in MS, most of the reported physical 
problems were appeared across all the conditions. Symptoms were reported directly by 
the patients and sometimes by the carers. Physical issues accompanied the patients 
throughout all the course of the disease but were more intense and prevalent in the 
advanced stages. Physical problems were cause of reflections about end of life choices 
in some cases. 
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3.5.2.3.4 The content analysis of the psychological needs 
 
In chart 3.2 the content analysis of the psychological needs that emerged from the 
interviews are shown. Because psychological themes could be related to both patients 
and carers needs data are presented separately for the two typologies of participants: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chart 3.2: the psychological needs 
 
 
 In table 3.4 psychological needs are listed in figures and percentage 
 
PSYCHOLOGICAL NEEDS 
quotes in the 22 interviews 
Patients* 
(%) 
Caregivers** 
(%) 
feeling abandoned, confused, 
concerned for the future 
21 (95) 14 (67) 
mood instability, rage, fears,  
anxiety, depression 
22 (100) 3 (14) 
feeling overwhelmed, impotent, 
struggle for everything 
7 (32) 10 (48) 
coping and expectations 17 (77) 2 (10) 
shame, load,  dignity,  guilt, 
privacy 
13 (59) 3 (14) 
need of self independence and  
control 
10 (45) - 
family concerns, burden of care 4 (18) 10 (48) 
express need of psychological 
support 
3 (13) 6 (29) 
End of life, death and dying 9 (41) 3 (14) 
Table 3.4: the psychological needs 
Footnotes:  
*needs related to patients were expressed by patients for themselves or by caregivers on behalf 
of the patient when he or she was not able to communicate 
** % on caregivers were calculate on N=21 because one patient living alone did not have any 
caregiver participating at the interview 
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3.5.2.3.5 The psychological needs detailed analysis 
 
In this session data about the psychological issues that came out from the 22 interviews 
will be shown. Symbols and short forms are the same adopted for the physical needs. 
Quotes can be from patients or carers or both, but it will be specified who they are 
related to, in order to identify if the displayed need is a patients’ or carers’ need. 
 
3.5.2.3.5.1 Feeling abandoned, confused, concerned for the future 
 
This group of needs was very frequently reported by participants:  
In all interviews these themes appeared, sometimes directly from patients’ voice, in 
other occasions introduced by the carers and could be related to all participants. 
Usually there was a strong agreement between patients and carers about these needs. In 
the next citation both participants at the same interviews talked about feeling abandoned 
by friends and relatives: 
 
PMS1 (Male 53 years old, diagnose of MS 18 years ago, quadriplegic, using 
NIV in the night, CMS1 his wife) 
P=“we would need a magic wand!”  
I= why do you say so? 
 P= “ to solve everything! Because we are abandoned. 
C=The disease takes away people, relatives and friends. It’s also our fault. We 
create barriers. Maybe we have too many expectations on them.  
 
Indifference and isolation are used as synonymous and relate to the sense of 
abandonment that is the opposite of the need of love and belongings described by 
Maslow (Maslow, A 1970) 
 
PMS2 ( male, age 43, EDSS 9, quadriplegic) CMS2 his wife 
 P= mine is one of those cases where people say: “ If you need a hand call me” 
but they think “ if you don’t call it’s better. And if you call, well do it only once.” 
C= yes, there’s a lot of indifference.  
I= do you feel like a sense of isolation, void? 
C= yes, but you learn to let it slide over.   
P= you don’t have to think about it, because if you do it… 
 
Loss of friends is seen by participants as an example of abandonment. Those persons 
who used to have plenty of friends and visitors try to explain the reasons for this loss. In 
the following example the carer talked on behalf of the patient who couldn’t speak, but 
clearly agreed with his wife position: 
 
PALS1 (man, 48 years old, bedridden, quadriplegic, totally aphonic, 
tracheostomized.  Fully aware of his situation. He communicates using an alpha-
numerical table).Caregiver CALS1, his wife. 
C= we are isolated. We lost many friends. He used to have so many friends and 
people who came to see him. But that is because he was a town councillor and 
they needed him. Since he’s ill they disappeared. Few of them helped us when he 
was in the hospital, but when we came home they vanished.  We looked for them, 
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but the plea is always the same: “ we can’t see him like this” or “we are too 
sorry for him”. 
 
The same carer continues complaining about the fact that because they seem copying 
very well with the disability and the organization of care, friends, professionals, social 
assistants abandoned them thinking that they do not have unmet needs. 
 
C= I want to underline that you see us like this (e.g. well organized) for a series 
of lucky circumstances. That’s because he devoted himself. He didn’t lose his 
heart. (…) But you have to know that it’s not easy at all to live in our condition, 
this situation is slightly heavy to carry on.  
But this, somehow, plays against our interests. You see people think that as long 
as we are well organized and independent we don’t have needs. They tend to 
leave us in a corner. But you can’t always wait until last minute to obtain what 
you need. Help is needed when it’s useful, not when nothing can be done 
anymore.  
 
This MND/ALS patients’ wife describe the frustration felt because friends got lost due 
to the communication impairment, and how in a first stage it was the patient who turned 
away his visitors because he felt ashamed of his condition 
 
PALS2 (male 39, tracheostomized, quadriplegic, diagnosed 14 years ago, totally 
aphonic and cognitively not impaired) and his caregiver (wife) CALS2. The 
patient communicates through an alphanumerical table with his wife and mother, 
the only family component able to use it. 
C= the problem with the use of the tab to communicate are outsiders. Hardly 
people coming here want to try. Maybe friend are worried to mistake. You 
exhort them, but they don’t want. At the end you isolate yourself because people 
comes once and don’t comes back because feel embarrassed(…) 
C= friends are very few. 
P= you can count them on the tips of one’s fingers. 
C= we are isolated.  
I= aren’t you a cause of it? 
C= not now. In early years yes, because he was ashamed of his condition. 
 
Another example of abandonment from friends and families as well 
 
PMS6 ( male 53, diagnosed 16 years ago wheelchair bound, moves with many 
difficulties his upper limbs, drinks using a feeding bottle. He is cognitively not 
impaired, but he looks like if he were living in a dream) and his wife CMS6 
C= we are isolated. Many of the things we used to do before we had to leave it. 
We went out with friends, we had to renounce to it. Friends and relatives don’t 
come to visit him. I think it’s because of his drooling, or because he lost his 
urine from the catheter… it can be disgusting (…) 
C= even with his family we had problems. His mother didn’t want to come here 
and spend sometime with him. They put him aside. They do many things for his 
sister who’s healthy and has got a child, but nothing for him. 
 
 
Participants felt abandoned by the professional carers as well. Following some example 
of these experiences are displayed. 
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CMS3, wife of PMS3 (Male 46 years old, blind because of MS, EDSS 9.5 
quadriplegic, almost unable to speak. Fed by PEG). She is talking about their 
experience with the GP who did not want to help them at home and rejected the 
patient after he was discharged from the hospital: 
C= (..) I called his GP.I was really angry. He answered me:- There’s nothing I 
can do. It’s not useful that I come and visit him. He’s just coming from the 
hospital, if they weren’t able do something for him there…- (and added) - It’s up 
to you to convince yourself that your husband conditions are very serious. You 
can’t keep him at home. You have to take him in a place, you can’t manage him 
a home.- This is what they told in hospital too, but I wasn’t convinced.  
(…) 
C= (after her GP rejected them as patients): Goodness me! What if we won’t find 
another family doctor! I came home really disconsolate.(…) one thing is being 
helped by supportive persons, another is being alone and feeling abandoned. 
(…) when you’re left alone sometimes you can’t be rational and objective 
enough to manage him. 
 
In this case the wife of this PD patient in really bad conditions admitted in a nursing 
home for respite care complains about the neurologist behaviour 
 
PPD3 (male in his 70, diagnosed 27 years ago. Cognitive impairment. Patient 
able to consent to the interview, but participate very little. Continuously shaking 
his limbs and constantly moaning. Sometimes he cries. Wheelchair bound.) and 
his wife caregiver, CPD3. the patient is staying in a nursing home 
C= I’m really angry with the neurologist that has always cared for him. I 
expected him to come here and visit him because he had always followed his 
situation, so once (…) he should have come to see how he is going on. (..) If you 
need an help there is no-one available!  
 
Another cause of abandon can be the disease itself. This MS patient reports what 
happened to her marriage after the diagnosis 
 
PMS4 (woman , 69 years old, diagnosed 42 years ago. She lives alone, cared for 
by paid carers, spends alone most of the day and the night. Wheelchair bound, 
she can move, with plenty of difficulties, her right hand. Left hemiplegic, left 
amaurosis ) 
 P= 10 years after diagnosis and 15 after our wedding my husband left me. We 
had a 14 years old son. He left me alone with  my mother saying that he didn’t 
want to be my nurse anymore. Later we divorced.  
 
Carers can fear to abandon their loved ones even when a respite admission has been 
carefully planned. This carer describes her feelings when she had to leave the patient  in 
a specialized facility for rehabilitation and respite 
 
PMS7 (Male, age 73, diagnosed 25 years ago. Wheelchair bound, anarthric, 
cognitively slightly impaired) CMS 7 his wife. 
 
C= the second respite care admission at Piancavallo was the most difficult. We 
came back home earlier than planned because I couldn’t leave him there alone 
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(…) he wasn’t able to speak, to move and on that time he was losing his hearing. 
He was isolated, how could I leave him alone? 
 
 
Another cause of suffering is confusion about what is happening that is related to the 
difficulties to cope with the disease and concern for the future. This makes carers and 
patients life very hard to organize.   
 
PMS2, (man, 43 years old, married, with a 10 years old daughter, quadriplegic) 
and CMS2 his wife. 
C= when we had the diagnosis we were 8 months far from our wedding. We 
were confused, we didn’t know what to expect from it (the disease). Personally 
I’ve never thought to abandon him. There was love (and there’s still), so  we 
went on.  
 
Confusion can be generated by the therapeutic options as well. Sometimes advance 
directives (not legally binding in Italy) are not adhered to and this can be a cause of 
confusion and regret 
 
PMS5 (man, 49 years old, diagnosed 24 years ago, unable to communicate, 
legally unable to make decisions his mother is his legal guardian. The patient 
seems favourable to the interview. Wheelchair bound, fed by PEG, several gags 
for his dribbling.) CMS5 is his mother. 
C= when he was admitted for high fever and choking, they suspected an 
aspiration pneumonia, we had a visit from a psychologist. They came to obtain 
is consent to do the PEG.  
I= was he contrary to that? 
C= yes, definitely! We ask the neurologist If this was to be considered 
therapeutic heroism (overtreatment) and he said no. He added that PEG would 
have prolonged his life of 2-3 years (….) but he was firmly contrary. At that time 
he had moderate  speech impairment, but he could express himself very well. But 
at once, one of the doctors came and told me: “ Mrs X this is not good. Even if 
he’s contrary we have to do it. We need his consent because he can’t go on like 
that. He must do it. So they convinced him that after PEG he could continue to 
eat normally. But that was false! Nothing, he can’t even swallow a sip of water.  
Now 4 years have passed! 
 
Confusion and abandonment can lead to fear for the future. In the next citations 
examples of these feelings are reported. 
After being discharged from the A&E because the doctors said her husband was dying 
and that was not the right place of care for him and after being rejected by their GP who 
was not keen on caring for such a problematic patient, his wife says: 
 
CMS3, wife of PMS3 
C= obviously now, anytime something wrong happens to his health conditions to 
me is a nightmare! What if I should call the emergency again? I take him back to 
the A&E and the doctor will tell me again: - are you here again?- well, I start 
thinking a little and say: - I don’t know-. 
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Fear of bad symptoms can lead to fear for the future 
  
Patient PPD2 (male 70 years old. Diagnosed 6 years ago.)  
P= I have the psychosis and the fear of swallowing problems. I am aware that 
this will happen and I’ll have to suffer also for this problem. 
 
When patients are dependent on life sustaining devices like mechanical ventilators 
patients can dread technical failure and this can have a bad impact on their quality of 
life 
PALS3( male, age 60, on a wheelchair, severely dyspnoeic, diagnosed 5 years 
ago. In NIV at home) and his wife CALS3. 
P= I fear that the ventilator could break, maybe in the night. I’m terrified. Or 
between Saturday and Sunday… 
(…) 
P= I’m really worried about the future.. I think at tomorrow, how it will finish.  
C= lately yes, very much. He wasn’t like this. After diagnosis I was really bad 
and he helped me with that. But now, as he realize that his strength is 
decreasing, he is really suffering on that side. 
 
3.5.2.3.5.2 Mood instability, rage, fears, anxiety and depression 
 
Issues related to these domains were present in all interviews and generally related to 
patients. Only three carers reported these problems related to themselves.  
 
The most frequently reported theme was patients’ mood instability usually detected and 
reported by the carer.  
 
CMS1 is the wife of PMS1 (man 53 years old, MS diagnosed 18 years ago) 
C=His mood changes daily. It depends on the day. 
 
Emotional incontinence is another form of mood instability as well described by this 
pair 
 
PPD2 (male 70 years old. Diagnosed 6 years ago). His wife CPD2. 
C= he’ very emotional. 
P= yes, but there are moments in life where it’s easier to control emotions… 
 
Carers as well reported difficulties related to their mood due to their role of caregiver of 
a very disabled patient 
 
PMS7 (Male, age 73, diagnosed 25 years ago. Wheelchair bound, anarthric, 
cognitively slightly impaired) CMS 7 his wife. 
C= (..) I should go to a psychologist to understand the way I am. (….) I realize 
that I have strange reactions like laughing or crying, that are odd for an 
equilibrate person as I am. I’m aware I’m in troubles. 
 
Rage is another emotion who came out from the interviews. Again it could be directly 
reported by the patients 
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PALS3( male, age 60, on a wheelchair, severely dyspnoeic, diagnosed 5 years 
ago. In NIV at home) and his wife CALS3. 
C= but the neurologist told you that there are many new experimentations..  
P= come on, how long will they take! Look at me now, look at the way I am 
now! I can’t stay all this time here, set on the chair, with nothing to do. I can’t 
concentrate on the things I can do. If I have to use tools such a computer, I don’t 
have patience. After 2-3 minutes I quit. What’s the meaning in living like this? 
 
Suggested by the carer when talking about the patient 
 
CMS3 is the wife of PMS3 (male 46 years old, blind because of MS, 
quadriplegic, almost unable to speak. Fed by PEG) 
C=after two car accidents due to his visual loss he had his drive licence 
suspended and had quit driving, he couldn’t go to work and began shutting 
himself up in his grief and rage. 
 
Rage was also described as the result of unsatisfactory relationships with health 
professionals supposed to care for their beloved ones. 
 
CPD3= I’m really angry with the neurologist that has always cared for him. I 
expected him to come here and visit him because he had always followed his 
situation, so at least once (…) he should have come to see how he is going on.  
 
CMS3= (..) I called his GP.I was really angry. He answered me:- There’s 
nothing I can do. It’s not useful that I come and visit him. He’s just coming from 
the hospital, if they weren’t able do something for him there… 
 
Another expression of psychological suffering were fears. 
 
Patients and carers talked about their fears of the disease and its consequences  
 
PALS7(woman 60 years old, diagnosed 12 years ago, in NIV 24 hours a day and 
considering about the PEG and the tracheostomy)  
 P= mine is a very long story, 12 years. I’m a long lasting, am I not? But talking 
about this there’s a scaring aspect: slow is the disease, slow is the agony. 
Everything is longer. 
(…)what scares me more is the slowness of the agony. I’m afraid of the day 
where I won’t be able to talk and I won’t be able to open my eyes. That’s 
scaring. Because you feel you don’t have any chance to do something. (…) I 
know of a woman from Brindisi that couldn’t shut her eyes. Her husband closed 
them for her using patches for the night and in the morning he removed it. Poor 
lady! 
 
PPD2 (male 70 years old. Diagnosed 6 years ago.) his wife CPD2. 
P= I’m very scared. I’m always terrified to fall. 
 
CALS8 is the wife of PALS8 (male in his 70, diagnosed 9 years ago wheelchair 
bound, totally anarthric, fed via PEG, cognitively not impaired, communicates 
via alpha numerical table) 
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C=we both participated to the informative meetings held by the ALS group. They 
were interesting, but the session where the neurologist spoke of the disease was 
terrifying for us. The world collapsed on us. We arrived home… if I think at that 
I still cry… 
 
And other causes of fears were uncertainty about the future and death and dying 
 
PALS3( male, age 60, on a wheelchair, severely dyspnoeic, diagnosed 5 years 
ago. In NIV at home) and his wife CALS3. 
P= I fear that the ventilator could break, maybe in the night. I’m terrified. Or 
between Saturday and Sunday… 
 
PALS5 (male in his 70ies, quadriplegic, aphonic, on a wheelchair.) his wife 
caregiver CALS5. 
C= he has so many fears… he fears to die. 
 
Anxiety and depression were explicitly mentioned in some interviews.  
 
This happened when discussing about therapies or when participants were asked about 
psychological problems 
 
PPD1, (male 80 years old PD diagnosed 9 years ago) and his wife CPD1 
C= Often he cries and is sad. A neurologist prescribed him Elopram, but now 
they stopped it. Anyway, sometimes his mood is very low.  
C= he has moments where he’s anxious. He wasn’t so before this disease. Now 
he’s in therapy with Alprazolam for insomnia, but…  
 
PMS6 (male 53, diagnosed 16 years ago, wheelchair bound) and his wife CMS6.  
C= he was depressed. He’s in treatment with seropram. He doesn’t speak a lot 
about the disease. I try to stimulate him, I scold him because he let himself go. 
He acts like if he said: ”I’m ill and that’s it!” I don’t like it. Other patients are 
more reactive than he is.    
 
 
 
3.5.2.3.5.3 Feeling overwhelmed, impotent, struggle for everything  
 
These needs emerged from numerous interviews and were equally distributed between 
patient and carers.  
 
Participants described their sense of impotence regarding the evolution of the disease, 
their feeling of being spectators of the disease without having any chance to modify the 
impact of the disability on them. 
 
PMS4( 71 years old woman diagnosis 42 years ago. Paraplegic, wheel chair 
bound, lives alone helped by paid carers) 
P= I don’t want to do nothing! No more therapies. I refuse it because if you say 
I don’t do nothing and then you accept… when you see that they don’t work… 
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it’s a terrible disappointment. And delusion kills. This is the MS reality. Don’t 
hope, accept it. 
 
PMS2 (male, age 43, quadriplegic, can only move his neck, totally dependent in 
ADL) 
P= when you have to go in a one way street.. you can’t turn or do a U-turn. 
(looking at his wife) you must accept it. (…)if my nose is itchy I need someone to 
scratch it. 
 
Impotence can be experienced when patients’ physical troubles impede the normal daily 
activities, by affecting those skills that patients were used to have and that suddenly 
become overwhelming.   
 
PPD2 (male 70 years old. Diagnosed 6 years ago) his wife CPD2 
P=Once I was queuing in my GP’s ambulatory and there was another patient 
waiting. He was older than me, but I was rigid as… my legs were chained. The 
sensation is awful, like having lead blocks at your feet and you can’t raise them 
from the floor. As if they were stuck. 
  
Impotence is also when carers cannot help patients because they are not able to 
understand what is happening  
 
CMS3 is the wife of PMS3 (male 46 years old, blind because of MS, 
quadriplegic, almost unable to speak. Fed by PEG) 
C= he had fever, I tried to talk to him, but it was not possible. When he’s like 
that it’s absolutely impossible to communicate. This is another terrible aspect, 
it’s devastating because he tries to speak, but it’s impossible to understand  what 
he means. So you stay there and don’t know what to do. 
 
There is also the fear of being overwhelmed by the experience of the disease and 
become unable to control emotions 
 
CMS1 is the wife of PMS1 (man 53 years old, MS diagnosed 18 years ago) 
I= what about a psychological help? 
C= I don’t know….. I’m concerned that emotions would overwhelm me 
 
Struggle for everything was denounced by carers and, although in less number, patients 
talked about the difficulties related to having to fight to obtain help and consideration 
from others. 
 
This could be related to other family members as described by the wife of this MS 
patient:  
 
CMS1 is the wife of PMS1 (man 53 years old, MS diagnosed 18 years ago) 
Anything you need you have to ask and ask and ask… 
(…)Relatives are like new shoes, after a while they hurt, they are tight. However 
you always have to ask, they don’t see your needs. Once I had to do a hole in the 
wall. They knew it but no one offered to do it. They were expecting me to ask 
them for it. When I argued they said: - why didn’t you ask?-. they should be 
more sensitive about our needs. 
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Others described how difficulties came from professionals, both health and social 
workers. In the following citations carers complain about the social assistants who are 
accused not to be of help when asked to provide help, causing them to struggle to obtain 
economic support or technical devices 
 
CALS1 is the wife of PALS1 a man 48 years old, bedridden quadriplegic, totally 
aphonic, tracheostomized.. He communicates using an alpha-numerical table. 
He’s waiting an electronic communicator (MyTobii) that will allow him to have 
a voice decoder, e-mail access. This device is very expensive but could have a 
dramatically positive impact on his QoL   
C= to obtain what we now have got, we had to pester the life out of them. Ask 
and ask and ask. And the strange thing is that they came here to interview us 
asking us about what things could be done to improve the quality of life of the 
patient, his family and all this staff... these are good initiatives, but then when 
you have to go to the NHS office to obtain the authorization for devices or 
subsidies or aids.. well nobody cares about you! 
 
PMS2 is a 43 years old man, quadriplegic, spending his days stuck in the 
wheelchair. He lost his job and his wife had to reduce hers to 4 hours per day 
only in order to have time to care for him and for their 10 years daughter. 
P= (when the social assistant came home to evaluate their economic status to 
decide if they could receive a social allowance) She didn’t even have a look at 
the person on the wheelchair, who was the real problem! (meaning that she was 
only interested in the house to evaluate their economic status rather than the real 
problem that was his physical inability) 
 
This carer is really frustrated and negative about the possibility to receive any kind of 
help after years spent struggling to obtain what she felt were her unmet needs 
 
CPD3 is the wife of PPD3 (male in his 70, diagnosed 27 years ago, wheelchair 
bound., totally dependent in the ADL)  
C=If you need an help there is now one available! 
 
3.5.2.3.5.4 Having to cope with losses, having unmet expectations 
 
These issues were frequently raised by patients or by carers when talking about patients’ 
feelings. This group of needs, very consistently with other published experiences, 
involves difficulties in accepting the physical disability caused by the disease, the 
relentless progression of the symptoms, the loss of social activities, the loss of loved 
people and goes towards the uncertainty of what will happen seeking for cure through 
improbable and costly journeys to far east countries and looking for strange therapies 
found on the internet. 
 
This MS patient is talking about the difficulty to accept the wheelchair. His wife refers 
that their coping strategy is based upon making fun of the disability and they act like if 
she is trying to harm him in order to make jokes and laugh of it. They both state that 
crying is not a good coping strategy and does not induce other people to provide help. 
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PMS2 (male, age 43, quadriplegic, can only move his neck, totally dependent in 
ADL), CMS2 his wife. 
 P= when you have to go into a one way street. you cannot turn right or left or 
do a U-turn.( looking at his wife) you must accept it. (…) 
C= we try to make some fun of it. Sometimes people who don’t know us well 
says:-Gosh, are you killing him?- and sometimes he says to his doctors:- Look 
that if you can’t explain my death.. it was her who killed me, it’s an homicide!- I 
know this does not seem appropriate, but if you don’t act like that… what can 
you do? You can cry once, twice.. and then what? 
P= if you cry once people can tell you they are sorry.. poor man. The second 
time they grow weary, they’re fed up with you. 
C= crying is not useful. Doesn’t solve any problem. 
P= and doesn’t even patch it.  
 
Difficulties to accept disability and problems related to the disease progression are well 
described by this PD patient, fully aware about the disease and what can happen in the 
future because he is an active member of the PD patient society and read many books 
about movement disorders 
 
PPD2 (male, age 70, fluctuating motor symptoms with freezing episodes 
alternate to severe dyskinesias) CPD2 his wife 
 
P= with the progression of the disease, which is degenerative, being limited in 
the therapy because of side effects what happens to me? Things that once I 
gladly did, now I do reluctantly, they cost me fatigue. I perceive my slowness in 
movements, it’s a feature of the disease (…) 
C= we can’t play cards with our friends anymore, he falls asleep. 
P= because of the drugs. It’s not my fault. 
C= we can’t go sightseeing too, as we were used to. 
P= it’s due to the disease progression. I’m limited because of the drugs. (He 
shows us his book about PD related problems and adds):” if I had written this 
manual I would have done it identical”. 
 
Disability can drive to other losses like job loss that can cause economical problems, but 
moreover impact really badly on patients’ expectations and self esteem 
 
CMS3 is the wife of PMS3 (male, age 46, blind, quadriplegic, muscular 
spasticity, fed by PEG) 
C= after the hospital admission (when he was diagnosed) I hoped he could come 
back home fully recovered. Unfortunately it wasn’t like that because his is a 
Secondary Progressive MS, so it worsened continuously.(…) 
C= losses were continuous, month after month. He found a new job as telephone 
operator, he could do it being blind, but it didn’t last for long because he lost the 
sensibility of the skin of his fingers and couldn’t feel the keys. 
 
The following example shows how difficulties in coping with symptom progression can 
lead to trying many alternative approaches in foreign countries, hard therapies like 
abstinence from food or being eager to participate to any new drug trial. 
 
PALS2 (male, age 39, tracheostomized, fed by PEG, quadriplegic, diagnosed 14 
years ago, totally aphonic) and his wife CALS2 
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P= the most tragic period was when I fell 
C= he fell continuously. He had 2 devastating years. That was an horrible 
period where psychologically you don’t accept the disease. You don’t believe  
your doctors.. and we went abroad looking for alternative solutions. 
We tried everything: Germany for injection of stem cells, France for 
macrobiotics, Perugia for fast. For the official biomedicine we participated to a 
trial with IGF (…) and Rilutek. But then attending at medical conferences you 
see that when there are benefits they are limited in time and disillusioning and 
so you wonder if it’s worthy to continue.  
P= I refused the PEG in the beginning because I didn’t want to lose the pleasure 
of eating.  
C= but they told you that you could continue eating something, I think it was 
also a psychological refusal.  
P= food was the only thing that was left to me. It so true that now I look at TV 
programmes about cooking.  
 
Alternative therapies can become an obsession in those families where the disease 
progression is not accepted as shown below 
 
PALS4 (male, 61,  quadriplegic, on a wheelchair, cachectic, severely dyspnoeic 
in NIV diagnosed 3 years ago) and his wife CALS4 
C= we went twice to Beijing where he had 2 stem cells transplantations. Our 
neurologist tried to discourage us, but he wanted to try. Fortunately our 
insurance covered the costs. 
P= the question is always the same: What I do have to lose? 
C= since they couldn’t offer him any alternative!  
P= it can work or not… but if it works.. than it’s just money, until we have it! 
(…) 
C= this disease is so quick that you don’t have time to obtain what you need that 
you have to face another loss.  
 
Patients realise that research is far from being of help for them and this causes 
disappointment as appears in the following citation 
 
PALS3( male, age 60, on a wheelchair, severely dyspnoeic, diagnosed 5 years 
ago. In NIV at home) and his wife CALS3. 
C= he was a very active and sporting man. Immobility destroys him 
psychologically. Being forced in a wheelchair is something unnatural. 
P=yes, it’s terrible.(…) 
P= last respiratory control they told me I was improved…   
C= maybe because ventilator is doing its job 
P= I can’t be improved. 
C= well the disease is progressing.(…), but the neurologist told you that there 
are many new experimentations..  
P= come on, how long will they take! Look at me now, look at the way I am 
now! I can’t stay all this time here, set on the chair, with nothing to do. I can’t 
concentrate on the things I can do. If I have to use tools such a computer, I don’t 
have patience. After 2-3 minutes I quit. What’s the meaning in living like this? 
 
Patients who are aware of their conditions because diagnosis was not told or because 
they don’t want to discuss it tend to be unhappy about their health carers 
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This recently diagnosed patient is severely dyspnoeic and thinks that his breathing 
problems are not well treated by his lung specialist. 
 
PALS9 (male, age 77, diagnosed 8 months ago, in NIV, he was not informed 
about his diagnosis) and CALS9 his wife 
P= I need a doctor able to cure my breath! (…) I don’t say that doctor that is 
caring for me are not good, but my breath doesn’t improve. 
(…) 
P= (abruptly, without forewarning) Isn’t it possible to be cured from this 
illness? 
C= this is what he’s interested in! please talk to him about it. 
  
In the following experience the patient lost his speech and was very closed in himself so 
it was not possible to know how much he knew about the disease progression. The only 
clue that we obtained was that his coping strategy was the hope in new research as his 
wife referred. 
 
CMSA1 wife of PMSA1 a gentleman 73 years old, diagnosed 4 years ago. 
Bedridden with muscular rigidity and serious communication impairment 
I= your husband talked to the neurologist about the disease, about prognosis..? 
C= he didn’t talk a lot of his disease. We talked a lot about research. He knew 
perfectly about his diagnosis, he read the examinations reports, probably he 
commented about it with his doctors, but not with us.  
(…) I restate that he was aware of his disease, but didn’t talk with us. And he 
knew that we were aware too. (…) 
 
 
When the disease progression shows patterns different from what are normally 
expected, patients and carers can be deceived that this is the effect of alternative 
treatments. This can create false expectations and delusions. 
 
PALS1 (male 48 years old, bedridden quadriplegic, totally aphonic, 
tracheostomized) and  CALS1, his wife 
C= our GP is a homoeopath, and cures him with her therapies. Because of it we 
eliminated almost all of his drugs. Now we don’t know if these homoeopathic 
drugs works, but actually we must say that his disease is still. He’s one o the few 
cases where this disease is not progressing. 
 
This evidence shows the many losses experienced by an MS patient with an extremely 
long illness experience. From her words shines the different physical, emotional, 
relational losses that she had to cope with 
 
PMS4 ( 71 years old woman diagnosis 42 years ago. Paraplegic, wheel chair 
bound, lives alone helped by paid carers. She is divorced after being abandoned 
by her husband who said he could not cope with her disease) 
 
P= it’s a continuous of losses: job, satisfactions, divorce, disabilities (…) 
(after I divorced) I found another man, with MS as well. We fell in love. He was 
divorced as well, a former football player. He was an excellent company. (…) 
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than something unexpected happened. Liver cancer, the worst type. He died in 
1995. (…) so an extra suffering. Each time a worst relapse on me  (….)  
I accepted the wheelchair only when my partner died. On one side it’s an 
advantage, but on the other side you quit doing those little movements you used 
to do before.(…) … what can I do? I can cry and I’ll soon have liver trouble, or 
I can crush my head against the wall, throw myself out of the balcony, but I 
can’t because I’m unable to stand anymore, poison myself… but I don’t have 
drugs with me.. so or you accept it or otherwise… it’s the same! 
I’ve had enough, I lived my life. If you only knew how many people and friends I 
saw dying because of this disease. The last one was a friend of mine, a woman 
with MS: she was only 44! 
 
Carers also experience difficulties when they have to cope with their loved one losses. 
These result in a growing workload for them and satisfactions are not easy to find out as 
this participant testifies  
 
CPD3 is the wife of PPD3 a gentleman in his 70, diagnosed 27 years ago. 
Cognitive impairment, Wheelchair bound, living in a long term facility)  
C= I’m sorry if I said weird things. This is my experience: suffering and 
sacrifices. No satisfaction. 
 
3.5.2.3.5.5 Feeling a burden for others 
 
The sensation of feeling a burden for people living around is both common and very 
negative for participants 
An MS patient explain this feeling with the following sentence 
 
PMS1 (male, age 53, diagnosis of MS 18 years ago, quadriplegic, using NIV in 
the night, CMS1 his wife): 
 “after so many years you start feeling a like load for the others. A deathly load. 
Because I have a must condition and alter other people’s choices. You always 
need to ask. I don’t like it.”  
 
This ALS/MND patient, even though recently diagnosed, report how the need to rely on 
other member of his family affects his independence and force his relatives to stay 
behind him 
 
PALS9 (male, age 77, diagnosed 8 months ago, in NIV, CALS9 his wife) 
P= if I could drive I’d go wherever I like…. But like this…I have to ask them to 
drive for me. I lost my independence.  
 
When physical dependence becomes total, like in the following case, even simple tasks 
like scratching one’s own nose is not possible and someone has to do it on patient’s 
behalf 
 
PMS2 (male, age 43, quadriplegic, can only move his neck, totally dependent in 
ADL)  
P=I literally need someone always behind me…. if my nose is itchy I need 
someone to scratch it. 
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In this dramatic testify the extreme consequence of feeling a burden is told. This patient 
tried to commit suicide in order to relieve his loved wife from the burden of his own 
care 
 
CALS8, wife of PALS8 (male in his 70, diagnosed 9 years ago wheelchair 
bound, totally anarthric) 
C= this winter he tried to take his life. (…)I went to see him in the night and he 
had stuffed a handkerchief in his mouth. (the patient smiles). I took it off and 
asked him why… he said he was doing this for me, because I’m full of troubles 
and infirmities. I answered him that my infirmities would continue anyway and 
is would have been a further problem to me. He promised not to repeat it, but 
four nights later he stuffed 2 handkerchiefs in his mouth. So I got angry and told 
him that if he succeeded police would have charge me for murder. (…) 
 
In some case carers report that caring for patients totally disabled for many years is 
really troublesome. This MS patient’s wife said this sentence when the patient was not 
listening to her, but obviously these feelings cannot stay hidden in a long relationship 
like theirs is. 
 
PMS7 (Male, age 73, diagnosed 25 years ago. Wheelchair bound, anarthric, 
cognitively slightly impaired) CMS 7 his wife. 
C=I don’t want him to listen to.. he has never understood what it really meant to 
me… I can’t tell you these things right now! He has never understood the 
troubles that we had…if he knew he’d live too bad 
 
3.5.2.3.5.6 Shame, dignity, privacy  
 
These words were also used to express feelings that can be grouped in the previous set 
of needs. These are all uncomfortable sensations related to the lack of self esteem, 
respect from the others, achievement. 
  
These uncomfortable feelings concur to patients isolation. In the following example a 
patient talks about shame and closure 
PMS4 (71 years old woman diagnosis 42 years ago. Paraplegic, wheel chair 
bound, lives alone helped by paid carers) 
P= I’m not participating the patients meetings organized for the patients 
association. My partner didn’t like it. When you go and see, after 1 year, how 
other patients worsened you mirror your worsening. So I don’t go to these 
dinners. Cheese and bread on my own are better!  
(…) 
P= I don’t go out because of a sense of shame. I’m ashamed of being ill, of the 
wheelchair, I fear to fall. It happened once, just downstairs on the sidewalk in 
front of the house door. There was a little gap among tiles and it blocked the 
wheels. I fell and hit my face. I felt worst for the sense of shame than for the 
injury.  
 
Disability itself can cause sense of shame in some participant. The typical signs of a 
movement disorder are unbearable to be shown for this PD patient 
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PPD2 (male, age 70, fluctuating motor symptoms with freezing episodes 
alternate to severe dyskinesias)  
P= I’m a proud man. I feel ashamed as if I were a thief. (..) I’m ashamed when 
people see me like this, blocked. I know that it’s not my fault, but it’s disgraceful 
being like this. Shame is the most invalidating problem of the disease to me. It’s 
humiliating. I’m hurt when I read sorrow in other people’s eyes. 
 
And when a young man is completely dependent in the daily activities privacy can be an 
issue. This patient had to accept his parents help for his own care while his wife is out to 
work. He clearly states how he does not have time to stay alone by himself because, 
being tracheostomized, he need continuous control of his life sustaining machines.  
PALS2 (male, age 39, tracheostomized, quadriplegic, diagnosed 14 years ago, 
totally aphonic) and his wife CALS2. 
P= another unsatisfied need is privacy! I’d like to stay alone for a while. 
C= (…) he had to accept a carer out of his parents because they are getting old. 
He yielded only when he understood that it was necessary 
 
3.5.2.3.5.7 Need of self independence and control 
 
Terms to express this group of psychological needs were the following: 
Need to feel useful, to be able to do things on their own, to communicate with others 
when speech is impaired, to cope without external help.  
These issues represent the opposite face of physical dependence and often were 
proposed by those participants who were concerned for being a burden for the others. 
 
The next citation is from a carer who has been involved directly in the care of her ill 
husband for 25 years and, in the mean time, she had to care for their son and daughter 
and, eventually lost her job not to leave the patient in other people’s hands 
 
CMS 7, wife of PMS7 (Male, age 73, diagnosed 25 years ago. Wheelchair 
bound, anarthric, cognitively slightly impaired)  
C= I’ve always refused help from others, like volunteers and now I’m regretful 
for this. I didn’t want to involve my son and my daughter because I didn’t want 
to affect their lives 
 
The same carer (talking on behalf of her husband who could not talk because his speech 
was completely affected by the disease, but who agreed not verbally to these sentences) 
describes how important is self independence for a man who has always lived an active 
life and that progressively lose these capabilities 
 
C=Imagine that one day he called me to show how he was still able to tighten a 
screw. Is it possible that a man need to show something like that? 
 
One coping strategy, shown below, adopted by this couple formed of the ill husband 
and his active wife to maintain independence and control is to fight together against the 
disease trying to stay compact and leaving the rest of the family out 
 
PALS6 (male, age 50, diagnosed 13 years ago, tracheostomized, bedridden – 
wheelchair, quadriplegic, aphonic) CALS6 his wife 
P= we are serene because we are foolhardy! 
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C= we had our crisis, but perhaps it’s a matter of temperament. He has a strong 
determination to fight against his disease, I follow him… so we plucked up 
courage. But this doesn’t mean that we didn’t have problems or obstacles. We 
had it. 
We don’t involve our relatives in our problems. We gave us a commitment, we 
have to manage alone. Our son, well he’ll have his own life so we don’t want to 
involve him too much. 
 
Patients, above all in early stages of the disease tend to refuse external help because 
accepting it would mean accept the progression of the disability. This elderly man, 
completely aware of the nature of his illness, refused to accept a necessary aid like the 
wheelchair because he wanted to show that he could cope with the increasing disability 
without external help. At the time of interview he was very disabled, he completely lost 
his speech and was stuck on the wheelchair, but when his wife told this story he smiled 
confirming that these were his real intentions. 
 
CALS8, wife of PALS8 (male in his 70, diagnosed 9 years ago wheelchair 
bound, totally anarthric) 
C= he has always been a tough man. When we went to the legal visit for the 
invalidity pension he refused to go with the wheelchair despite the fact that some 
suggested him to do it. He wanted to go with his cane.  
 
Aids can be of extreme help for those patients who want to fight against disability. Loss 
of communication skills affects deeply one owns quality of life. When patients obtain 
and accept external devices like electronic communicators their regain some degrees of 
freedom and really appreciate it. 
 
PMS2 (male, age 43, quadriplegic, can only move his neck, totally dependent in 
ADL) 
 P= the laptop? It’s a Saint, a blessing! Because at least with it I feel useful 
having something to do.  
 
These  two patients, both tracheostomized, cognitively not impaired and  showing a 
high level of life attachment, confirm the importance of electronic communicators as 
tools to enhance their independence, to stay in touch with the world and to improve 
their self esteem 
 
PALS6 ( male, age 50, diagnosed 13 years ago, tracheostomized, bedridden – 
wheelchair, quadriplegic, aphonic), CALS his wife 
C= we are looking forward to obtain a new vocal communicator. It would be so 
important for him. He likes very much when people come here to meet him. A lot 
of people don’t want to came afraid to disturb us. Marco would be so happy! 
I= what if volunteers came here to spend sometime with you? 
P=Please, send them! 
(…) 
P= (communicating with the eyes through an alpha numerical table) to me the 
possibility to communicate means a lot. It would improve my quality of life. Even 
my psycho- physic balance would be enhanced.  
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PALS2 (male, age 39, tracheostomized, quadriplegic, diagnosed 14 years ago, 
totally aphonic) and his wife CALS2. 
P= as long as I could I surfed on the internet and I was full of friends with my 
disease. We could communicate, share suggestions.  
C= this gave him a good support both moral and psychological. 
 
3.5.2.3.5.8 Family concerns, burden of care  
 
Family is one of the most important factor for the quality of life of people living with 
advanced neurodegenerative disorders. 
It is both an essential part of their care, because it allows the patient to be cared for in 
their homes, because it provides practical help, love and social relationships, but it can 
be a cause of concern. Family carers, from their side feel the importance of their role, 
but they complain also about the hardness of their task, lack of external help and, 
sometimes they ca not cope with their loved ones disability and decide to abandon the 
patient. 
 
This PD patient shows his disappointment for not being able to provide support to his 
wife who has recently been hit by an acute stroke and is slowly recovering 
 
PPD2 (male, age 70, fluctuating motor symptoms with freezing episodes 
alternate to severe dyskinesias) CPD2 his wife 
P= another cause for my suffering is that I can’t help her (crying), and she has 
her physical problems too. 
 
But patients suffer a lot when they feel they have been abandoned because they were 
affected by their neurological conditions 
 
PMS4( 71 years old woman diagnosis 42 years ago. Paraplegic, wheel chair 
bound, lives alone helped by paid carers) 
P= 10 years after diagnosis and 15 after our wedding my husband left me. We 
had a 14 year old son. He left me to my mother saying that he didn’t want to be 
my nurse anymore. Later we divorced.  
 
In some families the disease is not an obstacle to the normal relationship as the carer of 
this totally impaired patient testify 
 
PALS1 (male 48 years old, bedridden quadriplegic, totally aphonic, 
tracheostomized) and  CALS1, his wife 
C=despite the disease if we have to quarrel we do it easily. Our relationship 
didn’t change.. if things were not going well before, well they aren’t going well 
neither now ( and smiles) right dear?  
P= (using the alpha numerical table) yes! (smiling) 
 
Tiredness and burn out of the carers is really an issue as testified by the following 
experiences.  
 
PMS7 (Male, age 73, diagnosed 25 years ago. Wheelchair bound, anarthric, 
cognitively slightly impaired) CMS 7 his wife, SMS7 is their son 
C= about myself I must say that that I’m burned out.  
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S= it’s what me and my sister are trying to explain to her.(…) it’s not just a 
question of money, it’s she that doesn’t want to accept a concrete help. (…) it 
might be a relief to know that there’s a paid carer able to stay with dad and give 
you 2 hours to do what you like. 
 
PALS1 (male 48 years old, bedridden quadriplegic, totally aphonic, 
tracheostomized.) and  CALS1, his wife 
C= personally I’m very distressed! I’m tired, I don’t even have 5 minutes to do 
what I like. I can’t go out, I mean anything. (….) since he has been 
tracheostomized we can’t leave him alone not even for 1 minute! 
.  
Carers can feel preoccupied of what could happen if they had accidents and could not 
provide care to their loved ones 
 
CMS1 is the wife of PMS1 (male, age 53, diagnosis of MS 18 years ago, 
quadriplegic, using NIV in the night) 
C= The disease is present and we have to live with it. I never ask anything to 
anyone, but life would be much easier if I knew that someone were available. 
I’m anxious when I have to leave and drive: what if something happens to me?  
 
CALS6 is the wife of PALS6 (male, age 50, diagnosed 13 years ago, 
tracheostomized, bedridden – wheelchair, quadriplegic, aphonic) 
C= I’m terrified to fall ill. If it had to happen… who’d care for my husband! 
 
Inside families there is not always concordance about the strategies to adopt for 
patients’ care 
 
DMSA1 is the daughter of PMSA1 a gentleman 73 years old, diagnosed 4 years 
ago. Bedridden with muscular rigidity and serious communication impairment. 
She talks about her mother who is providing care to the patient and does not 
follow their physicians prescriptions about therapies 
D= my mother is like this. She continuously cuts his drugs… it’s not easy. 
I= do you think she has unattainable hopes about the disease progression? Is 
she aware of what will happen? 
D= I think she knows everything. 
 
Other family members can represent a further cause of concern above all when they are 
fragile and cannot cope with what is happening 
 
PALS4 (male, 61, quadriplegic, on a wheelchair, cachectic, severely dyspnoeic 
in NIV diagnosed 3 years ago) and his wife CALS4 
C= me, my daughter and my son we all are in psychotherapy. Above all my son 
he is very shut off, is difficult to communicate with him. He suffered a lot for his 
father condition. He is depressed now. He’s 26, probably he is more frail than 
we are… he wasn’t able to study anymore and this was frustrating to him. He 
saw his father’s conditions worsening and became intractable. 
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3.5.2.3.5.9 End of life issues  
 
Psychological unmet needs contribute to end of life decisions. Some participants talked 
about their position about life sustaining devices or decision related to take their lives 
when were talking about their psychological status 
 
PMS1 (male, age 53, diagnosis of MS 18 years ago, quadriplegic, using NIV in 
the night, CMS1 his wife): 
P=Sometimes I say I’ll go to The Netherland’s, so I’ll avoid problems. 
Sometimes I think… well, maybe if they change a little our laws.. they should 
change our laws. When one arrives to an unbearable level. I don’t say it for me. 
It’s for people around me. It’s not good to sacrifice people. 
I= so you say you’d purchase euthanasia because you feel like a load for your 
family? 
 P=” as well. (the dog starts barking)… but without me even the dog would die. 
 
PALS3( male, age 60, on a wheelchair, severely dyspnoeic, diagnosed 5 years 
ago. In NIV at home) and his wife CALS3. 
P= I really wonder if taking these drugs is worthwhile… 
I= can you tell me something about the psychological difficulties in coping with 
this disease? 
P= I don’t want to think about it (…) if I think at what will happen to me… I 
don’t want to arrive at the tube solution (tracheostomy). When.it’ll be necessary, 
well to be bedridden, eyes fixed on the ceiling… I can’t accept it. And when I 
think about Welby (an Italian ALS tracheostomized patients who ask for the 
withdrawing of his invasive ventilation), he just wants to die. But if you do it 
than the doctor will be persecuted. Can not a man just decide on his own?  
(…) I’m very sorry for my family, my wife, my son, but this is not life. If there 
were other exits, but like this… 
 
Uncertainness about end of life choice (that in Italy are not clearly regulated by law and 
advance directives are not legally bounding the doctors choices) can be a cause of 
concern and worry for both patients and carers 
 
PALS4 (male, 61,  quadriplegic, on a wheelchair, cachectic, severely dyspnoeic 
in NIV diagnosed 3 years ago) and his wife CALS4 
P= I don’t want to be tracheostomized. But I can’t be sure that this advance  
directive will be respected because in Italy they aren’t recognized by the law. 
C= a person we know was tracheostomized in a hospital against his will.  
P= you know the world is full of dick-heads! 
C= I fear to face a supporting interventionism doctor, of those ones supporting 
life against everything. I believe in self determination. If it were for me.. hurrah 
for euthanasia, hurrah for the Netherland’s! 
 
CALS5 is the wife of PALS5, a totally dependent gentleman wheelchair bound 
and severely dyspnoeic  
C= he doesn’t want an invasive ventilation. He’s very determinate in that. He 
prepared a living will stating this. I agree with him. 
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3.5.2.3.5.10 Need of psychological support 
 
Psychological support was discussed in several interviews and positions about this help 
were disputed. 
Good experiences were reported by some participants 
 
PPD5 (woman age 78, cared for by her husband -CPD5- at home) 
C= 2 years ago the Italian Parkinson’s disease patients association organized a 
respite care admission for both of us in a nursing home. We spent 15 days with 3 
other couples with the same disease. It was very good, we also had the chance to 
have talks with psychologists. It was very helpful for us.  
I= would you like to have someone to talk to, to give vent your spleen to?  
P= I feel this need! 
 
PALS7, (woman 60 years old, diagnosed 12 years ago, quadriplegic, dysarthric, 
dyspnoeic, NIV 24 hours a day) and her husband CSLA7. 
P= psychological support is so important. It’s not just talking to someone, but it 
‘s receiving help. I learnt that in the morning I have to create a list of the things 
that must be done. Anytime I complete one I cancel it from the list. It  helps a lot 
by keeping your mind busy and don’t let worries enter.  
Another point was the importance for relatives to save some spare time for them. 
This helps them to clear their mind from my needs and to me because when they 
come back they are motivated and fresh. You hardly understand these things by 
yourself. The psychologist helped us a lot.  
 
 
Other participants were contrary or not satisfied about the help received from 
psychologists 
 
PALS4 (male, 61,  quadriplegic, on a wheelchair, cachectic, severely dyspnoeic 
in NIV diagnosed 3 years ago) and his wife CALS4 
C= he attended for a long period the psychologist of the ALS centre. Now we 
have a psychotherapist coming here. She comes each 7-10 days. We pay for this 
service.  
P= now it’s more a friendly relationship than a professional one! I don’t have 
enough strength to talk, so she talks to me about movies, news etc. it’s no more a 
therapy 
 
PALS2 (male, age 39, tracheostomized, quadriplegic, diagnosed 14 years ago, 
totally aphonic) and his wife CALS2. 
C= we denied the psychological support from the ALS group. We weren’t 
interested in it. I know they have groups of patients and relatives that meet there, 
but I don’t want to go. It’s to heavy to me. Many of them are at the beginning of 
this disease, I don’t want to revive those moments. (…) if I see them I can just 
cry and can not stop.(…) 
When we were in Perugia for this alternative approach of the fast he had to meet 
the psychologist, it was scheduled. He hated it  because he was told that the 
disease was his fault, that was a kind of answer of the body because he didn’t 
want to accept certain situations.  
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In some cases the position was not clear and participants were undecided about to try a 
support or not 
 
PMSA1 (MALE 73, bedridden, caregivers are his wife and one of his daughter 
CSMA1 and DSMA1) 
I= ever tried a psychological support? 
D= no. 
D= (crying, when her mother isn’t in the room) she’s the problem! Anytime one 
of us says something, she replies that we don’t understand, and that we cannot 
understand! 
 
3.5.2.3.5.11 Summary 
 
A huge range of psychological themes emerged from the content analysis of the 
interviews. The raised issues regarded many different aspects of the psychological 
human needs. Some were about the personal feeling of being abandoned by the 
professional carers or by friends, relatives because of their conditions. This imply 
confusion and concerns for the future. 
Mood instability, leading towards anxiety and depression were sometimes declared by 
the participants, but in many interviews could be detected from non explicit statements 
or comments. Difficulties in coping with the disabling disorders arouse frequently often 
accompanied by unrealistic expectations of clinical improvements. Other issued 
reported were the unpleasant feeling of losing control, feeling impotent or overwhelmed 
by the disease, worries about being a burden for the others. Less frequently, but highly 
significant for the participants who talked about this feelings, were conditions like loss 
of dignity, need of more privacy and sense of shame. 
The need for a specific psychological support was discussed by participants who had 
already experienced it with different opinions and satisfaction. Psychological issues 
triggered some comments from participants about end of life decisions. 
Family carers took the chance of the interviews to testify how difficult and exhausting is 
the long term care of their loved ones and the worries that they feel about what could 
happen to the patients if something happened to them.  
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3.5.2.3.6 The content analysis of the social needs 
 
The content analysis of the social needs which emerged from the 22 interviews is 
summarized in the chart 3.3 and table 3.5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Quotes in the 22 
interviews Percentage 
Need of respite care 4 18.8% 
Transport, holidays 10 45.5% 
Family problems, divorce 13 59% 
Isolation (lack of social 
network) 10 45.5% 
Isolation (living alone) 10 45.5% 
Isolation (disease) 13 59% 
Isolation (physical barriers) 8 36.4% 
Financial issues 8 36.4% 
Difficulties to obtain social 
benefits 12 54.5% 
Loss of job 5 22.3% 
Difficulties for services, devices 9 41% 
Need of paid carers 16 72.8% 
Need of volunteers 8 36.4% 
 
Table 3.5: the social needs  
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paid carer
volunteers
fight for services, devices, expensive aids
loss of job
economic issues
difficulties to obtain benefits
isolation due to physical barriers
isolation due to the disease
isolation due to living alone
 lack of social network
family troubles, divorces
transport problems, holidays
respite
N=22
 
Chart 3.3: the social needs 
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3.5.2.3.7 The social needs detailed analysis 
 
Results related to the social needs of participants to the interviews will be displayed in 
this section. Abbreviation forms will be used as described for the physical needs 
section. 
Social needs were grouped in four main categories as shown with the different colours 
in chart 3.3. 
Each group will be presented and described with citations extract from the interviews 
used as data. 
 
3.5.2.3.7.1 Isolation  
 
This group of unmet social needs was the most represented in all the content analysis. A 
total of  
41 citations in the 22 interviews were related to these themes. 
Lack of social network was one of the main cause of isolation of both patients and 
carers. Friends and relatives often do not collaborate and tend to vanish over time like 
this carer reports 
PALS1 (male 48 years old, bedridden quadriplegic, totally aphonic, 
tracheostomized.) and  CALS1, his wife 
C= friends were very helpful when he was at the hospital, but since we came 
home they aren’t so collaborative. Some of them disappeared and we lost them 
before he was admitted to the hospital. Some were very close to him, we 
wouldn’t expect them to vanish like this. 
 
This carer was talking about the decision to admit her husband to a long term facility 
because she was not able to manage him at home. Even though they have relatives they 
cannot be of help because of other serious health problems 
 
CPD3 is the wife of PPD3 a gentleman in his 70, diagnosed 27 years ago. 
Cognitive impairment, Wheelchair bound, living in a long term facility 
C= our relatives aren’t much of help for us because they have their own 
problems. My niece has a congenital malformation and so she’s often in the 
hospital and my daughter has to stay with her.  
 
Some families are really alone because they do not have relatives living close to them 
and no other help from neighbours or from the community  
 
PPD1 (male, age 80, cognitively slow but able to understand and severely 
disabled in his movements.) CPD1 his wife. 
C= we have 2 sons, but they’re married and live far from (…). At home we are 
alone and I have to do everything by myself.  
I= do leave him at home alone? 
C= yes, he stays at home alone. I don’t go away half a day, but a couple of hour 
to go shopping .. yes. 
 
Another situation where the elderly couple is really isolated, not having anyone able to 
provide help. They do not have sons or daughters nor close relatives. 
PPD5 (woman age 78, cared for by her husband -CPD5- at home) 
I= do you have sons or daughters? 
C= no, we are alone! 
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(…) 
I= do you think that a priest could help you to cope with your disease related 
distress? 
C= well, we have been living here for 4 years and.. well volunteers from the 
church say that priests are few and have so many people to visit.. 
We had 1 priest who came in the past, but now he disappeared 
(….) 
C= I have to go shopping, on errands and to manage the house. She stays at 
home with the paid carer we have. She’s staying here for 3 hours in the morning 
and sometimes in the afternoon if I have to go out.  
 
In this situation the patient’s wife complains about their state of loneliness in which 
even their close families do not provide help 
 
CMS6 wife of PMS6 a 53 years old gentleman, fed by PEG, almost totally 
dependent in the ADL 
C= even with his family we had problems. His mother didn’t want to come here 
and spend sometime with him. They put him aside. They do many thing for his 
sister who’s healthy and has got a child, but nothing for him. 
 
This carer suggests how things change over time. In 25 years of caregiving to her 
husband she felt her needs becoming higher and the help provided by friends being less 
concrete and satisfactory. 
 
CMS7 is the wife of PMS7 (Male, age 73, diagnosed 25 years ago. Wheelchair 
bound, anarthric, cognitively slightly impaired). 
C= we are isolated because I have always refused to be helped. 
I am plenty of needs, but this is the way I am. (…)I’d feel to go and leave him 
only if I knew he’s very well cared for. (…) 
C= friends have always been supportive to us. When I worked they spent their 
mornings with my husband(…). But now thing are worse. They come here and 
find him cleaned and prepared and don’t do anything. I know this discourse is 
unpleasant, it look like if I didn’t need help from people. I have plenty of needs. 
They were so helpful when my son and daughter went to school. I changed my 
shifts to manage our lives. Then since I retired, my life is finished. Before I had 
some time for me, I went out for a pizza with my colleagues.. now I’m shut in this 
house and I know it. I reached a point where I can’t have a chat with others. 
 
This carer recognize to be the only one able to care for her wife, even though he has to 
care for is mother too, who is living with them and is very ill having a cancer in 
advanced stage. In this case visits from friends and other people of the community 
seems not being much of help 
 
PPD4 (woman, age 60, care for by her husband –CPD4- at home, in DBS) 
C=I am the only one who takes care of her. I’m retired now and tale care of 
home management and errands..  
(….) 
C= we know that AIP (PD  patient’s association) organize meeting, parties etc, 
but we don’t participate. We don’t even have contacts with our Parish church or 
other social centres. We just have friends and neighbours coming for some 
visits.   
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In the following citation we have both physical problems who concur to limit the visits 
of friends and the loneliness of the patients’ wife who does not receive enough help and 
has to leave the patient alone 
 
PALS9  male, age 77, diagnosed 8 months ago, in NIV, CALS9 his wife, DALS 
9 one daughter 
C= he’s very happy when his friends and the priest come to visit him they talk 
about their past, things they did together (…) unfortunately hiss breath gets 
short quickly when he talks and he needs the mask. With it he can’t talk 
anymore. 
(….) 
C= knowing that there’s a person who can spend 2-3 hours one afternoon per 
week would very important to my mother. She could plan her shopping without 
feeling in a rush.  
D= it’d be important for dad too, he likes so much talking with people!  
 
Another cause of isolation is the disease itself. Participants describe how symptoms and 
signs of an advanced disease can scare other people and cause sense of shame resulting 
in closure and isolation. 
  
PPD2 (male, age 70, fluctuating motor symptoms with freezing episodes 
alternate to severe dyskinesias) CPD2 his wife 
C= we were used to go out: we went out to play cards with some friends of us, 
but now we can’t anymore because he falls asleep. 
P= my immobility is self-evident. I can’t walk, I have many difficulties to enter 
in the car because I can’t open the door and because I continuously move like 
dancing. 
(….) 
C= we can’t go out for tourism, as we were used to, because he’s ashamed and 
so, in conclusion,  we are always blocked at home. 
 
Here there is a further example of how patients feel the disease can take people away 
 
CMS6 wife of PMS6 a 53 years old gentleman, fed by PEG, almost totally 
dependent in the ADL 
C= we are isolated. Many of the things we used to do before we had to leave it. 
We went out with friends, we had to renounce to it. Friends and relatives don’t 
come to visit him. I think it’s because of his drooling, or because he lost his 
urine from the catheter… it can be disgusting. 
 
Physical barriers are another cause of social isolation. Carers and patients complained 
about their difficulties when they have to leave their homes and often have to renounce 
and stay at home when going out could be very important for their lives 
  
PMS1 (male, age 53, diagnosis of MS 18 years ago, quadriplegic, using NIV in 
the night, CMS1 his wife): 
P=My daughter had her degree on May, but I couldn’t participate to the 
ceremony because of the stairs. 
Chapter 3. The Qualitative Needs Assessment 
 106 
 
C=It’s difficult to go out with the wheelchair because of obstacles. Even where 
there are ramps, often they are dangerous; I feel like the chair slips away from 
me. 
 
PPD1 (male, age 80, cognitively slow but able to understand and severely 
disabled in his movements.) CPD1 his wife. 
C= we have the problem to go out because of the stairs we have in our 
apartment building. We should place a lift, but we don’t know if the other 
tenants will agree. 
 
In the following two reports carers explain how physical barriers and lack of external 
help cause patients to spend lots of time alone in their homes when they have to go out 
on errands and cannot take their loved ones with them 
 
PALS3 (male, age 60, on a wheelchair, severely dyspnoeic, diagnosed 5 years 
ago. On NIV at home) and his wife CALS3. 
C= leaving home is a problem: there are stairs, then we have to book an 
equipped taxi and it takes 24 hours to book it. For this reason I quit going out, it 
is ages since I left home last time.  
(….) 
C= unfortunately I’m alone and I have to do all the shopping, errands etc. so I 
have to leave him home alone. 
 
CMSA1 wife of PMSA1 a gentleman 73 years old, diagnosed 4 years ago. 
Bedridden with muscular rigidity and serious communication impairment, 
DMSA1 his daughter 
D= how can we go out with dad? He doesn’t leave the house. There are so many 
physical  barriers to leave the house that we can’t push him out. 
(…) 
C= I’m always so busy. I’ve got to go to the GP’s ambulatory for prescriptions, 
or to  the district office for authorizations fro medications, to go shopping and 
other errands… I don’t have anyone who can help me in this daily tasks.  
 
Barriers are not only physical, sometimes human component contribute to the physical 
isolation as this carer explained 
 
CMS6 wife of PMS6 a 53 years old gentleman, fed by PEG, almost totally 
dependent in the ADL 
C=Unfortunately, even if we had a good aid to go down from the stairs, when we 
were in the cortile we couldn’t exit because the other inhabitants of the building 
left their car everywhere precluding our way out.  
 
Families sometimes had to move to better places to overcome physical barriers. In the 
following citation the carer talks about these issues and adds how being alone in the task 
of caring for her highly disabled husband means having to involve their only son in his 
daily needs. Patient and carer tried not to be a burden for their son, but obviously an 
external help would be of help. 
 
PALS6 (male, age 50, diagnosed 13 years ago, tracheostomized, bedridden – 
wheelchair, quadriplegic, aphonic). They’re considered a “social family” and 
live in a council flat 
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C= we had to move to this flat because where we were living before we didn’t 
have a lift and to go out we went through a slide. 
(….) 
C= I’ve always tried not to involve our son too much in his father’s care. I don’t 
want him to be oppressed by this hardship. But he has always helped me a lot. 
(…) 
C= when we are alone we try to manage ourselves our problems. We ask for 
help only if strictly necessary. If he needs to go to the toilet and we are alone he 
wants me to call our son at work. So he asks me when he’ll be out of his turn of 
duty. But I say to him:” let’s do it ourselves… and we do it!” 
 
Isolation is also the consequence of being abandoned. The following two quotes are 
related to two patients who have been abandoned by their spouses because they said 
they could not cope with the disease 
PMS4( 71 years old woman diagnosis 42 years ago. Paraplegic, wheel chair 
bound, lives alone helped by paid carers) 
P= after the divorce (…) now I live alone. 
P= I spent 15 days as a prisoner in my house because the transport footboard 
that enables me to descend last steps of the stair to go out, went out of work. It 
has been working there for 40 years. I did maintenance interventions when 
required. Now I applied for a new one. The city council will contribute with 
2500 euros that will be reimbursed to me in 2009. the rest will be charged to me. 
Total cost is 7500 euros plus manpower.  
PMS5 (male, 49 years old, diagnosed 24 years ago. Quadriplegic, fed by PEG, 
cognitively impaired, barely able to consent to the interview ) and his mother 
CMS5 
C= he is married and has got a son. His wife left him when he was seriously ill. 
His son comes to see him sometimes, or call to have news, but in fact, he is alone 
and I am the only one who takes care of him 
 
A consequence of being isolated can be the fear of falling ill and having to place the 
patient into hospital or in a long term facility. This carer highlights how her work is not 
recognized by the community as helpful and cost saving. She underlines how external 
help could prevent problems to her health status and the costs of hospitalization for both 
of them.  
 
PALS8 (male in his 70, diagnosed 9 years ago wheelchair bound, totally 
anarthryc, cognitively not impaired, communicates via alpha numerical table) 
and his wife CALS8 
C= I’m afraid of what could happen if I fell ill. I don’t know how much would it 
cost to the community if they had to hospitalize both of us. 
(…) 
C= I can’t manage this situation alone because I’m old and ill. 
 
3.5.2.3.7.2 Economic issues 
 
In this group of unmet needs the following categories were gathered: financial issues, 
loss of job, difficulties to obtain economic benefits, equipment, services and expensive 
aids. 
About economic related troubles we had the following information: 
• 5 participants said they lost their job because of the disease, 
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• 8 declared to be in serious financial troubles, 
• 12 stated their difficulties to obtain sick benefits 
• 9 reported difficulties in  obtaining equipment, services or important expensive 
aids, such as  electronic communicators. 
 
Job loss, financial issues and benefits 
 
The loss of a job has economical and motivation implications. It is another loss that, 
added with physical losses, has a very bad impact on patients’ quality of life, self 
esteem and self actualization. (Maslow, A. H. 1943) 
Following two different examples of how this loss contributed to amplify patients 
dissatisfaction.   
 
PMS4( 71 years old woman diagnosis 42 years ago. Paraplegic, wheel chair 
bound, lives alone helped by paid carers) 
P= I lost my first job because of the disease. It was very important to me. I 
created the company where I worked, together with my boss. I left that place 
because of the several hospital admissions I had in that period. I had to quit 
because I couldn’t go on like that anymore. It was a great loss. I entered there 
when I was 18 and left married with a son… that was a family to me. (…). After 
the divorce my sister in law found me another place of work as a secretary in a 
school. I had to quit that too because I had to climb some stairs and I reached a 
point where I couldn’t afford it anymore. 
 
This MS patient complains about their economic restrain after his wife decision to leave 
her job in order to care for him  
 
PMS1 (male, age 53, diagnosis of MS 18 years ago, quadriplegic, using NIV in 
the night, CMS1 his wife): 
P=My wife lost her job in order to have time to care for me. I expected them to 
give her some money for it. Nothing. She had to retire earlier from her job, and 
so she’s having a smaller pension. We are living with my disability pension and 
the disability cheque..  
  
And this carer describes how hard is to care for his very ill husband having health 
troubles herself. She states that their incomes are not enough to engage paid carers.  
 
PPD1 (male, age 80, cognitively slow but able to understand and severely 
disabled in his movements) CPD1 his wife. 
 C= his pension is about € 1000 per month. If I had to pay for caregivers day 
and night… I couldn’t afford it. So if I had a problem like a back pain… I don’t 
know what I could do (…) I had 2 hips replacement, shoulder surgery, I must 
take care of myself. 
 
This MS patient wife testify how her decision to reduce her working time resulted in 
financial straits for their family  
 
PMS2 (male, age 43, quadriplegic, can only move his neck, totally dependent in 
ADL), CMS2 his wife. 
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C= I had to cut my salary changing my full time job to a part time one. Now I 
work 4 hours a day to care for him and our daughter ( she’s affected by  juvenile 
rheumatoid arthritis).  
We have to pay a mortgage for our flat, a loan at interest for the van. But they 
said that as long I work and he has his pension we are wealthy and they won’t 
give us nothing. 
 
Paid carers are scarce resources and family have to pay for them. This woman didn’t 
know that she could apply for a sick benefit, a monthly cheque provided by the town 
council specifically aimed at supporting family who are caring for seriously disabled 
persons in their homes. 
 
PALS1 (male 48 years old, bedridden quadriplegic, totally aphonic, 
tracheostomized.) and  CALS1, his wife 
I= do you have a sick benefit for his condition? 
C= no, he receive a pension and the accompaniment subsidy. We don’t even 
know what the sick benefit is (….) the lady who is caring for him, I should ask 
her to stay 1 week-end per month, day and night, in spite of the fact that she has 
her daughter to look after. But she’s staying here 5 days a week and then it 
costs. If we were extremely rich I could pay for a carer 24\24 and my life would 
continue exactly as it was before.  
 
This wife obtained a sick benefit enough to provide paid carers for her disabled 
husband, but she was not reassured about its continuation into the following year. This 
is a great cause of concern for her who is still working in a high responsibility position 
 
CMS3 is the wife of PMS3 (male, age 46, blind, quadriplegic, fed by PEG). 
C= I don’t ask for nothing. I just want to care for my husband at home. I think 
that, as a citizen, I’ve my rights, not only duties. I have the duty to work, to care 
for my husband and I think I’m socially useful because if I put him in a structure 
it’d be much more expensive for the society(….) 
C= (..) now things are worse. He needs assistance 24 hours a day. Now, after a 
long bureaucracy, we obtained a sick-benefit. It allows us to pay a caregiver 8 
hours a day, 5 days a week, while I’m at work. It was approved for this year, I 
hope they’ll renew it and maybe increase a little so I can have this carer helping 
me on Saturday morning when I have to bath him. 
 
Here similar examples of how social supports are not tailored on families’ needs are 
shown. 
 
CALS6 wife of PALS6 (male, age 50, diagnosed 13 years ago, tracheostomized, 
bedridden – wheelchair, quadriplegic, aphonic) 
C= my son has just started his first job. The welfare assistant told me they’ll cut 
our subsidies because of this. But his intake is e very low and he just uses it for 
his leisure… 
(….) 
C= I left my job 6 years ago, when they conceded him the accompaniment 
cheque. I was working part time and it wasn’t worthwhile to work and pay a 
carer for doing what I could do. My husband now receive the invalidity subsidy, 
the accompaniment cheque and since the beginning of this year a sick benefit 
that allows me to pay for this carer 2 hours a day. It’s not enough at all, I’ll go 
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and discuss with the welfare assistant to increase its amount. The social office 
send us also another person for 2 hours per week. He wasn’t useful at home, so 
we agreed that he goes shopping or goes on errand for us.  
 
 
CPD3 is the wife of PPD3 a gentleman in his 70, diagnosed 27 years ago. 
Cognitive impairment, Wheelchair bound.  
C=. I don’t receive any taxi coupon and I have to pay for ambulances.  
(….) 
C= money is a problem: he receive 1100 euros for his pension and 400 euros for 
the accompaniment check. Here the charge for us is 1200 euros per month. But 
as I take only 230 euros for my pensions I have to live with 530 euros. It’s not 
much, barely enough to survive. 
 
3.5.2.3.7.3 Material, medications, bureaucracy 
 
Four participants talked about social difficult related to aids delivery, bureaucracy. 
Having to assist disabled patients for very long time caused carers to report difficulties 
related to the procedures that are to be renewed cyclically and cause waste of time in 
NHS offices.  
 
PMS2 (male, age 43, quadriplegic, can only move his neck, totally dependent in 
ADL), CMS2 his wife. 
P= why anytime I need something I have to do that long bureaucracy?  
C= I’m like one of the family in that counter. I go for the bedpans, catheters, 
jelly water.. I spend so much time there and I have to subtract it from my work 
or from the family. 
 
PALS2 (male, age 39, tracheostomized, quadriplegic, diagnosed 14 years ago, 
totally aphonic) and his wife CALS2. 
C= we have some problems with the provision of material from the NHS and the 
pharmacy and the company delivering these things.  
 
Patients and carers recognize that domiciliary aids like wheelchairs, orthopaedic beds, 
lifters are very useful and necessary, often difficult to accept because when they are 
required they mean a progression of the disease. In the following example this patient’ 
wife suggest that neurologists, rehabilitation specialists and providers should be more 
efficient and prescribe these facilities earlier in the course of the disease. 
 
PALS3( male, age 60, on a wheelchair, severely dyspnoeic, diagnosed 5 years 
ago. In NIV at home) and his wife CALS3 
C= for this kind of patients aids should be provided quickly. Maybe anticipating 
their needs. Now he has a good electric bed, but we in the beginning they gave 
us another mechanical one and we had to change it after a short time. Why 
didn’t they prescribe this one at the beginning? They know the way the disease 
progress. The same with the wheelchair. 
 
Even palliative drugs are not always reimbursed from the NHS and their cost can be a 
real burden for families in long periods.  
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CPD3 is the wife of PPD3 a gentleman in his 70, diagnosed 27 years ago. 
Cognitive impairment, Wheelchair bound, living in a long term facility)  
C= our neurologist prescribed to my husband a drug to substitute apomorphine. 
I had to go to buy it in a Pharmacy far from our city. It wasn’t reimbursed by the 
NHS and was very expensive. I had to pay about 230 euros each box. It was 
effective, but we had to stop it.  
 
Expensive devices 
 
Participants highlighted the difficulties they met when they needed expensive aids. For 
people severely disabled lack of electronic communicators or cars adapted for disability 
can be fundamental facilities can cause social isolation. In Italy there has been big 
discussion about the possibility to provide these aids to people severely affected by 
neurodegenerative conditions.  
 
PMS1 (male, age 53, diagnosis of MS 18 years ago, quadriplegic) 
P=If you need aids they give them to you only if they are disease related, I mean 
wheelchairs, hospital bed, air mattress etc, but as I need expensive remotes to 
control my electronic devices, or I had to buy a special van where I can enter 
with my chair using an elevator… well they didn’t help me at all. 
 
This family pioneered the request to obtain computer based communicators. The patient 
is a former local politician and raised his problem to the public opinion. He produced a 
video and broadcasted it on the internet to produce awareness about this issue. 
 
CALS1 is the wife of PALS1 (male 48 years old, bedridden quadriplegic, totally 
aphonic, tracheostomized.  Fully aware of his situation. He communicates using 
an alpha-numerical table. He’s waiting an electronic communicator that will 
allow him to have a voice decoder, e-mail access etc. )  
C= this new device, the communicator,(MY TOBII software package)  is too 
important for him. It’ll arrive next week, we had the chance to try it in a session 
at the hospital. It’s great. But it’s very expensive (€ 21.000). we applied for it at 
the NHS office, but they denied it. As it is fundamental for his Quality of life we 
decided to have it in any case. So he created an association called “A voice for 
Michele”. They are doing fund raising for it. On a parallel plane we continued 
asking to the NHS, he wrote to the town council, to the member of the regional 
committee in charge for public health and an the end they approved the grant. 
Now they say that they are providing it to him, but it was us who had to fight and 
ask and pester them! 
 
The following testimonial shows the similar problems in a tracheostomized ALS/MND 
patient 
 
PALS6 (male, age 50, diagnosed 13 years ago, tracheostomized, bedridden – 
wheelchair, quadriplegic, aphonic) and his wife CALS6 
I= what would you think could be helpful to you now? 
C= communicator, we are anxiously waiting for it! 
(….) 
P= (in the letter to the director of district NHS office to obtain the 
communicator) I need 24\24 assistance and for this, fortunately there is my wife 
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who does this impeccably. I really need this communicator. I tried it on June at 
the hospital. It’d allow me to navigate on the internet and write and send e-mails 
with its eye controlled device. On the screen there’s the fundamental alarm key 
that can be activated with only a glance! It’s an extraordinary tool for people in 
my conditions. If you won’t authorize this tool I won’t be able to afford it, 
because I’m a social case… 
 
 
3.5.2.3.7.4 Transport, holidays and respite  
 
Overall 14 participants raised unmet needs that could fit into these categories.  
 
Transport 
 
7 participants referred problem related to difficulties in transport. Adaptation of private 
cars, high cost of ambulance or taxis adapted for disability were the main topics of this 
category.  
 
This carer was explaining the reasons that induced her to admit her husband to a nursing 
home. One of the causes was lack of transport for his needs, when he had to go to his 
rehabilitation sessions, ambulatory controls etc.  
 
CPD3 is the wife of PPD3 a gentleman in his 70, diagnosed 27 years ago. 
Cognitive impairment, Wheelchair bound, living in a long term facility)  
C= I have to pay for all transports. I don’t receive any taxi coupon and I have to 
pay for ambulances.  
 
But it is not only a financial problem since even those participants whose transports 
were free of charge were not satisfied by public transports. 
  
PALS2 (male, age 39, tracheostomized, quadriplegic, diagnosed 14 years ago, 
totally aphonic) and his wife CALS2. 
C= to transport him to the hospitals for his routine controls is a problem. We 
don’t  pay for the ambulance because it is offered by the district domiciliary 
service. But we must wait for them hours, above all when it’s time to come back 
home. 
 
To move persons with high disability means moving equipments as well. Families 
report difficulties for this reason 
 
PMS2 (male, age 43, quadriplegic, can only move his neck, totally dependent in 
ADL), CMS2 his wife. 
C= we had to buy a Doblò (van that can host the patient on the wheelchair) to 
move. The problem is that if I drive I can’t look after him and his arm falls 
down… so, when we have to go for his visits, pump titrations etc, we call the 
AISM (patients association). Their volunteers come with their van, but you have 
to book their service about 8 days before, so sometimes we’re late at the visits. 
 
Patients struggle to go out and to leave their rooms in which they are often confined for 
long time.  
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CALS6 is the wife of PALS6 ( male, age 50, diagnosed 13 years ago, 
tracheostomized, bedridden – wheelchair, quadriplegic, aphonic) 
C= it’s so important to him to go to his home village in summer. When he’s 
there he recuperates. He has his friends, his land.. It is located 800 kilometres 
far from here. 
But to go there we have to rent an ambulance where we can plug the ventilator 
and the in-exsufflator. It’s very expensive. We travel when they come in these 
whereabouts to transport another patient, so we can save some money travelling 
in there way back. 
 
Holidays 
 
When asked about important issues 10 patients and families participants raised their 
desire to go on holiday. This was not just for leisure, but really to have a break far from 
the disease, from the setting where they have to face disability, isolation and losses. It is 
an attempt to reinforce normal family relationships, play with children and feel 
“normal”. Unfortunately it seems that it is not so easy to satisfy this need. 
 
PMS2 (male, age 43, quadriplegic, can only move his neck, totally dependent in 
ADL), CMS2 his wife 
P=It’s a long time since I can’t go on holiday (….) it’s not just a question of 
where, but also of how I can get there 
C= if I drive our car I have to choose if carry him or his belongings, his 
baggage, 2 wheelchairs…. AISM (patients’ association) doesn’t offer this 
service. You feel discouraged when have to move so many aids like pads, devices 
etc .  
 
Respite 
 
Some carers talked about their tiredness due to the burden of the care they have to 
provide. 
This carer describes how heavy is to care for her tracheostomized MND/ALS husband 
 
PALS1 (male 48 years old, bedridden quadriplegic, totally aphonic, 
tracheostomized.) and  CALS1, his wife 
C= personally I’m very distressed! I’m tired, I don’t even have 5 minutes to do 
what I like. I can’t go out, I mean anything. (….) since he has been 
tracheostomized we can’t leave him alone not even for 1 minute!  
 
Similar feelings appear in this interview with the wife of a very ill MSA patient 
 
CMSA1 wife of PMSA1 a gentleman 73 years old, diagnosed 4 years ago. 
Bedridden with muscular rigidity and serious communication impairment 
C= I’m always so busy. I’ve got to go to the GP’s ambulatory for prescriptions, 
go to the district office for authorizations, to go shopping and other errands… I 
don’t have anyone who can help me in these daily tasks.  
 
This MS patient’ wife testify how hard is to accept to be helped. Even though she states 
to be really tired and in need for respite she is not sure about a hospice admission 
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because she would feel guilty and is not confident about the quality of care that her 
husband could receive in her absence. 
 
PMS7 (Male, age 73, diagnosed 25 years ago. Wheelchair bound, anarthric, 
cognitively slightly impaired) CMS 7 his wife. 
C= I have always refused to be helped. I am plenty of needs, but this is the way I 
am. (…)I’d feel to go and leave him only if I knew he’s very well cared for.(…) A 
respite care admission would really be of help. (…) 
C=Before I had some time for me, I went out for a pizza with my colleagues.. 
now I’m shut in this house and I knew it. I reached a point where I can’t have a 
chat with others.(…) 
C= about myself I must say that that I’m burned out. (…) 
C=I need to go away for some days, to walk off, to sleep… also in the day, even 
if he‘s quite without troubles I’ve always my ear pointed on him. I want to stay 
alone!   
I think a respite care could be helpful, but I have to see if I’d be able to leave 
him. 
It’s so hard to leave. I left him only twice, always to go to visit my daughter 
who’s living abroad. I need a strong motivation and the certainty that he’s well 
cared for. 
 
3.5.2.3.7.5 Need for paid carers and volunteers 
 
In 16 interviews out of 22 need for paid carers able to provide help in the care of the 
patient came out. 8 participants stated that they would be happy to receive visits from 
volunteers. 
This is a striking need showing different problems: it can be due to financial issues 
because paid carers often are totally at families charge, but it can be a problem of 
acceptance since many participants testified how hard is to trust unknown people giving 
them hard responsibilities from which their loved ones lives can depend.  
 
Paid Carers 
 
Some carers urge for practical help in the house 
PMS2 (male, age 43, quadriplegic, can only move his neck, totally dependent in 
ADL), CMS2 his wife. 
C= we called them (the social service managers) because we need help. A 
person who can spend the morning with him. I don’t need a nurse, because I do 
everything of it. Just someone who stays with him 
P= that’s our main need! 
 
 
This carer reinforce this concept stating how help is required for many different tasks 
 
PALS4 (male, 61, quadriplegic, on a wheelchair, cachectic, severely dyspnoeic 
in NIV diagnosed 3 years ago) and his wife CALS4 
C= in terms of needs, we need help for everything! Family management, 
housekeeping are very challenging. You are keen to help as much as possible, 
but you’re so busy! So if there were another person who could help in the day 
this  would be so useful! 
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(… )people  totally unable to do necessary things should receive constant 
assistance! 
 
Similar findings came out in this interview where the patient’ wife and their two 
daughters were discussing about their needs at home 
 
PALS9 (male, 77 diagnosed 8 months ago) and his daughter CALS9, his wife 
WALS9, and a second daughter DALS9 
W= he needs assistance for the whole night. It’s a problem because he has wires 
and tubes all around him. 
C= he sleeps in his bed and one of us  has to spend the night close to him. We 
work on shifts, one night each.  
D= so, every now and then, we have to pay for a carer who gives us a rest. 
 
This patient recognises that his wife needs help. He complains about the absence of help 
and about financial support 
 
PMS1 (male, age 53, diagnosis of MS 18 years ago, quadriplegic, using NIV in 
the night, CMS1 his wife) 
The first need we have is a help for my wife! My wife had to be admitted to the 
hospital for surgery. She is my only caregiver and I’m totally dependent on her. 
I didn’t have any form of assistance. I had to pay a private carer days and 
nights. And when I ask to detract its cost from the taxes they didn’t allow me. 
Not even an Euro. The more you are down the more they push you down. If you 
have money you can afford it, but if you don’t, well..  
 
This PD patient’ wife talks about the impact of her poor health status on her difficulties 
to care for her husband. She is really worried about what could happen if she was not 
able to care for him for an acute disease 
 
PPD1 (male, age 80), CPD1 his wife 
C= his pension is about 1000 euros per month. If I had to pay for caregiver day 
and night… I couldn’t afford it. So if I had a problem like a back pain… I don’t 
know what I could do. (…) I had 2 hips replacement, shoulder surgery, I must 
take care of myself. 
 
This other carer is already helped by paid carers, but she complains because with the 
worsening of her husband disability she needs more help. 
 
PMS3 (male, age 46, blind, quadriplegic, muscular spasticity, fed by PEG), 
CMS3 his wife. 
C= I just want to be helped a little more than I was in the past years. What I 
need is not to be left alone ( in the management of my husband), because 
otherwise sometimes you are not rational enough. (…). Now things are worse. 
He needs an assistance 24 hours a day. Now, after a long bureaucracy, we 
obtained a sick-benefit. It allows us to pay a caregiver 8 hours a day, 5 days  
week, while I’m at work. It was approved for this year, I hope they’ll renew it 
and maybe increase a little so I can have this carer helping me on Saturday 
morning when I have to bath him 
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Other similar data appear in the following citations were participants, both carers and 
patients, recognise how the need for good paid carer is not satisfied in their situations. 
 
CALS5 is the wife of PALS5, a totally dependent gentleman wheelchair bound 
and severely dyspnoeic. PALS5 (male in his 70ies, quadriplegic, aphonic, on a 
wheelchair. He is a retired doctor). 
C= I have to pay for a private assistant. He’s living with my husband 15 hours a 
day. He’s very good, we couldn’t stay without him. I can’t manage to toilet him 
or move him anymore. In the hours when we he is off duty I’m alone and I’d 
need a help. I’m very tired. 
 
This MSA patient’ daughter adds how in their experience paid carers do not collaborate 
with their programme of care and they cannot rely on them. 
 
PMSA1 (MALE 73, bedridden. caregivers are his wife and one of his daughter 
CMSA1 
C= it’s not easy to find a good paid carer. We changed a couple of them. They 
don’t do what you ask them to. My father has to some physiotherapy exercises 
during the day. But if you don’t control them they don’t do it. 
 
This couple reports other problems with their paid carers 
 
PPD5 (woman age 78, cared for by her husband -CPD5- at home) 
C= I have to go shopping, on errands and to manage the house. She stays at 
home with the paid carer we have. She’s staying here for 3 hours in the morning 
and sometimes in the afternoon if I have to go out. (…) 
C= in the morning she stays home with the carer. We have several problems 
with these persons (…) we had to change many of them because they are not 
Italian, they are from eastern Europe and are irregulars. Many of them they 
steal in our flat. We had their names from a volunteer of our church. She said 
she knew a friend of her… 
P= this one is even worse than the others. 
C= the problem is that I have to leave her at home with them.  
 
In this situation paid carers are absolutely necessary because the patient lives alone and 
without this help she could not stay in her preferred place of care 
 
PMS4 (71 years old woman diagnosis 42 years ago. Paraplegic, wheel chair 
bound, lives alone helped by paid carers) 
I live alone. I’m receiving a paid caregiver since 16 years. She’s paid for the 
social assistant for 2 hours and 1\2 in the morning. Than there’s a boy who 
helps me when I have to go to bed or get up.. sometimes he goes on errand for 
me. 
I= is the municipality paying for him? 
P= yes.  
I= is he paid for an amount of hours?  
P=yes, about 60 hours per month. We manage it depending on my needs. 
 
The following data is from an interview with an MS patient wife during which their son 
arrived at home and provided some comments about his mother attitudes in the care of 
the patient. 
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PMS7 (Male, age 73, diagnosed 25 years ago. Wheelchair bound, anarthric, 
cognitively slightly impaired) CMS 7 his wife and SMS7 is their son. 
S= it’s not an economic problem. It’s her difficulty to accept help now (…). We 
would need to be addressed to a service that could help us.  
S= it’s what me and my sister are trying to explain to her.(…) it’s not just a 
question of money, it’s she that doesn’t want to accept a concrete help. (…) it 
might be a relief to know that there’s a paid carer able to stay with dad and give 
you 2 hours to do what you like. 
 
Volunteers  
 
Issues about the need and the role of volunteers appeared in the data with different 
meanings. In some case they were available, but their role was not clear at participants 
eyes. 
 
PPD5 (woman age 78, cared for by her husband -CPD5- at home) 
I= do you have volunteers who come here and stay with you? 
C= yes, volunteers from the parish church. They come to bring us the 
Communion. (….) volunteers, if we really need them, come and give us a hand.. 
P= (Angrily!) What do you say? I’ve never seen a volunteer here washing a 
plate! 
C=(..) there are 2-3 volunteers from the church.  
P= But what do they do? 
C= nothing… they just come and visit us.  
I= are you happy that they come? 
P+C= yes. 
 
This carer feels that volunteers could be a solution for their needs, but she says that she 
could not find any and she fears that they could not cope with her husbands’ problems 
 
PALS1 (male 48 years old, bedridden quadriplegic, totally aphonic, 
tracheostomized.) and  CALS1, his wife 
C= here voluntary service don’t exist. We would have really benefit from it. 
Maybe to ease a little our carer during the day. She has a child and sometimes 
would require some rest. And then it would be money saving for us! We went 
asking to our parish church, but they don’t have anyone. And then I fear that 
when they see such machines they’d flee.  
 
This patient identified clearly how a volunteer could help her for. 
 
PALS7, (woman 60 years old, diagnosed 12 years ago, quadriplegic, dysharthric, 
dyspnoeic, NIV 24 hours a day)  
P= I’m looking for a volunteer to help me by turning my books pages. It would 
be very important to me because real books are better than electronic ones. 
 
This patient looked enthusiastic at the idea to receive volunteers  
 
PALS6 ( male, age 50, diagnosed 13 years ago, tracheostomized, bedridden – 
wheelchair, quadriplegic, aphonic) 
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I= wouldn’t you feel invaded or oppressed if other people came here? 
P= no! 
C= many don’t come saying they don’t want to disturb… My husband on 
contrary, would be so happy to have them here! 
I= what about volunteers, would you be happy to have someone coming here to 
chat with you? 
P= please send them here! 
 
This carer says volunteers can be a good idea for the next future, even though they had 
never thought about it. 
 
PPD2 (male, age 70, fluctuating motor symptoms with freezing episodes 
alternate to severe dyskinesias) CPD2 his wife 
C= we have never looked for volunteers because we can manage things by 
ourselves. But tomorrows who knows. I am of his age and have my problems.. I 
hade a mild stroke and still have problems at my left side. 
 
3.5.2.3.7.6 Summary 
 
Among the different categories of social needs reported in the interviews the sense of 
social isolation for both the patients and the carers was the most frequent and 
burdensome. Economic and financial problems were also discussed together with the 
need of home care assistants and volunteers required to provide help, but difficult to 
obtain from the existing services.  The long duration of the diseases together with the 
high disability of the patients  raised other peculiar  social issues like the problematic of 
the transports and the need of holiday and respite. 
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3.5.2.3.8 The content analysis of the spiritual needs 
 
Spiritual issues were less frequently reported by participants than other categories of 
unmet needs. Often researchers had to probe this group of existential needs with direct 
questions. In only a few interviews participants talked about these themes at the 
beginning of their stories. Usually this group of needs was discussed at the end of the 
events and, in some cases, participant recognised that spirituality was very important for 
their QoL.  
In the following chart 3.4 and table 3.6 the results of content analysis related to the 
spiritual themes emerged from the interviews are summarized 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chart 3.4: the spiritual needs 
 
 
 
 
Spiritual needs and themes 
 Number of citations Percentage  
Meaning 11 50% 
Justice 6 27% 
Hope 5 23% 
Rage, loss of control 7 32% 
Faith, religion, love 5 23% 
Spiritual support 12 55% 
Tab 3.6 the spiritual needs 
Chapter 3. The Qualitative Needs Assessment 
 120 
 
 
 
3.5.2.3.9 Spiritual needs detailed analysis 
 
In this chapter a detailed analysis of the spiritual content of the interviews is presented. 
Participants will be identified with the same short forms used for the physical needs. 
 
3.5.2.3.9.1 Meaning 
 
Searching for a meaning of the lived experience is a typical spiritual need (quote). 
Some participants reported to have found a meaning in their experience of disability and 
life threatening condition, but this does not mean that they accept it easily. Others stated 
to believe they can find that meaning in the future. 
This patient recognises her difficulties in accepting her condition 
 
PALS7 (woman 60 years old, diagnosed 12 years ago, quadriplegic, disharthric, 
dyspnoeic, NIV 24\24 by nasal mask that enable her to talk). 
P=This doesn’t mean that I accept this disease. I deal with it. I’m sure that I’ll 
discover the reason for this when I’ll be up there. Because down here I don’t see 
any reason for this.  
 
This patient was experiencing a strong revision of her life and she felt that the impact of 
the disease had been so bad for her and her husband that she would have changed her 
mind about her choices in life if she had known it beforehand.  
 
PPD4 ( woman, age 60, cared for by her husband –CPD4- at home, in DBS) 
P= if I knew that I was going to fall ill one year after our wedding I wouldn’t 
have married.  
 
This carer, after having described the psychological difficulties of their younger son in 
coping with his father disease resulting in deep changes in his behaviour talks about the 
meaning of such devastating experience for the other familiars and the role of external 
help 
 
CALS4 is the wife of PALS4 (male, 61, quadriplegic, in a wheelchair, cachectic, 
severely dyspnoeic in NIV diagnosed 3 years ago)  
C=We believe in psychotherapy. For our family it is very important. It is helping 
my son that is very depressed (…) and it is not easy to have him like that 
wandering in the house in that condition. It’s also a matter of spirituality in a 
sense 
 
Decisions and choices at the end of life can be affected by having found a meaning for 
what is happening in that experience. 
This carers explains that being aware that her husband is likely to die changed her plans 
about the place of care for her loved one 
 
CMS3 is the wife of PMS3 (male, age 46, blind, quadriplegic, muscular 
spasticity, fed by PEG),  
C= doctors told me that my husband arrived at the end of his life. For this 
reason they wanted me to place him in a nursing home because I wasn’t going to 
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be able to manage him at that stage, at home. I said:” What?  I’ve cared for him 
for years alone and now that you say that he’s at the end I should park him 
somewhere else? Absolutely not! We’ve never been divided except for the short 
time when I had surgery. I’ll take care of him in our home. 
 
There were contrasting findings between similar situations that caused completely 
different decisions. This was particularly clear about end of life decisions. Patients who 
found a meaning in life even with high disability coped well with choices who 
prolonged their life in spite of higher disability. Some would do the same choices again, 
some do not want to consider it. All these choices hide different meanings deeply found 
by participants in their lives when physical conditions dramatically change. 
 
This citation is from a ALS/MND patient who was tracheostomized in emergency for a 
respiratory arrest even though he had previously refused this option. Following this 
decision he is happy and would do it again. His wife is very supportive of his choice 
despite the high burden of care that she as to face. 
 
PALS1 (male 48 years old, bedridden quadriplegic, totally aphonic, 
tracheostomized.) and CALS1, his wife 
P= well, I think I’m lucky because my disease is stable. 
I= would you consent again to the tracheostomy? 
P= yes. 
I= do you mean it’s worthwhile living like this?  
P= yes 
C= my idea is that living is always worthwhile. I can’t accept the idea of dying. 
(….) my opinion is that life must be lived in any condition. This is true only if  
you’re conscious, because if you’re not others will have to decide for you.  
 
In contrast another patient with the same diagnosis decided not prolong his life because 
he could not find a meaning in his life in that condition. 
 
PALS3 (male, age 60, on a wheelchair, severely dyspnoeic, diagnosed 5 years 
ago. In NIV at home) and his wife CALS3. 
P= I don’t want tracheostomy. That is not life. 
(…) 
P= everyone can think what prefer. I don’t want to suffer for these things. 
Please, let’s give a blow, I don’t want to suffer more. 
 
Another patient reports the same decision and his wife talks about their concern not to 
be respected in their decision. 
 
PALS4 (male, 61, quadriplegic, on a wheelchair, cachectic, severely dyspnoeic 
in NIV diagnosed 3 years ago) and his wife CALS4 
P= now I state that I don’t want to be tracheostomized, but the neurologist told 
that even if a prepare a living will it might not be respected by a doctor if I were 
took to an intensive care unit, in case of emergency. 
C= I think I’d like that every person could decide freely about his end of life 
decisions. 
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This patient gave his consent to tracheostomy and mechanical ventilation, but he says 
that sometimes he thinks to withdraw it. Having found a meaning in his actual life he 
endures in his decision to stay alive 
PALS6 ( male, age 50, diagnosed 13 years ago, tracheostomized, bedridden – 
wheelchair, quadriplegic, aphonic) 
P=Sometimes I wonder, without finding  any answer: “ there is  more courage in 
living or in dying?” if euthanasia were legal perhaps… but then not, I can’t and 
I don’t want to quit. 
 
This very religious woman thought a lot about the decisions at the end of life. She was 
considering tracheostomy and PEG at the time of the interview because her breathing 
and swallowing were both deteriorating quickly. Asked about these decisions and the 
implication of the meaning in her choices she said: 
PALS7, (woman 60 years old, diagnosed 12 years ago, quadriplegic, dysharthric, 
dyspnoeic, NIV 24 hours a day)  
P= I read the letter written by Cardinal Martini and I found it wonderful 
because, talking about heroic treatment, he says that:” don’t allow a person to 
reach the end of his life means refuse his or her meeting with the Father that is 
waiting for him or her.” And that’s true. Everyone of us has its own time 
 
She wanted to comment about the discussion that was on the news on those days in Italy 
about the request of a tracheostomized ALS/MND patient to withdraw his mechanical 
ventilation and to die peacefully. She commented about the meaning of that decision 
stating that it was morally correct because that man fought with all his energy against 
the disease, but at the end his suffering became meaningless: 
  
I think that Welby’s case,  the ALS patient who died when his doctor sedated him 
and switched off his ventilator and is under a trial for euthanasia, shouldn’t be 
considered euthanasia because a man who lived 20 years communicating with 
the eyes, tracheostomized, with a PEG, showed a strong attachment to life. If 
then, in spite of his invasive ventilation, he had apnoeas and suffered for 
breathlessness this means that his body couldn’t go on anymore…. So let’s 
unfurl the sails!  
 
Finding a meaning can be described as the sense of completeness of one owns life as 
testified by this patient    
  
PMS4 (71 years old woman diagnosis 42 years ago. Paraplegic, wheel chair 
bound, lives alone helped by paid carers) 
P= What I cannot accept is therapeutic heroism, overtreatment. If necessary I’ll 
state it on a written form. It’s useless, it just prolong absurd suffering, delusions. 
This is what I think.  
(…) 
My respiratory tests were totally unsatisfactory, but I refused mechanical 
ventilators. I’ve had enough, I lived my life. 
 
 3.5.2.3.9.2 Injustice  
 
When the sense of meaning cannot be found a sense of injustice about what is 
happening to affect patients and families. 
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Sometimes it appears under the form of a recrimination towards God or the fate when 
participants feel not to deserve their conditions 
 
PMS1 (male, age 53, diagnosis of MS 18 years ago, quadriplegic, using NIV in 
the night) 
P=I’ve never hurt anyone and I’m not even able to swear… and that’s the nice. I 
never swear, I store all inside, also pain, and the is the way they pay me back. 
 
 
This patient has been affected by MS for decades and is actively involved in the local 
MS patients association. She stated that she accepted her conditions, but she feels unfair 
to see younger people facing worsening disability without having the possibility to stop 
it. 
 
PMS4 ( woman, 69 years old, diagnosed 42 years ago, quadriplegic, living 
alone) 
P= we have so many young people affected by this disease in our association. 
Boys that didn’t receive anything in this life. 
 
Injustice is also described as the lack of reward for having lived a socially correct life, 
with the expectation to enjoy serene years after retirement.  
 
PALS3 (male, age 60, on a wheelchair, severely dyspnoeic, diagnosed 5 years 
ago. In NIV at home)  
P= I worked 37 years and never asked for sick-leave. (…) can you imagine 37 
years without a single day of sick-leave? Then I retire, I was so well.. and now 
this. I cannot accept this, no way! 
 
Having to struggle to obtain what participants thought to have the right for evoke 
another sense of injustice. This patient feels he has the right to obtain an electronic 
communicator and wrote a letter to the Health District manager complaining about the 
refusal that he had received. He uses a metaphoric expression to state his sense of 
injustice for not having had his need satisfied because he politely avoided to quarrel 
with the involved office.   
 
PALS6 (male, age 50, diagnosed 13 years ago, tracheostomized, bedridden – 
wheelchair, quadriplegic, aphonic) 
P=Unfortunately I learnt that in some people’s life I’d rather enter and exit on 
the tip of the feet.  
 
A further cause of injustice can be caused by the sense of guilt that is well explained in 
the interaction between this patient’ wife and her daughter 
 
CMSA1 wife of PMSA1 a gentleman 73 years old, diagnosed 4 years ago. 
Bedridden with muscular rigidity and serious communication impairment. 
DSMA1 their daughter 
C= when you have to face with experience like this one .. life changes so much. 
You don’t have time for yourself. 
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D= she could have time if she let us help her. But she doesn’t permit to be 
helped because if she saves some time for her then she feels guilty and she feels 
like if this was unjust.   
 
3.5.2.3.9.3 Hope 
 
The spiritual meaning of hope can be seen as having the hope to improve ones own 
physical condition. 
 
PALS2 (male, age 39, tracheostomized, quadriplegic, diagnosed 14 years ago, 
totally aphonic) and his wife CALS2. 
P= the only thing that really support me is hope. I hope to recover. Is the hope 
that one day they’ll find a cure for me. Is this a visionary hope? Well it helps to 
boost my morale!  
 
Hope can also be an attempt to justify strange decisions, such as in the following 
example where this couple went twice to China for a stem cells transplantation (that did 
not provide any improvement) against the neurologist’s advice 
 
PALS4 (male, quadriplegic, on a wheelchair, cachectic, severely dyspnoeic in 
NIV diagnosed 3 years ago) and his wife CALS4. 
P= what did I have to lose? 
C= no one could offer him alternatives. 
 
 Lack of hope can lead to desperation and confusion  
 
PMS1 (male, age 53, diagnosis of MS 18 years ago, quadriplegic, using NIV in 
the night)  
P=After so many years of my disease I don’t know what to hope, what to think, 
what to say, what to do. 
 
Hope can be seen as the opposite of acceptation  
PMS4( 71 years old woman diagnosis 42 years ago. Paraplegic, wheel chair 
bound, lives alone helped by paid carers) 
P= these are MS realities: It’s useless to have hope. You just have to accept. 
 
Carers can experience frustration when they feel that their loved one lost his or her hope 
and do not fight against the disease. 
 
CMS6 wife of PMS6 a 53 years old gentleman EDSS 9, fed by PEG, almost 
totally dependent in the ADL 
C=He really speaks very little. It’s due to the disease. I try to scold him, to 
stimulate him because he let himself go. He doesn’t react as others do. It’s like if 
he said:” I’m ill and it’s fine, let me stay”. I don’t like it, it’s like if he lost his 
hope. 
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3.5.2.3.9.4 Rage and Control 
 
When asked about their spiritual feelings evoked by the experience of disease 
interviewees talked about the rage and the loss of control caused by the disease.  
 
PPD2 (male, age 70, fluctuating motor symptoms with freezing episodes 
alternate to severe dyskinesias)  
P=I become angry with the Chief Clerk who stays over there (meaning God) and 
I tell him: “ Please look on another side, is it possible that you always have to 
look here!” 
 
PMS1 (male, age 53, diagnosis of MS 18 years ago, quadriplegic, using NIV in 
the night) P=It looks like I’m the only crucified here! I’ve always been correct 
with the other people, polite with everyone. This is the way I’m paid back. 
 
Relentlessness of the disease progression cause rage and affects the coping strategies of 
the families. 
 
PMS2 (male, age 43, quadriplegic, can only move his neck, totally dependent in 
ADL), CMS2 his wife. 
P=It’s because of all that happens to you. When you say, come on perhaps we 
can breathe a little, we can have a break, suddenly something worst happens! 
 
Rage can be the strength enabling patients’ to go on in life as testified by this patient 
who gave us part of a letter that he wrote with the computer to the NHS manager who 
should approve his application for a new computer based communicator 
 
PALS6 (male, age 50, diagnosed 13 years ago, tracheostomized, bedridden – 
wheelchair, quadriplegic, aphonic) 
P= “I know I’m a load for everyone, but what can I do? My disease takes away 
everything: strength, voice and dignity. I can’t recover, but help me to survive. 
According to statistics I should have been dead a long ago. But I have a strength 
and a rage inside that I could smash the world.” 
 
Rage can also be a symptom of frustration for being stuck in a wheelchair and totally 
dependent on the others. 
 
PMS4 (female, 69 years old, diagnosed 42 years ago) 
P= for the family you’re just a heavy load. This is the dark thing, this is the thing 
that makes me curse, swear. 
 
The importance of being in control of what will happen and to maintain autonomy in 
decisions can be associated with the sense of frustration reported by participants about 
the potential loss of this aspect of life. 
 
PALS7 (woman 60 years old, diagnosed 12 years ago)  
P= about living will I agree but: it must be done when I am very close to a 
decision. I can’t state now about issues that will happen in 10 years. Then it’s an 
absurd that to do this you have to go to a notary. 
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PALS4 (male, 61,  quadriplegic, on a wheelchair, cachectic, severely dyspnoeic 
in NIV diagnosed 3 years ago) and his wife CALS4 
P= now I state that I don’t want to be tracheostomized, but the neurologist told 
that even if a prepare a living will it might not be respected by a doctor if I were 
took to an intensive care unit, in case of emergency. 
C= I think I’d like that every person could decide freely about his end of life 
decisions. 
 
3.5.2.3.9.5 Faith, religion and love 
 
Spirituality and religiousness are not synonymous. Love is often described as the main 
characteristic of God and has a profound religious meaning. Participants talked about 
these themes highlighting their different feelings and position about these issues. 
  
This patient totally impaired in his speech, showed us this prayer that he wrote on his 
computer to express his faith 
PALS5, male in his 70ies, quadriplegic, aphonic, on a wheelchair. he tries to 
communicate using a computer keyboard. Very slow. He is a retired doctor)  
P= “ Faith to me is  the pursuit in the fatigue, in the dark of doubt. I don’t 
believe in sudden flashes, in the graces meant as miracles. Doubt, discount, 
light. Grace is for very few on Damascus road. My Lord, this is not the time to 
search the reasons for faith. Highest Grace is abandon myself in You. Total trust 
in your hands, my Lord. To live in daily precariousness with my angels and in 
Your Love” 
 
And this woman talks about the importance to have faith and how she can justify what 
happens in life, find a meaning, because she believes in God’s plans 
 
PALS7, (woman 60 years old, diagnosed 12 years ago, quadriplegic, dysarthric, 
dyspnoeic, NIV 24 hours a day)  
P= faith helps in the important things of life. This was our lives journey. I’ve 
never thought to be immune from illnesses. I had friends who died of cancer, 2 
sons of our friends died for car accidents… nobody was born with guarantees. 
 
(and talking about withdrawing vital support treatment) 
 
P=I think that is a way to say: let me go up there, because up above someone is 
waiting for me. 
 
This couple is very religious and found a deep support in their faith. The patient was not 
able to talk, but he strongly wanted to testify his faith and agreed with his wife 
statement 
 
PMS7 (Male, age 73, diagnosed 25 years ago. Wheelchair bound, anarthric) 
CMS7 his wife. 
C= after diagnosis my husband put his life in Our Lord’s hands. 
(….) 
C= I try to explain my husband’s point of view about the meaning of this disease 
and relationship between spirituality and this experience, I’ll ask him to confirm 
or not if this is correct: in the beginning of the disease he said – I’ll never ask to 
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Our Lord to heal me, because if he wants to he does it anyway. If he gave this 
disease it must be of use for something or someone 
 
Faith is not always seen as having a positive impact on participants’ experiences. 
 
PMS2 (male, age 43, quadriplegic, can only move his neck, totally dependent in 
ADL), CMS2 his wife. 
C= We are believing, but… sometimes you ask yourself if you have to believe or 
not… 
 
CMS6 wife of PMS6 a 53 years old gentleman EDSS 9, fed by PEG, almost 
totally dependent in the ADL 
C= we used to attend the church. Now he doesn’t feel like going anymore. Once 
two priest of our parish came for dinner, it was nice. But then they changed and 
we didn’t have the chance to meet the new ones.  
  
3.5.2.3.9.6 Religious support 
 
Support provided by priests or other religious assistance was very well accepted and 
recognized as positive by a part of our participants and refused or not seen as useful by 
others. 
This can be affected by having been religious persons (or not) before the experience of 
the disease, but also by the possibility of being supported by someone who can or is 
supposed to provide religious support. The following citations testify how good 
relationships with religious professionals result in a good spiritual support during the 
disease. 
 
PPD1 (male, age 80, cognitively slow but able to understand and severely 
disabled in his movements. During the interview was admitted in the 
neurological ward for symptom control) CPD1 his wife. 
C= he has always attended our parish church. He went to the Mass. (…) now the 
priest should come to meet him. I always say that I should go and tell him to 
come! 
P= I follow the Mass in television.  
C= (..) it helps him, because he’s so sad and often cries.  
 
PMS1 (male, age 53, diagnosis of MS 18 years ago, quadriplegic, using NIV in 
the night) 
P=Once a month a priest comes here to meet me. He gives me the Holy 
Communion. We exchange 2 words, we talk about some things. It’s a small 
relief. 
 
PMS4 (71 years old woman diagnosis 42 years ago. Paraplegic, wheel chair 
bound, lives alone helped by paid carers) 
P= as religious support I’ve a good relationship with the parson. (…) he knows 
that I curse like a Turkish, but he says that the Lord understands everyone’s 
intentions. He’s a person with whom I can talk about everything. He’s a real 
support. According to our Church dispositions I shouldn’t receive the Holy 
Communion, being divorced. He and his predecessor have always given it to me.  
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Once he went to the hospital where my partner was admitted for his cancer. He 
went to meet him and told him he was there by chance, just because he went to 
see a parishioner admitted in the same hospital. Later on I happened to know 
that it wasn’t true. He went there just to meet him. We found responsible people. 
 
 
PALS9 (male, age 77, diagnosed 8 months ago, in NIV, CALS9 his wife) 
C=He’s very happy when the priest and his friends come and talk about their 
past, the things they did together… 
 
Sometimes a religious support would be well accepted, but this need cannot be satisfied 
because it is not available 
 
PPD5 (woman age 78, cared for by her husband –CPD5- at home) 
I= do you think that a priest could help you to cope with your disease related 
distress? 
C= well, we have been living here for 4 years and.. well volunteers from the 
church say that priests are few and have so many people to visit.. 
We had one priest who came in the past, but now he has disappeared. 
 
Lack of contacts with the local church can be due to little no interest of patients or 
families about it 
 
PPD4 ( woman, age 60, cared for by her husband –CPD4- at home, in DBS) 
C= we don’t have any contact with our church. We just have friends or 
neighbours who come and visit us.  
 
Some participants wanted to state clearly that they were not religious persons and, 
consequently did not want to receive any form of spiritual support  
 
PALS4 (male, 61,  quadriplegic, on a wheelchair, cachectic, severely dyspnoeic 
in NIV diagnosed 3 years ago) and his wife CALS4 
C= we are not religious at all and we don’t believe in religious support. 
 
Religious support was sometimes tolerated, though not really felt as important or not 
specifically tailored on peoples’ needs 
 
PALS1 (male 48 years old, bedridden quadriplegic, totally aphonic, 
tracheostomized) and CALS1, his wife 
C= there’s his uncle, he’s a retired priest, sometimes he comes to visit him.  
I= is he helpful? 
P= (he smiles ironically) 
C= I think that these issues are depending on the person. Or they help you and 
you start believing or… personally I live the sense of this experience day by day. 
 
Chapter 3. The Qualitative Needs Assessment 
 129 
 
3.5.2.3.9.7 Summary  
 
Spiritual needs themes that could be extract from the interviews focused mainly on the 
concept of meaning of the experience of the disease and ambivalence about the role of 
faith, religiousness and spirituality at these stages of the disease.  
Other profound spiritual issues reported by participants were the sense of justice or 
injustice related to what was happening to them, the need and difficulty to hope, the 
sense of rage and fear to lose control of their existential values.  
 
 
3.5.2.3.10 Service satisfaction 
 
Patients and their informal carers provided comments about the degree of satisfaction 
related to the available services that they experienced in the advanced stages of the 
diseases.  
Results from the content analysis of the interviews are presented in this section of the 
thesis.  
Comments could be either positive or negative in terms of effective help received when 
needs occurred. The primary aim of this enquires was to determine what could be done 
by the experimental new SPCS to integrate existing services by: 
• providing effective help in those fields were existing services were lacking or 
not tailored on patients needs 
• on the other hand, not to double existing services when they were fully 
satisfying participants needs. 
 
3.5.2.3.11 Content analysis of the service satisfactions’ themes 
 
The content analysis of the transcript verbatim of the interview revealed the following 
fields of interest to be explored: 
 
• Hospital based services 
• Primary home care and emergency services  
• Other services like respite facilities, physiotherapy, speech and language 
therapy 
• Social services, technical support    
 
Results revealed various levels of satisfaction in the different analyzed services.  
In table 3.7 these results are summarized and presented categorized in terms of 
satisfactory and not satisfactory outcomes from the participants perspective. 
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Service Satisfied Not satisfied 
Hospital based services 16/22 8/22 
Primary home care and 
emergency services 
 
9/22 22/22 
Other services like respite 
facilities, physiotherapy, 
speech and language 
therapy 
 
11/22 17/22 
Social services, technical 
support 
 
7/22 14\22 
Table 3.7: satisfaction or not satisfaction of participants about different specific services. 
In each interview more than one comment could happen about the same group of 
service, for this reason the sum can exceed the number of interviews 
 
Some comments were also captured from participants’ reports about their point of view 
about a new experimental SPCS aimed at providing help in their conditions. 15 
participants provided a positive comment about this possibility, none were contrary. 
 
3.5.2.3.12 Detailed analysis of the service satisfactions’ themes 
 
Data from the interviews related to the degree of satisfaction about the available 
services are now presented. 
Participants were invited to describe the service that they had experienced, were 
experiencing or that were required. Some data was extracted indirectly from the 
transcript verbatim when occasionally comments about services appeared. 
 
Hospital based services 
 
All interviewees experienced hospital based services during the course of the disease. 
Generally they were in charge to a specific neurological clinic or cared for by the 
respiratory team. Some also experienced nutritional services or were admitted for 
sometime in a general hospital ward.  
Overall both patients and carers were satisfied about the support received by hospital 
services. Neurologists and respiratory services were generally reported as satisfying 
participants’ needs.  
 
Patients and carers appreciate the effort of professionals to provide a comprehensive 
care even when it is out of their duty or specialty 
 
PMS4, 69 years old woman, wheelchair bound, diagnosed 42 years ago 
P= the neurologist who diagnosed my MS, 42 years ago, Prof M, is like a 
brother for me, a relative, a  real friend. For all my needs (work related, 
familiar, personal etc) I’ve always relied on him. He has always been available 
with me… to me he’s a person to be put on a pedestal. 
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PPD2 (man 70 years old. Diagnosed 6 years ago. Severe dyskinesas and 
freezing)  
P= the neurologist that is caring for us is one of the best available, we’re very 
satisfied of him 
 
They recognise the positive attitude of those professional carers that try to compensate 
the lack of existing home services by visiting them when necessary. They seem also 
happy to be involved for scientific and educational purposes as described in the 
following citation where this tracheostomized patient was filmed by the respiratory 
team and the video displayed in scientific meetings to show their home organization and 
good coping with the disability.  
 
PALS1 (man 48 years old, tracheostomized, bedridden, quadriplegic, totally 
aphonic) caregiver CALS1, his wife. 
C= We are cared for by Dr Z. He’s the best for us. They have always been very 
supportive with us, even when we came back home. 
I= who trained you on how to manage respiratory devices? 
C= they did it, in hospital. But when we came home we modified some of them… 
when we arrived home we were a bit unprepared. You know in hospital if 
something doesn’t work you simply call for help, but at home… he needed some 
time to learn how to recognize symptoms and troubles and to realize if we had to 
worry or not. But to achieve this some time was needed.  
I= what about the respiratory service of the hospital: do they come here?  
C= no. well if they come they do it when they’re not on duty. Dr Z. comes, the 
others as well. They are happy to come and see the way we are organized. They 
filmed our place and showed it in a congress. 
 
When participants complained about hospital based services it was usually because they 
felt that their needs were not being met by the service or because they felt abandoned by 
their carers when the disease progressed and professionals could not be of help 
anymore. 
In the following sentence appears how this MS patient did not feel safe during routinely 
respiratory controls feeling in danger for his health rather than helped by the tests and 
visits 
 
PMS1 (Man 53 years old, diagnosis of MS 18 years ago, quadriplegic, using 
NIV for respiratory insufficiency) 
P=I stopped going to follow up visits for the ventilator. I used to go each 6 
month. They visited me, controlled my oxygen saturation with a sample of 
arterial blood. Once they were doing an X-ray scan to my back. I could not 
control my chest and neck and I was falling down; if it were not for my wife, who 
quickly caught me, I would have broken my neck and that would have been the 
end of the story. This happened 2 years ago. Since then I decided not to go to 
these control visits anymore. Another point is that they analyzed my respiratory 
functions with those tests where I had to inspire and expire in a tube. What if the 
patient before me had a chest infection? I’ve enough problems like this, I don’t 
want to risk. Yes, they changed the nosepiece, but the tube? That is the same for 
all patients!  
 
Next is an example of not satisfaction about the neurologist who diagnosed and cared 
for this patient for a long time. His wife complains because she felt like he discharged 
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them when he became very ill and now he had to be admitted to a nursing home because 
she was not able to care after him at home anymore. 
 
PPD3 (man in his 70es, diagnosed 27 years ago) and his wife CPD3. 
C= we have always had a good service from our neurologist. Lately he washed 
his hands about our situations. (…) when we were in need there were not 
available places for us. We had to book for the visit but the waiting list was of 
about 5-6 months. Even if it was urgent we had to wait. (…) 
C= the day I was carrying  him back home from the clinic (where he had been 
admitted for symptom control and were his condition worsened and they caused 
him a bedsore) a neurologist of the clinic took me aside and whispered to me: “ 
I want to suggest you one thing, if you own a flat sell it, and with the money you 
obtain put him somewhere. Your husband is not to be cared at home.”  
I answered him: “Do you tell me this? Do you know how many stairs I had to 
clean, how many toilets I had to wash to have these four walls? I’ll do anything 
but selling the flat to park my husband.” 
 
Primary home care and emergency services  
 
Available home care services were reported as less satisfactory from participants. These 
services are provided by the Italian National Health Service (NHS) and are free of 
charge for patients. They are coordinated by the general practitioner (GP) and are based 
on the intervention of district nurses (DN). Usually the primary home care intervention 
consist of scheduled visits of both GP and DN that manage infusions, medications, 
wound dressing. 
 
GENERAL PRACTITIONERS 
 
Of the 14 participants who talked about their GPs results were ambivalent. 6 reported 
good satisfaction, 8 not. 
The following is a list of citation from participants who stated to be satisfied about their 
GPs involvement. On average those declaring satisfaction seem not to rely very much 
on GPs’ clinical interventions, but they rather appreciate collaboration, availability of 
domiciliary visits when required, easiness in prescription and bureaucracy.    
 
PMS2 (male, age 43, quadriplegic, can only move his neck, totally dependent in 
ADL), CMS2 his wife. 
C= our GP she’s very collaborative. She doesn’t come regularly to visit him 
here. Sometimes I call here and she comes, takes his blood pressure etc.  
 
PALS1 (male 48 years old, bedridden quadriplegic, totally aphonic, 
tracheostomized.) and  CALS1, his wife 
C= our GP, well, she is very good. When she is in service. She’s so much busy 
that she’s often missing. There are her substitutes and she explains them very 
well about our problem when she’s off, so it’s ok 
 
 
PALS2 (man, age 39, tracheostomized, quadriplegic, diagnosed 14 years ago, 
totally aphonic) and his wife CALS2. 
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C= The GP is collaborative. She has to come each month on schedule to prepare 
prescriptions. We opened ADI (district domiciliary service), but we only use it 
because of ambulance free transport 
 
 
On the contrary those patients and carers not satisfied about their GPs complain about 
their doctors’ lack of keen to visits patients at home or difficulties to contact them out of 
hours. 
 
CPD1, wife of PPD1(man 80 years old PD, diagnosed 9 years ago, unable to 
leave his house for muscular stiffness and gait problems)  
C= (our GP) doesn’t come frequently to visit him at home. Once I told him: - 
Come to visit my husband-, but he is not so keen to come! 
 
 
CMSA1 is the daughter of PMSA1 a 73 years old gentleman bedridden totally 
unable to move, communicate and completely dependent in the ADL. The 
patient’ main caregiver is his old wife 
C= my mother is continuously moving between GP and district office. I cannot 
believe that. I think that the GP should come to visit my father at home at least 
once each 2 weeks and prepare his prescriptions here. But he doesn’t come at 
all! 
 
Another source of not satisfaction is related to the lack of knowledge of GPs and their 
substitutes about the specific neurological conditions. For this reason participants tend 
not to call them knowing that they are of little, no help. 
 
PPD4 (woman, age 60, cared for by her husband –CPD4- at home, in DBS) 
P=Our GP is not always on duty, and even when he is, he’s not able to manage 
most of the problems related to the disease.  
C= often he’s out of service and his substitutes don’t even know her.  
I think that a continuity of care is lacking. 
 
PALS7, (woman 60 years old, diagnosed 12 years ago)  
P= unfortunately GPs often cannot give correct information about this disease, 
and are not always attentive to patient’s needs. This is my experience. 
 
Finally sometimes the relationship of care between the GP and the patient can become 
unbearable due to the high intensity of the required assistance. In the following situation 
the carer of this very ill patient told the story of an intense personal relationship between 
her husband and his GP which ended dramatically because the doctor was really too 
much involved in the assistance for many years and decided to refuse to care for the 
patient leaving him and her wife in despair.  
 
CMS3 is the wife of PMS3 (man, age 46, blind, quadriplegic, muscular 
spasticity, fed by PEG). 
C=(…) he was bad again, flaccid, with fever. I called our GP, he said he was 
not coming to see him because: “ If they didn’t help him at the hospital, what 
can I do?” I insisted. He came, did not visit him, just prescribed an immediate 
admission to the hospital and called the ambulance (…) 
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The patient goes back to the hospital where he is immediately discharged home 
because the hospital doctor said to the carer that he was not to be admitted in the 
hospital for high risk of complications. 
 
C= (as soon as we arrived back home) I called his GP. I was really angry. He 
answered me like this :” There’s nothing I can do. It’s not useful that I come and 
visit him. He’s just coming from the hospital, if they weren’t able do something 
for him there… (and added) It’s up to you to convince yourself that your 
husband conditions are very serious. You can’t keep him at home. You have to 
take him in a place, you can’t manage him a home.” 
 
In a few days they received a letter from their GP in which he rejected the 
patient and his wife 
 
C= (after the GP rejected them as patients): Goodness me! What if we won’t 
find another family doctor! I came home really disconsolate.(…) one thing is 
being helped by supportive persons, another is being alone and feeling 
abandoned. (…) when you’re left alone sometimes you can’t be rational and 
objective enough to manage him. 
 
DISTRICT NURSES SERVICE 
 
Public home nursing service is called ADI (domiciliary integrated assistance). Usually 
this service provides technical nursing support managing iv infusions, bed sores 
dressings, and other specific nursing tasks that cannot be done by informal carers. This 
service was not designed to provide continuous care for chronically ill patients. Among 
the advantages of this service are the direct provision of medications and equipment 
without bureaucratic burden for families and direct access to free transports with 
ambulance towards hospitals and ambulatories. District nurses see many patients during 
their daily activity and their telephonic accessibility is normally limited at the early 
morning hours. They work in strict collaboration with GPs. DNs do not receive a 
specific education in palliative care and are not specialist in symptom control or 
counselling. They work on shifts and for this reason there is not continuity of care for 
their patients resulting in daily visits everyday from different professionals. 
Due to the characteristics of this service only few of the interviewees  experienced this 
service and could provide comments about it. Generally those who had been discharged 
from the hospital with fluid infusion or need for PEG management had the chance to be 
cared for by the DNs service. 
Comments from those participants who received the service were collected and are now 
presented in terms of satisfaction or not satisfaction. Some participants did not have the 
service, but talked about its potential need.  
Overall in 10 interviews issues about DNs was arisen. In 2 cases this was reported as a 
good and helpful, 8 did not report this as helpful or stated that they felt not to require it. 
 
One carer said she was happy of the DNs service because nurses enabled her to become 
confident with the management of her husband PEG and tracheostomy.  
 
CALS6 is the wife of PALS6 (male, age 50, diagnosed 13 years ago, 
tracheostomized, bedridden – wheelchair, quadriplegic, aphonic) 
C= ADI’s nurses came for a period o time to medicate his PEG and 
tracheostomy. Now they taught me how to do and I do it by myself. 
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This MS patient lives alone and needs extemporary  bladder catheterisations during the 
day. This was possible because DNs come regularly to perform it at her home. She is 
very happy with this service, but she recognises that in the future this service could be 
discontinued and she is worried about this. 
 
PSM4 ( female, 69 years old, diagnosed 42 years ago) 
P= I’ve district nurses coming 3 times a day for extemporary catheterisations, 
Monday to Friday and twice a day Saturdays and Sundays.  
(…) 
I’m concerned about the district nursing service. I don’t know how long they’ll 
be able to continue to come 3 times a day for my catheterisations. I heard 
they’re planning a reorganization of their service and chronic patients will be 
discharged. 
 
Some carers felt that the DNs service is only temporary and that the aim of it is 
ultimately to discharge them. Probably the process of education to the management of 
the equipment that the DNs carry on aims at enabling the family to deal with the 
management of the tracheostomy and PEG, but this is seen by families as an attempt to 
leave them alone. 
 
PALS1 (male 48 years old, bedridden quadriplegic, totally aphonic, 
tracheostomized.) and CALS1, his wife 
C= we have the ADI service now (district nurses service). They came to 
medicate his tracheo wound, but they want us to learn how to do it ourselves,  
we’re learning it. They used to come daily, I mean Monday to Friday. Now they 
just pass 3 times a week. Probably they will stop coming very soon. 
(…)The same happens with the domiciliary assistants that come to wash him, 
and change his postures. They came everyday, then 5 times a week, now only 3… 
I feel they will leave us early. Yes, they informed us they can always come back  
if you call them … but…I feel they want to get rid of us. 
 
Some families experienced bad service from DNs and reported it during the interviews 
 
CMS6 wife of PMS6 a 53 years old gentleman, fed by PEG, almost totally 
dependent in the ADL 
C= district nurses came a couple of times to dress his PEG wound. I’d rather 
they not came! They weren’t of help at all  and their dressing wasn’t good for 
him. I got rid of them quickly!  
 
PPD5 (woman age 78, cared for by her husband -CPD5- at home) 
C= I do the dressing of her PEG wound. District nurses came for the first times, 
then I learnt how to do it. Now it’s clean and neat. I renewed it this morning. 
Material was provided by district nurses when they came. We still have some 
and I use it. When it will be finished off I will go to my GP and she will prescribe 
it, I guess. Now, if I were in trouble, I would go to the neurological ambulatory 
of the hospital  where they know us well and can be of help. I do not want to 
have the DNs around anymore. 
 
Another cause of frustration is bureaucracy required to obtain the service. In the 
following rows this is well explained: by the time needed to be seen by the DNs family 
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themselves achieved their outcome and when they arrived the problem had already been 
solved. 
 
CALS8, wife of PALS8 (male in his 70, diagnosed 9 years ago wheelchair 
bound, totally anarthric.  
C= when he had his bedsores our GP advised me that we had to activate the 
district nurses service (ADI). We did the papers and when they called me back to 
know what I needed It one month had passed. I cured him in the meanwhile and 
he had fully recovered. If they came earlier I’d have saved a lot of money as they 
give materials without any charge. On the contrary I paid everything.  
PMS2 (male, age 43, quadriplegic, can only move his neck, totally dependent in 
ADL), CMS2 his wife. 
P= an informative office is needed. They should advise about your rights, 
bureaucracy… where you go if you have particularly needs and they answer . 
C= I didn’t know the jelly water. It was the speech therapist who advised me of 
it. Why the district nurses didn’t say nothing about it? 
They should improve their organisation and the homecare service office should 
quickly give information and support.  
 
Some declared to use just some benefit from the homecare public service like transports 
  
PALS2 (male, age 39, tracheostomized, quadriplegic, diagnosed 14 years ago, 
totally aphonic) and his wife CALS2. 
C= We opened the ADI (district domiciliary service), but we only use it because 
of ambulance free transport.  
P= (writing on his electronic communicator) We don’t need district nurses to 
come here. 
 
EMERGENCY SERVICES 
 
Emergency services in Italy are organized in a quick intervention ambulance team with 
a national phone number (118) that can be called by anyone who is facing an health 
emergency. After a first telephonic triage a nurse decides which colour code to assign to 
the call. This can be: 
• white code (inappropriate call, refer the patient to his or her GP), 
• green code (not life threatening condition, send a simple ambulance to transport 
the patient to the local hospital), 
• yellow code (not immediate risk of death, but serious condition, send an 
ambulance with a specialized nurse to treat first problems and then take the 
patient to the hospital), 
•  red code (immediate risk of death, send an ambulance with an emergency team 
with physician and nurse) 
In the local hospital patients are admitted in the Emergency and Acceptation department 
(A&E). in that setting if the patients conditions are life threatening they are seen by an 
anaesthesiologist-resuscitator  that decides the appropriate treatment. Because in Italy 
advanced directives are not recognised by the law if a patient arrives at the A&E 
unconscious it is up to the physician to decide if undertake cardiopulmonary 
resuscitation or tracheal intubations. This is a major cause of concern for those patient 
(usually with motor neurone disease) who decided not to be resuscitated in case of acute 
respiratory insufficiency.  
 
Chapter 3. The Qualitative Needs Assessment 
 137 
 
The following quotations from the interviews testify difficulties faced by the families 
and patients who participated at our interviews about this issue. 
 
CALS8, wife of PALS8 (male in his 70, diagnosed 9 years ago wheelchair 
bound, totally anarthric) 
C= my husband doesn’t want to be tracheostomized at all. But he’s scared that 
once in the hospital they could do it against his will. For this reason we had to 
discuss one full day because he didn’t want to go to the hospital when he had an 
aspiration pneumonia(…) One day, it was Saturday, he had a persistent cough, 
fever and was breathing badly. He refused to go to the hospital because he 
feared that they’ll put him a tracheostomy (…) in the evening I was very scared 
because of the incoming night. I called our sons to convince him to go to the 
hospital but he didn’t consent to it. (…) he did not even want to call the doctor 
on duty for the general practise, he was really terrified. His cough was 
continuous and shaking. Fortunately we called this doctor and he was very 
good. He said he needed to go to the hospital, but reassured him that being 
conscious now one could ever do something against his will. at the end we went 
to the hospital.  
 
Another similar situation was testified by this ALS/MND patient completely impaired 
in his speech, but strongly determined not to be tracheostomized. 
 
PALS5, (man in his 70s, quadriplegic, aphonic, on a wheelchair. He tries to 
communicate using a computer keyboard, but is very slow. He is a retired 
doctor. He wants us to read his living will form that had been filled with a 
notary. He asks us to use its content for our research) 
P= with this Living Will I affirm that I am aware to be affected by the motor 
neurone disease. I know that I can have a respiratory arrest at any time. If this 
happens I do not want to be resuscitated and I do not want no invasive 
ventilation, nor a tracheostomy. I ask to the emergency team that could be called 
in case of an acute respiratory insufficiency to avoid any life sustaining 
treatment on my person. This is my will and I am determined to obtain what I 
desire for myself even though this is not recognised by the actual Italian 
legislation (…) 
 
Another cause of complain in our participants sample was due to the organization of the 
emergency departments. 
When a totally paralyzed patient arrives for an emergency there is the risk to be treated 
like a not physically impaired person. This implies the risk of being let on a stretcher for 
a long time with a high risk of skin damage and symptoms due to immobilization. 
 
PMS1 (male, age 53, diagnosis of MS 18 years ago, quadriplegic, using NIV in 
the night, CMS1 his wife): 
 I= what happened when you had to go to the A&E?  
C= it was because of respiratory troubles in the night: I called the emergency 
because he was not breathing (...) they came quickly and took him to our local 
hospital where they are not used to treat neurological patients (…), that was my 
fault, I talked to the people of the ambulance, but I could not convince them to 
drive him to the S. Luigi hospital, where he’s well known. 
 P= it was Christmas Day and I had to spend the whole day on the stretcher! It 
was terrible and I can not describe what happened to my skin… 
Chapter 3. The Qualitative Needs Assessment 
 138 
 
 
Organization can be critical when a physically impaired patient is to be cared for in the 
emergency department also because they are structured to face acute events, but there is 
a lack of coordination with the domiciliary services. Emergency doctors are invited to 
keep these very ill patients at home, but if therapeutic options do not work and patients 
must go to the A&E there is the risk of being seen as an inappropriate admission in the 
wrong setting. This can cause problems as reported below 
 
CMS3, wife of PMS3 (male, age 46, blind, quadriplegic, muscular spasticity, fed 
by PEG) 
C=  (…) I lived again the drama that happened when he was in coma for his 
pneumonia. The paid carer was at home with him; he called me at work telling 
me that my husband was breathing badly, with secretions out of his mouth. I told 
him to call 118 (emergency). I arrived home while the doctor was visiting him. 
He said that he had high fever and prescribed an antibiotic. He added that fever 
would have gone and that it was not useful to go to the hospital (…) After 5 days 
of fever ( I’ve never seen him so bad), one night he started vomiting. He vomited 
his soul! What a shambles. At that time in the night I could only call the on call 
service of the NHS.  He had fever, his temperature was 40.6°C. the doctor on 
call did not come to visit him at home, he just told to wait the effect of the 
antipyretic. After half an hour he called me back. Fever was 40.5°C. He said it 
was going better, just to put ice on his forehead. (…) I really felt alone! I had to 
clean vomit, care for him, I spent the whole night with thermometer in my 
hands…(…). The day after we went to the hospital with our GP’s prescription 
for an emergency admission . Another terrible quarrel. The A&E doctor looks at 
me and says: “What are we going to do with your husband? Anytime he doesn’t 
feel well you bring him here?” I show him our GP admission letter. He 
answered me that I had to convince myself that my husband was terminally ill 
and so I did not have to take him to A&E,  it would only be worst for him for 
high infection risks. Anyway, they put him in a small dark room. Time passes 
and nothing happens. I wanted them to do some exam to understand the origin of 
fever. I was scared of pneumonia. They told me I wasn’t supposed to teach them 
their job. (…) they didn’t have any available bed, he had to stay on the stretcher. 
They told me to look for another accommodation outside the hospital. The day 
after I called S. Luigi hospital, the social assistant… nothing. No one could help 
me (…). 
 
Again lack of coordination can be a cause of bad service for patients who need the 
emergency service being affected by a chronic condition 
 
PMS7 (Male, age 73, diagnosed 25 years ago. Wheelchair bound, anarthric, 
cognitively slightly impaired) CMS 7 his wife. 
C= we had many problems with the hospital and emergencies services because 
of lack of coordination. We had an urologist who came home for catheter 
substitution who claimed that we had to be cared for by the urologists working 
in the hospital where we’re in charged. Of course the latter said that we already 
had the former… during that quarrel we spent two years with my husband who 
yelled in the nights because of bladder pain. We called the emergency and told 
us that this was not a situation that they could manage. What are they there for? 
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Sometimes informal carers are more experienced than professionals working in A&E in 
the management of particular devices. In the following report this old carer was used to 
manage his wife’ DuoDopa infuser connected to the PEG, but when they had to go to 
the A&E he was not allowed to stay with his wife and nurses did not know how to use 
that pump.   
 
PPD5 (woman age 78, cared for by her husband -CPD5- at home) 
C= Emergency department of our local hospital now is fine. It was not since like 
this few years ago. (…) We are usual customers (laughing)  We had to go there 
twice in last month: once for a bronchitis, the second time for a stomach pain. 
The problem was that they didn’t allow me to stay close to my wife and I’m the 
only one able to manage her duodenal pump, so the alarm biped and… they  
should let me stay, I know there’s a law for it, but they said that relatives were 
not allowed… 
 
 
Finally for patients living alone even the call to the emergency can be a problem, like in 
this case where the patient is physically impaired and spends the night alone. A paid 
carer in the evening put her in bed and then comes back in the morning. 
 
PMS4 (71 years old woman diagnosed 42 years ago. Quadriplegic, wheel chair 
bound, lives alone helped by paid carers) 
I= what if something happen when you are alone at home. Do you have someone 
you can call? 
P= yes, my cat! (joking).  
I= have you ever called emergency? 
P= once I did it, but they didn’t come. I was alone in the night and had an acute 
diarrhoea due to a mistreatment that I received during a physiotherapy session. 
So I called the emergency and the doctor on call replied me that it was a kind of 
antibiotics overdose. He suggested me to wait until next morning and then to go 
to the hospital for controls. So I did. But I spent the night alone, with constant 
diarrhoea (…) 
 
Other services: physiotherapy, speech and language therapy, respite facilities 
 
PHYSIOTHERAPY AND SPEECH AND LANGUAGE THERAPY 
 
The physiotherapy (PHT) and speech and language therapy (SLT) services are provided 
by a private non profit organization (Don Gnocchi) in collaboration with the NHS. 
These services are activated by both GPs and hospital specialists and offer packages of 
interventions at home as courses of 15-20 treatments that are to be renewed time to 
time. Being these services very important for both symptom control, prevention of 
complications and maintaining of physical mobility they are strongly required by 
patients. Unfortunately many participants complained about the lack of continuity of 
PHT and SLT claiming that, when many months pass between two courses they lose the 
advantages of the previous intervention. 
 
Some participants recognised the benefits received from the PHT and SLT provided by 
the Don Gnocchi 
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CPD1 wife of PPD1, man 80 years old, diagnosed 9 years ago. 
C= we had a physiotherapist who came home for 15 sessions from Don Gnocchi 
service. He also called the SLT, she’s very good. It helps him swallowing water.  
 
PALS3 (male, age 60, on a wheelchair, severely dyspnoeic, diagnosed 5 years 
ago. On NIV at home) and his wife CALS3. 
P= I have a PHT coming once a week for physiotherapy sessions. She comes 
from Don Gnocchi service. Well she a nice girl, she makes those nice massages, 
lovely.  
C= well, the neurologist said he has to do passive PHT. She has to work on his 
limbs. It’s a good service. The physiatrist comes, prescribes a course of sessions 
and the physio comes once a week. Renewal is almost automatic. 
 
PALS8 (male in his 70, diagnosed 9 years ago) wife CALS8 
C= we are very satisfied of the Don Gnocchi physiotherapist service. They come 
here regularly and courses are renewed automatically. They could provide 
speech therapy as well, but he doesn’t want it anymore 
 
This patient lives in a village in a rural area outside the city of Turin where the NHS 
district directly provides PHT and SLT service. She was very satisfied with it 
 
PALS7, (woman 60 years old, diagnosed 12 years ago)  
P= we are very lucky in this area. Our local NHS district provides everything we 
need, very quickly. We have a superb FKT service 
 
Other participants though reported less satisfaction about this kind of service. 
Main reason of not satisfaction was lack of continuity of the home PHT service 
 
PMS1 (male, age 53, diagnosis of MS 18 years ago, quadriplegic, using NIV in 
the night) 
P=Physiotherapy: they should do it at home, maybe just a couple of time per 
week ,but continuously. 
 
PMS2 (male, age 43, quadriplegic, can only move his neck, totally dependent in 
ADL), CMS2 his wife. 
C= (about PHT and SLT) we have both the services from Don Gnocchi. The 
problem is that they come and they are very useful, only for a course of about 15 
sessions. After that we have to renew the request and obtain the authorisation. It 
takes months. 
P=  it’s a plague! It should be automatic.  
C= if you know that a young man needs passive physiotherapy… you can’t think 
that at the end of the course he’ll walk again 
P= I’d love to have PHT in a swimming pool, they say it would be very helpful 
for my symptoms! 
C= yes, and they have the pool at the Don Gnocchi centre. But you know what? 
If he goes there, there are physiotherapists to treat him in the water, but no one 
will take his napkin off! And because I must go to work I can not accompany him 
there. I can’t lose other working days. 
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P= I need a person with me 200% of the time, I can not do anything by myself 
being so paralyzed . For this reason I had to refuse admissions in places where 
they could do water gym. 
 
PALS4 (male, 61,  quadriplegic, on a wheelchair, cachectic, severely dyspnoeic 
in NIV diagnosed 3 years ago) and his wife CALS4 
C= physiotherapy is a problem. It’s very useful, but Don Gnocchi provides only 
one course of 15 sessions and then there’s a hole of 4 months. We have to pay 
for another therapist to have a continuous service.  
 
PPD5 (woman in her 70es wheelchair bound.) and her husband CPD5 
C= physiotherapy: we have just finished one course from Don Gnocchi 
domiciliary service. Now, to renew it I need a visit from the  physiatrist. I went 
to reserve it and they gave an appointment for January 2008 (the interview 
happened on June 2007). And after the visit I’ll need the authorization from the 
NHS district. And after that there will be the Don Gnocchi waiting list… 
Furthermore she needs more speech therapy than physio. She requires it to 
improve her swallowing. But she should receive it when needed it, not one year 
later! 
 
Other participants complained about the efficacy of physiotherapy itself because they 
did not obtain the expected results or because they were not satisfied by the relationship 
with the therapists. 
 
CSM5, mother of  PSM5 (male, 49 years old, diagnosed 24 years ago.)  
C= he had a physiotherapist who came to treat him from Don Gnocchi, but it 
wasn’t helpful, it didn’t change his conditions at all, so… There’s nothing that 
works. 
 
CMS6 wife of PMS6 a 53 years old gentleman EDSS 9, fed by PEG, almost 
totally dependent in the ADL 
C= physiotherapy was provided by Don Gnocchi. First courses were fine, but 
this year they sent to us a physiotherapist who wasn’t reliable at all. He was 
always late, his treatment were very light, he just moved up and down his 
forearm and his leg. 
P= he called it physiotherapy! (laughing) 
C= so I complained to the service, but they said they couldn’t change him. Since 
then he’s not doing any physiotherapy. 
 
Other participants did not receive the home physiotherapist service and discussed about 
other bad experience faced when they used territory based facilities 
 
CPD3, wife of PPD3 (male in his 70, diagnosed 27 years ago)  
C= he did physiotherapy, but not at home. I had to accompany him to the PHT 
centre and I had to pay a taxi for it. I applied for taxi free coupons three years 
ago. We are still waiting! 
 
PPD4 (woman, age 60, cared for by her husband –CPD4- at home, in DBS) 
C=We went to do speech therapy to the local centre here, but it didn’t work.(…) 
We would require domiciliary physiotherapy and speech therapy. 
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P= I think that a domiciliary physiotherapy would be very useful. If I have to go 
to do sessions to the physio-centre I feel down before leaving my house. When I 
arrive there I’m not able to do anything. It becomes useless. It’s also a mental 
difficulty. When you’re not expecting it, this disease takes you in. (…) you feel 
frail and you fear the things you have to do. 
 
RESPITE FACILITIES 
 
Patients living with long term neurological conditions spend long periods of time at 
home. Respite admissions in non hospital settings can be required to alleviate the 
caregivers burden and sometimes are used for physiotherapy intensive treatments or 
complementary therapies courses. 
No participants experienced an hospice admission because hospices in our region do not 
offer admission for non cancer patients. 
Interviewees reported comments - both positive or negative - about previous 
experiences in respite settings. 13 of them stated to be keen on a respite admission or 
that they had had a previous good experience with this kind of service. Four were 
contrary to this possibility for previous bad experiences or because did not want to leave 
their homes. 
Some carer recognise openly their need of a period of relief from their task of 
caregiving, above all when they face the risk or the need to be admitted in hospital for 
some health trouble. 
 
CMS1, wife of PMS1 a 53 years old gentleman, diagnosed 18 years ago, 
quadriplegic, using NIV in the night, totally dependent in the ADL 
C=About assistance well, being retired I can manage him at home: but a respite 
care admission is necessary! When I had to went to the hospital for surgery they 
told me that the only possibility to care after him when I was there  was to admit 
him in the hospital also, that’s very sad..”   
 
PPD2 (male, age 70, fluctuating motor symptoms with freezing episodes 
alternate to severe dyskinesias) CPD2 his wife 
C= last week I asked if there were structures were he could stay just in case I 
had to be admitted for a stroke.(…) Yes, because I had a mild one recently and if 
it should  happen again? He can not live alone. We would need a place where he 
could stay for 1-2 weeks if I had to be admitted. 
 
Others consider the option of an admission period in specialized rehabilitation centres in 
order to have time to deal with other problems like the wife of this patient testifies 
 
PMS2 (male, age 43, quadriplegic, can only move his neck, totally dependent in 
ADL), CMS2 his wife. 
C= I could let him to be admitted at Don Gnocchi for 20 days.. he’d have his 
water gym, but who’d stay next to him? I can’t, I must take care of my daughter 
too. She suffers of a juvenile form of rheumatoid arthritis and, you know, I have 
to go to Milan twice a week for her injections!  
P= yes, in cases like ours 1+1 is not 2, but 3 or 4! (meaning the burden of care 
on his wife that has to care for him and their daughter) 
 
Some participants had already experienced respite admissions and discuss pros and 
cons. 
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This patient was very enthusiastic about her respite admissions in two centres far from 
Turin city, but specifically adapted for patients with advanced neurological diseases 
 
PALS7, (woman 60 years old, diagnosed 12 years ago, quadriplegic, dysharthric, 
dyspnoeic, NIV 24 hours a day) and her husband CALS7 
C= in Dr Mora centre in Pavia there’s the chance to stay with her in the same 
room. That’s important. Pavia is very well organized. 
P= yes, before we stayed in Veruno. There’s the neurology department now 
directed by Dr Pasetti. Pavia somehow is better because they have the social 
assistant inside that indicates all bureaucracy pathways to receive aids and 
services and, if necessary, directly contact your local social assistant. In Pavia 
you receive PHT daily, there’s the SLT, nutritionists, and psychologists(…) 
P= Veruno is a private, but operating with the NHS, centre where I spent a 
period of time. My husband was not with me. I had my electrical wheelchair (my 
Ferrari!) and I went around on my own. There were volunteers who spoon fed 
my at dinner and the nurse who did it at lunch. Personal care was provided by  
the centre personnel.  
 
This family experienced a respite admission in China where they went to try an 
experimental therapy with stem cells. Although the therapy was not successful because 
the disease was not relented they had a very positive impression of the care received. 
 
ALS4 (male, 61, quadriplegic, on a wheelchair, cachectic, severely dyspnoeic in 
NIV diagnosed 3 years ago) and his wife CALS4 
C= respite care is fundamental. We received it in Beijing in China. He had 2 
sessions of physiotherapy per day, speech and language therapy, massage (…). 
We, as family members, had the chance to stay with him, have meals with him, 
sleep in his room, but we could also go out and have a rest as well because he 
was very well cared for by the clinic personnel. It was like an hospice! 
 
One carer talked about the costs that she has to pay to have respite periods for his very 
disabled husband in a nursing home 
 
CPD3 is the wife of PPD3 a gentleman in his 70, diagnosed 27 years ago. 
Cognitive impairment, Wheelchair bound, staying in a long term facility 
I= how did you find this nursing home? 
C= he was in the waiting list. It’s his third re-entry here. Before he came for 1 
month, I paid for it, and them he came back home. It’s not free. The respite care 
admission has to be paid. 
Now he’s been here for 10 months. I pay a part of the charge, the rest is paid for 
the municipality.  
 
Experiences were not all positive. This MS patient with four decades of diseases on her 
shoulders is one of the founders of the Turin MS patients association section and 
collaborated to the creation of respite admissions between the association and Don 
Gnocchi centre. Despite this she reports not to be satisfied of her periods spent in that 
facility 
  
PMS4( 71 years old woman diagnosis 42 years ago. Paraplegic, wheel chair 
bound, lives alone helped by paid carers) 
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P= sometimes I spend 20 days in Don Gnocchi centre, it’s a kind of respite 
admission. They know me very well and so give me this chance. I don’t like it 
very much because I have to share the room with elderly women praying all the 
time, or crying, and after few days you became more depressed than before. 
Than somehow, you lose your independence. I won’t go this year for these 
reasons 
 
There are also situations where carer and patients do not agree about this issue. Carers 
feel the need of a respite period, but patients can feel this as an attempt to place them 
out of their homes 
 
CMS6 wife of PMS6 a 53 years old gentleman EDSS 9, fed by PEG, almost 
totally dependent in the ADL 
C= once per year he spends 3 weeks in Piancavallo, a rehabilitation centre 
where he goes for respite care. 
P= I don’t like it because it’s a hospital. I like my home, I want to stay in my 
place (…) 
C=Another key point are respite care admissions in the hospice. They are 
strongly required.   
 
Some facility specifically created to provide respite care for neurological patients can 
not satisfy the needs of very advanced guests who are too ill to participate to social 
activities resulting frustrated and abandoned. 
 
PMS3 (male, age 46, blind, quadriplegic, muscular spasticity, fed by PEG), 
CMS3 his wife. 
C= he spent a period of time at Villa Fiorita, a nursing home specialized in MS 
care. I had to put him there because I was going to be operated and then I 
needed a period for recovery. I went to meet him before my operation and it 
wrung my heart. He was alone in a corner of the living room. While other 
patients were consuming their meals he couldn’t because he is fed by PEG. 
Nobody was caring for him. His nose was dirty… once his PEG tube lost some 
liquid, but nobody saw it and I discovered it when he was all mucky.. He was the 
one in worst conditions.. the others talked to each others, had meals together.. 
he couldn’t because he didn’t speak or eat. 
 
Some setting like general nursing homes can even worsen physical conditions of 
patients admitted for respite, this was certainly the case of this old couple 
 
PPD5 (woman age 78, cared for by her husband -CPD5- at home) 
C= we had a respite care admission in a private nursing home paid for the NHS. 
We both went there because I was very tired, having to care for her alone, and 
she required some physical therapy. It was our GP who filled the application 
form for us. She had daily sessions of physiotherapy and speech therapy. It 
wasn’t very good. We had a double room where we could stay together, but food 
wasn’t good at all. I had worsening of my rheumatic pain. When I came back 
home I wasn’t able to walk anymore. Imagine that I entered walking on my legs 
and when I came back home I needed a wheelchair!  Fortunately I recovered 
after 20 days.  
 
Chapter 3. The Qualitative Needs Assessment 
 145 
 
This couple, even if previously declared to be tired and in need of help, clearly decline 
the possibility of a respite admission 
 
PALS1 (male 48 years old, bedridden quadriplegic, totally aphonic, 
tracheostomized.) and  CALS1, his wife 
P=(communicating through an alpha numerical table) Respite care? I won’t go 
anywhere out of here (he wants her to show us the rest of the house and the 
garden) 
C= me too, if I have to be helped I prefer someone coming here. I don’t want 
him to risk further infections or other complications 
 
Social services and technical support  
 
Patients severely disabled for a progressive neurological disease are likely to need some 
help from the welfare social service. In Italy social assistants are professionals working 
for the local offices of the ministry of the welfare. This service can be accessed by 
anyone with economical hardship, physical disability or social impairment. The main 
help provided by these professionals to families in which a severely disabled person 
lives is based on financial benefits like the sick benefit, accompaniment check or other 
grants to be used to pay for home assistants that care for disabled patients. They also 
provides information about available services to the person and can refer applicants to 
transport companies to obtain ambulances or equipped taxis to move patients toward 
hospitals or ambulatories for routine visits, physical therapies and so on. Finally these 
offices are those providing technical equipment like electronic communicators, 
wheelchairs, orthopaedic beds, aids and devices. 
 
EQUIPMENT DELIVERY, FINANCIAL BENEFITS AND TRANSPORT 
 
Interviewees reported their experience when they met these services.  
Some were very satisfied for the received benefits.  Often this is the case of ALS/MND 
patients because this has been recognised as a rare condition in Italy and therefore 
neurologists can directly prescribe the necessary equipment. More difficulties were met 
by families of patients with MS or movement disorders that do not have the same 
facilitations 
 
PALS3 (male, age 60, on a wheelchair, severely dyspnoeic, diagnosed 5 years 
ago. On NIV at home) and his wife CALS3. 
C= for aids provision bureaucracy is simple. It’s enough a prescription from the 
neurologist and NHS district office provides everything. 
 
PALS7, (woman 60 years old, diagnosed 12 years ago, quadriplegic, dysarthric, 
dyspnoeic, NIV 24 hours a day)  
P= I have 2 ventilators. Now they approved the delivery of a new battery. In 
case of an electric black out I have about 20 hours of autonomy (…). We are 
very lucky in this area. Our local NHS district provides everything we need, very 
quickly. We have a superb PHT service, we had all the aids: wheelchair, bed, 
mattress, hoist, electrical wheelchair. 
Even though the social system seems reasonably efficient in the normal equipment 
provision problems can arise when very expensive devices are required 
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PALS1 (male 48 years old, bedridden quadriplegic, totally aphonic, 
tracheostomized) and  CALS1, his wife 
C= we obtained our aids: wheelchairs, hospital bed, air mattress, ventilators, 
aspirator, in-exsufflator etc. But when we asked for other needs like the 
computer based communicator, which is very expensive but can dramatically 
change my husband’s quality of life)  well that was a tragedy! 
 
Some families experience bureaucratic difficulties due to numerous steps to go across 
cyclically  
 
PALS2 (male, age 39, tracheostomized, quadriplegic, diagnosed 14 years ago, 
totally aphonic) and his wife CALS2. 
C= aids delivery is a long procedure. Each month we need a prescription from 
our GP, an authorisations from the NHS district office, than we should go to the 
pharmacy to retire. But now they contract private companies to deliver this 
material. The problem is we don’t have a person like the pharmacist to talk face 
to face when a problem occurs. And the service from one of this company is fully 
unsatisfactory. With other things go well.  
 
PALS4 (male, 61, quadriplegic, on a wheelchair, cachectic, severely dyspnoeic 
in NIV diagnosed 3 years ago) and his wife CALS4 
C= our lung specialist prescribed a new mask because he had this skin sore due 
to the previous mask. If we had to wait for the normal procedure of the NHS we 
were to wait 20 days…luckily he had one and gave it us (…)Procedures to have 
aids authorizations and delivery are tricky. We fortunately found a good clerk at 
the call centre. Many times he helped us when we were in trouble because 
companies delivered wrong material or we run out of it.  
C=. Even if I immediately go to our GP for prescriptions  aids provision 
procedures are long. 
 
Transports can be critical and expensive for patients with movement disability and 
families require some financial support as testified below 
 
PPD3 (male in his 70, diagnosed 27 years ago. his wife caregiver, CPD3 
C= a free transport service would really be needed to go to the hospital visits.  
They wanted me to bring him there with an ambulance, even if he could go by 
taxi. I had to pay for this and it was very expensive. (..) 
 
When participants were not satisfied of the social service it could be simply because 
they had never experienced it being not confident about the possible help 
 
PMS1 (male, age 53, diagnosis of MS 18 years ago, quadriplegic, using NIV in 
the night, CMS1 his wife): 
 I= what about the social assistant: did you ask this service some help for you 
wife who has to care after you day and night? 
 P= we have never been to the social assistant. We heard that they can send us 
someone at home. I think it would only be a trouble, we have our routine and 
don’t want someone else wandering around the house.  
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Financial support is very important to help families to pay private home carers to help in 
daily assistance to their loved ones. Interviewees reported their experience about this 
crucial point. 
 
PPD4 ( woman, age 60, cared for by her husband –CPD4- at home, in DBS) 
C= nowadays she has her invalidity pension and the accompaniment check. We 
don’t have any other sick benefits nor paid carers helping us at home. No 
domiciliary services at all. 
 
 
HOME ASSISTANCE 
 
When social assistances provide paid carers to families caring for very disabled persons 
often packages of services are tailored around the needs of the family. Our participants 
reported some criticisms about their perception of the results of this intervention. 
Sometimes the help provided by the social service is seen as not helpful like if they had 
to accept prepared package of assistance not fitting their needs 
 
CMS6 wife of PMS6 a 53 years old gentleman EDSS 9, fed by PEG, almost 
totally dependent in the ADL 
C= the welfare assistants provide for us a girl who come 3 hours a day, but 
honestly it’s not enough. They give us a podologist  once a month and the 
barber. He doesn’t want this barber, he wants to go to the one he likes.  
 
Paid carers need specific education to be of help. Sometimes their presence is not 
enough to provide relief 
 
PALS2 (male, age 39, tracheostomized, quadriplegic, diagnosed 14 years ago, 
totally aphonic) and his wife CALS2. 
C= we have a paid carer who comes everyday and a second one who comes 
some afternoons and Saturday in the morning. But this organization seems me 
stupid and a strong limit to the service. They offered us a domiciliary assistant, 
but she can’t aspirate him. So she’s not of use at all. They said their nurses are 
on call, but I can’t call them each 20 minutes to aspirate him. They should train 
the assistants to aspirate!  
 
In some case the time spent by the paid carers is not enough to provide adequate help 
 
PALS6 (male,age 50, diagnosed 13 years ago, tracheostomized, bedridden – 
wheelchair, quadriplegic, aphonic), CALS6 is his wife 
C= now there’s a domiciliary assistant paid for the welfare office. She’s very 
good and collaborative. But she’s paid only for 2 hours a day. In the beginning 
this was enough, but now it’s not. She often has to stay longer to help me with 
him. 
 
Many participants advocated the need of paid carers to provide help for patients’ 
necessities.  
 
PPD1 (male, age 80, cognitively slow but able to understand and severely 
disabled in his movements. During the interview was admitted in the 
neurological ward for symptom control) CPD1 his wife. 
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C= if they could come in the morning to help me in his toilette, or shower him… 
because it’s getting hard to me.  
 
PALS1 (male 48 years old, bedridden quadriplegic, totally aphonic, 
tracheostomized.) and  CALS1, his wife 
C= home service: we have domiciliary help provided by the welfare assistant. 3 
mornings and 2 afternoon they come to help the carer to mobilize him. But 
frequently they told us that as long as the carer is able to care for him they 
weren’t keen to do it. But even if the lady who cares for him does it, she doesn’t 
have to. It’s their task! 
 
TECHNICAL ASSISTANCE 
 
Comments were also captured about the technical assistance provided by those 
companies which deliver technical equipment such mechanical ventilators that require 
revision and technical assistance 
 
PALS3 (man, age 60, on a wheelchair, severely dyspnoeic, diagnosed 5 years 
ago. In NIV at home) and his wife CALS3. 
C= ventilator has a free assistance guaranteed 24\24. we have the free 
telephone number. But we never needed. 
 
PSLA9 (man, age 77 diagnosed 8 months ago) and his daughter CSLA9. 
D= we have 2 ventilators. The only problem is that batteries doesn’t last for 
long. Technical assistance is very good.  
 
 
SPECIALIST PALLIATIVE CARE SERVICE 
 
After participants reported the lived experience of the disease, discussed the unmet 
needs and provided comments on the received services, researchers asked their opinions 
about the experimental new SPCS that was under construction. They explained the 
aims, the organization, the philosophy of palliative care and the resources available 
asking the interviewees their opinions about its usefulness.  
15 participants stated to be keen to receive a service similar to what a SPCS can 
provide, (sometimes just partial like volunteers or physiotherapy) none of them declared 
to be contrary to such a service 
Some comments are now presented 
 
PPD2 (man, age 70, fluctuating motor symptoms with freezing episodes 
alternate to severe dyskinesias) CPD2 his wife 
C= I hope that if in the future he’ll have further problems in movement a 
domiciliary service with the characteristics that you explained to us will be 
available.  
I= do you think that now a SPCS could be useful to you now? 
P= sincerely I’ve never felt this need till now. For the future it will be welcome. 
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PMS1 (man, age 53, diagnosis of MS 18 years ago, quadriplegic, using NIV in 
the night, CMS1 his wife): 
I= Would you accept a SPCS at home?  
C= I was very happy when our GP started to do regular visits each month: if 
there was something else it would be welcome. Our house door is always open. 
P+C= very useful would be a service on call. 
PALS1 (male 48 years old, bedridden quadriplegic, totally aphonic, 
tracheostomized.) and  CALS1, his wife 
C= we would appreciate a home care service, available at weekends too. 
Someone who can substitute me or the carers for some periods of time.  
 
CALS8, wife of PALS8 (male in his 70, diagnosed 9 years ago wheelchair 
bound, totally anarthric) 
C= we both would be definitely pleased to receive a SPCS service like yours at 
home. If you start, please contact us. 
 
PPD4 (woman, age 60, cared for by her husband –CPD4- at home, in DBS) 
C= we’d really need a service like the one you are presenting. We would require 
domiciliary physiotherapy and speech therapy. 
P= I think that a domiciliary physiotherapy would be very useful.  
 
Summary 
 
 
Participants provided a number of precious information about the existing services for 
people severely affected by neurodegenerative conditions living in Turin area. Specialist 
clinics services were generally reported as positively satisfying the patients’ needs, 
although this is not equally shared among the different conditions. Primary care home 
services seemed lacking because they are not organized to meet the chronic needs of 
very disabled people. Those patients requiring technical equipment like mechanical 
ventilators were satisfied by the technical assistance available. Specialist rehabilitation 
domiciliary services, although present, did not provide homogeneous and continuous 
support and participants reported difficulties of access to the services. Finally social and 
welfare services seemed far from being of help to the social needs for this population. A 
service with characteristics similar to those provided by a SPCS was strongly advocated 
by the majority of the interviewees.  
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3.5.3 Focus Groups results 
 
In this section the results of the 3 focus groups with professionals involved in the care 
of patients severely affected by neurodegenerative conditions will be shown. 
3.5.3.1 Participants  
 
From May 2007 to August 2007, 3 focus groups with a total of 11 professionals 
involved in the care of the patients who were interviewed and whose results have been 
reported in the previous sessions were run. 
All the participants of the focus groups were professionals working in the 2 hospitals of 
Turin involved in this study: Molinette hospital and S. Luigi Gonzaga hospital. They 
were recruited from the specialist clinics of these hospitals directly involved in the care 
of ALS/MND, MS and PD and movement disorders. 
A list of participants is displayed in table 3.8   
 
Nine  participants were physicians: 
• 8 specialist in neurology. Of these 3 were MS specialists, 2 PD specialists, one 
was an ALS/MND specialist and one had interests in palliative care. 
• 1 was a rehabilitation specialist working in a respiratory centre were mechanical 
ventilation and cough assisted devices were prescribed.  
The remaining two professionals were one physiotherapist and one speech and 
language therapist both collaborating with the rehabilitation specialist. 
 
3.5.3.2 Focus groups general results 
 
The 3 events were run in the selected hospitals. The focus groups were advertised at the 
participant services through the direct involvement of the directors of the centres. 
Professionals interested in the participation were volunteers and did not receive any 
payment for their presence. 
focus number participants gender professional role specific interest 
1 EPD1 f neurologist PD 
1 EMS1 f neurologist MS 
1 EMS2 f neurologist MS 
1 EMS3 m neurologist MS 
1 EPC f neurologist PC 
2 EALS1 m neurologist ALS 
2 EPD2 m neurologist PD 
2 EMS4 m neurologist MS 
3 EALS2 m physiatrist ALS 
3 PHT f physiotherapist ALS 
3 SLT f speech&language therapist ALS 
Tab 3.8: Participants of the focus groups 
EMS= Multiple sclerosis expert 
EPD= Parkinson’s disease expert 
EALS= Amyotrophic lateral sclerosis expert 
EPC= Palliative Care expert 
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They signed the participants’ module of the informed consent as required by the local 
Ethics Committees. Each event was conducted by 2 researchers, were audio and 
videotaped and transcript verbatim was performed. The duration of the groups was of 
one hour of time on average. All participants talked about their professional experience 
in the care of people severely affected by neurodegenerative conditions.  
 
The general framework of each event was based upon a personal introduction of each 
participants. They were asked to declare their experience in this field, where they were 
working, their annual mean case load and the characteristics of their patients. 
General rules about the secrecy of the contents of the event, privacy and professional 
behaviour were discussed. Interaction among participants was encouraged. The 
facilitator introduced the aims of the study and declared the interest in the following 
aspects: 
• Physical, psychological, social and spiritual unmet needs of the people severely 
affected by neurodegenerative conditions  
• Impact of these needs on the families, caregivers burden 
• Their  knowledge about the service available for this population in Turin city 
and Turin area, quality of the home care of their patients 
• End of life issues: how and where do their patients die, choices and policies 
about end of life decisions 
• Opinions about the involvement of a SPCS for the home care and the hospice 
care. 
 
A content analysis of the transcript verbatim was then performed by 2 researchers and 
then main contents were grouped in a common file. 
Main results coming out from the three focus groups are presented in the next session 
 
3.5.3.3 Focus groups content analysis 
 
A content analysis of the main themes arose from the three focus groups are now 
presented.  
Data are grouped in four main areas: 
• General experience  
• Palliative care unmet needs of the patients (including caregivers burden of care 
and end of life issues) 
 
3.5.3.3.1 General experience 
 
In this section the following the analysis of the following aspects will be presented: 
• number of patients severely affected by neurodegenerative conditions potentially 
eligible for a SPCS 
• available services 
• comments about a new SPCS 
 
Number of potential users 
 
The potential number of people severely affected by ALS/MND, MS and movement 
disorders living in Turin area can be estimated by prevalence data of the specific 
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conditions, even though there is a lack of information about the advanced stages of the 
specific diseases. Participant were asked to report the number of patients with the 
diagnosis above indicated and to define how many of these could be considered in 
advanced stage and, therefore, potentially eligible for a new SPCS. 
Data were different depending on the dimension of the centre were participants were 
working for and for the different diagnosis. Data are not meant to provide information 
about the prevalence of the disorders, nor to establish how many people severely 
affected by these conditions were living in Turin or its metropolitan area, but to 
consider the proportion of people in advanced stages compared with the overall 
caseload of the involved centres. 
MS specialists reported about 10% of their patients to be in advanced stages 
 
EMS3:    ” I’m the director of the MS centre in this hospital. We can estimate in 
80-100 severely affected MS patients cared for by our centre. We must define 
what we mean for it, but it is about 10% of all our patients” 
 
EMS1: “ we can add 15-20 more MS severely affected patients of our service” 
 
EMS4:  “it’s hard to estimate for the MS. I do not know if we lose the most 
disabled ones, usually we see them one or twice per year. I think that bed bound 
patients seen in our service are about 25-30”.  
 
ALS/MND report a higher proportion of patients being in an advanced stage and not 
able to go to the ambulatory  
 
EALS1:    ”An estimate of ALS patients cared for by our tertiary clinic can be of 
70-100. About 25 are the ones that would require a domiciliary service” 
 
Professionals working in the respiratory centre report higher numbers of ALS\MND 
patients with respiratory problems cared for by their hospital service 
 
EALS2:      ”if we consider both patients in non invasive and invasive ventilation 
we have about 100, only ALS. We have a high turnover” 
PHT:     “in relation to the dimension of our service it's a big load” 
 
Movement disorders are much more prevalent and very difficult to predict in terms of 
potential SPCS users. This neurologist working in the tertiary clinic for Parkinson’s 
disease reports: 
 
EPD2: it's difficult to say because the worst ones are lost at follow up. As long s 
they can't come to the ambulatory we don't know what happens to them. But 
compared to the numbers that my colleagues are citing now I fear that for all 
extra pyramidal syndromes, considering also demented patients, we should 
imagine a number 100 times higher. I'd estimate hundreds of patients eligible for 
a home care service in Turin area”  
 
Available services 
 
When asked about the availability of specific services for people severely affected by 
neurodegenerative conditions in Turin city and metropolitan area, professionals 
described an heterogeneous picture. 
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ALS/MND though being a rare condition seems to have a better network of specific 
neurological services above all aimed at supporting advanced patients at home. In spite 
of this transports and social benefits are difficult to obtain 
 
EALS1: “For home bound patients we can provide a domiciliary service with 
neurologists than go and visit patients in their homes more or less each 2 
months. No transport services for ALS patients is provided. Social benefits are 
difficult to be obtained. Our neurological service is free of charge for them, but 
they need paid carers and can receive social benefits only if very poor and 
lonesome. They are charged for everything they need“. 
 
This is not true for movement disorders where neurologists are concerned about the 
quality of the assistance provided by primary care alone 
 
EPD1: “I don't know what happens when patients are at home: how are they 
managed, is the carer able to recognize complications? Are GP's able to 
manage it? It happens that our patients go to A&E of other hospitals for bad 
dyskinesias, maybe because they swallowed 5 tablets instead of one and their 
therapy is completely changed when it would have been enough to wait the drug 
effect.. and consequences are worst!” 
EPD2: “I think that a good domiciliary service can improve many outcomes for 
PD advanced patients. One aspect can be PEG management for those patients 
using DuoDopa continuous infusion via PEG. We had local complications 100-
1000 times more frequent than other experiences in Northern Europe. We think 
this can be due to a better home care service provided there... this is a palliative 
intervention because we don't have any therapy that can improve survival in 
PD” 
 
For MS there is no specific home care service except for the transport service provided 
by the local patients association that is seen very positively by professionals 
 
ESM4: “AISM ( patients association) provides a transport free service to MS 
patients. This allows also very impaired patients to come to our centre to be 
visited. This doesn't happen for other categories of patients.  
 
When asked about their feelings about the quality of services available for their patients 
MS specialists show frustration and impotence 
 
ESM2:” we have structural limits, but specific projects aimed at this aspect 
should be enhanced. A good domiciliary service ease our job. Patients are more 
satisfied, better managed and more compliant with therapy (…)I feel impotent. 
There are structural limitations. We do our best, but….” 
 
Even respiratory team report frustration about the impossibility to provide telephonic 
support to domiciliary patients 
 
EALS2: “most problematic patients have my personal cellular number (I must 
say that in our service this is not always seen as positive). But usually they have 
to call here the service and the secretary office isn't always on call, just during 
the normal office time.” 
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Some participant discussed about lack of instruments and adequate education in their 
hospital based teams about specific issues very common in palliative care like, 
emotional support, supervision meetings or team work strategies 
 
PHT: “we don't have any clinical multidisciplinary supervision, we just have a 
project for us physiotherapists” 
SLT:” we shouldn't answer to our patients’ emotions and deep questions just 
with our feelings or emotions. But here any operator has its own background 
and education, we don't have common pathways or guideline. It's not easy” 
EALS2” these are hard experience that we have to keep inside. We don't have 
any form of meeting among ourselves because of lack of time” 
 
3.5.3.3.2 Professionals points of view about a new SPCS 
 
Participants seemed very interested about the creation of a new SPCS for neurological 
patients. 
 
EALS2: “We were just waiting for a service like the one you're organizing.” 
SLT: “It would be really important for patients and families because they 
wouldn't feel alone. They complain about ADI service not only because they're 
not efficient, but because they don't visit them regularly, above all in the first 
days after discharge from the hospital they have to manage 24\24 a patient, 
perhaps with a tracheo.. it's not easy.” 
 
Home care for advanced stages is strongly advocate to avoid hospital complications for 
very ill and frail patients 
 
EMS3: for advanced stages we should think about strategies to reduce infections 
rates. Enhancing home care is fundamental. Hospital admissions should be 
avoided in far advanced MS, but PD also, above all in winter time, because it 
expose these frail patients to aggressive bacteria, with high risk of death and 
bad agony due to prolonged antibiotic treatments.” 
 
EMS4: “a service able to treat complications at home would really be important 
for this population. Manage fever occurrences, prevent urinary infections etc.” 
 
Professionals are confident that a SPCS could reduce inappropriate hospital admissions 
or unwanted treatments: 
 
EALS1: (do you think a specific SPCS for this population could be of use?) ” 
Yes, definitely, above all in these situations where a close follow up could 
prevent inappropriate treatments.” 
 
EALS2: “absolutely yes. Often patients come here because they know that we 
are here. Rarely I go to visit them at home. A SPCS could really prevent 
inappropriate admissions. I think mostly at NIV patients that don't want a 
tracheostomy. They need a strong and supported domiciliary service.” 
 
SLT: “I think that about the place of death many relatives call the emergency 
when they feel that the patient is choking to death. I think that must be 
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overwhelming, so it's an instinct to run to the emergency. If a palliative care 
team could be present at home and help.. that could be helpful…. but being 
alone must be scaring. 
 
EPD2: “I think it would help very much for caregivers education. This is so 
important. They should be able to recognize early signs of aspiration, cough etc. 
families aren't easy to foretell. Sometimes they would like to stop treatments very 
early, in other situation they want heroic treatments in far advanced stages.. 
Domiciliary treatment of infection would prevent hospital admissions in wards 
were unprepared professionals aren't able to recognize simple problems: any 
simple infection can precipitate general conditions of PD patients.” 
 
Another specific role of a SPCS identifies by professionals could be to provide support 
and education to those carers who face difficulties in the management of complex 
devices like mechanical ventilators. They recognise that the training period that is 
provided in the day hospital is not always sufficient to enable the carers to be self 
sufficient at home 
 
SLT: “I think that a home training to continue education on what they learnt 
here would be precious for our patients and carers” 
 
EALS2: “this is a problem: we educate carers to use respiratory devices only for 
2-3 hours here in day hospital, then we see them after a 3 months period of time. 
Personally, if I foresee problems due to a difficult in understanding I tend to call 
the family after 1 week. but this is not the normal procedure and not everyone 
here agree. It is not uncommon to recognise that after three months the 
ventilator is still at home packed in the original box because they did not feel 
able to use it” 
 
Even rehabilitation centres in our area are not satisfactory for all patients, above all for 
the very advanced one, because they require continuous assistance and these facilities 
are not always prepared to care for totally disabled people, and because they tend to be 
placed far from the city. 
 
EMS1: “ they really need respite, I mean to be relieved a bit. But then patients 
admitted in facilities feel abandoned. There's another centre (Peveragno) where 
MS patients can be admitted for respite, but they feel abandoned when are very 
disabled because they are placed on their wheelchair, fed by PEG, they cannot 
communicate with the other guests and do not have their families with them. 
 
EPD2: “we can admit PD patient in a clinic where they are treated with 
physiotherapy and assessed and followed up annually after Deep Brain 
Stimulation. The problem is the waiting list that is very long. Frequently we have 
to declare that the patient needs physiotherapy, when it's just a respite care, 
otherwise it wouldn't be reimbursed. If there was  a place of care for respite 
admission it would be really useful  in our area.  
 
Terminal care could be another interesting option for our participants 
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EALS1: “terminal sedation for acute respiratory failure in ALS/MND patients  
usually happen at home or in our ward, theoretically it could happen in an 
hospice if a bed would be quickly available when needed”. 
 
Last role discussed about palliative care facilities was the role of the hospice for respite 
care or terminal care. 
Professionals revealed the difficulties to find appropriate places to admit very disabled 
patients for limited periods of time, recognizing that hospital wards are not a good 
solution 
 
EMS1: “Respite care wards able to admit these patients when far advanced are 
lacking. Hospital wards are not the best place for them. In last 3 months we had 
3 MS patients admitted in the hospital for routine assessment and procedures 
who had hospital acquired infections. 2 of them died. If infections could be 
managed at home it would be better for patients. 1 patients had 6 episodes of 
pneumonia at home and always recovered, when he had the first in hospital died 
for it.” 
 
When patients are young nursing homes are not seen as good solutions because of the 
high age of the other guests 
 
EMS2: “MS patients tend to die at home, even because there are not so many 
facilities for them. The only ones available are geriatric nursing homes. So a 
man in his 30ies, not cognitively impaired can't stay in a nursing home! There is 
a clinic in Mappano held by nuns where we can admit some young patient with 
high disability” 
 
3.5.3.3.3 Palliative care unmet needs  
 
Professionals discussed about the unmet needs faced by their patients. They underlined 
some difference between this population unmet needs and cancer patients in general. 
Problems were grouped in physical, psychological, social and spiritual ones as 
previously presented in the results of the interviews. End of life issues and caregivers 
burden of care where also explored and are presented in the following paragraphs 
associated to the specific related patients problems. 
 
Physical needs 
 
Each specialist introduced the symptoms and other physical features typical of the 
different diagnosis. These conditions show peculiar and common symptoms due to the 
natural evolution of the illnesses. Some neurologist declared that their perception of 
patients’ symptoms is not always correspondent to what their patients report:  
 
EPD1: for PD advanced patients physical needs are evident from the observer 
point of view. Patients tend to accentuate them during the visits. But they’re also 
objective.  
 
EMS2: “MS patients with EDSS > 7,5-8 they all are wheelchair or bed bound. 
Physical needs are so evident. All our patients are treated for symptom control 
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(…) And then a strong rate of them have cognitive impairments, so their 
symptom perception is different from the professional perception. .” 
 
The overall symptom load in these conditions seems to be very high as described by the 
experts who participated to our groups: 
 
EALS1: in ALS physical suffering is very high. Not very much pain, because pain 
is mostly secondary, it's not due to the disease, but.. There are certainly 
symptoms to be controlled that can justify a medical intervention at home. Other 
palliative intervention required are postural education ( very useful for postural 
pain), respiratory management and skin care. For skeletal pain physiotherapy 
and repositioning are fundamental and effective. 
 
EPD2: many aspects in PDs patients are similar to those descript for ALS ones, 
high symptom load and physical suffering. I cannot say if monitoring these 
patients at home can improve their symptom control.  
 
 
In the following paragraphs some specific physical symptoms will be explored 
 
1. Pain  
 
Pain control is considered as one of the most important goal to be achieved in palliative 
cancer care. Neurologists and the other professionals involved in the care of people 
severely affected by neurodegenerative conditions express different opinions about the 
prevalence and the impact on patients’ QoL in their patients. 
Some recognise that pain is an issue, but they feel impotent about its control: 
 
EPD2: Pain is definitely misdiagnosed in PD and related disorders. It's frequent 
and we are impotent. Pain killers are used, but generally it is an undertreated 
symptom. 
 
EPD1: Pain and gait problems and are the most affecting on quality of life. For 
pain control we do what we can do. At a certain point it seems unavoidable. 
 
 
On the other hand some participants think that pain is not a very important symptom for 
their patients or tend to consider this symptom not as caused by the disease, but a 
possible complication. From their words it seems that this symptom is not on the top of 
the list of their worries about their patients’ care.  
 
EMS4: in MS pain isn't so frequent. There are painful symptoms due to 
complication of chronic immobility. Those patients are often referred to pain 
clinics. But it's not so frequent. Results aren't so clear. Many patients are 
cognitively impaired so we don't understand very well. 
 
EALS1: In ALS  pain is not so relevant. In advanced stages, when the patient is 
tracheostomized and can live for a long time postural pain can be a problem.  
 
Painful syndromes are frequent in these conditions and are labelled with different names 
like cramps, spasms or painful fasciculations. 
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FKT: Spasticity in MS, muscular hypotrophy, cramps or fasciculations in ALS 
and rigidity in PD impact very badly on patients QoL. Not only because of 
limitations in their job, but also because they can be painful and impact on for 
family relationships. They can't have meals with their loved if they can't 
swallow, they lose many important moment of normal family life. 
 
EMS2: Spasticity is an important symptom not always controlled with oral drugs 
such as baclofen, so we obtain good results by positioning baclofen intrathecal 
pumps. 
 
 
 
When asked about the use of opioids professionals report a general lack of confidence 
with these drugs for many reasons ranging from fears of side effects to lack of 
experience. 
 
EPD2: in PD and related disorders these drugs are scarcely used. There is the 
problem of chronic constipation the always affect our patients and that can be 
worsened by opioids (like tramadol). for this reason in my personal experience 
they're not so frequently used. Patients complain about leg pain gait bound and 
usually complicated by ostheoarthrosis, back pain etc. we refer them to the pain 
clinic where they're treated with local injections of steroids, or prescriptions of 
acetaminophen, and steroids if necessary. For this reason I must say that my 
experience with opioids is like zero.  
 
EALS1: Generally these pain aren't very responsible to opioids, they respond 
better to frequent changes of their positions. On average they're used at low 
doses, but some patient can need high doses. For analgesic purposes also 
Fentanyl patches are used, with dosages of 25-50 µg\hr. 
 
Other drugs, generally used as adjuvant for pain therapy in chronic cancer pain, seem to 
make neurologists more confident about their use, even though in the Italian National 
Health Service they are not reimbursed if prescribed for pain not cancer related. 
ALS/MND being labelled as a rare condition is an exception: 
 
EPD2: adjuvants such as anti epileptic drugs are effective for neuropathic pain. 
The problem is that for our patients these drugs aren't reimbursed by the NHS 
and so patients can't afford it. It reduce our therapeutic choices. 
 
EMS4: we also used a lot gabapentin or pregabalin, but now we can't use it 
anymore because of their cost. 
 
ALS1: we use gabapentin and pregabalin for fasciculations and cramps. 
Pregabalin is helpful for anxiety also. Fortunately ALS is considered a rare 
disease and so all drugs are refunded by NHS 
 
2. Dyspnoea and respiratory symptoms: 
 
Shortness of breath is commonly faced by ALS/MND patients, but palliative options 
seem to be scarcely known in our reality.  
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EALS2: dyspnoea is the main symptom. Due to the respiratory pump deficit. 
With anxiety it create a self sustaining loop. This is particularly true in ALS 
where patients are aware of prognosis and psychological reaction doesn't help. 
 
Experts in respiratory management are strongly committed in this symptom  relieve, but 
they focus their interventions on mechanical ventilation. 
 
EALS2: Physiotherapy is ventilation. Even when patients are not yet in 
respiratory insufficiency a mechanical ventilation (maybe only for 20-30 minutes 
per day) can expand pulmonary parenchyma acting as a PHT. It can help also to 
mobilize bronchial secretions 
 
Other specialist do not report dyspnoea as a major concern, they focus on pulmonary 
infections as a possible cause of death rather than a cause of suffering: 
 
EMS3: in MS respiratory troubles are less frequent than in ALS. In advanced 
stages we have seizures and recurrent respiratory and urinary tract infections. 
These problems can cause patients death.  
 
Inadequate cough is seen as a common problem for neuromuscular patients: 
 
EALS2: another symptom is weak cough. It's more frequent in MS than  in ALS. 
It can occur in patients with normal ventilation without respiratory impairment. 
It cause bronchial secretions, choking etc. This can cause the difficult decision if 
tracheostomise these persons or not. Most of them are tracheostomized at the 
end. we have a patient who was tracheostomized for week cough. he has a 
ventilator at home, but he never use it, he just need to be aspirated. other drugs 
to reduce secrections aren't so useful and then just delay the tracheo decision. 
you can prescribe antibiotics, if they work infection will come again. it's a tough 
task for us. often we feel impotent because of this. 
 
Treatment of respiratory symptoms is generally based on mechanical ventilation that 
can be invasive or not. Compliance to this vital support is reported as problematic by 
professionals. There is the feeling that it can be related to the attitude of patients to 
accept and cope with their illnesses and disabilities: 
 
EALS2 : control of breathlessness is a very subjective issue. Some patient is very 
satisfied,( sometimes it looks a little big exaggerated like if he was trying to be 
rewarding us), others are more negative and tell you that it didn't help at all. we 
may say that, on average, there's a good satisfaction in our patients. only one 
refused it completely. 
 
FKT: I think that NIV acceptation depends on the psychological acceptation of 
the disease. Patients with little acceptation of the disease tend to have more 
difficulty to accept respiratory help. Usually they can appreciate the positive 
effect after a period of NIV. Patients with better social situation cope better with 
NIV. The most informed ones surf the internet and it can arise questions about 
the NIV. Very important is the degree of information they received and their 
level of acceptation of the bad news. 
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Opioids are not commonly used to relieve shortness of breath. Some believes their use 
is limited to terminal sedation, others confess not to be experienced to their use: 
 
EALS1: to control dyspnoea as symptom we don't use morphine because the 
symptom is very progressive and its use’s not suggested by international 
guidelines, so we use it for terminal sedation only. Opioids have always been 
used with caution, like benzodiazepines. recently they have become of common 
use, but experience is not yet so wide. 
 
EALS2: Opioids for dyspnoea? I heard about it, but we're not experienced at all 
 
 
 
3. Drooling and mouth problems 
 
Participants mentioned this group of physical problems as frequent and difficult to treat 
 
EPD2: Drooling is a symptom difficult to treat even if you visit the patient daily. 
 
EALS2: Drooling is a big problem. Some anticholinergic drug like scopolamine 
works, but.. 
 
EALS1: Than there are difficult symptoms in general like drooling. it's a very 
distressing symptom, very hard to control. basic research is required to better 
understand and manage this symptom. Amitriptyline and scopolamine are used, 
but not so efficient. 
 
4. Participants listed other physical uncontrolled symptoms experienced by their 
patients 
 
EPD1: our patients experience gait problems, tremors, rigidity, non motor 
related troubles, urinary problems, gastrointestinal problems, dysphagia, many 
other problems. 
 
EMS2: out of spasticity and pain,  urologic troubles are very frequent in MS and 
very advanced patients are mostly catheterized. 
 
EMS2: Most invalidating symptoms in cognitively not impaired patients are 
mobility troubles, dysphagia, speech impairment and fatigue. 
 
 
Psychological needs 
 
The psychological problems faced by patients severely affected by neurological 
conditions appeared in the discussions proposed by professional carers. 
Depression, dementia and cognitive changes, difficulties in coping with the disease and 
the continuous losses, problems related to providing adequate psychological support 
emerged as important themes seen by the professional point of view. 
In this paragraph data related to these issues are presented. 
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1. Anxiety and Depression 
 
Anxiety and depression are common findings in people affected by advanced diseases. 
For some specific condition like PD and related disorder this depression can be a 
specific feature of the disease, sometimes preceding the diagnosis 
 
EPD1: in PD the impact of these symptoms is equal to motor symptoms. 
Depression, in the end, affects everyone. Often it precedes diagnosis. 
 
Depression can appear in all diagnosis as the consequence of disability and loss of self 
control. Therapies prescribed to limit the progression of the disease can worsen 
depression as well  
 
EMS1: depression is present at every stage of multiple sclerosis. There's always 
fear of something worst that could happen. In advanced stages they recognize 
that they won't recover. We must add that some of psychological symptoms are 
worsened by specific treatments. For instance interferon is contraindicated in 
patients with psychiatric co-morbidity. 
 
Anxiety is often associated to depression expressing the fear for the future and the 
uncertainty of the present. 
 
EMS2: I confirm that depression is common in all the stages of MS. Being the 
course of the disease unpredictable patients have anxious conditions even in 
periods of stability. High risk of relapsing cause anxiety and depression. In 
progressive forms of MS drugs aren't effective and so patients must assist the 
progression of their disability without any chance of improving.  
 
EALS1: anxiety and depression are obviously common in ALS/MND as well. 
These symptoms are challenge our assistances in parallel with the clinic activity 
(physical symptom control. Above all long surviving patients tend to arise these 
problems.  
 
Therapies offered to relieve these symptoms are available and effective, but patients’ 
compliance is not always optimal and difficulties in the follow up of very disabled 
patients can affect the result. 
 
EMS3:  anti depressants are effective, but it depends if patients want to receive 
it. 
 
EPD1: SSRI (inhibitors of the reuptake of serotonin) are effective, even if a 
compulsive obsessive disturb occurs, but they must be titrated and patients are 
to be followed up carefully. This is not always the case of our physically 
impaired patients who are hardly transportable. 
 
The importance of a psychological support was strongly recognized by the participants 
and its strengths and weaknesses will be discussed later on in this subchapter.  
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2. Dementia and cognitive changes  
 
With the disease progression cognitive disabilities can appear in all conditions. This is 
particularly frequent in movement disorders and multiple sclerosis where frank 
dementia or psychiatric symptoms are common, but in motor neurone disease as well 
fronto-temporal dementia can occur causing behavioural changes and problems related 
to decision making. 
 
EPC: thinking about Parkinsonisms and ALS I'd highlight speech impairment 
without cognitive impairment that cause bad aphasias and have an awful impact 
on QoL. Dementia and other cognitive impairment impact badly on families. 
Physicians tend to focus on memory disturbances, but families are more 
concerned about other psychiatric features like aggression. 
 
Patients with high physical disability are difficult to assist at home and when admissions 
are required their cognitive status can challenge this decision. Nursing homes, facilities 
usually admitting elderly demented people, cannot be the best place for young not 
cognitively impaired patients 
 
EMS2: MS patients tend to die at home, even because there are not so many 
facilities for them. The only ones available are geriatric nursing homes. So a 
man in his 30ies, not cognitively impaired can't stay in a nursing home! There is 
a clinic in Mappano (a village near by Turin) held by nuns where we can admit 
some young patient with high disability. This is the only facility that provides 
admissions for very disabled MS patients, cognitively impaired or not. When 
they are demented probably they do not understand where they are, but when 
they are competent it is very hard for them to accept to stay and eventually die in 
that setting.  
 
3. Coping with the disease progressions and continuous losses 
 
Professionals are aware of the difficulties faced by people experiencing relentless 
disability. 
They report their difficulties in providing help and the resistance of patients to accept 
aids that could ease their invalidity because when they propose these devices patients 
understand that the disease is progressing and they do not want to accept it. 
 
EMS3:  decisions about PEG or baclofen pumps cause high psychological 
suffering to patients. (…)MS patients hardly accept efficient therapies even when 
they are very effective on symptomatic outcomes. Patients tend to refuse because 
to accept it they should accept the progression of their disease. Once they accept 
it they're happy with their decision. So it's not enough to offer an aid, often we 
receive a refusal. This is frustrating because you, as a professional, know that 
they need that help, but you recognize their feelings and often have to wait until 
they cannot cope anymore to prescribe these aids. 
 
Physicians report to be challenged by questions about relational aspects like sexuality, 
arguments in which they do not feel to be sufficiently prepared to provide help 
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EPD1: they always ask me about this! When they enter in the ambulatory and I 
ask How they are… they say they want to talk about their sexual courses. Often 
is the first thing they mention. It is a little bit embarrassing for me because I do 
not know what to say.. 
 
Decision making and the acceptance of the disease progression are strongly related. Life 
sustaining treatments, such as mechanical ventilation, are effective on symptom control 
and can significantly extend life, although can not relent the disability progression. 
Professionals working in the respiratory clinics recognize the importance of the 
psychological support on the compliance of patients and families with these devices, 
and, as a consequence, on the outcomes of the treatments. 
 
EALS2:  psychological distress in our patients is the most distressing to me as a 
professional, and often we work with the psychologist on this theme. Some 
patient cope extremely well. We have some that being tracheostomized and 
quadriplegic can surf the web and send us e-mail. Unfortunately others do not 
cope at all. Usually these are the ones who do not accept the disease and its 
complications 
 
SLT: Many patients and their families aren't prepared at all when they have to 
decide. I don't mean they should decide serenely, but at least they should be 
prepared. Three out of four patients attending our department are not prepared 
to take the decision about tracheo when required. The prepared ones had 
previously received an adequate support. 
 
PHT: We saw patients with a tattoo on their throat reporting that they didn't 
want to be tracheostomized… 
 
SLT: yes, but we also have to say that some patient refused tracheostomy until 
the moment they became breathlessness. At that time they changed their mind. 
When they felt they were choking they asked for tracheo. 
 
 
Patients who cannot cope with their invalidating conditions often arise issues about end 
of life decisions. This aspect of caring is a main concern for professionals working in 
the hospital setting. 
Discussing about euthanasia, suicide and decisions related to patients will to end their 
lives evoked an interesting debate among our participants 
 
EPC: I remember a 60 years old ALS patients who asked his neurologist if he 
could end his life. He had just been diagnosed. He discussed with me and the 
other colleague about euthanasia. He was a cultured man who knew how he 
could die because of the disease and explicitly asked to die. Another patient with 
MSA, after an evident worsening of her conditions asked about how to terminate 
her life, she asked why in Italy it's not possible to be helped to die. I've never had 
a patient who took his life, but with these diagnosis the problem is real. 
 
EMS2: fortunately I didn't have any experience like this. In MS the problem is 
due to the disease progression. ALS patients are vigilant until the end of their 
life. MS patients, luckily, have cognitive impairment in far advanced stages and 
this helps. They are not so aware of their conditions. Carers, well, they are more 
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aware of this. Diagnosis is a difficult moment, than generally patients accept it 
because there are remissions, there is a lot of research... 
 
EMS3: these situations (suicides, request of euthanasia) are more common than 
in cancer because it's a longer disease. Even advanced stages can survive for 
years. We had patients who attempted suicide, but never succeeded. Some of 
them are at risk. Above all the early and the far advanced stages. They do what 
they can, with drugs overdose or trying with their hands.. above all young 
patients in relatively good conditions that don't accept it. 
 
EPD1: in literature these problems are reported. I don't have this experience. It 
may be due to the fact that PD patients tend to be older than MS, or because of 
their particular character.. If they talk about this probably they're trying to keep 
your attention on them, it's more a provocation. Sometimes it happened with 
younger patients who said:" What do you think doctor, wouldn't it be better to 
end up this situation? But if my wife does it I'm happier!" Probably younger 
patients are more at risk because of the long life they have to live with the 
disease, but fortunately they respond well to therapies. 
 
4. Role of the psychological support 
 
when asked to describe which kind of psychological support their services were able to 
provide to these population professionals reported different experiences. Some groups, 
such as the ALS/MND one, are better organized and have a proper psychological 
support service available for both patients and relatives, even though it is basically 
hospital based and so difficult to reach homebound patients 
 
ALS1: We have a psychological support service that works very well. Patients, 
carers and friends are supported in a very good way. The problem is that our 
psychologist can't go out of the hospital and so when the patient is bedbound 
often cannot be of help anymore.  
 
Specialists recognise that this support is very important throughout the course of the 
disease 
 
SLT: I think that a psychological support should start soon after diagnosis. They 
have to focus on end of life decisions, like if they are to decide for a  tracheo, yes 
or not. It would be sensible  if psychologists  were included in the information 
and support pathways. In facts, in our reality, they are not. 
 
In conditions other than ALS/MND the available psychological support is not well 
established and no home service is available. In MS ambulatories a psychologist is 
available and provides counselling for both patients and families and contributes to help 
in therapeutic decisions 
 
EMS4: we have a psychologist who helps us in caring for our patients. She is of 
help above all for new diagnosed patients that have to cope with such a bad 
news. She works on treatments compliance too. Certainly in advanced stages a 
support would also be required, but we're not so experienced on that. Being a 
long term disease patients have their time to use adaptation for their disease. 
 
Chapter 3. The Qualitative Needs Assessment 
 165 
 
In movement disorders psychologist are involved mainly for therapeutic decisions. 
Patients are tested for selection about deep brain stimulation (DBS), in fact only those 
without signs of cognitive deterioration can be selected for this treatment. This service 
is of little, no use for psychological support 
 
EPD2: our patients are continuously tested by our psychological group, but 
they're tested in order to monitor their cognitive performance as it is important 
to decide if they can be candidates to DBS or in follow up after its placement. In 
ordinary visits we try to support them in informal ways, but we don't have any 
specific team dedicated to this point. There are big necessities for this kind of 
support as nothing is available for our population 
 
 
Social needs 
 
Professionals who participated in the three focus groups dedicated some comments to 
the social unmet needs of their patients. They declared that their opinions were largely 
based on what patients and families described during the clinics, rather than a direct 
experience based on having seen their homes or their social environments because only 
a few of them could visit patients at home. 
Social isolation, financial concern and caregivers burden were the most prevalent 
themes which emerged from the discussions. 
 
1. Sense of social isolation and lack of social support 
 
Isolation can happen because patients are abandoned by their partners who are scared by 
the diagnosis or by the disease progression 
 
EMS1: a frequent problem is patients abandoned by their spouse due to the 
disease. It's awful, above all when young mothers with MS are abandoned with 
young children. So divorces and abandonment are more frequent that in general 
population. MS is a scaring disease and many husbands can't cope with it. What 
surprise us is that it happens just after diagnosis, not after a long time when 
disabilities impact badly on QoL. 
 
But patients can be isolated even in their own families because they lose physical skills 
like eating and therefore do not participate in familiar meetings and meals 
 
SLT: This happen when a member of the family thinks that if the patient stays 
around the table with the others he'll suffer because he or she is incapable to eat 
like the others. But this cause isolation and loss of the familiar role. When you 
don't feel like a person anymore you stop your interactions with the others. In 
the end you don't communicate with your family. Some patients just lie on a 
wheelchair with the PEG, ventilator.. sometimes someone pass in front of you, 
tell you a couple of words, but you can't answer… that's isolation. 
 
Isolation is also worsened by lack of help provided in the place of care (home) and in 
the required way. 
 
EALS1: home care should provide domiciliary assistants to mobilize patients 
and to enable them to go out when possible. Many tracheostomized patients can 
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go out with the wheelchair and a portable respiratory machine. Nowadays it is 
rare that a severely disabled neurological patient can obtain a good home care 
service 
 
Professionals believe that little practical help and suggestions could have a strong social 
impact for patients and caregivers if available 
 
EPD2: very easy suggestions at their home could really impact on their QoL. 
They could really be helpful for carers. Often carers ask me how to achieve 
services and I don't have any idea of it. Patients tend to be isolated because of 
lack of transport services. I suggested a number of possible interventions to a 
patient who came in our ambulatory, but his carer told me that it wasn't feasible 
because the real trouble was to transport him, and if this problem can not be 
overcame we in the hospital cannot provide any help. 
 
2. financial and job related problems 
 
When disability impairs patients they lose their capability to work. This is recognized as 
a further loss by professionals, being both cause of diminished financial income and 
cause of social isolation 
 
EMS2:  another issues are job related problems. Patients tend to hide diagnosis 
not to be discriminated on their place of work. Or if they work on their own 
there's the problem of how to manage it when they'll be disabled. 
 
EALS: when patients are homebound, above all if they are totally dependent by 
a mechanical ventilator, they require continuous assistance. If they are young 
and have already lost their employment the problem becomes worst because 
often their spouse has to leave their job to care for them. 
 
3. caregivers burden 
 
This aspect was described above when discussing the need for respite care admissions 
and can be implemented by the previous comments about the need of social support in 
terms of home care assistants and financial support. 
Specifically professionals recognize the high burden of care induced by having to care 
for very disabled patients for months and sometimes years with little no time to rest or 
to take some time for their own lives. 
 
EMS1:  they really need respite, I mean to be relieved a bit. 
 
EALS1: respite admission is very important for caregivers. It would be so 
important to have facilities available for respite periods here in Turin. I think 
that for our patients respite admissions can be very useful to support their  
carers. Maybe they could use 15 days just to sleep!  
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Spiritual needs 
 
Existential questions are reported by participants to the focus group as inevitable in the 
advanced stages of neurological diseases. Often these are triggered by end of life 
decisions or spontaneously discussed by patients during routinely clinics. 
Professionals declare that they do not feel at ease when these issues come out in their 
practise. 
 
EPD1: typically patients report something like this: You see dear doctor  the 
main question is “Why me?” And above all “Why now?”  I worked all my life 
and now that I could enjoy it… the matter is that we don't know how to answer, 
there's non one we can refer them to. 
 
Some participant recognise their potential role in enabling their patients to raise these 
issues 
 
EPC:  it depends very much on how much place you dedicate to communication. 
If you let these questions arise or not. I think that every patient feels these needs. 
Support provided is still very low. There are psychological support dedicated 
services with social workers too, but not about spirituality. Often these questions 
are asked to physicians because they don't feel a professional judgement. If you 
leave enough space these questions will arrive. 
 
Spiritual themes can be addressed by relatives after the patients’ death, or by patients 
themselves when the future appears scaring and full of doubts, as this participant testify 
 
EALS1: about spiritual issues they tend to arise in familiars after the patient’ 
death because the disease is so quick...  but sometimes in those long term 
tracheostomized patients (that I personally consider over-treatment or heroic 
treatment) the existential problems become more important than the practical 
ones. We receive questions about anguish of the future, fear of what could 
happen.. 
 
Spiritual questions can challenge ones own beliefs and involve professionals in their 
private intimate life. Sometimes this can be a cause of difficulties in maintaining the 
professional role and therefore specific spiritual support seems required 
 
SLT:   patients with advanced respiratory troubles talk of spiritual questions and 
these should be addressed to a spiritual assistant or chaplain. We became aware 
that these heavy questions are asked to us. So we try to answer without giving 
personal beliefs but… what kind of answers can we provide? (..) this is a further 
reason to provide a psychological and spiritual support from the time they are 
diagnosed. 
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3.5.3.3.4 Summary 
 
The professionals that participated to the focus groups provided deep insight about the 
various aspects of the care of patients severely affected by neurodegenerative 
conditions. They confirmed the difficulties to determine the number of potential people 
in advanced stages that could require specialist palliative care. Professionals denounced 
their difficulties to provide supportive care to patients very disabled unable to go to the 
clinics. The end of life phases are not easy to be identified for the unpredictability of the 
trajectories of the disorders. They are aware of the high burden of physical, 
psychological, spiritual and social unmet needs faced by their patients and their family 
carers and some recognize their lack of expertise in managing the peculiar problems 
caused by the advanced stages.  The potential role of specialist palliative care, both for 
the home assistance and for the hospice respite admissions, was widely recognized and 
participants confirmed their keenness to help the development of a new SPCS for their 
advanced patients.  
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3.6 Discussion of the qualitative study 
 
In this chapter the results emerging from the qualitative study are discussed. 
The general framework of the discussion is based upon the following key points: 
1. General discussion of the results 
2. The physical, psychological, spiritual and social components of the unmet needs  
3. Potential role of a new SPCS aimed at meeting the unmet needs 
4. Limitations of the study 
5. Summary  
 
3.6.1 General discussion of the results 
 
Results of the NeuNeeds qualitative study can be summarized as follows: 
• 22 in depth interviews with patients severely affected by ALS/MND, MS, PD 
and related disorders and their informal carers and 3 focus groups with 
professionals involved in their care were performed. 
•  Audio and videotaping and field notes of the events were collected, transcript 
verbatim performed and a multi step coding procedure allowed to highlight 
various categories of needs and issues related to patients’ quality of life, 
caregivers’ burden and comments on the available existing services dedicated to 
this population. 
• The inter-rater reliability among the 3 independent researchers was higher than 
70% in the coding procedure. This represents a clear indication of how explicitly 
participants identified the needs and themes in a way that independent observer 
can detect the underlying meaning with little no difficulties. 
• The large amount of data results from this study: interviews and focus groups 
had a mean duration of about 60 minutes each. Transcript verbatim of the 25 
events resulted in about 108000 words with an average of 4300 word for each 
event. Inevitably some information got lost in the coding process, even though a 
conspicuous amount of data was analyzed. 
• Participants seemed interested in the study and keen to collaborate. None 
declined to participate to the interviews. Focus groups were more complicated to 
organize and manage as described in details in the limitation section. This can be 
interpreted as a general interest of patients and families about new initiatives that 
can have a positive impact on the assistance, while it confirms that for many 
professionals palliative care is not on the top of the list of their agenda.     
 
3.6.2 The physical, psychological, spiritual and social components 
of the unmet needs  
 
The content analysis of the results coming out from the 22 interviews and the 3 focus 
groups reveal a huge number of problems that patients severely affected by 
neurodegenerative disorders living in Turin city and its metropolitan area (and their 
families)  have to face and that are not fully satisfied by the existing dedicated services. 
All the components of the so called “total pain” (Clark 1999) are represented in the 
transcript verbatim of the various events. Professionals involved in the care of this 
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population agree with their patients about the high number of distressful symptoms and 
other non physical components of their suffering. 
Even though the qualitative design of the study was chosen to provide a deep insight of 
this population’s daily troubles, rather than to quantify the number of the unmet needs, 
the content analysis showed numerically the big load of troubles present in the sample 
and can be confronted with previously published data. 
In the following sections the various categories of needs are discussed 
 
3.6.2.1 The physical needs 
 
The published systematic review of the symptom prevalence among people affected by 
advanced and progressive neurological conditions (Saleem, Leigh and Higginson 2007) 
allows a comparison between the findings of the study and what is known about these 
issues. 
 
Overall 169 physical symptoms were discussed in the 22 interviews with an average of 
13 physical problems each event. Professionals focused more on the major symptoms 
such as pain, respiratory troubles or typical neurological features like movement 
impairment, and were less likely to not mention other problems usually well known in 
the palliative care settings such as the quality of sleep, oral symptoms, or problems of 
the skin. Voiding functions were also rarely reported by professionals as important 
problems, whereas patients and families talked frequently about it. Professionals were 
more concerned about medications, prevention of medical complications and respite 
admissions.  
 
Pain 
 
Pain is reported both frequent and severe as evidenced in recent literature reviews in this 
population (Ganzini, Johnston and Silveira 2002, Lee et al. 2006c, Higginson, I. J. et al. 
2006a, Saleem, Leigh and Higginson 2007). In our study more than 80% of participants 
had some kind of pain or painful conditions. These were not necessarily related to their 
main diagnosis, but were cause of suffering for patients affected by chronic disability 
and in their last months/years of life. Some patient reported pain spontaneously, others 
had to be given hints and support to discuss this issue. Some participants seemed 
ambiguous about this symptom because they felt that their painful condition was not 
directly caused by the neurodegenerative condition. They felt relieved when researchers 
underlined the importance of recognising the impact of any kind of pain in the palliative 
philosophy of care. Several different definitions were used by participants to talk about 
painful symptoms and this finding is similar to what described by Saleem et al. in his 
review about  the physical symptoms in neurodegenerative conditions (Saleem, Leigh 
and Higginson 2007). 
It appeared that pain was undertreated and participants stated that their physicians 
feared to use pain killers because of potential side effects like respiratory depression and 
this confirms what has been described in patients with neurological conditions since 
many years ago (O'Brien, T. 1993b). 
 
Pain is certainly one of the most known physical symptoms in the palliative care setting 
and in the past was seen as an inevitable condition for people dying for cancer. The 
development of the modern palliative care and hospice philosophy allowed millions of 
cancer patients to be relieved of this awful symptom (Hanks and Forbes 2005). The 
Chapter 3. The Qualitative Needs Assessment 
 171 
 
assumption is that painful syndromes caused directly by the neurodegenerative 
conditions or complicating the clinical conditions as co-morbidities can be better 
controlled if a SPCS can intervene offering its skills as shown for ALS/MND in some 
hospices (Oliver 1998, Oliver 1996, Oliver and Webb 2000, O'Brien, T., Kelly and 
Saunders 1992).  
 
Breathlessness and respiratory problems 
 
Respiratory symptoms, particularly causing dyspnoea, appeared in more than 80% of 
the interviews. This is a very well known condition for ALS/MND advanced patients 
(Saleem, Leigh and Higginson 2007, Neudert et al. 2001b, Lyall and Gelinas 2006), but 
in our study it was reported by patients affected by MS and movement disorders as well. 
It is known that for patients with neurodegenerative conditions and severe disability the 
main cause of death is  infection, particularly a chest infection (Sadovnick et al. 1991, 
Koch-Henriksen, Bronnum-Hansen and Stenager 1998, Litvan et al. 1996, Beyer et al. 
2001). Shortness of breath was also found to be correlated with QoL in  hospice setting 
(Steele et al. 2005). Participants in this study talked of numerous episodes of respiratory 
tract infections during the advanced stages of these diseases, causing shortness of breath 
and scaring both patients and carers. These occurrences often cause the hospitalization 
of the patients exposing them at the risk of further hospital acquired infections, as 
reported by the professionals who participated at the focus groups. 
 
Another important finding of this study was that the management of respiratory troubles 
in patients with severely advanced neuromuscular problems is focused on the possibility 
to provide an efficient respiratory support, preferably through non invasive ventilation, 
which has been shown to improve the QoL of the patients and have appositive impact 
on survival, although is not a curative treatment and cannot arrest the progression of the 
muscular paralysis (Eng 2006, Mitsumoto et al. 2005, Miller et al. 1999). Invasive 
ventilation is a possible option that is offered when non invasive respiratory support no 
longer control the symptoms or the arterial gas analysis shows an excess of CO2. 
Another group of patients that often require invasive ventilation are the bulbar patients, 
especially for ALS/MND, for whom the ventilation through the mask is often not 
applicable because the patients cannot control the upper airways (Albert et al. 1999b, 
Albert et al. 2009). 
 
In Piedmont, the Italian north western region, where these study was set up, there is a 
prospective regional register for ALS/MND (Chio et al. 2009) containing data of all the 
diagnosed cases of this disorders since 1995. Recently the neurologists working in the 
tertiary clinic for ALS/MND in Turin published a retrospective analysis of this register 
aimed at evaluating the frequency, the clinical characteristics and the outcome of 
tracheostomy in these patients. This study evidence that the prevalence of tracheostomy 
is of about 10% and of those  patients who had this option they were more likely to be 
men and young. The median survival time was of 253 days after the tracheostomy and 
longer survival was related to young age, presence of PEG, being married and cared for 
by a tertiary clinic (Calvo et al. 2009). In this study 3 patients with ALS/MND were 
tracheostomized and ventilated 24 hours per day. They were all long survivors because 
they had been tracheostomized respectively 4, 3 and 2 years before and were clinically 
stable. All of them reported to be happy with this choice, even though one of them had 
it in emergency and had not been  not keen on the intervention beforehand. None of 
them discussed the possibility of  being disconnected from the ventilator. This subject 
appeared in other interviews with patients with non invasive ventilation that feared this 
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option because they had been told that if they chose it they could not be withdrawn with 
the Italian laws. This is certainly a difficult decision even though in most western 
country it is both legally and ethically accepted (Oliver 2004, Ankrom et al. 2001, Moss 
et al. 1996, Borasio, Gelinas and Yanagisawa 1998, Borasio and Voltz 1998). 
 
 
What appeared to be lacking in the care of these patients was the palliative management 
of the respiratory symptoms. Experts involved in the focus groups confessed their lack 
of knowledge in the use of opioids to control breathlessness. Physicians involved in the 
respiratory management declared to feel impotent when the patients refuse or do not 
tolerate a non invasive ventilation. They reported that when patients are brought to the 
hospital for respiratory insufficiency they are more likely to be tracheostomized  even if 
they would not want it because there are not an alternative to control breathlessness. 
Neurologist stated that morphine was to be used for pain control or for terminal 
sedation, but that there were not an indication for this drug to control dyspnoea even 
though this option, commonly used in hospice and palliative care settings (Jennings et 
al. 2002, Lyall and Gelinas 2006, O'Brien, T., Kelly and Saunders 1992, Oliver 1998). 
Furthermore the indication for using morphine to control breathlessness has been 
published in guidelines for the management of the ALS/MND patients by neurologists 
in many occasions (Miller et al. 1999, Mitsumoto et al. 2005, Eng 2006). 
For these reasons it was thought that the skills of a SPCS could have been of use to 
enable patients who refuse mechanical ventilation and that suffer for shortness of breath 
to receive adequate palliation of their symptoms and to have their advanced directive 
respected. 
 
Sleep related problems 
 
The quality of sleep in very ill patients is often poor and these symptoms represent a 
common feature in different advanced conditions (Hockley, Dunlop and Davies 1988, 
Solano, Gomes and Higginson 2006, Saleem, Leigh and Higginson 2007). 
In this study 64% of participants reported problems causing sleep disturbance. Often the 
poor quality of the sleep is due to uncontrolled physical symptoms or fear and anguish 
that may emerge during the night. It is known that insomnia is one of the symptoms that 
can indicate poor oxygenation of the blood at night time due to respiratory failure – a 
condition frequent in ALS/MND (Borasio, Voltz and Miller 2001); can be caused by a 
restless legs syndrome that affect particularly PD’s patients (Lee et al. 2007); or by 
painful neuropathic syndromes in MS (Henze, Rieckmann and Toyka 2006). 
Being a common condition that impacts badly on the QoL of both patients and their 
carers this domain was included among the physical symptoms to be assessed in the 
evaluation of the new SPCS. 
 
Intestinal symptoms  
 
Constipation, diarrhoea, problems due to dietary changes caused by dysphagia and the 
consequent need to alter the consistence of the food, the placement of a PEG and the 
feeding through enteral nutrition, the side effects of drugs like the L-Dopa are common 
findings in patients with advanced neurodegenerative conditions.  
In the present study more than 70% of the interviewed patients reported problems 
related to their bowels. 
The intestinal symptoms were also described by the professionals involved in the focus 
groups that reported these problems as both frequent and difficult to manage. 
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SPCS have to deal with intestinal problems due to the use of opiods, partial or total 
intestinal obstruction  in malignancy,  and cancer related diarrhoea among the others. 
Constipation is also used as an excuse to avoid the use of opioids and this was been 
reported by neurologists, patients and carers involved in this study. One of the tasks of a 
SPCS is to convince the service users that constipation can be improved by applying 
protocols that are part of the normal routine activity of the hospice teams. 
 
Urinary symptoms  
 
Urinary problems frequently affect neurological patients at the end of life. Voiding 
dysfunctions are associated with common neurological disorders involving difficulties 
with emptying and storage. Typically MS patients suffer from detrusor external 
sphincter dyssynergia when they have a spinal cord involvement. This can lead to 
urological complications such as hydronephrosis, vescico-uretral reflux, sepsis and 
urilithiasis (Andersen, J. and Bradley 1976). In PD’s patients up to 72% have symptoms 
of bladder dysfunction, usually a detrusor hyperreflexia (Shah and Badlani 2004, p. 
264.) ALS/MND should spare patients from sensitive and autonomic deficits, but when 
very advanced difficulties related to incontinence or need to use pads, external catheters 
or sometimes indwelled bladder catheter can appear. When patients lose the ability to 
eliminate completely the urine from the bladder and some remains stored extemporary 
catheterization may be  necessary. This task is often performed by the patient if he or 
she maintain a sufficient ability in their upper limbs, or more frequently in the advanced 
stages by their carers. Patients must not stay wet to avoid the risk of skin ulcers and this 
cause a high burden of care for their families. 
In this study about 60% of participants reported symptoms and problems related to the 
urinary tract. This group of symptoms is again of common management for a SPCS. 
 
Oral symptoms 
 
In this group of symptoms were grouped all the difficulties related to the mouth 
discomfort,  like drooling and dribbling of saliva, dry mouth, problems with secretions 
and oral pain. If the swallowing issues such as aspirations, choking for food and 
dysphagia problems are added we can see that almost all the interviewed patients 
reported at least of these issues . 
It is known that ALS/MND, especially for the bulbar forms, may cause drooling and 
dribbling of saliva, not from an excess of production, but for the difficulties in 
swallowing it (Oliver et al. 2007, Mitchell, Temperley and Duff 1995, Miller et al. 
2009) and this happens in MS (Rousseaux and Perennou 2004) and in PD’s as well 
(Bunting-Perry 2006, Calne and Kumar 2003, Clough and Blockley 2004, MacMahon 
1999, Wenning et al. 2004).  
Drugs can cause dry mouth, especially anticholinergics, amitriptyline and opioids. All 
these categories of drugs are commonly used in palliative medicine and therefore SPCS 
know well the therapeutic balance between positive and side effects. 
 
Other physical symptoms 
 
Among the coded groups of physical needs other categories found were movement 
difficulties that obviously affected all the interviewed patients and this can be easily 
understood from the high disability degree of the sample. Skin troubles and other less 
common symptoms like fever, visual loss and speech impairment were also reported 
and patients testified how they impacted on their individual QoL. These conditions are 
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described in the content analysis of the physical needs, in the results section of the 
qualitative study. For the purpose of this project the physical symptoms that were 
chosen, among the ones who emerged from the interviews and the focus groups, were 
those for which it was though that the input of  new SPCS could make the difference 
inducing positive change due to its specific knowledge and competence. Of course this 
cannot be possible for the movement disability, visual loss or loss of the speech.  
 
3.6.2.2 The psychological needs 
 
Abandonment  
 
The sensation of being abandoned by the persons on whom patients and families rely 
upon, is a very unpleasant feeling leading toward the sense of insecurity. This is what 
was proposed by Maslow as a fundamental need for the human beings when he 
described the safety needs: 
Practically everything looks less important than safety,(even sometimes the 
physiological needs which being satisfied, are now underestimated). A man, in this 
state, if it is extreme enough and chronic enough, may be characterized as living almost 
for safety alone. (Maslow, A. H. 1943). 
   
Participants reported to feel abandoned by their relatives, friends, doctors and other 
healthcare specialists. The causes of this abandonment were defined as caused by the 
patients’ difficulties to ask for help, the lack of sensitiveness of the people that should 
perceive the difficulties of the physically impaired patients and offer themselves to help, 
the lost of interest of professionals that lose interest in patients when are very ill and can 
not be cured. The consequences of this awful sensation can be the anxiety, confusion, 
fears of the future and closure. Recommendations have been suggested by other authors 
so that attention is given to emotional support, which specifically addresses three main 
areas of dealing with loss and change for people that are severely affected--physical 
issues, independence and relationships (Edmonds et al. 2007b). Similar conclusions 
were reached by other researchers for PD patients and carers, highlighting, among the 
others, the difficulties faced by their interviewees in the advanced stages (Hudson, Toye 
and Kristjanson 2006). Many patients and carers feel abandoned by their medical 
attendants when they reach the end stage and are often told that "nothing more can be 
done"(Gonsalkorale and Morris). Abandonment is strictly related to the quality of the 
relationships and a key point for palliative care professionals is to put the patients’ and 
the families’ needs  in the centre of the attentions, fighting the negative common 
practice in medicine of tending to ignore  the dying and treating them differently. 
 
From the professionals point of view this was confirmed by the sense of frustration 
reported by the focus groups participants. They reported how they feel impotent when 
patients become too ill to be able to go to the hospital or the ambulatory clinics  and 
they are lost at follow up. Some declared not to know what happen to the patients once 
they do not come to the appointments. Others reported lack of confidence in the existing 
domiciliary services provided by the NHS. 
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Coping with the disease 
 
Difficulties in coping with the neurodegenerative disorders and the coping strategies 
adopted by the participants were a very interesting finding of this study. It is known that 
advanced neurological disorders can cause desperation and lead to concerns at the  end 
of life, leading towards suicide (Sadovnick et al. 1991) or medical decisions to shorten 
one’s own life (Ganzini et al. 1998, Veldink et al. 2002, Van der Wal and Onwuteaka-
Philipsen 1996). Depression is not the only cause of these decisions, but other 
conditions such as hopelessness, fear to die with suffering and difficulties to accept 
multiple losses can induce people to take decisions like these (Albert et al. 2005, 
Kumpfel et al. 2007, AAN 1998, McCluskey 2007). 
 
One of the tasks of a SPCS is to help patients and families to cope as better as possible 
with the diseases and the losses and changes caused by the progressive course of the 
illnesses (Edmonds et al. 2007b, Adelman et al. 2004). 
 
From the interviews of this study it results how many causes of losses can affect the 
patients and their carers. It was possible to detect issues related to difficulties to cope 
with losses or having unmet expectations (which can be considered as a loss) in 17 out 
of the 22 interviewed patients. Most reported difficulties were about physical troubles 
such as having to accept limitations in movements and autonomy, but other  losses were 
reported such as losing a  job or the possibility to communicate. Rage, fears, anxiety 
and depression were again consequences of these difficulties. Some participants spent 
their time and money seeking for alternative therapies, often having to pay a great deal 
of  money taking journeys of hope in far countries like China. 
 
Family carers reported difficulties defined as having to struggle for everything they 
needed (Edmonds et al. 2007a) because doctors and social assistance were not of help 
for them, and they had to go through difficult bureaucratic passages to satisfy the 
patients needs. Some reported that they preferred to quit asking because they lost the 
hope to be helped confirming that specialised psychosocial care is necessary for carers 
of very ill and disabled patients (Oliver and Gallagher 1998). 
Another psychological need found out in the study was the unpleasant sensation of 
being a burden reported by the patients (Chio et al. 2005). This was usually denied by 
the carers, even though some declared to be very tired and in burnout syndrome. This 
sensations confirms what published in the literature about the different perceptions 
between patients and carers of one another’s quality of life and existential issues 
(Adelman et al. 2004, Bolmsjo and Hermeren 2001, Goy, Carter and Ganzini 2008, 
Kristjanson, Aoun and Oldham 2006).  
 
 
 
Anxiety and depression 
 
The methodological design of this study was not meant to detect signs or symptoms of 
these specific psychiatric disorders, but when direct references to these issues were 
made the researchers coded it into these categories. This happened also when indirect 
citations were related to these mood disorders. Even though direct sentences using the 
terms anxiety or depression to describe the psychological condition of the patients were 
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seldom used, in all interviews appeared some mentions to the alteration of the patients’ 
mood. 
 
The prevalence of mood disorders in patients with severe neurodegenerative disorders is 
widely discussed. Depression ranges from 25-50% in MS (Minden and Schiffer 1990, 
Patten et al. 2003, Sadovnick et al. 1996), whereas anxiety affects about 36% of these 
patients (Galeazzi et al. 2005, Korostil and Feinstein 2007). In ALS/MND advanced 
patients depression was found in 19% of patients (Rabkin et al. 2005), but it can affect 
up to 50% and it is strictly correlated with hopelessness impacting deeply on the 
individual QoL (McLeod, J. E. and Clarke 2007). Anxiety has been described between 
19- 24% of patients in an Australian and an  Irish survey respectively (Kristjanson, 
Aoun and Oldham 2006, Clarke, S. et al. 2001). For PD’s patients anxiety is reported 
between 43-62% (Chaudhuri and Martinez-Martin 2008, Lee et al. 2007) and 
depression between the 20-40% (Kristjanson, Aoun and Oldham 2006, Chaudhuri and 
Martinez-Martin 2008), although using other instruments it has been found in lower 
percentages (3-16%)(Lee et al. 2007). 
 
To obtain these prevalence data authors used validated tools that were not part of this 
study design. From the interviews it emerged clearly how patients and their families’ 
mood were proved by the experience of the disease and participants were facing worries 
that impacted badly on their QoL. Some experienced fears and concerns for the future, 
others reported loss of hope for their own future and for their families. Another used 
term was impotence as to describe the impossibility to do something to improve their 
conditions. Frequently patients’ mood was described as instable, probably a feature 
difficult to be detected by traditional tools, but recognizable by their carers. 
All these conditions impact negatively on the quality of life of both patients and family 
members and a psychological support should be of help, aside of medical treatment, 
trying to reduce the negative effects of mood disorders.  
 
Other psychological themes 
 
The need of psychological support was discussed by some participants. The opinions 
were divided between those who had already successfully experienced this service and 
those who had a negative impact or that were prejudiced against it. Probably this is not 
very different from what normally happen in cancer care when often patients and 
families are not keen at receiving psychologically help, but then realize how helpful it 
can be to be accompanied during  a painful and hard experience  so that it may prevent 
further suffering to the ill persons and pathological bereavement in the survivors. 
Less frequently, were other psychological issues raised by the participants: sense of 
shame for being in such a poor conditions, need of privacy that is completely lost when 
patients completely paralyzed need someone to wash them, change their clothes, feed 
them and so on. Someone reported a sense of loss of dignity which is striking for 
palliative care professionals that have the dignity of the dying person as a guide line for 
their job. 
Need of self independence and control was expressed in some interview and this reflects 
others’ findings in the advanced stages of incurable diseases (Cotterell 2008).  
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 3.6.2.3 The spiritual needs 
 
Among the spiritual themes that were discussed by the participants of this study the 
most frequent were related to the meaning of the experience of the disease (50%) and 
those related to the faith, religiousness and spiritual issues like the role of the spiritual 
support (78%). Other less frequent arguments were the debate about justice/injustice for 
what is happening to them (27%), the concept of hope (Centers 2001) (23%), usually 
referred to the hope to find a cure for their conditions (miracles, alternative therapies) 
and the concept of control (32%) where interviewees were divided between those who 
said that were losing control and rage usually supervenes taking its place, and those for 
whom staying in control of their situation is an important defence against the 
uncertainty of the future. 
In the following paragraphs the two most represented groups will be discussed: the 
sense of meaning and the role of faith, spirituality and religiousness. 
 
The meaning of the experience of the disease 
 
Half of the sample discussed about the following question: Did you find a meaning in 
the experience of disease that you are doing? Does this make sense in your life? These 
questions were not part of the scheduled interview scheme, but were among the hints 
that researchers provided when and if participants asked what did we mean for spiritual 
needs. 
 
Previously research showed how patients severely affected by neurological disorders or 
malignancy change their personal values shifting from self-enhancement values towards 
self-transcendence ones and this could be seen as a coping strategy at the end of life 
(Fegg et al. 2005). What is not clear is the relationship of these domains with the 
individual QoL. Maintaining a meaningful quality of life centres on psychological, 
supportive, and spiritual factors, as opposed to physical status (Stromberg and Weiss 
2006). From the data of this study it appears that participants with ALS/MND who had 
been tracheostomized were keener on talking of these items and that they had to find 
new different meanings in their lives after that important decision to prolong their lives, 
even if their physical disability did not improve, but continued to worsen. On the other 
hand those who chose not to be tracheostomized reported more difficulties to find 
meaning in their lives, as if they were just waiting for the end. Some said that having 
found a meaning does not mean to accept the situation (Albert et al. 2005). So patients 
who clearly decided not to prolong their lives shift the meaning of their life towards the 
importance of having their choices respected (Bolmsjo 2001) (in Italy advanced care 
planning or advanced directives are not yet legally binding and therefore it can be up to 
the resuscitation specialist in A&E to decide if  to resuscitate a patient who lost 
consciousness for a respiratory arrest, even if he or she had previously stated that did 
not want a CPR). For others the problem of meaning is widened to their previous 
choices, for instance one said that if she had known that she was going to fall ill she 
would not have been married, probably she could not find a meaning in her role of wife 
being totally dependent by her husband. 
 
Now an important question could be if the input of a SPCS could have an impact on the 
sense of meaning of the lived experience in these patients. In the published literature are 
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reported the importance of the personal existential values (Bolmsjo 2001, Mockford, 
Jenkinson and Fitzpatrick 2006), but whether they can be affected  positively or 
negatively by being cared for by professionals working in an end of life setting remains 
unclear. 
 
Faith, spirituality and religiousness 
 
Are faith, religiousness, spirituality positive resources that can help to cope with severe 
disability and life limiting conditions? Or at the opposite persons with a strong spiritual 
belief are challenged in their faith when such a disastrous disease bursts into their lives? 
Can a SPCS modify in part these aspects improving the relationship between a dying 
person and his or her spirituality? 
These open questions can summarize the discussion of this point. Information about 
spirituality, relationship with God, faith and religiousness were collected from those 
participants who wanted to talk about these themes. 
Overall in almost 80% of the interviews something related to these issues came out. For 
some participants the faith in a God that is love and that has the answer for their 
unbearable conditions is the meaning in life. Someone discovered his or her 
religiousness during the phases of the disease, others strengthened their liaison with 
God after having fallen ill. 
For others faith brings with doubts and the experience of the disease challenged their 
relationship with the church. Plahuta et al studying psychosocial factors in ALS/MND 
patients, showed that the extend degree to which spiritual beliefs help to cope with ALS 
is not a significant predictors of hopelessness (Plahuta et al. 2002). This finding seems 
in contrast with what reported by the interviewees of this study for whom, when 
spirituality was lived as a positive resource, it appeared easier to cope with the disease 
and to be more positive about the hope. 
 
Spiritual and religious support, that are not synonymous (Murray et al. 2004, Strang, 
Strang and Ternestedt 2002, Clark 1999, O'Neill and Kenny 1998), were also discussed 
by participants. The sample was divided in a group who stated the importance of 
receiving spiritual support and the consequent positive impact on the existential aspects 
of their lives, and a group that was not interested and did not feel that this support could 
improve their quality of life. Someone sadly reported that a spiritual support would have 
been welcome, but due to their impossibility to leave their homes they were not 
receiving an adequate spiritual care.  
 
SPCS have professional spiritual assistance in the staff and often the other “non 
spiritual” members develop attitudes and skills towards the spiritual aspects of the end 
of life, chronic disability and other spiritual issues. Professionals who participated at the 
focus groups recognised the importance of the spiritual needs of their patients even 
though the definition of the various spiritual components of the spiritual care was not so 
clear. This is congruent with other studies about this topic (Strang, Strang and 
Ternestedt 2002). 
Do SPCS make the difference for these items? No evidence in the literature was found 
related to the impact on the spiritual issues of a SPCS for people with 
neurodegenerative disorders. 
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3.6.2.4 The social needs 
 
Numerous social unmet needs were discussed by the participants of this study (see table 
3 and chart 3 in the qualitative results section). Some were expected by the researchers 
because had previously been described in the literature, such as the economic and 
financial problems due to the loss of the job sometimes for both the patient, that losses 
the ability to work and for the carer (often a spouse carer) that has to dedicate most of 
the time for the caregiving tasks (Mockford, Jenkinson and Fitzpatrick 2006). Social, 
and financial issues, should be addressed early in the course of the disease and family 
carers are to be supported because so often play a central role in management and care 
of the patients (Mitsumoto and Rabkin 2007). Enduring financial hardship was one of 
the themes developed in the data analysis of a qualitative study with caregivers of PD 
patients aimed at exploring the palliative care needs in patients and families affected by 
this neurodegenerative disorder (Hudson, Toye and Kristjanson 2006). Financial 
support is one of the variables that can help families to keep at home patients who 
choose to be cared and die at their homes (Grande, Addington-Hall and Todd 1998). A 
Dutch study quantified the monthly cost of caring for patients with ALS/MND at home 
as higher than 1000 €uros per month (Van der Steen et al. 2009) independently by the 
kind of service received (specialist or general care).  
 
The fact that SPCS can reduce the cost of care for terminally ill patients has recently 
been challenged by a literature review (Zimmermann et al. 2008) even though for the 
families receiving a comprehensive package of services including physicians, nurses, 
physiotherapists, psychologists and other professionals for free is certainly a precious 
benefit. The reported financial problems were not only related to the reduction of the 
incomes or the excess of money spent to pay for paid carers or home assistants to care 
for the ill patient, but also the difficulties to obtain social benefits like the monthly 
checks that in Italy are provided to those families who decide to care for relatives with 
chronic illness in their homes, or difficulties to obtain costly technical devices such as 
the electronical communicators that allow the patients with severe aphonia or aphasia to 
stay in touch with the external world by communicating with the others. Adequate 
physiotherapy and speech and language therapy at home was not always possible 
without having to pay for it. 
 
Other unexpected social problems were the high rate of divorce and family troubles that 
were reported as caused by the disease, difficulties in transport and the need of respite 
admissions and holiday periods for both the patients and the exhausted carers. 
These themes were collected and examined by the researchers trying to see where a 
SPCS could be of help by improving some aspects of the social unmet needs. 
 
Social isolation 
 
It appeared straightforward that the main group of needs that can be faced and improved 
by a SPCS are those related to the social isolation of the patients and the carers. The 
lives of many neurological patients are significantly limited in social interaction 
(McLeod, J. E. and Clarke 2007). 
Many causes of this condition appeared in the interviews and all were cause of suffering 
and frustration for all the family members. The disease itself is the main cause of social 
isolation. The fact that patients experience high disability limits their mobility and 
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causes their conditions of being homebound. Furthermore friends, relatives and other 
components of the normal social network around the patient and the family tend to 
disappear when the disability progress and the condition becomes chronic. Some 
patients specifically talked of their wish to be visited by volunteers that could just spend 
some time with them to offer a break from the long hours of solitude. The availability of 
internet connection, possible even for totally paralyzed people with only spared ocular 
movements, was described as wonderful by some participants because it allows them  to 
create virtual communities with other persons around the world. Communicators 
allowed  group of ALS/MND tracheostomized and quadriplegic patients to write a book 
just using their eyes to control a piece of software similar to a word processor on their 
desktops (Brownlee and Palovcak 2007). The problem was that other patients could not 
enjoy these facilities because were older, unable to deal with informatics or with severe 
visual losses that withdrew them from the use of these facilities. 
 
Various studies highlight the need of social support for families and patients where 
neurodegenerative conditions caused this social isolation. According to a qualitative 
study in PD for patients and carers there is a need for more specialised and individually 
adjusted support (Birgersson and Edberg 2004). Other authors underline how action to 
reduce the burden of care for caregivers better attention to the patients’ functional status 
and to the caregivers depressive symptoms is important (Caap-Ahlgren and Dehlin 
2002) and this task could be done by a SPCS. Social isolation is one of the contributors 
to the reduction of the QoL of PD patients followed overtime (Karlsen et al. 2000) as 
well as for patients with respiratory disorders(Skilbeck, J. et al. 1998). 
 
Patients with a chronic illness die with many unmet needs and care teams are frustrated 
by the lack of resources available to them and admit to be ill-equipped to provide for the 
individual's holistic needs. Some clinicians described difficulty in talking openly with 
the patient and family regarding the palliative nature of their treatment. This last 
statement was among the conclusion of  mixed methods study exploring the unmet 
palliative care needs of end-stage heart failure, renal failure or respiratory disease 
patients (Fitzsimons et al. 2007) and overlaps with some statements of the professionals 
involved in the focus groups in this study as well. People who found it difficult to  talk 
openly with the patients justified this with the explanation that is was due to the 
impossibility to offer a continuity of care outside the hospital and therefore the 
professionals felt that  they have  lost the patients, when they become too ill to go to the 
scheduled visits. Remarkably, some patients describe their most stable form of social 
interaction as being their visit to the doctor or clinic (McLeod, J. E. and Clarke 2007). 
This is lived as a cause of isolation from the other side, the patient and the family, that 
experience this distance occurring with the physician as a cause of social isolation.  
 
One question rising from these considerations is the following: it is clear that patients 
severely affected by neurodegenerative conditions and their carers experience a high 
burden of social isolation, but in which extent a SPCS can reduce these problems? 
Theoretically by providing regular home visits, periods of respite care in hospice, 
providing volunteers and helping the family to engage experienced paid carers known 
by the service the SPCS could improve the person’s experience. It can also facilitate the 
connections with other services by networking with the specialists working in the 
hospital that no longer provide active care to the patients, but that can collaborate with 
the SPCS professionals for specific issues, symptoms or prescriptions. This last 
consideration covers one of the issues described in the qualitative study of the unmet 
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palliative care needs of advanced MS patients that was the lack of continuity of care and 
communication between professionals (Edmonds et al. 2006). 
 
The problem is that no prospective studies are available in the published literature that 
demonstrated that these social outcomes have really been achieved by SPCS in the care 
of neurological patients. For these reasons the social isolation, in both patients and their 
informal carers, was chosen among the items to be assessed in the evaluation of the 
forthcoming new SPCS for people severely affected by neurodegenerative disorders and 
their caregivers. 
 
Service satisfaction 
 
Services aimed at meeting the needs of people affected by neurological progressive 
disorders need  to be flexible and tailored on the patients and family carers needs 
(Kristjanson, Aoun and Yates 2006). 
Being cared for by tertiary clinics with multidisciplinary teams has been described as 
having positive impact on clinical outcomes, such as survival and lower hospitalization 
rates in neurodegenerative disorders (Chio et al. 2006) although recently other authors 
suggested that further prospective studies are needed to confirm the positive impact on 
outcomes that can really impact on patients’ and caregivers QoL (Ng, Khan and 
Mathers 2009).  
 
From a different perspective the involvement of SPCS in the care of people affected by 
chronic illnesses that span long periods of time, such as PD, entails negotiating the 
chronic-palliative interface and requires continued multi-disciplinary professional 
involvement as well as the integration and recognition of the care provided by family 
caregivers (Lanoix 2009). Furthermore the interaction among neurology, rehabilitation 
and palliative care evidence some specific areas of competence for each specialty, but 
also highlights common areas in which the different specialities, and therefore the 
various services operating in each sector, must collaborate to fulfil the unmet needs of 
the patients (Turner-Stokes et al. 2007). 
 
In this study participants spontaneously discussed their satisfaction or dissatisfaction of 
the experienced services. All patients experienced hospital based services, mainly 
neurology clinics, rehabilitation services, dietitian services or respiratory units. Some 
needed the intervention of emergency services as well, both at home after calling the 
ambulance and in the A&E departments of the hospitals. Some participant also 
experienced home care services, usually provided by the primary medicine facilities, 
home physiotherapy or SLT. Respite admissions in different inpatients units and social 
– welfare services were also used by some of the interviewees and comments were 
collected. 
None of the interviewees had experienced a SPCS, nor hospice inpatients admission 
before the interviews were conducted but some participants wanted to know what these 
service are and then provided some personal judgements about these facilities.  
  
Those families in which the patient needed particular technical equipment, like 
mechanical ventilation, electronic communicators, nutritional pumps or orthopaedic 
aids, technical support services discussed their level of satisfaction or dissatisfaction. 
Participants commented on the perceived quality of the received services, if they 
wished. The aim of this part of the interview was to find out which services were 
operating in the area where the forthcoming new SPCS was going to operate, their mode 
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of operation and their impact in terms of user satisfaction. The ultimate objective was to 
avoid to duplication of existing services, and potentially reinforce, integrate or 
substitute the less satisfactory services and care they had received. 
 
Overall patients and family carers seemed satisfied of the specialist hospital based 
services, confirming that specialised units, often multidisciplinary, satisfy the needs of 
these people (Chio et al. 2006). Some criticisms of those services were about the 
difficult in accessing help rapidly in case of urgent needs. Less satisfaction were 
reported about the emergency services that seem not prepared to face the difficulties 
experienced by persons with chronic conditions and high disability. Primary care 
satisfaction depended mostly on the relationship that participants had with their GPs, the 
willingness of the latter to be involved in the home assistance of the patient and the 
specific expertise of the family doctors related to the medical problems faced by the 
patients. District nurses home care assistance was usually not seen as an appropriate 
service for these chronic conditions. Technical equipment services were generally 
defined as fine for those who needed it.  
 
Social – welfare services were the most criticized together with the emergency services. 
These two services, in the area where the study was conducted, are not tailored on the 
needs of people with progressive, degenerative and life threatening conditions. Negative 
reports where directed against the welfare system for its delay in providing the 
necessary benefits and for the lack of sensitiveness of the operators towards the needs of 
the families. Carers testified how they had to struggle to obtain their rights and this is 
coherent with other published evidences (Edmonds et al. 2007a). Emergency services 
are thought and designed to meet the urgent needs of acute patients and their main goal 
is to save lives rather than improve the QoL. Patients were scared that inappropriate 
interventions from these services could result in unwanted aggressive treatments, such 
as intubation and invasive ventilation in neuromuscular patients who did not want any 
life prolonging measures. Unfortunately advanced care planning is not yet recognized 
by the Italian law and the risk to be subject to inappropriate treatment exist in Italy; 
lately the final decision if intervene or withhold is up to the emergency doctor, if the 
patient lost his or her capacity to communicate. This situation was so frightening for 
some patients that they decided not to call the emergency in problematic situations so 
not to be over treated.  
 
In addition professionals working in A&E demonstrated a lack of communication skills 
about the end of life conditions and this was cause of further confusion for the patients 
and carers who needed to go to the hospital for acute care  that complicated the chronic 
course of the neurological disorders. 
Specialist services at home like the physiotherapy, SLT and the neurology visits (the 
latter provided for ALS/MND patients only) were very appreciated except for the fact 
that often they were intermittent. Physiotherapy and SLT, were provided in courses of 
15-20 sections and often many months had to pass before receiving a second course. 
This inconvenience caused the loss of most of the therapeutic advantages achieved with 
the previous treatment. 
 
Professionals interviewed in the focus groups reported frustration about the lack of 
continuity of the available services, regretted their sense of impotence due to the 
impossibility to provide care out-side the clinics to the very ill patients and recognized 
the potential positive role of a SPCS for both the home palliative care and for the 
potential use of respite admissions into the hospice. 
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The comments of those patients and carers who decided to discuss the potential role of a 
SPCS with respect to the potential help in their conditions were generally positive, even 
though some participants wanted to state that their conditions are different from cancer 
and (mostly MS patients) did not see themselves as terminally ill, but chronically ill. 
3.6.3 Potential role of a new SPCS aimed at meeting the unmet 
needs 
 
After the discussion of the various categories of unmet needs in this study participants 
researchers had to choose those domains, among those who emerged in this study, to be 
evaluated in the following quantitative study.   
Among the various potential outcomes it was decided to choose those that were 
potentially modifiable by a SPCS. 
In the physical symptoms group were identified the following:  
• pain (and painful syndromes) 
• breathlessness (and respiratory troubles) 
• sleep disturbances 
• intestinal symptoms 
• urinary symptoms 
• oral symptoms 
In the psychological group were chosen: 
• depression 
• anxiety  
• abandonment 
• coping with the disease 
In the social categories: 
• Sense of isolation of both patients and carers 
• Perceived quality of the experienced service for both patients and carers 
In the spiritual group: 
• The “meaning” of the lived experience of disease 
• The help received from faith/religiousness  
 
In addiction the Quality of life of the patients and the Caregivers burden of care were 
chosen as main outcomes for the next study. 
The forthcoming new SPCS is supposed to have a positive impact on some of the listed 
domains that are all part of the direct experience of patients, carers and professionals 
who face these situations every day. 
 
3.6.4 Limitations of this study 
 
1. The prevalence of problems revealed by the study is not to be considered as 
extendable to the general population, but it reflects the experience of the sample 
involved in the present study. Qualitative, by definition, this study was not 
aimed at calculating any epidemiological information about symptoms or other 
non physical problems related to the considered disorders. Information was in 
fact intended to explore the lived experiences of participants and to provide a 
direct in depth contact between potential users of a new SPCS and operators 
experienced in the palliative care assistance of people with cancer. 
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2. Sampling: participants were referred to the study by professionals involved in 
their care in hospitals (usually their neurologists). This was considered as a good 
source of potential participants with homogeneous problems and similar 
conditions. Professionals were asked to refer neurological patients with 
advanced disease and with unmet palliative care needs. The limit is, by 
definition, a potential selection bias due to the referers’ vision about what the 
advanced stage was and their personal involvement with both patients and their 
carers. A further limit was the necessity to interview patients not completely 
cognitively impaired. This was necessary to obtain their consent to the interview 
and to receive some information by them, even if just a non verbal assent or 
deny to their carers declarations about the issues. Unfortunately this caused the 
potential patients in worst conditions, the ones with severely cognitive 
impairment, to be excluded by the study and, therefore, some important piece of 
information (mainly from their caregivers, of course) can have been lost in the 
current study. 
3. Gender: 18 out of 22 patients were males. This was due to chance because 
gender equality was not considered as a referral goal of this study. Professionals 
justified this difference as the real situation of their follow up list of patients. In 
fact it is known that ALS/MND and PD tend to affect more males than females 
and that even though MS tend to affect more women than men, being male 
represents a higher risk for a worst prognosis and higher disability progression. 
Gender is not considered a discriminate for palliative care problems, therefore 
results can be claimed as reliable even if in presence of such an inbalance 
between the sexes in the sample.  
4. Heterogeneous problems: needs and problems which came out from the 
interviews and the focus groups were very many and heterogeneous. This is 
expected in qualitative research when using in depth interviews led by 
participants when large amount of data are generated from relatively few sources 
(Payne 2007, p 149). Codes were generated to overcome this difficulty by using 
a systematic comparison of similar findings in the various events (Strauss and 
Corbin 1998, p 95) 
5. Focus groups participants: Professionals involved in the 3 focus groups were all 
working in hospital. This happened because a fourth focus group with GP’s and 
DN’s working in a primary medicine district was scheduled, but participants 
decided not to participate at the last moment. The official justification was the 
very little experience that they have with the home care of patients severely 
affected by the neurological diseases studied in the present research project. A 
further limitation is the absence of nurses in the focus groups. When invited to 
participate nurses of the different clinics agreed to join the study, but they were 
present in any of the groups. Neurologists reported that this fact could be due to 
the difficulties of the nurses working in their departments to feel at ease in a 
group with physicians, specialists in neurology and rehabilitation. To overcome 
this a further focus groups for nurses only was set up in one of the hospital 
involved in the project, but again, at the last moment, potential participants 
denied to participate justifying their absence with problems related to their shifts 
in the ward or ambulatories. 
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3.6.5 Summary  
 
From the content analysis and the detailed analysis of the interviews with patients 
severely affected by severe and progressive neurodegenerative disorders and from the 
focus groups with professionals involved in their care, many categories of potential 
palliative care unmet needs were found. 
These needs were classified into the following categories: physical, psychological, 
social and spiritual unmet needs. Comments regarding the quality of the available 
services operating in the geographic area where the study was conducted were also 
captured and analyzed. 
The main aim of this study was to identify, with a qualitative approach, a number of 
potential outcomes to be subsequently assessed in a phase II RCT trial, aimed at 
evaluate the impact of a new SPCS on the palliative care outcomes of this population. 
These parameters were chosen  from the unmet needs reported in the qualitative study. 
The chosen domains were six physical symptoms, four psychological issues, two social 
aspects, two spiritual themes in addiction to the patients’ Quality of life and the 
Caregivers burden of care, that are to be considered as traditional palliative care 
outcomes. 
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4. The quantitative study 
 
4.1 Introduction 
 
In this chapter of the thesis the quantitative component of the research project is 
reported. 
This explorative randomized and controlled study was called Ne-Pal from the initials of 
Neurology and Palliative Care. 
It represents the last experimental part of the research project and can be seen as a phase 
2 study of the MRC framework (Campbell et al. 2000) as shown in the figure 7. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 7: the MRC framework phase 2; the exploratory trial (Campbell et al. 2000) 
 
 
4.1.1 Rationale of the study 
 
Palliative care is no longer a luxury, but can now be defined as a necessity. Recently 
two major authors, both very well known for their important contributions to the 
development and the evaluation of palliative care services, stated that: “The time has 
come to recognize palliative care as a necessity, and to invest in services and care and 
in the knowledge to develop them effectively and efficiently” (Higginson, I. and Foley 
2009). In the published literature several studies, book chapters (Borasio, Voltz and 
Bausewein 2003, Higginson, I. 1997a, Addington-Hall, J. M. and Higginson 2001) and 
some specific specialist books (Voltz et al. 2004, Oliver, Borasio and Walsh 2006, 
Byrne et al. 2009) have reported aspects related to the palliative care issues affecting 
patients with neurodegenerative disorders, and their caregivers. The majority of research 
has been based on specific diagnostic groups such as PD (Hudson, Toye and 
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Kristjanson 2006), ALS/MND (Mitsumoto and Rabkin 2007), or MS (McLeod, S 2001) 
and often focus on precise objectives such as the physical symptoms (Oliver 1998, 
Ganzini, Johnston and Silveira 2002, Goy, Carter and Ganzini 2008, Mancardi 2006, 
Saleem, Leigh and Higginson 2007, Lee et al. 2007, Elman et al. 2007, Higginson, I. J. 
et al. 2006a), the psychosocial aspects (Rabkin et al. 2005, Chio et al. 2005, Dawson 
and Kristjanson 2003, Gallagher, D. and Monroe 2006, Kristjanson, Toye and Dawson 
2003, Love et al. 2005, Wasner et al. 2004, O'Brien, M. T. 1993a, Koopman 2003, 
Birgersson and Edberg 2004, Pasetti et al. 2003) or the spiritual issues (Lambert 2006, 
Murphy et al. 2000, Taylor and Herr 2004). Some discuss the role of the available 
services (Goodyear-Smith 2005, Kristjanson, Aoun and Oldham 2006, Wollin, Yates 
and Kristjanson 2006, Higginson, I. J. et al. 2006b, Chahine, Malik and Davis 2008, 
Kristjanson, Aoun and Yates 2006, Addington-Hall, J., Fakhoury and McCarthy 1998, 
Giles and Miyasaki 2009), but very few aimed at quantifying the impact of SPCS for 
this patient group (Edmonds et al. 2006, Higginson, I. J. et al. 2009). No studies were 
found in the literature exploring the impact of a SPCS for people severely affected by 
ALS/MND, MS, PDs (considered as a whole group of very ill neurological patients) on 
the main palliative care outcomes (Higginson, I. 1997a, p. 220, Doyle et al. 1995).  
 
The issue of assessment of palliative care  has been widely debated for cancer care and a 
recent review  claims that the evidence for benefit from specialized palliative care is 
sparse and limited by methodological shortcomings (Zimmermann et al. 2008). 
Carefully planned trials, using a standardized palliative care intervention and measures 
constructed specifically for this population, are needed. In contrast with this position the 
project ENABLE 2 (Bakitas et al. 2009) showed with a RCT that QoL and depression 
were improved by the SPCS, even though the physical symptoms were not.  A  
literature review stated that SPCS provide significant benefits in advanced cancer 
(Higginson, I. J. et al. 2003). 
The qualitative assessment, described in the previous section of this thesis, highlighted 
various unmet palliative care needs in both patients and their informal carers, and 
provided a list of potential outcomes to be measured in this quantitative phase. 
4.1.2 Brief precis of the study 
 
To assess the potential impact of a new SPCS on some Palliative Care Outcomes (PCO) 
of people severely affected by ALS/MND, MS and PDs an explorative, randomized, 
phase 2 study, was set up by FARO Foundation in collaboration with the neurological 
clinics of two main hospital of Turin and its province. 
The main aims were to quantify the impact of the new service on patients’ QoL and 
caregivers’ burden of care. Physical symptoms, psychosocial and spiritual issues were 
considered as part of participants’ QoL and were also included among the outcomes. 
These domains were chosen among those which came out from the qualitative part of 
the research project (Neu-Needs). 
Other  objectives were to observe recruitment, drop out rate, mortality and, in general, 
the feasibility of a prospective randomized study in this population.  
Methods, results, discussion and recommendations are presented and discussed  in the 
following subchapters.    
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4.2 Aims of the study 
4.2.1 General aim 
 
To assess the impact of a new SPCS on some PCO in patients severely affected by 
ALS/MND, MS, PDs and in their informal carers 
4.2.2 Specific aims  
 
To compare the effects of a four months provision of a SPCS versus standard care on: 
1. primary outcomes: 
a. Patients QoL 
b. Caregivers burden of care 
2. secondary outcomes 
a. Patients’ symptom control, psychosocial needs and spiritual needs 
b. Caregivers social needs 
c. Overall service satisfaction 
3. further outcomes: 
a. recruitment process 
b. attrition rate 
c. mortality in the groups 
d. feasibility of the study 
 
4.3 Methodology of the quantitative study  
 
 
The study methodology was a Randomized Controlled Trial adopting the Fast Track 
(FT) versus Standard Track (ST) design (also called waiting list study). 
This prospective randomized controlled study was previously tested in a similar study 
on MS patients and their carers by the Palliative and Supportive Care Research Group 
of the King’s College, London (Higginson, I. J. et al. 2008). The authors concluded that 
this methodology was both feasible and reliable in a study of palliative care in which the 
prognostic features of participants would allow a wait similar to the length of the usual 
waiting list. 
 
In this experimental design two arms of the study are created:  
 
• a FT group in which the allocated participants receive immediately the 
intervention, in our case the SPCS. 
 
• a ST group where the allocated participants wait for a period of time established 
by the study protocol (16 weeks), before receiving the intervention. In this 
period of time (the waiting list) participants of the ST receive the conventional 
available standard service (Best Standard Practice) that in this study was 
represented by the primary medicine service and the specific neurological 
hospital based services. 
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In figure 8 a flow chart of the study design is shown. 
 
 
 
Potential participant were referred to the study by their professional carers, neurologists 
or other specialists working in hospital services (e.g. respiratory or rehabilitation 
clinics). Professional carers involved in participants’ recruitment were part of the 
network of hospital based services involved in the overall service development and 
evaluation procedure. They had previously been informed of the inclusion and 
exclusion criteria (described below). They were asked to identify and refer patients in 
pairs each week, so that each pair was made of two patients with the same diagnosis 
and, possibly, similar clinical features (e.g. both with no respiratory equipment or both 
with non invasive ventilation or both in invasive ventilation). Professionals were also 
taught to introduce the general principle of the study in order to exclude those patients 
and their families not keen on participate at an experimental study.  
 
Having obtained a preliminary informal consent to the participation in this study, the 
hospital specialists referred the potential participants to the research team. The 
researcher contacted patient or their family by telephone to explain the aims and the 
methodology of the study. The presence of the informal carer was encouraged at the 
first visit during this contact. If consent was obtained the research team set up a first 
visit at the participants’ home, or in another setting if this was wished. During the first 
visit the study protocol was explained in details and a written copy of it was left for the 
participants, together with an informative letter for the GP, and a formal written consent 
form to be completed and signed by participants.  
 
Each 2 weeks 2 
potential
participants were
referred to the 
SPCS
Randomization in 
that same week
First visit:
Consent
Letter to the GP
First assessment (baseline)
Time 0 (T0)
Allocation:
1 patient in the FT, 
1 patient in the ST
FT: receiving the SPCS
ST: in waiting list
FT = on charge at 
the SPCS, seen by
the team, palliative 
care program set up
ST = no contacts
with the SPCS. Still
receiving the 
standard care
Time 1 (T1)
Second
assessment
End of the 
study
16 weeks
Scheme repeated for 25 
weeks:
50 patients and 50 carers
25 FT
25 ST
After 16 weeks all participants
receive the SPCS free of charge
for the required time
 
Fig 8: the RCT flow chart 
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As difficulties in the signing and completion of the forms was expected for some  
patients with severe disability, an oral or a clear consent expressed in the presence of the 
researchers and the informal carer was considered valid. 
 
After this formal phase had been completed the two researchers started the baseline 
assessment (T0). One researcher interviewed the patient while the second interviewed 
the caregiver. Usually this happened in two different rooms giving the chance to talk in 
depth of  the participants’ experiences. At the end of the visit the questionnaires and test 
sheets  were collected and stored by the main researchers.  
 
After the two potential participants were interviewed, the randomization occurred. This 
happened at the end of the same week of the interviews. Participants were immediately 
informed by telephone about the group they had been allocated in. The FT one was 
informed that they were going to be contacted by the SPCS at the beginning of the 
following week, while the ST was told that he or she would have been contacted in 16 
weeks. The professionals who had referred the patients were then informed about the 
result of randomization. 
 
During the 16 weeks of intervention participants in the FT group received the SPCS 
(described in details in the following subchapters), and could also receive the standard 
care if they wished. The ST group received the standard care and did not have any input 
from  the SPCS. 
After 16 weeks the 2 participants were reassessed by the research team, if still alive and 
not lost at the follow up. 
This T1 interview represented the end of the study for both the FT and the ST 
participants, but it was also the starting point for the ST to receive the SPCS, while the 
FT could continue to be cared for by the SPCS if wished. 
This sequence repeated for 50 weeks allowed the enrolment of 50 patients and their  
carers. 
This simple methodology allowed a comparison between two groups of patients and 
their carers. Both were assessed at T0 (baseline) before being randomized. After 16 
weeks FT had already received the SPCS, while the ST not, therefore a comparison 
among the groups reveals which differences was due to the SPCS input – at T1. 
4.3.1 The Specialist Palliative Care Service 
 
The SPCS represents the intervention in this study. It was a newly formed service set up 
by FARO Foundation in Turin in 2006. It was an extension of the existing specialist 
care palliative home service for cancer patients, operating in Turin city and its province 
since 1999, and the hospice inpatient facility with 14 beds, operating in Turin city since 
2001. 
The domiciliary team comprises physicians expert in palliative care and symptom 
control, nurses with specific training in palliative care, psychologists and 
physiotherapists. A team of volunteers collaborates with professionals providing help to 
the families. 
 
When patients are cared for by the SPCS  they receive regular home visits by both the 
doctor and the nurse (called the “mini-team”) and can be seen by the psychologist 
and/or by the physiotherapist if the mini-team members recognise the needs, which 
would be appropriate for further input. A bereavement service is offered after the death 
of the patients for the family components. 
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Visits are scheduled depending on patients’ needs: in cancer patients they are seen on 
average twice per week by the doctor and twice by the nurse. The mini-team is on call 
for their patients Monday to Friday 08.00-20.00. In week-ends, or bank holidays, two 
doctors and four nurses are on call for all patients under the care of the SPCS. During 
the nights the service does not work, but there is an agreement with the emergency 
service to provide home assistance in case of serious problems occurring in the night 
hours that families could not solve with the indications previously provided by the mini-
team. Medical notes are left in the patients’ home and can be used by other 
professionals to ascertain the on-going therapy and the programme of care.  
 
The Hospice facility is located inside an hospital of the city of Turin. The personnel 
work in shifts, covering 24 hours per day providing continuous assistance to the in-
patients. Physicians working at the hospice are members of the home care team, visit 
patient daily and are on call in the night if emergencies occur. 
Overall the FARO SPCS is composed by 60 professionals. All of them participated to 
the education programme included in the new SPCS for neurological patients. The 
professionals participated in lectures about the main palliative care needs of this 
population, attended  field experiences in hospital wards and ambulatory clinics  to 
learn about the use of respiratory devices and other technical equipment and were 
encouraged  to participate to specific courses and congresses regarding palliative care in 
non cancer conditions.  
4.3.2 The standard care 
 
For standard care are meant all those social and health services provided by the Italian 
NHS in the area of the study (Turin city and its province). 
Standard care included: 
• the patients’ General Practitioners.   
• the District Nursing service.  
• Neurologists, dieticians, rehabilitation specialists, respiratory specialists 
working in hospital ambulatory clinics .   
• Emergency services. 
• Social services, including paid carers and benefits advice .  
4.3.3 Specific measured domains 
 
According to the results of the qualitative analysis a number of relevant domains 
potentially modifiable by the intervention of the SPCS were identified: 
 
1. Patients Qol 
2. Caregivers burden of care 
3. Physical symptoms: 
a. pain  
b. shortness of breath  
c. quality of sleep 
d. urinary problems 
e. intestinal problems 
f. oral symptoms 
4. Psychological issues 
a. feeling abandoned 
b. coping with the disease 
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c. anxiety  
d. depression 
5. Social issues 
a. social isolation 
b. service satisfaction 
6. Spiritual issues 
a. meaning of the experience 
b. help from faith 
 
4.3.4 Measurement tools 
 
The following tools were used to assess the previously listed domains: 
1. Patients QoL: The Schedule For The Evaluation Of Individual Quality Of Life- 
Direct Weighting (SEIQoL-DW) (Mountain et al. 2004, O'Boyle, C. et al. 
1996a, O'Boyle, C. et al. 1996b, Hickey et al. 1996) 
2. Caregivers’ burden of care: The Caregiver Burden Inventory (Novak and Guest 
1989).  
3. Physical symptoms (Pain, Breathlessness, Sleep disorders, Urinary symptoms, 
Intestinal symptoms and Oral symptoms): Visual Analogue Scales (VAS) or 
Numerical Rating Scales (NRS) 0-10 
4. Psychological issues: 
a. For Anxiety and Depression the Hospital Anxiety and Depression Scale 
(HADS)(Zigmond and Snaith 1983) 
b. For the other domains (Feeling abandoned and Coping with the disease): 
Visual Analogue Scales (VAS) or Numerical Rating Scales (NRS) 0-10 
5. Social issues (Social Isolation and Service Satisfaction rate) 
a. Visual Analogue Scales (VAS) or Numerical Rating Scales (NRS) 0-10 
6. Spiritual issues (Finding a meaning in the experience of disease, Help received 
from faith) 
a. Visual Analogue Scales (VAS) or Numerical Rating Scales (NRS) 0-10 
 
Patients were also assessed at baseline (T0) for: 
 
• cognitive status: using a short form of the mini mental state test 
called  abbreviated mental test score (AMTS) (Hodkinson 
1972) to exclude the effect of a cognitive impairment on the 
results in the 2 groups 
• physical disability using: 
1. general tools to evaluate the daily activity performances: 
the Activity of Daily Living (ADL) and Instrumental 
Activity of Daily Living (IADL) tests (Kempen and 
Suurmeijer 1990). 
2. specific disability scales for the three diagnostic groups 
a. ALSFRS-R for ALS/MND patients (Cedarbaum et 
al. 1999) 
b. Expanded Disability Status Scale (EDSS) for MS 
patients (Kurtzke 1983) 
c. Hoen and Yahr (H&Y) for PDs patients (Hoehn 
and Yahr 1967) 
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• the pressure sores risk and other skin problems related to 
disability using the Braden scale (Bergstrom et al. 1987) 
 
All the used tools were translated in Italian and the participants records were gathered in 
personal folders (Case Record Forms- CRF) by the main researcher (SV). 
An English version of the used forms is attached in the appendix section (Appendix 2, 
chapter 9.2). 
The measurement tools were selected applying the following criteria: 
• evidence from the literature of previous utilization and validation in studies 
involving patients with these diagnosis in a palliative care setting. 
• advice from palliative care specialists involved in the clinical practice of this 
group of patients. 
 
According to these principles some tools were validated and previously used to 
measure similar outcomes in patients with neurodegenerative disorders. 
The Schedule For The Evaluation Of Individual Quality Of Life- Direct Weighting 
(SEIQoL-DW) 
 
The SEIQOL-DW (Lee et al. 2006b, Chio et al. 2004a, Pollmann, Busch and Voltz 
2005) had been used to measure the QoL in all the diagnostic groups. It has 
demonstrated reasonable construct validity for use in assessing individual quality of life 
in a group of individuals with other neurological disorders (LeVasseur, Green and 
Talman 2005) even though in patients with cardiac diseases seems to be a good 
instrument to determine patients determinants of QoL rather than a quality of life 
instrument (Moons et al. 2004).  
The schedule for the evaluation of individual quality of life (SEIQoL) was developed to 
assess quality of life from the individual's perspective (McGee et al. 1991, O'Boyle, C. 
A. et al. 1992). It is an interview based instrument. The investigator can assess the level 
of functioning in, and relative importance of, those areas of life nominated by the 
respondent. This tool has been defined as a complex measure of a complex process and 
its use in routine clinical situations may prove impractical (Hickey et al. 1996). To 
overcome this difficulty a shorter form has been created: the SEIQoL-direct weighting 
(SEIQoL-DW) (O'Boyle, C. et al. 1996a, O'Boyle, C. et al. 1996b). 
The direct weighting instrument is a simple apparatus consisting of five interlocking, 
coloured laminated circular disks that can be rotated around a central point to form a 
type of piechart. The laminated disks are mounted on a larger backing disk, which 
displays a scale from 0 to 100, and from which the relative size of each coloured 
segment can be read. 
Each segment is labelled with a life area nominated by the respondent as being 
important to his or her overall quality of life. The respondent adjusts the disks until the 
size of each coloured segment corresponds to the relative importance of the life area 
represented by that segment. These segments may be adjusted and readjusted until 
respondents are satisfied that the proportion of the pie chart given to each life area 
accurately reflects the relative weights they attach to those life areas. The weighting 
procedure is quick to administer, colourful, tactile, and easy to understand. The 
SEIQoL-DW was developed and validated and found to be a valid and reliable measure 
of explicit weighting policies for quality of life domains (Hickey et al. 1996). 
The SEIQOL-DW index is the overall measure of individual QoL. It is the result of a 
formula involving the satisfaction and the weight of each elicited area and is a number 
ranging from 0-100 - the higher meaning a higher QoL. 
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The Caregiver Burden Inventory (CBI) 
 
The Caregiver Burden Inventory (CBI) is a 24-item, five-subscale multidimensional 
measures of caregiver burden giving a sensitive reading of caregivers' feelings and a 
sophisticated picture of caregivers' responses to the demands of caring (Novak and 
Guest 1989). In a previous study with caregivers of ALS/MND patients authors 
demonstrated a correlation between the level of quality of life of the informal carers 
and the worsening of patients' disability (Chio et al. 2005).The five sub-scales explore 
time dedicated to:     
• the care 
• impact on life  
• physical fatigue 
• social factors  
• emotional issues.  
or each item, carers are asked to indicate how often they have felt that way (0-4). The 
final index is a composite measure, combining the different aspects of caregivers’ 
reactions to their involvement (Higginson, I. and Harding 2007, p 107). The sum of 
the scores of the subscales (ranging from 0-96) provides the overall final index. The 
higher results indicate a higher burden of care and, consequently, a lower QoL of the 
carers. 
 
Visual Analogue Scales (VAS) and Numerical Rating Scales (NRS) 
 
VAS and NRS are common measurement tools used in palliative care (Caraceni et al. 
2002). They are simple instruments used in clinical and research settings generally used 
to measure the intensity of a phenomenon (Hauser and Walsh 2008).  
VAS are represented by a linear row, usually 10 cm long, in which at both endings the 
measured object is defined. One extreme of the line is defined as the absence of the 
symptom or problem, the other is the maximum intensity imagined by the participant. 
Participants are asked to define one point of the line representing the intensity of the 
studied problem. Researchers, using a ruler, report the intensity of the symptom as the 
closest number 1-10 from the point indicated by the participant. 
NRS are similar to VAS, but in this case numbers are shown 0-10 and the responder 
has to elicit the intensity of the problem from the same interval.  
These tools are defined as interchangeable showing overall good feasibility, reliability 
(internal consistency), and convergent validity and can be chosen depending from the 
physical ability of participants to draw a point on the line or respond to the numerical 
scale choosing the identified number (Hollen et al. 2005). 
 
In the present study VAS and NRS were chosen to assess those domains identified 
from the qualitative study for which no validated measurement tool could be found in 
the literature. General and specific outcome measurement tools widely applied in the 
palliative care settings, such as the Palliative Outcome Score, recently extended and 
used in a study on MS (Higginson, I. J. et al. 2009), measure many of the listed 
problems, but are not validated for ALS/MND or PD. For this reason, and considering 
the explorative purpose of the present trial, the research team decided to measure the 
impact of the SPCS on the physical, psychological, social and spiritual issues 
highlighted in the previous qualitative study, singularly, by using these simple tools in 
which participants could rate the problem intensity before and after the intervention or 
the standard care. 
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The Hospital Anxiety and Depression Scale (HADS) 
 
This tool has been used to assess the presence of anxiety and depression in palliative 
care (Doyle et al. 1995). 
It consist of two scales, one for anxiety and the second for depression both formed of 7 
items. Each item has a four point (0–3) response category so the possible scores range 
from 0 to 21 for anxiety and 0 to 21 for depression. An analysis of scores on the two 
subscales could be regarded as being in the normal range if the score is of 0 to 7 for 
either subscale, a score of 11 or higher indicating probable presence ('caseness') of the 
mood disorder and a score of 8 to 10 being just suggestive of the presence of the 
respective state(Snaith 2003). 
The Abbreviated Mental Test Score (AMTS) 
 
This ten question test if the short form of the Mini-Mental State Examination-MMSE 
(Holsinger et al. 2007, Folstein, Folstein and McHugh 1975). Score 0-6 indicate a 
strong suspect of dementia, 7-8 can relate to a certain degree of mental confusion, 9 or 
10 mean normal cognitive status (Hodkinson 1972).  
The Activity of Daily Living (ADL) and Instrumental Activity of Daily Living 
(IADL) test 
 
This general tool is formed of two subscales measuring the capability of patients to be 
independent or dependent in the daily living activities, such as feeding, bathing, 
clothing, moving independently and the voiding functions (ADL) or their possibility to 
use instruments like the telephone, money, drugs, transports, home cleaning, cloth 
washing, cooking, and shopping (IADL). The two subscales ranges respectively from 0-
6 (ADL) and 0-8 (IADL), the higher scores indicating better performances (Kempen 
and Suurmeijer 1990). This instrument was used to have an inter diagnostic parameter 
of disability in order to evaluate the degree of general physical impairment in the group 
of study. 
The Amyotrophic lateral sclerosis functional rating scale revised (ALSFRS-R) 
 
The ALSFRS-R is a well-established and widely distributed score for the functional 
status of patients with ALS (Cedarbaum et al. 1999). It is based on 12 items, each of 
which is rated on a 0–4 point scale. The rate of total functional disability thus ranges 
from 0 (maximum disability) to 48 (normal) points. 
The Amyotrophic lateral sclerosis functional rating scale revised (ALSFRS-R) score 
and its progression rate have been debated as survival predictors (Kollewe et al. 2008). 
The Expanded Disability Status Scale (EDSS) 
 
The Expanded Disability Status Scale (EDSS) is a disability scale used in MS. It ranges 
from 0 (no physical impairment, normal neurological exam) to 10 (death due to MS) 
with steps of 0.5 points. EDSS steps 1.0 to 4.5 refer to patients who are fully 
ambulatory, 5.0 to 7.5 present progressive physical impairment to ambulation. 8.0 or 
more are patients essentially restricted to bed or chair, 9.0 are defined helpless patients 
still able to eat  and talk. 9.5 of EDSS is a patient unable to communicate effectively or 
eat/swallow (Kurtzke 1983).   
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The Hoehn and Yahr score (H&Y) 
 
The Hoehn and Yahre score is a disability scale for people affected by movement 
disorders. It is formed of five stages 1-5. Stage 1 describes minimum no physical 
impairment due to the neurological disorder. Stage 4 is described as severely 
debilitating and stage 5 is for bed bound patients (Hoehn and Yahr 1967). 
H&Y 3,5 or more is defined by Bunting-Perry as an advanced stage of PD (Bunting-
Perry 2006), probably this overlap with the definition of palliative care stage proposed 
by Thomas and Mc Mahon (Thomas and MacMahon 2004a). 
The Braden Scale  
 
The Braden scale is a risk assessment tool for pressure ulcers. It is a scale ranging from 
4-23 points that considers 6 indicators: humidity, sensitivity, nutritional status, 
movement, friction and slip. Lower scores relate with higher pressure sore risk. 16 is 
considered a cut off point below which prevention strategies are to be started to avoid 
the risk of pressure sore appearance (Bergstrom et al. 1998, Bergstrom et al. 1987).  
4.3.5 Participants 
 
Participants of the Ne-Pal study were patients severely affected by neurodegenerative 
conditions and their main informal caregivers. Inclusion and exclusion criteria are now 
described. 
4.3.5.1 Inclusion criteria 
 
Participants of the pilot RCT were adult patients of both genders severely affected 
by ALS/MND, MS and PDs and their informal caregivers. 
Patients had to be resident in Turin city or in the metropolitan area (territory of 
provision of the FARO SPCS). 
The severity of the disease was defined according to the Gold Standards Framework 
prognostic indicators specific for the different conditions as shown below (The-
Gold-Standards-Framework 2008): 
 
For ALS/MND: At least one of the following conditions were to be satisfied: 
 
• Evidence of disturbed sleep related to respiratory muscle weakness in 
addition to signs of dyspnoea at rest 
• Barely intelligible speech 
• Difficulty swallowing 
• Poor nutritional status 
• Needing assistance with ADL’s 
• Medical complications eg pneumonia, sepsis 
• A low vital capacity (below 50% of predicted, hypercapnia) 
 
For Multiple Sclerosis: 
 
1. EDSS ≥ 8,5 
2. presence of at least one of the following conditions: 
• Significant complex symptoms and medical complications 
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• Dysphagia (swallowing difficulties)  
• Admissions with sepsis and poor nutritional status 
• Communication difficulties e.g. Dysarthria + fatigue 
• Mild cognitive impairment  
• Breathlessness  
 
For PD, MSA o PSP presence of the following criteria: 
 
1. Hoehn and Yahre stage ≥ 4 
2. No  indication for neurosurgical procedures 
 
The presence of 2 or more of the following criteria:  
 
▪ Drug treatment is no longer as effective / an increasingly complex regime of 
drug treatments 
▪ Reduced independence, need for help with daily living 
▪ Recognition that the condition has become less controlled and less predictable 
with “off” periods 
▪ Dyskinesias, mobility problems and falls 
▪ Swallowing problems 
▪ Psychiatric signs (depression, anxiety, hallucinations, psychosis) 
4.3.5.2 Exclusion criteria  
 
• Diagnosis other than those listed 
• Severe cognitive impairment 
• Unable to express their views even with communication aids 
• Unable to give consent 
• Resident outside of the territory covered by FARO SPCS 
4.3.6 Referrals 
 
Participants were referred to the study by their specialists, generally neurologists, 
respiratory specialists or rehabilitation specialists working in the participant centres. 
The study protocol was sent to the specialist neurological services of the two hospital 
involved in the project: Molinette Hospital of Turin city and San Luigi Gonzaga 
Hospital of Orbassano. 
Professionals involved in patients recruitment selected the potential participants 
according to the previously listed inclusion criteria, asked a preliminary consent to their 
patients and then communicated the patients contact details to the research team. 
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network
 Dept of Neurology 1 (Prof. Mutani).
ALS/MND expert centre
Resp. Prof. A Chiò
 Dept of Neurology 1(Prof Mutani). 
MS centre
Resp. Dr.ssa P. Cavalla
 Dept of Neurology and 
rehabilitation.
Movement disorders ambulatory
Resp. Prof. Loppiano, Dr M.  Zibetti
 Universitary division of neurology
(Prof L. Durelli)
 Palliative care and pain clinic 
service (Dr. P.Ghio)
 C.R.E.S.M. MS centre (Dr. A. 
Bertolotto)
 Dept of physical rehabilitation (Dr. 
F. Gamna)
S. Luigi Gonzaga hospitalMolinette hospital
4.3.7 Participant Centres  
 
Participant centres are listed in figure 4.3 
 
 
 
 
 
 
 
 
 
 
 
4.3.8 Research team 
 
The research team was composed of five researchers: two palliative care physicians, 
two nurses and one neurologist. 
The role of the team members was: 
• To receive referrals from the participant centres 
• To assess participants at T0 and T1 
• To randomize and allocate patients in the two study groups 
• To collect patients forms and to analyse data 
One of the two palliative care physician (SV) was the main researcher and is the author 
of this thesis. 
4.3.9 Data Collection 
 
Each participant was identified with an alpha numerical code. Each patient had a paper 
form were demographics, clinical evaluation and consent form were collected. 
The main researcher was responsible for the data collection and the privacy of the 
content. 
Assessments were conducted by a team of two researchers, one doctor and one nurse. 
During the interviews usually the doctor interviewed the patient while the nurse 
assessed the carer. 
Participants’ forms were filled at T0 and reused at T1 in order to have a single 
participant form to be analyzed at the end of the data collection process. 
Figure 4.3: the network of 
the participant centres 
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4.3.10 Sample size 
 
Being an explorative pilot study the sample calculation was not made on statistical 
methods, but it was determined on the increase of the work load of the FARO SPCS 
expected during the enrolment and follow up phases. 
FARO regular patients load is about 100 patients at any time. It was considered as 
acceptable an increase of 50%, represented by the new neurological assistances. This 
allowed a sample size of 50 participants divided in 25 in the FT and 25 in the ST. 
4.3.11 Data Analysis  
 
Data analysis plan is composed of two main aspects: a clinical and a statistical analysis. 
4.3.11.1 Clinical analysis 
 
The clinical analysis consider the differences in the two study groups (FT and ST) in 
terms of clinical significance. Clinical significance yields information on whether a 
treatment is effective enough to change a patient’s diagnostic label or to make a 
significant change in patients’ condition. For pain and sleep disturbance this change has 
been described as bigger than 13% and 10% respectively (Gallagher, E. John, Liebman 
and Bijur 2001, Nava and Tali 2003). Published works have demonstrated that a change 
of 50% of the standard deviation of any QoL tool can be considered a clinically 
significant change. This translates to a change of 8 to 10 points on a 100-points scale 
(Sloan 2002). 
Changes in participants’ tests can be either positive or negative from baseline (T0) and 
the second assessment (T1). The clinical interpretation of the results in this study has 
been categorised in three possible groups: 
• No clinical significance if the difference between T1 and T0 is lower than 10% 
of the scale used to measure that domain 
• Moderate clinical significance if that difference is between 10 - 19% of the 
same scale 
• Relevant clinical significance when the difference is 20% or higher. 
4.3.11.2 Statistical analysis 
 
The statistical analysis plan includes: 
• descriptive statistics to evaluate the comparability of the two study groups. 
• use of group comparison test to detect differences between the two study groups 
that can be caused by the intervention. The aim of this procedure is to determine 
the efficacy analysis. Depending on the characteristics of the variables the 
Analysis of Covariance (ANCOVA), independent t-test, Chi Square test or non 
parametric tests have been used to highlight statistical changes between the two 
groups. 
 
Statistical analysis will be conducted at three different moments: 
1. at baseline (T0) to describe the characteristics of the sample 
(demographics, disability etc), calculate the prevalence of the explored 
needs and compare the two groups for the outcome measures. The mean 
scores at baseline will be used as covariate for the ANCOVA test. 
2. at T1, after that the FT group will have received the SPCS. This groups 
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comparison will highlight those variables whose scores will be 
significantly different between the groups. The latter will be used as 
dependent variables in the ANCOVA test. 
3. comparing mean T1 and T0 scores. This procedure will be performed 
by: 
  subtracting the mean differences of the outcome measures at T1 
– T0 and then calculating the differences obtained between the 
two groups. This allows to calculate the eventual clinical 
significant difference between the two groups that can be due to 
the intervention (having received the SPCS). 
 Performing the ANCOVA test. This allows to determine the 
eventual statically significant difference between the group due 
to the intervention. For those variables resulting statistically 
different at this test the null hypothesis (see below) can be 
refused.  
 
In the data analysis comparing the two groups (T1-T0) only those participants who 
completed both the baseline and the post intervention assessment will be included. The 
death rate will be compared between the two groups to evaluate if the intervention 
could affect mortality. Patients lost at follow up or that voluntarily ask to leave the 
study are considered as “drop out”. The dataset was saved both in Microsoft Excell and 
SPSS software packages to be analyzed. 
The null hypothesis   
 
The null hypothesis of this study is that no changes are to be found between the treated 
and the control groups after the intervention represented by the provision of the SPCS in 
the treated group versus the best standard care in the control group. 
Alpha value 
 
The alpha value, determining the statistical significance found in this study, is set at 
0,05. Bonferroni adjustments can be applied in case of multiple variable analysis. In 
particular this adjustment will be applied for the ANCOVA between the two groups 
using the T1 mean scores as dependent variables, the two groups (FT/ST) as 
independent variable and the T0 mean scores as covariate. This test will be applied for 
the variables that will be significantly different between the groups at T1 and the 
Bonferroni adjustment will be applied by dividing the pre-set α value (0.05) for the 
number of the considered variables. The new value obtained will be considered as the 
new α value determining the statistical significance between the two groups. 
4.3.12 Randomization process 
 
The randomization process is very simple and straightforward. It is repeated each week 
after the recruitment of each pair of participants. The participants CRFs are wrapped in 
two identical white folders, anonymous and without any possible sign of recognition. 
The main researcher put both folders on one of the FARO Foundation secretary’s 
workdesk asking him or her to choose one. The selected one became the FT participant, 
while the other is allocated in the ST group. 
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4.4 Ethics  
 
The study protocol was submitted and approved by the Ethics Committee (EC) of 
FARO Foundation. The approval was later sent to the two involved hospital EC’s and 
both declared to be satisfied by the FARO EC approval and did not proceed with a 
further analysis. The University of Kent Ethics Committee was later informed of the 
ethics approval of the protocol. A copy of the FARO EC approval is appended in the 
appendix section of this thesis (Appendix 2, Chapter 9.4.3) 
4.4.1 Informed consent 
 
Before the enrolment in the study researchers provide the explanatory sheet and the 
consent forms (approved by the EC) to the patient and to his or her carer. This allows 
participants to be informed of the study aims and methodology according to the 
Declaration of Helsinki developed by the World Medical Association (WMA 2008). A 
copy of the information letter to the patient’s general practitioner is also given to the 
family asking them to deliver it to their family doctor at the first occasion.  
 
4.4.2 Case record form (CRF) 
 
The main researcher is responsible for all the information included in the CRF. The 
latter is available for revision in case of control during the trial and afterwards.  Data are 
stored safely by the main researcher both in paper and electronic format. 
 
4.5 The quantitative study results 
 
In this section the results of the Ne-Pal (quantitative randomised control study) study 
are shown.  
4.5.1 Participants  
 
4.5.1.1 Referred patients 
 
From March 31st 2008 to February 28th 2009 52 potential participants were referred to 
the Ne-Pal study for recruitment by professionals working in the participating centres 
listed in the methods section. 
Participants referred had the following diagnosis: 
• Multiple Sclerosis (MS) n=20 
• Amyotrophic Lateral Sclerosis (ALS\MND) n=16 
• Movement disorders (PDs) n= 16 (PD n=12, MSA n=2, PSP n=2) 
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4.5.1.2 Potential participants who denied consent 
 
Two out of the 52 referred patients (3,8%) did not consent to participate  in  the study - 
both with  a diagnosis of MS: 
• One said that he did not feel seriously ill and for this reason did not want to be 
cared for by a SPCT.  
• One  had recently been diagnosed a breast cancer and was going to start 
chemotherapy and for this reason decided not to enter into the study protocol. 
 
4.5.1.3 Enrolled participants 
 
The remaining 50 patients and their 50 informal caregivers gave their informed consent 
to the participation and were therefore enrolled in the Ne-Pal explorative pilot 
randomized controlled study. 
 In table 4.1 participants demographics are shown. 
  
4.5.2 General considerations 
 
 
 
 
 
 
 
 
Patients N= (%) 
Enrolled 50 
Randomized 25 FastTrack (50%),  
25 StandardTrack (50%) 
Gender M=30 (60%) F=20 (40%) 
Diagnostic groups ALS/MND=16 (32%) 
MS=18 (36%) 
PDs=16 (32%) 
Age classes (in years) <44     =8 (16%) 
45-64  =17 (34%) 
>65     =25 (50%) 
Informal caregivers  
n=50 (100%) 
Wife=25(50%), Husband=12(24%), 
Daughter=4(8%), Son=1(2%), Mother=1(2%), 
Sister=1(2%), Brother=1(2%), Friend=1(2%),     
Paid Carer=4(8%) 
Table 4.1 Ne-Pal participants’ demographics and general characteristics 
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All the 50 participants enrolled in the study met the inclusion criteria. Two patients 
were not able to complete the SeiQol-DW interview and therefore their QoL index at 
baseline is missing. All patients were able to complete the assessment of symptoms. The 
psychosocial and spiritual assessment was completed by all participants but two.  
Patients were asked to identify their main informal caregiver and decide whether he or 
she could answer to the tools used for carers. Five patients did not wish their carer to be 
involved so 5 carers scores have not been included. 
Of these five patients who did not want their carers to be involved: 
- four were cared for by paid carers 
- one was cared for by his wife. 
 
4.5.3 The results at baseline (T0) 
 
 
4.5.3.1 Outcome measures results at baseline (T0) of the overall sample  
 
In this sub chapter the results of the overall sample are displayed.  
The analysis of the tests performed at baseline (T0) revealed the following results 
 
 
The patients’ Quality of Life  
 
The SeiQoL-DW was the first test performed during the baseline assessment. On 
average it took about 30 minutes to be completed. 48 of the 50 participants could 
answer to the interview, even though very few could manipulate the disk and for this 
reason researchers moved it for them until the desired result was achieved.  
 
 
SeiQoL-DW Elicited cues 
 
The 48 patients who completed the SeiQol-DW at baseline elicited a total of 239 cues: 
47 chose 5 cues each, while one only elicited 4.  
In the following table (4.2) a list of the elicited cues at baseline is reported and results 
are compared to the 203 clues elicited at T1 by the remaining 41 patients who 
completed the test. Results are displayed in absolute figures and percentage of the 
sample size. 
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Cues categories T0 elicited cues. 
N=48, (%) *first 5 
ranks 
T1 elicited cues 
N=41, (%) 
* first 5 ranks 
Family  48 (100%) *1 41 (100%) *1 
Spiritual life 22 (46%) 18 (44%)  *5 
Enterteinment 30 (62.5%) *2 40 (97.5%) *2 
Independence  23 (48%) *5 9 (22%) 
Symptoms  16 (33%) 9 (22%) 
Health status  26 (54%) *3 23 (56%) *3 
Friends- relationships 23 (48%) *4 21 (51%) *4 
Finance-economic concerns  11 (23%) 8 (19.5%) 
Social concerns  14 (29%) 9 (22%) 
Information – communication 7 (14.5%) 3 (7.3%) 
Others  20 (41.6%) 22 (53.5%) 
Total 239 203 
Tab 4.2: List of the SeiQol-DW cues elicited by the patients at baseline (T0) and 
after the intervention (T1) 
 
 
The elicited cues, components of the individual QoL of the patients, showed that family 
is the most frequent cue being present in 100% of the interviews both at baseline and 
after the follow up period. Entertainment related cues occupy the second position in the 
choices of the patients with a higher frequency at T1. Health status cues are in the third 
position at T0 and T1, even though symptoms were considered as a separate group. If 
these 2 categories were grouped they would represent the 87% of the elicited cues at 
baseline and 78% at T1. Friends and relationships were in the 4th position in both 
assessments, whereas at the 5th standings there were independence at baseline and 
spiritual life at T1. 
 
SeiQol-DW index 
 
The mean QoL level at baseline of the overall sample is described by the SeiQoL-DW 
index resulting from the following formula:  
 
SEIQoL Index = Σ(levels x weights)/100 
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Higher SEIQoL-DW index values indicate higher Quality of life. 
  
SEIQoL index at baseline N=48           mean=62,8   (SD=19,45) 
Table 4.3: the overall sample SEIQoL-DW index mean value (SD) 
 
The mean score of QoL in the enrolled patients at baseline was 62,8 on a scale 0-100 
(see Table 4.3). 
 
The Caregivers’ Burden of Care 
 
The burden of care was assessed using the CBI inventory. This tool was completed by 
45 informal carers at time 0.  
The CBI inventory results on the overall sample of carers are reported in table 4.4 
divided in the 5 sub-domains (time dedicated to the care, impact on life, physical 
fatigue, social factors and emotional issues) and the final index. Higher values indicate a 
higher burden of care. 
 
Domain 
N= Number of respondents 
Mean= Mean value within the sample 
SD= Standard Deviation 
Time dedicated to the care 
(Range 0-20) N=45             mean=16,51         SD=4,346 
Impact on life 
(Range 0-20) N=45             mean=13,78         SD=5,965 
Physical fatigue 
(Range 0-16) N=45             mean=8,69         SD=5,464 
Social factors 
(Range 0-20) N=45             mean=4,38         SD=4,019 
Emotional issues 
(Range 0-20) N=45             mean=1,42         SD=1,971 
OverallCBI index 
(Range 0-96)   N=45             mean=44,78         SD=14,953 
Table 4.4: CBI results at baseline 
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The Physical symptoms 
 
The explored physical symptoms were pain, breathlessness, quality of sleep, urinary 
symptoms, bowel symptoms and oral symptoms. Symptoms were assessed using Visual 
Analogue Scales (0-10 cm) or Numerical Rating Scales (NRS 0-10) depending on the 
movement possibility of the patients. The value 0 meant absence of the symptoms, the 
value 10 meant the worst possible symptom experience. 
The physical symptoms prevalence and intensity at baseline, for the overall sample,  
are reported in the tab 4.5. 
 
Symptom Prevalence 
Categorical intensity: 
Mild=1-3 
Moderate= 4-7 
Severe= 8-10 
Continuous 
Intensity 
VAS (0-10 cm) or 
NRS (0-10 points) 
Pain (N=50) 35/50 (70%) 
Mild=19 (38%) 
Moderate=8(16%) 
Severe= 8(16%) 
N= 50 
mean=3,38        
SD=3,17 
Breathlessness 
(N=50) 36/50 (72%) 
Mild=19 (38%) 
Moderate=15(30%) 
Severe= 2(4%) 
N=50             
mean=3,24        
SD=2,71 
Sleep disorders 
(N=50) 34/50 (68%) 
Mild=14 (28%) 
Moderate=12(24%) 
Severe= 8(16%) 
N=50              
mean=3,34        
SD=3,16 
Urinary symptoms 
(N=50) 35/50 (70%) 
Mild=11 (22%) 
Moderate=13(26%) 
Severe= 4(22%) 
N=50              
mean=4,14         
SD=3,53 
Bowel symptoms 
(N=50) 40/50 (80%) 
Mild=9 (18%) 
Moderate=19(38%) 
Severe= 12(24%) 
N=50              
mean=4,96         
SD=3,46 
Oral symptoms 
(N=50) 42/50 (84%) 
Mild=15 (30%) 
Moderate=19(38%) 
Severe= 8(16%) 
N=50              
mean=4,32         
SD=2,93 
Tab 4.5 Symptom prevalence and intensity at baseline for the overall sample 
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The Psychological symptoms 
 
The  prevalence and intensity of Anxiety and Depression at baseline, for the overall 
sample, are reported in the tab 4.6. 
 
Symptom 
Prevalence= 
Borderline + 
Caseness 
 
Categorical classification 
Normal=0-7 
Borderline= 8-10 
Caseness= 11+ 
Continuous 
Intensity 
VAS (0-10 cm) or 
NRS (0-10 points) 
Anxiety 
HADS-A N=48 18 (37,5%) 
Normal=30(62.5%) 
Borderline=9(18.75%) 
Caseness=9(18.75%) 
N=48             
mean=6,98         
SD=4,34 
Depression HADS 
D N=48 18 (37,5%) 
Normal=30(62.5%) 
Borderline=8(16.7%) 
Caseness=10(20,8%) 
N=48             
mean=6,75         
SD=4,04 
Tab 4.6: Anxiety and Depression prevalence and intensity at baseline for the 
overall sample 
 
The other two psychological domains were assessed using Visual Analogue Scales (0-
10 cm) or Numerical Rating Scales (NRS 0-10) depending on the ability to move of the 
patient. The value 0 meant that the patient felt totally abandoned or could not cope with 
the disease at all, whereas the value 10 meant that the patient was not feeling abandoned 
at all or could cope perfectly with the disease. 
The mean intensity of the two measured psychological domains, Feeling abandoned and 
Coping with the disease, are reported in the tab 4.7.  
 
 
Psychological domains Continuous Intensity VAS (0-10 cm) or NRS (0-10 points) 
Feeling abandoned 
N=49 
mean=7,45 
SD=2,82 
Coping with the disease 
 
N=49 
mean=5,02 
SD=3,16 
Tab 4.7 Feeling abandoned and Coping with the disease mean intensity at baseline 
for the overall sample 
 
The Spiritual issues 
 
The spiritual issues measured were the “meaning of the experience” related to the 
disease and the “help received from faith”. 
These domains were assessed using Visual Analogue Scales (0-10 cm) or Numerical 
Rating Scales (NRS 0-10) depending on the movement possibility of the patients. The 
value 0 meant that the patient did not find any meaning in the lived experience of the 
disease or did not feel helped by the faith at all, whereas the value 10 meant that the 
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patient found a full meaning of the lived experience of the disease or felt totally helped 
by the faith. Results are summarized in table 4.8 
 
Spiritual domains Continuous Intensity VAS (0-10 cm) or NRS (0-10 points) 
Meaning N=49            mean=3,76          SD=3,77 
Help from faith 
 
N=49           mean=5,08           SD=3,70 
Tab 4.8 Spiritual domains mean intensity at baseline for the overall sample 
 
 
The Social issues 
 
The social domains assessed were the sense of social isolation due to the disease and the 
satisfaction of the services received. These social issues were assessed both in the 
patients and the carers. 
The sense of social isolation was assessed using Visual Analogue Scales (0-10 cm) or 
Numerical Rating Scales (NRS 0-10). The value 0 meant that the participants felt totally 
isolated because of the disease, whereas 10 represented that participants did not find 
isolated at all. 
The service satisfaction was assessed using the same uni-dimensional scale were 0 
meant that participants were totally unsatisfied by the available services, while 10 meant 
total satisfaction. 
The results of these two domains assessed both in the patients and the informal 
caregivers are shown in tab 4.9. 
 
Social issues Continuous Intensity VAS (0-10 cm) or NRS (0-10 points) 
Sense of social isolation for the patients N=48              mean=5,27         SD=3,23 
Sense of social isolation for the carers N=46              mean=5,76         SD=2,98 
Service satisfaction for the patients 
 
N=48              mean=6,83         SD=2,22 
Service satisfaction for the carers 
 
N=46              mean=6,41         SD=2,41 
Tab 4.9 Social issues mean values at baseline for the overall sample 
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4.5.3.2 Baseline results and groups comparison  
A description of the sample with comparison between the two groups of the study (Fast 
Track and Standard Track) is now shown. 
 
 Overall (%) Fast Track (%) Standard Track (%) Statistical 
comparison 
Gender M=30 (60%) F=20 (40%) 
M=16 (64%) 
F=9 (36%) 
M=14 (56%) 
F=11 (44%) 
no statistical 
difference, 
χ²=.083, p=.77 
Phi= .082 
Diagnosis 
ALS/MND=16(32%) 
MS= 18 (36%) 
PDs= 16 (32%) 
ALS/MND=7(28%) 
MS=10 (40%) 
PDs 8 (32%) 
ALS/MND=9(36%) 
MS=8 (32%) 
PDs=8 (32%) 
no statistical 
difference, 
χ²=.472, 
p=.790 Phi= 
.097 
Age 
Groups 
<44=8 (16%) 
45-64=17 (34%) 
>65= 25 (50%) 
<44=2 (8%) 
45-64=12 (48%) 
>65=11 (44%) 
<44=6 (24%) 
45-64= 5 (20%) 
>65= 14 (56%) 
no statistical 
difference, 
χ²=5.242, 
p=.073 Phi= 
.324 
Disability 
specific 
scales 
ALSFRS-r=10,2 
EDSS=8,5 
H%Y=4,2 
ALSFRS-r=10,7 
EDSS=8,6 
H%Y=4,25 
ALSFRS-r=9,8 
EDSS=8,4 
H%Y=4,12 
Independent 
samples t-test 
ALSFRS=p.83 
EDSS=p.58 
H&Y=p.554 
ADL 
N=50             
mean=1,08         
SD=1,589 
N=25             
mean=1,04         
SD=1,513 
N=25              
mean=1,12     
SD=1,691 
Independent 
samples t-test 
no statistical 
difference, 
p=.861 
IADL 
N=50             
mean=0,98         
SD=1,36 
N=25             
mean=1,20         
SD=1,5 
N=25              
mean=0,76      
SD=1,20 
Independent 
samples t-test 
no statistical 
difference,  
p=.258 
BRADEN 
SCALE 
N=50             
mean=15,86         
SD=3,289 
N=25             
mean=16,28         
SD=3,298 
N=25              
mean=15,44      
SD=3,292 
Independent 
samples t-test 
no statistical 
difference,  
p=.372 
AMTS 
N=46             
mean=9,30         
SD=1,33 
N=25            
mean=9,52         
SD=1,0 
N=21           
mean=9,05        
SD=1,6 
Independent 
samples t-test 
no statistical 
difference,  
p=.235 
Tab 4.10: Patients demographics and main characteristics at the baseline assessment, 
groups comparison and statistical analysis 
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These results show that the two groups were similar in their characteristics and 
dependency.  
There were no statistically significant differences in gender, diagnostic groups and age 
groups between the two groups of the study.  
The disability levels were high for all the three diagnostic groups and similar for the two 
groups of the study. This is confirmed both by the specific disability scales and by the 
general ADL/IADL scales. As described in the methods for ALS/MND the ALSFRS-R 
scale ranges from 0 to 48 , where 48 means no impairment in all the considered domains 
and 0 is a totally dependent person. On the contrary the EDSS for the SM group ranges 
0-10 and the H&Y for the PDs from 0-5. In these cases lower values indicate  better 
performance and, therefore lower disability, whereas higher scores indicates higher 
disability. For these reasons we can conclude that patients enrolled in the Ne-Pal study 
were very disabled and their disease progression was to a advanced stage, causing   
severe physical impairment . No statistically significant differences were found between 
the two groups after randomization. The Braden scale, which is a tool used to assess the 
risk of pressure ulcers for patients with physical disability, confirms this evidence 
indirectly because the mean value of the overall sample and of the two groups was 
between 15 and 18 indicating that patients were at risk of bedsores. 
The other domain presented in table 4.10 was the Abbreviated Mental Test Score. This 
test was used because it was important to know if the participants were likely to answer 
about the trial outcomes tests. Mean values were in both the overall sample and in the 2 
subgroup, all above 9 indicating that participants did not have pronounced mental 
dysfunction. 
 
4.5.3.3 Outcome measure results at baseline compared between the two 
groups 
 
In the following tab 4.11 the results of the assessed items at baseline, compared between 
the two groups are shown 
 
Domain 
Overall sample 
N= number of 
respondents 
Mean= mean 
value 
SD= Standard 
Deviation 
Fast Track 
N= number of 
respondents 
Mean= mean 
value 
SD= Standard 
Deviation 
 
Standard Track 
N= number of 
respondents 
Mean= mean 
value 
SD= Standard 
Deviation 
Statistical 
comparison 
between 
groups 
Independent 
t-test 
SEIQoL-DW index 
(0-100) 
N=48         
mean=62,837  
SD=19,45 
N=25        
mean=66,172  
SD=18,13 
N=23           
mean=59,2    
SD=20,57 
no statistical 
difference,  
p=.222 
PAIN 
(0-10) 
N=50            
mean=3,38        
SD=3,17 
N=25            
mean=3,00        
SD=3,29 
N=25            
mean=3,76         
SD=3,07 
no statistical 
difference,  
p=.403 
BREATHLESSNESS 
(0-10) 
N=50             
mean=3,24        
SD=2,71 
N=25            
mean=2,96       
SD=2,74 
N=25            
mean=3,52        
SD=2,71 
no statistical 
difference,  
p=.471 
SLEEP 
DISTURBANCE 
(0-10) 
N=50              
mean=3,34         
SD=3,16 
N=25              
mean=3,4         
SD=3,46 
N=25            
mean=3,28       
SD=2,894 
no statistical 
difference,  
p=.895 
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URINARY 
SYMPTOMS 
(0-10) 
N=50              
mean=4,14         
SD=3,53 
N=25              
mean=3,68         
SD=3,497 
N=25              
mean=4,6         
SD=3,582 
no statistical 
difference,  
p=.363 
BOWEL 
SYMPTOMS 
(0-10) 
N=50              
mean=4,96         
SD=3,46 
N=25              
mean=4,52         
SD=3,97 
N=25              
mean=5,4         
SD=2,887 
no statistical 
difference,  
p=.375 
ORAL SYMPTOMS 
(0-10) 
N=50              
mean=4,32         
SD=2,93 
N=25              
mean=3,76         
SD=2,758 
N=25            
mean=4,88      
SD=3,059 
no statistical 
difference,  
p=.180 
ANXIETY         
(HADS-A 0-21) 
N=48             
mean=6,98         
SD=4,34 
N=25            
mean=6,56         
SD=4,0 
N=23           
mean=7,43      
SD=4,65 
no statistical 
difference,  
p=.492 
DEPRESSION 
(HADS-D 0-21) 
N=48             
mean=6,75         
SD=4,04 
N=25            
mean=6,32         
SD=3,8 
N=23           
mean=7,22        
SD=4,3 
no statistical 
difference,  
p=.448 
FEELING 
ABANDONED 
(0-10) 
N=49              
mean=7,45         
SD=2,82 
N=25              
mean=7,44         
SD=3,07 
N=25              
mean=7,46      
SD=2,604 
no statistical 
difference,  
p=.982 
COPING WITH THE 
DISEASE 
(0-10) 
 
N=49              
mean=5,02         
SD=3,16 
N=25              
mean=5,00         
SD=3,512 
N=25              
mean=5,04      
SD=2,836 
no statistical 
difference,  
p=.964 
MEANING (0-10) 
 
N=49              
mean=3,76         
SD=3,77 
N=25              
mean=3,16         
SD=3,965 
N=25              
mean=4,38      
SD=3,536 
no statistical 
difference,  
p=.264 
HELP FROM FAITH 
(0-10) 
 
N=49              
mean=5,08         
SD=3,70 
N=25              
mean=4,8         
SD=3,99 
N=24              
mean=5,38      
SD=3,449 
no statistical 
difference,  
p=.593 
SENSE OF SOCIAL 
ISOLATION 
(PATIENT 0-10) 
N=48              
mean=5,27         
SD=3,23 
N=25              
mean=4,88         
SD=3,308 
N=23              
mean=5,7      
SD=3,169 
no statistical 
difference,  
p=.388 
SERVICE 
SATISFACTION 
(PATIENT 0-10) 
 
N=48              
mean=6,83         
SD=2,22 
N=25              
mean=6,48         
SD=2,502 
N=23              
mean=7,22     
SD=1,858 
no statistical 
difference,  
p=.256 
SENSE OF SOCIAL 
ISOLATION 
(CARERS 0-10) 
N=46              
mean=5,76         
SD=2,98 
N=23              
mean=6,17         
SD=2,605 
N=23              
mean=5,35     
SD=3,325 
no statistical 
difference,  
p=.353 
SERVICE 
SATISFACTION 
(CARERS 0-10) 
 
N=46              
mean=6,41         
SD=2,41 
N=23              
mean=6,65         
SD=2,479 
N=23              
mean=6,17     
SD=2,387 
no statistical 
difference,  
p=.509 
CAREGIVER 
BURDEN OF CARE 
OverallCBI index 
(0-96) 
N=45             
mean=44,78         
SD=14,953 
N=24             
mean=46,67         
SD=17,574 
N=21              
mean=42,62      
SD=11,294 
no statistical 
difference,  
p=.371 
Tab 4.11: baseline groups comparison 
 
 
As shown in the tab 4.11 no statistical differences appeared between the two groups of 
the present study at baseline. 
In the following chart (4.1) the mean differences in the two groups at baseline of the 
measured outcomes will be displayed graphically. 
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outcome means at baseline between the 2 groups: no statistically significant 
differences (p<0.05)
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Chart 4.1: the outcome measures mean scores at baseline: comparison between the 
two groups. 
4.5.3.4 Baseline results summary 
 
As result of the recruitment phase of the Ne-Pal explorative randomized controlled 
study fifty out of the fifty-two referred potential patients were enrolled and randomized 
in the two groups of the study. Patients were then randomized giving 25 in the two 
groups. The Fast Track group received the service immediately, the Standard Track 
group had to wait for 16 weeks before receiving the service. All patients were assessed 
at baseline, 48 were able to complete the QoL interview, all completed the physical 
symptoms interview, one or two did not complete the psychosocial, and spiritual tests. 
The informal carers participated to the baseline assessment, five could not provide data 
about the burden of care interview because patients did not consent, therefore at 
baseline only 45 carers answered to the interview. 
Main results were a mean of the SEIQoL-DW index of 62.8 %, a prevalence of physical 
symptoms ranging from the 70% of pain to the 84% of oral discomfort, anxiety and 
depression 37.5%. No significant differences were found between the two groups for 
the studied domains. Baseline evaluation will be used as the covariate in the following 
statistical analysis of covariance. The assumption will be that because no significant 
differences existed at baseline if differences are found after the intervention it will be 
justified by the intervention itself. 
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4.5.4 The results after the intervention (T1)  
 
4.5.4.1 Outcome measures results after the intervention (T1) of the 
overall sample 
 
In this section the results obtained after 16 weeks are reported. In the next subchapters a 
general description of what was found in the overall sample and in the two subgroups is 
shown in terms of mortality, attrition and follow up issues. 
Mortality  
The sample decreased because four patients died, two in the Fast Track and two in the 
Standard Track groups. Mortality was 8% over the four months and equal in the two 
subgroups: 
- two  ALS/MND who were not tracheostomized  
- two with movement disorders (PDs) 
 No patients with a diagnosis of MS died during the four months of the study. 
Attrition 
 
Two patients voluntarily dropped out from the study (4%). Both were in the Fast Track 
group: 
One ALS/MND patient, who was not tracheostomized, and had been keen to participate 
to the study. He was enrolled and randomized in the intervention group but after three 
days researchers knew that he was already receiving a palliative home care service 
provided by the public health system (the only case known of an ALS/MND patient 
cared for by this service in Turin city at that time). The patient had to decide which 
service to receive and preferred the public one because he feared that FARO might  stop 
the care provided as this was part of the study. He was therefore discharged from the 
study. He declared that he did not want to be tracheostomized during the baseline 
assessment, but the research team knew that after few week he had received  a 
tracheostomy and later was discharged by the public palliative care service because he 
was not felt that he did not meet the criteria for palliative care.  
The second patient who voluntarily left the study was a man with MS who eagerly 
asked the MS specialists to be involved in the research, participated with enthusiasm at 
the baseline interview, was randomized and allocated in the intervention group. After 
few weeks he said to the SPCS professionals that he did not want to see them anymore 
because he was not a terminally ill patient and was not interested in the service and he 
was discharged from the study. 
 
Follow up issues  
 
During the study period no major events occurred  for the patients who survived. 
General Practitioners and the district nurses collaborated and families did not have 
further problems due to their participation at the study.  
Two patients were admitted to the local hospitals for acute events:  
- A PD patient allocated in the Fast Track group was hospitalized for an acute 
infection two days after receiving the service . The caring team did not have the 
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chance to provide the full care because they were only able to see the patient once 
before the acute event happened when  the patient’s wife decided to call the 
ambulance and take him to the hospital were he eventually died after few days. 
- A lady with MS, allocated in the Standard Track group, was admitted  to hospital 
with an aspiration pneumonia during the waiting list period . During the 
hospitalization period a PEG was placed, antibiotics were given and she recovered 
and was then cared for by the SPCS at home following her discharge from hospital 
and after the waiting period of 16 weeks had passed. 
 
4.5.4.2 Outcome measures results compared between the two groups 
after the intervention (T1) 
 
The same battery of tests used at baseline was performed on the participants after 16 
weeks. The sample was composed of 44 patients. The 6 missing were the four who died 
and the two who dropped out - 21 were in the Fast Track group and had already 
received the service, 23 were in the Standard Track group and were due to receive the 
SPCS following the T1 examination.  
 
In table 4.12 the results of the overall sample and of the two study groups are presented. 
 
Domain 
Overall sample 
N= number of 
respondents 
Mean= mean 
value 
SD= Standard 
Deviation 
Fast Track 
N= number of 
respondents 
Mean= mean 
value 
SD= Standard 
Deviation 
 
Standard Track 
N= number of 
respondents 
Mean= mean 
value 
SD= Standard 
Deviation 
Statistical 
comparison 
between 
groups 
Independent 
t-test 
SEIQoL-DW index 
(0-100) 
N=41           
mean=66,41     
SD=21,10 
N=20           
mean=78,95     
SD=11,76 
N=21           
mean=54,47     
SD=21,25 
Significant 
difference:  
p=.000* 
PAIN 
(0-10) 
N=44               
mean=3,86             
SD=2,84 
N=21               
mean=2,19             
SD=2,29 
N=23               
mean=5,39             
SD=2,42 
Significant 
difference:  
p=.000* 
BREATHLESSNESS 
(0-10) 
N=44             
mean=2,77          
SD=2,9 
N=21             
mean=1,14          
SD=1,39 
N=23             
mean=4,26          
SD=3,15 
Significant 
difference:  
p=.000* 
SLEEP 
DISTURBANCE 
(0-10) 
N=44               
mean=2,70          
SD=2,44 
N=21               
mean=1,57          
SD=1,93 
N=23               
mean=3,74          
SD=2,43 
Significant 
difference:  
p=.002* 
URINARY 
SYMPTOMS 
(0-10) 
N=44             
mean=2,82               
SD= 3,31 
N=21             
mean=1,57               
SD=3,04 
N=23             
mean=3,96               
SD= 3,20 
Significant 
difference:  
p=.015* 
BOWEL 
SYMPTOMS 
(0-10) 
N=44             
mean=3,98         
SD=3,61 
N=21             
mean=2,38         
SD=3,32 
N=23             
mean=5,43         
SD=3,28 
Significant 
difference:  
p=.004* 
ORAL SYMPTOMS 
(0-10) 
N=44                 
mean=4,07        
SD=3,46 
N=21                 
mean=2,71        
SD=3,16 
N=23                 
mean=5,30        
SD=3,31 
Significant 
difference:  
p=.011* 
ANXIETY         
(HADS-A 0-21) 
N=43             
mean=7,63          
SD=4,1 
N=21             
mean=7,62          
SD=4,18 
N=22             
mean=7,64          
SD=4,12 
No significant 
difference  
p=.989 
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DEPRESSION 
(HADS-D 0-21) 
N=43             
mean=7,67          
SD=4,3 
N=21             
mean=7,48          
SD=4,27 
N=22             
mean=7,86          
SD=4,48 
No significant 
difference    
p=.773 
FEELING 
ABANDONED 
(0-10) 
N=43             
mean=7,67        
SD=2,74 
N=20             
mean=8,00        
SD=2,36 
N=23             
mean=7,39        
SD=3,05 
No significant 
difference  
p=.474 
COPING WITH THE 
DISEASE 
(0-10) 
 
N=43             
mean=5,60          
SD=3,56 
N=20             
mean=5,10          
SD=2,06 
N=23             
mean=6,04          
SD=2,04 
No significant 
difference  
p=.393 
MEANING (0-10) 
 
N=43             
mean=3,42              
SD=3,86 
N=20             
mean=3,2              
SD=3,63 
N=23             
mean=3,61              
SD=4,12 
No significant 
difference  
p=.734 
HELP FROM FAITH 
(0-10) 
 
N=43                 
mean=4,79            
SD=3,79 
N=20                 
mean=4,50            
SD=3,90 
N=23                 
mean=5,04            
SD=3,77 
No significant 
difference  :  
p=.645 
SENSE OF SOCIAL 
ISOLATION 
(PATIENT 0-10) 
N=42               
mean=5,36             
SD=3,39 
N=20               
mean=6,25             
SD=3,29 
N=22               
mean=4,55             
SD=3,34 
No significant 
difference  
p=.104 
SERVICE 
SATISFACTION 
(PATIENT 0-10) 
 
N=42               
mean=6,93             
SD=2,31 
N=20            
mean=7,35             
SD=2,43 
N=22               
mean=6,55             
SD=2,17 
No significant 
difference  
p=.265 
SENSE OF SOCIAL 
ISOLATION 
(CARERS 0-10) 
N=43               
mean=5,98             
SD=3,47 
N=21               
mean=6,9             
SD=3,57 
N=22               
mean=5,09             
SD=3,20 
No significant 
difference  
p=.087 
SERVICE 
SATISFACTION 
(CARERS 0-10) 
 
N=43               
mean=7,09             
SD=2,56 
N=21               
mean=7,86             
SD=2,78 
N=22               
mean=6,36            
SD=2,15 
No significant 
difference  
p=.055 
CAREGIVER 
BURDEN OF CARE 
OverallCBI index 
(0-96) 
N=42               
mean=41,90             
SD=16,38 
N=21               
mean=41,24             
SD=17,83 
N=21               
mean=42,57             
SD=15,22 
No significant 
difference  
p=.796 
Tab 4.12: groups comparison after intervention 
*Significant difference shown at 0.05 level 
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outcome means at T1: (*) indicate statistically significant difference 
(p<0.05)
0 10 20 30 40 50 60 70 80 90 100
Pain 
Breathlessness 
Sleep disturbance 
Urinary symptoms 
Bowel symptoms  
Oral symptoms 
Anxiety 
Depression 
Feeling abandoned 
Coping  
Finding a meaning 
Help from faith 
PTS' isolation 
CGS' isolation 
PTS' service satisfaction 
CGS' service satisfaction 
CGS' Burden of care 
QoL 
FT (T1) ST (T1)
 
Comparing the two study groups after intervention a significant difference appeared in 
the QoL and the physical symptoms with an advantage for the Fast Track group. No 
differences were found for the other domains. 
In the following chart 4.2 the mean differences in the two groups after 16 weeks (T1) of 
the measured outcomes will be displayed graphically. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chart 4.2: the outcome measures mean scores after the intervention (T1): 
comparison between the two groups. 
 
(*) 
(*) 
(*) 
(*) 
(*) 
(*) 
(*) 
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4.5.4.3 Summary of the results after the intervention (T1)  
 
From the comparison between the groups at T1 it results that: 
• no significant differences (p<0.05) were found between the FT group, that had 
received the SPCS and the ST, that was going to receive it, (but at that moment 
had just received standard care) for demographics, disease groups, disability, 
cognitive functions, burden of care for the caregivers, all the psychological, 
social and spiritual domains included in the evaluated outcomes measures 
• patients in the FT group scored significantly higher in the QoL (p<.001) 
compared with the ST. 
• a significant difference in all the six assessed physical symptoms was found, 
always with an advantage for the patients of the FT group versus the ST: 
o  pain (p<.001), breathlessness (p<.001), sleep disturbance (p=.002), 
urinary symptoms (p=.015),  bowel symptoms (p=.004) and oral 
symptoms (p=.011)  
 
 
4.5.5 Comparison between the groups before and after the 
intervention 
 
In order to compare the results between the two groups that could be caused by the 
intervention of the SPCS new variables were created by subtracting the mean results of 
the test at T0 (baseline) from the ones obtained at T1 (after intervention). These new 
variables were called “difference variables” and results are shown in Tab 4.13. 
 
Domain 
Overall sample 
N= number of 
respondents 
Mean= difference 
mean T1 – T0 
SD= Standard 
Deviation 
Fast Track 
N= number of 
respondents 
Mean= difference 
mean T1 – T0 
SD= Standard 
Deviation 
 
Standard Track 
N= number of 
respondents 
Mean= difference 
mean T1 – T0 
SD= Standard 
Deviation 
Statistical 
comparison 
between FT 
and ST 
groups 
Independent 
sample t-test 
SEIQoL-DW index 
(0-100) 
N=41               
mean=3,58             
SD=19,01 
N=20              
mean=12,78 
SD=12,82 
N=21              
mean=-7,41      
SD=19,30 
p=.001* 
PAIN 
(0-10) 
N=44               
mean=0,48             
SD=3,47 
N=21              
mean=-0,76             
SD=3,20 
N=23              
mean=1,65             
SD=3,36 
p=.019* 
BREATHLESSNESS 
(0-10) 
N=44               
mean=-0,47             
SD=3,20 
N=21              
mean=-1,57             
SD=2,92 
N=23              
mean=0,69             
SD=3,12 
p=.017* 
SLEEP 
DISTURBANCE 
(0-10) 
N=44               
mean=-0,64             
SD=3,37 
N=21              
mean=-1,61             
SD=3,23 
N=23              
mean=0,52             
SD=3,23 
p=.034* 
URINARY 
SYMPTOMS 
(0-10) 
N=44               
mean=-1,32             
SD=3,78 
N=21              
mean=-2,09             
SD=2,79 
N=23              
mean=-0,34             
SD=4,40 
p=.128 
BOWEL 
SYMPTOMS 
(0-10) 
N=44               
mean=-0,98             
SD=3,81 
N=21              
mean=-1,90             
SD=4,08 
N=23              
mean=0,17             
SD=3,33 
p=.071 
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ORAL SYMPTOMS 
(0-10) 
N=44               
mean=-0,25             
SD=3,24 
N=21              
mean=-0,80        
SD=3,07 
N=23              
mean=0,43             
SD=3,34 
p=.207 
ANXIETY         
(HADS-A 0-21) 
N=42               
mean=0,65             
SD=2,97 
N=21              
mean=0,90            
SD=3,49 
N=21              
mean=0,38            
SD=2,41 
p=.575 
DEPRESSION 
(HADS-D 0-21) 
N=42               
mean=0,92             
SD=3,44 
N=21              
mean=1,00          
SD=3,14 
N=21              
mean=0,95        
SD=3,80 
p=.965 
FEELING 
ABANDONED 
(0-10) 
N=42               
mean=0,22             
SD=3,81 
N=20              
mean=0,45       
SD=3,69 
N=22              
mean=-0,22             
SD=3,97 
p=.572 
COPING WITH THE 
DISEASE 
(0-10) 
 
N=42               
mean=0,58             
SD=3,21 
N=20              
mean=0,3       
SD=3,62 
N=22              
mean=1,22             
SD=2,81 
p=.358 
MEANING (0-10) 
 
N=42               
mean=-0,34             
SD=3,81 
N=20              
mean=0,5       
SD=3,66 
N=22              
mean=-0,95       
SD=3,90 
p=.222 
HELP FROM FAITH 
(0-10) 
 
N=42               
mean=-0,29             
SD=2,27 
N=20              
mean=0,0       
SD=1,86 
N=22              
mean=-0,32            
SD=2,62 
p=.656 
SENSE OF SOCIAL 
ISOLATION 
(PATIENT 0-10) 
N=41               
mean=0,09         
SD=4,41 
N=20              
mean=1,35       
SD=3,71 
N=21              
mean=-1,04           
SD=4,77 
p=.0,82 
SERVICE 
SATISFACTION 
(PATIENT 0-10) 
 
N=41               
mean=0,10         
SD=3,09 
N=20              
mean=0,85       
SD=3,78 
N=21              
mean=-0,52          
SD=2,13 
p=.158 
SENSE OF SOCIAL 
ISOLATION 
(CARERS 0-10) 
N=41               
mean=0,22         
SD=4,59 
N=20              
mean=0,50      
SD=4,47 
N=21              
mean=-0,28          
SD=4,77 
p=.590 
SERVICE 
SATISFACTION 
(CARERS 0-10) 
 
N=41               
mean=0,68     
SD=3,32 
N=20              
mean=1,25    
SD=3,86 
N=21              
mean=-0,09         
SD=2,64 
p=.199 
CAREGIVER 
BURDEN OF CARE 
OverallCBI index 
(0-96) 
N=39               
mean=-2,28             
SD=9,89 
N=20              
mean=-4,20 
SD=10,01 
N=19              
mean=0,73       
SD=9,37 
p=.121 
Tab 4.13: groups comparison: differences in the means (after intervention – 
baseline) for the overall sample and for the two groups. 
*Significant at p<0.05 level 
4.5.5.1 Variations between after and before the intervention in the 
overall sample 
 
Data shown in the Tab 4.13 represent the new variables obtained from the mathematical 
difference between the means of each domain at T1 minus the means at T0. These 
“difference variables” were obtained comparing the means of the analyzed domains 
before and after the intervention, therefore they provide information about what 
changed in the four months time between the T0 (baseline) and the T1 assessment.  
These new data can be interpreted as showing what happened in the sample of 
participants in the various  domains overtime. In this section the variation in the overall 
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sample is analyzed, in the following sections the two groups of the study will be 
compared. 
Charts 4.3 and 4.4 show respectively the difference between the means in terms of 
absolute difference (Chart 4.3) and the difference in percentage (Chart 4.4) on the 
overall sample before and after the intervention. Negative bars reflect the worsening of 
that domain after the 16 weeks, whereas positive bars indicate that overall that domain 
improved after the follow up period. 
Focusing on  the overall sample it results that there have been minimal improvements in 
QoL (3.58%) and small to moderate improvements in all but one physical symptoms: 
- breathlessness (4.7%) 
- quality of sleep (6.4%) 
- urinary symptoms (13.2%)  
- intestinal symptoms (9.8%)  
- oral problems (2.5%) 
Pain is the only symptom that showed a small worsening in the overall sample (-4.8%). 
 
Looking at the psychological domains it results: 
A small worsening in: 
• anxiety (-3.1%), 
• depression (-4.4%), 
A small improvement in: 
• feeling abandoned (2.2%)  
• coping with the disease (5.8%). 
In the spiritual issues the overall sample showed small decrease in the mean results for: 
• the meaning of the experience of the disease (3.4%)  
• the help received from the faith or religion (2.9%) 
About the social explored domains it came out that: 
• Patients’ sense of isolation improved of 0.9% and patients’ satisfaction about the 
received services improved of 1.0%. 
• For the carers the sense of isolation improved of 2.2%, and the service 
satisfaction improved of  6.8%. The burden of care was reduced of  3%. 
Overall only urinary symptoms showed a variation higher than 10% of the scale used to 
assess the different domains and for this reason can be considered as a clinically 
moderate change applying the categories declared in the methods section.  
We can conclude that no significant changes occurred in the overall sample after the 
follow up period that coincided with the service provision for the FT group.  
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4.5.5.2 Variations between after and before the intervention between 
the two groups  
 
 
In Tab 4.13 results obtained by subtracting the means of the various tests at T1 – T0 are 
shown separately for the two groups of the study (FT and ST). The distance between the 
means of each domain in the two groups represent what happened in the two groups and 
can be reported as due to the intervention. In Tab 4.14 the distance in the means of the 
various domains at T1 – T0 were compared between the study groups and results are 
displayed in terms of absolute difference, difference in percentage with respect to the 
scale used to measure that specific item and the statistical significance using an 
independent t-test to compare the difference of the means. 
 
 
 
 
Domain 
∆ in the means 
T1-T0 
FT vs ST (∆ %) 
Statistical significance 
(independent t-test) 
SEIQoL-DW index 
(0-100) 
Higher scores= better QoL 
20,19 (20.2%) p=.001* 
PAIN 
(0-10) 
lower score= lower symptom 
-2,41 (24.1%) p=.019* 
BREATHLESSNESS 
(0-10) 
lower score= lower symptom 
-2,26 (22.6%) p=.017* 
SLEEP DISTURBANCE 
(0-10) 
lower score= lower symptom 
-2,14 (21.4%) p=.034* 
URINARY SYMPTOMS 
(0-10) 
lower score= lower symptom 
-1,74 (17.4%) p=.128 
BOWEL SYMPTOMS 
(0-10) 
lower score= lower symptom 
-2,07 (20.7%) p=.071 
ORAL SYMPTOMS 
(0-10) 
lower score= lower symptom 
-1,24 (12.4%) p=.207 
ANXIETY 
(HADS-A 0-21) 
lower score= lower symptom 
0,52 (2.5%) p=.575 
DEPRESSION 
(HADS-D 0-21) 
lower score= lower symptom 
0,04 (0.2%) p=.965 
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FEELING ABANDONED 
(0-10) 
Higher scores= lower distress 
0,67 (6.7%) p=.572 
COPING WITH THE DISEASE 
(0-10) 
Higher scores= better coping 
-0,92 (9.2%) p=.358 
MEANING (0-10) 
Higher scores= higher meaning 1,45 (14.5%) p=.222 
HELP FROM FAITH 
(0-10) 
Higher scores= better support 
0,31 (3.1%) p=.656 
SENSE OF SOCIAL ISOLATION (PATIENT 0-10) 
Higher scores= lower sense of isolation 2,39 (23.9%) p=.0,82 
SERVICE SATISFACTION (PATIENT 0-10) 
Higher scores= higher satisfaction 1,37 (13.7%) p=.158 
SENSE OF SOCIAL ISOLATION (CARERS 0-10) 
Higher scores= lower sense of isolation 0,78 (7.8%) p=.590 
SERVICE SATISFACTION (CARERS 0-10) 
Higher scores= higher satisfaction 1,34 (13.4%) p=.199 
CAREGIVER BURDEN OF CARE CBI index 
(0-96) 
Lower score = lower burden of care 
-4,93 (5.1%) p=.121 
Tab 4.14: comparison between ∆ means T1-T0 between the FT and ST groups 
*Significant at p=0.05 level 
 
 
These results are shown graphically in the chart 4.5. From these data it results that for 
all the measured outcomes participants in the FT had an advantage (blue bars) if 
compared with the ST, except for three psychological domains: Anxiety, Depression 
and Coping with the disease (white bars). The difference for these last three domains 
was not statistically (p>0.05) nor clinically (∆<10%) significant. 
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Chart 4.5: Differences in the means T1-T0 (in percentage) between the two groups. 
Blue bars represent those domains for which the FT showed  advantage versus ST, 
white bars are those domains in which ST showed advantage versus FT. 
(*) represent the domains for which a statistical significant difference (p<0.05) was 
found between the groups in the mean comparisons T1-T0.
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4.5.5.3 Clinical significance of the comparison between the groups 
 
According to the categories of clinical significance reported in the methods section the 
results of the Tab 4.14 and chart 4.5 can be grouped in the following categories: 
Results could be either favourable to the treated group (FT) if the difference between 
the means T1-T0 compared to the control group (ST) was better in the former group 
than in the latter one, or the other way around. 
Results could be considered clinically not significant if the difference was lower than 
10% of the scale used to measure that specific domain, moderately significant if the 
difference was between 11 and 19 %, or could be relevantly significant if the difference 
was 20% or more. 
According to this classification the following categories could be found: 
1. No clinically significant differences between FT and ST (∆ <10%) 
2. Moderate clinical advantage in FT versus ST or moderate clinical advantage in 
ST versus FT (∆ 10-19%) 
3. Relevant clinical advantage in ST versus FT or relevant clinical advantage in ST 
versus FT (∆ ≥20%) 
 
1. No clinically significant differences between FT and ST: 
No clinically significant differences (∆ <10%) between FT and ST could be detected 
in the following domains:  
• Anxiety 
• Depression 
• Feeling abandoned 
• Coping with the disease 
• Help from faith or religion 
• Sense of social isolation in carers 
• Burden of care for the carers 
 
2. Moderate clinical advantage (∆ 10-19%) in FT versus ST: 
• Moderate clinical advantage was observed in the treated group for the 
following domains: 
i. Urinary symptoms and oral symptoms 
ii. Finding a meaning in the experience of the disease 
iii. Satisfaction of the service in both patients and carers 
3. Moderate clinical advantage (∆ 10-19%)  in ST versus FT 
i. no domains showed moderate improvement in the ST versus the 
FT 
 
4. Relevant clinical advantage (∆ ≥20%) in FT versus ST 
Relevant clinical advantage was obtained in the treated group for: 
• Quality of life of the patients 
• Pain  
• Breathlessness 
• Quality of sleep 
• Intestinal symptoms  
• Sense of isolation of the patients 
 
5. Relevant clinical advantage (∆ ≥20%) in ST versus FT 
In no domains the ST group showed relevant advantages versus the FT one. 
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4.5.5.4 Statistical significance of the comparison between the groups 
 
4.5.5.4.1 Analysis of Covariance (ANCOVA) 
 
 A one-way ANCOVA between-groups analysis was conducted for those variables that 
showed a statistically significant difference between the two groups after the 
intervention (T1). The aim of this test was to determine whether adjusting these results 
for the covariate represented by the baseline assessment (T0) of the same domains the 
statistical significance was maintained. 
The seven variables with these characteristics were: Quality of life, and the physical 
symptoms (pain control, breathlessness, sleep disorders, urinary symptoms, intestinal 
symptoms and oral symptoms). 
It should be noted that at baseline no statistical significant difference could be found in 
any of these particular variables. 
 
Quality of life: 
 
One-way ANCOVA between-groups analysis was conducted to compare the 
effectiveness of the 2 different interventions received by the 2 groups of the NE-PAL 
study to impact on Quality of Life. The independent variable was the type of 
intervention: FT (Fast Track= receiving the SPCS), ST (Standard Track= receiving 
standard care). The dependent variables was the score on the SEIQoL-DW test 
administered after intervention was completed 
Participants’ scores on the pre-intervention administration of the SEIQoL-DW test 
(baseline) were used as the covariate in this analysis. No significant differences were 
found at baseline in the SEIQoL-DW index between the 2 groups. 
 
After adjusting for pre-intervention scores, there was a significant difference between 
the two groups on post intervention scores on the QoL (F1,38)=22,57, p=.000, partial 
eta square = .373.  
 
Symptoms: 
One-way ANCOVA between-groups analysis was conducted to compare the 
effectiveness of the 2 different interventions received by the 2 groups of the NE-PAL 
study to impact on the following symptoms: Pain, Breathlessness, Sleep disturbances, 
Urinary problems, Bowel problems and Mouth discomfort. The independent variable 
was the type of intervention: FT (Fast Track= receiving the SPCS), ST (Standard 
Track= receiving standard care). 
The dependent variables were the scores on the symptoms test administered (NRS 0-10 
with high scores meaning high symptom burden) after that the intervention was 
completed. 
Participants’ scores on the pre-intervention administration of the symptoms test 
(baseline) were used as the covariate in this analysis. No significant differences were 
found at baseline in the symptoms scores (Pain, Breathlessness, Sleep disturbance, 
Intestinal and Urinary symptoms and Mouth discomfort) between the 2 groups. 
 
Preliminary checks were conducted to ensure that there was no violation of the 
assumptions of normality, linearity, homogeneity of variance, homogeneity of 
regression slopes, and reliable measurement of the covariate.  
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After adjusting for pre-intervention scores, there was a significant difference between 
the two groups on all considered symptoms, in particular: 
 
Pain control: 
 post intervention scores on Pain (F1,41)=19,29, p=.000, partial eta square = .320.  
Breathlessness: 
post intervention scores on Breathlessness (F1,41)=15,78, p=.000, partial eta square = 
.278.  
Sleep disturbances: 
post intervention scores on Sleep disturbances (F1,41)=11,47, p=.002, partial eta square 
= .219.  
Urinary symptoms: 
post intervention scores on Urinary symptoms (F1,41)=6,08, p=.018, partial eta square 
= .129.  
Bowel symptoms: 
post intervention scores on Bowel symptoms (F1,41)=8,26, p=.006, partial eta square = 
.168.  
 
Mouth discomfort: 
post intervention scores on Mouth discomfort (F1,41)=4,38, p=.042, partial eta square = 
.097.  
 
ANCOVA conclusions 
The analysis of covariance shows a significant correlation (p<0.05) between the 
improvement in QoL and  the chance to obtain a better physical symptom control for the 
patients allocated in the FT group than for those allocated in the ST (control) group. 
 
4.5.5.4.2 Non parametric tests 
 
For the physical symptoms some concern arose about the normal distribution of the 
results. For this reason a nonparametric test was run on the variable T1 for symptoms to 
analyze the statistical differences in the two groups. 
 
Mann-Whittney U test for physical symptoms 
 
A Mann-Whittney U performed on symptoms score (pain, breathlessness, sleep 
disturbances, urinary troubles, bowels troubles and mouth discomfort) at T1 using as 
independent grouping variable the FT\ST one. 
The test (table 4.15) revealed a significant difference in all symptoms in the treated 
group (FT) compared with the control group (ST) 
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Symptoms  Study Groups 
(FT\ST) 
 Medians (md) and 
groups size (n=) 
U= Mann.whitey-U 
Z= z approximation test 
p= significance level 
r= Effect Size 
Pain 
 
FT (md=2, n=21) 
ST (md =5, n=23)  
U= 84, z=3,75, p=.000, r= 0,56 
Breathlessness 
 
FT (md=1, n=21) 
ST (md=4, n=23)  
U= 103,5, z=3,32, p=.001, r=0,50 
Sleep disturbances  
 
FT (md=1, n=21)  
ST (md=4, n=23)  
U= 115,5, z=3,01, p=.003, r=0,45 
Urinary symptoms 
 
FT (md=0, n=21)  
ST (md=5, n=23)  
U= 135, z=2,65, p=.008, r=0,40 
Bowels symptoms  
 
FT (md=0, n=21)  
ST (md=5, n=23)  
U= 121,5, z=2,88, p=.004, r=0,43 
Mouth discomfort  
 
FT (md=1, n=21)  
ST (md=5, n=23)  
U= 144,, z=2,32, p=.020, r=0,35 
Table 4.15: Mann-Whittney U at T1 to assess the difference between the two 
groups for the physical symptoms.  
All the symptoms were significantly better for FT (p<0.05 level) 
 
From these tests it appears that in all physical symptoms there have been an 
improvement in the FT group compared to the control one. In fact, as shown below, 
there were no statistical differences between the groups at baseline in symptoms scores 
 
 
Grouping Variable: FT \ ST 
Symptoms baseline 
assessment 
PAIN 
SCORE 
T0 
BREATH 
SCORE 
T0 
SLEEP 
SCORE 
T0 
URIN 
SCORE 
T0 
BOWEL 
SCORE 
T0 
MOUTH 
SCORE 
T0 
Mann-Whitney U 257,000 275,000 309,000 261,500 276,000 247,500 
Wilcoxon W 582,000 600,000 634,000 586,500 601,000 572,500 
Z -1,096 -,739 -,069 -1,006 -,715 -1,271 
Asymp. Sig. (2-tailed) 
p = ,273 ,460 ,945 ,315 ,475 ,204 
Table 4.16:  SPSS output of Mann-Whittney U test for physical symptoms at 
baseline (T0). No significant differences between the two groups (p<0.05) 
 
Non parametric test conclusion 
 
The Mann Whitney U non parametric test confirms that in all the six considered 
physical symptoms there was a statistically significant advantage (p<0.05) for the 
patients in the treated group compared with the control group after the intervention and 
that no such differences could be found between the groups at baseline. 
 
4.5.5.4.3 The null hypothesis 
 
The null hypothesis of this study was that no differences could be found in the two 
groups of the study after the intervention, and therefore that no advantages were showed 
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in the group that received the SPCS compared to the control group who received the 
standard care only. 
The null hypothesis was accepted for all those domains which did not show any 
statistical differences after the intervention and that are now listed:  
• Caregivers burden of care, 
• all the studied psychological domains (anxiety, depression, feeling abandoned, 
coping with the disease) 
• the spiritual domains (finding a meaning in the experience of disease, being 
helped by faith or religiousness) 
• the social aspects (isolation of the carer, service satisfaction for both patients and 
carers) 
 
For the other domains (QoL, pain, breathlessness, quality of sleep, intestinal symptoms, 
urinary symptoms and oral symptoms) a statistically significant difference was found 
between the two groups in all cases with an advantage for the treated groups using an 
alpha value set at <0.05. 
Being seven the variables that were analyzed using the analysis of covariance 
(ANCOVA) or the non parametric tests (Mann-Whittney U) a Bonferroni adjustment 
was used to reduce the probability to fall in a type 1 error, which is to refuse the null 
hypothesis when in fact it is true. So the alpha value was divided per 7, the number of 
compared variables, obtaining 0.007. This was the new alpha value to be used to accept 
or refuse the null hypothesis. 
According to this adjustment for the following 5 variables the null hypothesis can be 
refused: 
• Quality of Life: p=.000 
• Pain: p=.000 
• Breathlessness: p=.001 
• Sleep disturbance: p=.003 
• Intestinal symptoms: p=.006 
The same hypothesis is to be accepted for the remaining two variables 
• Urinary symptoms: p=.008 
• Oral symptoms: p=.020 
 
These results are summarized and reported graphically in chart 4.6 
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Chart 4.6: comparison between ∆ means T1-T0 (in %) between the FT and ST 
groups. 
• Red bars represent domains with both a statistical (p<0.007) and clinically 
relevant (∆>20%) advantage for FT versus ST 
• Green bar represents a clinical relevant advantage of FT vs ST, but no 
statistically significant difference. 
• Blue bars represent clinical moderate advantage (∆ 10-19%) for FT vs ST, but 
no statistically significant difference. 
• White bars represent domains where no statistical nor clinical significant 
differences were found betwenne the groups. 
  (*)Significant at p=0.007 level 
4.5.5.5 Power of the study 
 
Being an explorative pilot study the sample size was not calculated previously 
according to the expected number of participants to detect a significant difference 
between the groups on the main outcomes, but was decided based on the feasibility of 
the study which was calculated in terms of the affordable increase of the case load for 
the  FARO SPCS. That was defined in 50 patients cared for by the SPCS in one year . 
When the study was terminated and data analysis conducted, a post hoc calculation of 
the power of the study was performed based on the main explored outcome, the 
patients’ QoL, measured with the SEIQoL index. 
The power of a statistical test is equal to 1 − β, where β is the false negative rate. The 
power of a statistical test is the probability that the test will reject a false null 
hypothesis. In general it is defined as large power a study with a power higher than 0,8. 
According to the mean difference of the SEIQoL index between FT and ST group, the 
post- hoc power of the study was 0.99 with an Effect size of 1.42 using the Cohen’s d, 
as shown in tab 4.17. 
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t tests - Means: Difference between two independent means (two groups) SEIQoL 
OUTCOME 
Analysis:                                                        Post hoc: Compute achieved power 
Input: Tail(s) Two 
 Effect size  (Cohen’s d)               1.4254497 
 α err prob   0.05 
 Sample size group 1  20 
 Sample size group 2   21 
Output: Noncentrality parameter δ  4.562308 
 Critical t   2.022691 
 Df   39 
 Power (1-β err prob) 0.993566 
Tab 4.17: power of the study calculation based upon the QoL index (and estimated 
sample size at post hoc) 
 
 
This result means that the power of this study is very high explaining 98% of the effect 
for the main outcome (QoL) as due to the intervention, in other words participants who 
received the service had a significant improvement of the QoL and this allows to reject 
the null hypothesis. 
The same calculation post hoc was performed to calculate the sample size “a posteriori”. 
The result is that, with that difference observed in the QoL index, a sample of just 14 
participants per arm would have been enough to detect the result. In the study 25 
patients per arm were enrolled and the analysis was performed on 20 + 21 participants. 
 
The power of the study at post hoc was then calculated on the other statistically 
significant variables as well as the effect size and the sample size based upon the 
difference in the means T1-T0 between the two groups. Results are shown in table 4.18. 
 
Symptoms Effect Size Estimated patients per arm (estimated sample size) 
Power (1-β err 
prob) 
Pain ES=1.36    16+16=32 0.997 
Breathlessness ES=1.28    17+17=34 0.994 
Sleep disturbance ES=0.99     28+28=56 0.94 
Urinary symptoms ES=0.76    46+46=92 0.797 
Intestinal symptoms ES=0.92    32+32=64 0.912 
Oral symptoms ES=0.80   42+42=84 0.832 
Table 4.18: Power of the study calculation based upon the symptoms differences 
between the groups (and estimated sample size at post hoc) 
 
These results indicate that for pain, breathlessness, sleep disturbance and intestinal 
symptoms the power of the study was higher than 90% and the effect size higher than 
0,8 that is considered a large effect according to Cohen’s classification (Cohen 1988, 
p.22). for the first two symptoms the post hoc calculation showed that the sample size of 
this exploratory pilot trial was bigger than what could have been expected “a priori” 
with the observes mean difference. 
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4.5.5.6 Summary of the results 
 
To summarize the results of this explorative, pilot, randomized and controlled trial we 
can say that: 
• The study was feasible because no major problems happened during its design, 
recruitment and follow up. 
• Referred patients were keen to participate and only 2/52 (3.8%) refused to enter 
in the study. 
• Mortality was the same in the two groups (8%) during the period of the study. 
• Attrition rate was very low (4%). The two patients who dropped out were both 
in the treated group. All the patients who were randomized in the control group 
accepted the SPCS after the 16 weeks of wait meaning that they were keen to be 
cared for by the new service. 
• In none of the measured variables the FT group scores were significantly worse 
(clinically or statistically) than in the ST group. 
• In the following domains no clinical nor statistical differences were found 
between the two groups 
o Anxiety 
o Depression 
o Feeling abandoned 
o Coping with the disease 
o Help from faith or religion 
o Sense of social isolation in carers 
o Caregivers burden of care 
 
• Some domains showed a clinically moderate advantage for the patients in the 
FT group although no statistical significance was reached: 
o Urinary symptoms 
o Oral symptoms 
o Finding a meaning in the experience of the disease 
o Satisfaction of the received service for the patients 
o Satisfaction of the received service for the carers 
• A clinically relevant  improvement for the FT was observed for the  
o Sense of social isolation for the patients 
• There was a significant clinical and statistical advantage for the patients 
allocated in the treated group (FT) compared to the ones of the control group 
(ST) in the following variables: 
o Quality of Life of the patients 
o Pain control 
o Breathlessness 
o Sleep related problems 
o Intestinal symptoms 
• The power of the study, calculated at post hoc on the main outcome, patients 
QoL, was high being 1- β of 0,99. the effect size using the Cohen’s d was 1,42 
and the estimated sample size for this variable was of 14 patients per arm, lower 
than the analyzed sample size that consisted of 20 + 21 participants. High 
results at post hoc were confirmed for four physical symptoms:  Pain control, 
Breathlessness, Sleep related problems and Intestinal symptoms, all higher than 
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80%. These results coincide with the variables listed above for which both 
statistical and clinical significance difference was found in the FT group versus 
the ST. 
 
 
4.6 Nepal discussion 
 
In this chapter of the thesis the discussion of the Ne-Pal explorative pilot randomized 
and controlled study (RCT) will be presented. 
This study represents a phase II RCT of the MRC framework for the design and the 
evaluation of a new SPCS for patients severely affected by neurodegenerative disorders 
in Turin city and its metropolitan area (Campbell et al. 2000). 
According to the author’s knowledge this is the first trial aimed at evaluating the impact 
of a new SPCS on some palliative care outcomes in a sample of patients severely 
affected by ALS/MND, MS and movement disorders (PD, MSA, PSP). Previously 
similar research was conducted in the south-east of London by the Supportive and 
Palliative Care research group of the King’s College of London, lead by Professor I. 
Higginson, for people severely affected by MS (Edmonds et al. 2006). The present 
study tried to follow a similar methodology, but involving participants (and their 
informal caregivers) with various neurodegenerative conditions all characterized for 
being incurable, progressive and in the advanced stages.  
The study was a randomized, controlled, pilot-explorative trial that, based on the 
definition provided by Campbell, should  “Describe the constant and variable 
components of a replicable intervention and a feasible protocol for comparing the 
intervention with an appropriate alternative”(Campbell et al. 2000).  
The previous phases of the same protocol are described in the chapters of the general 
methodology and of the qualitative study (Neu-Needs). Having designed the service 
with the preclinical phase (theory) and having modelled the intervention on the needs of 
the participants that came out from the qualitative interviews with the potential users 
and the focus groups with the professionals (phase 1 – modelling), the protocol 
indicated this phase 2 would be developed as an explorative trial. The explored 
outcomes were identified among those unmet needs and important concerns that arose 
from the modelling phase (NeuNeeds study). In particular, for the purpose of this 
research project, the domains suggested by the participants of the qualitative study that 
were thought to be addressable by the new SPCS were identified, in particular : 
• For the patients: 
o The Quality of life of the patients, 
o Six physical symptoms usually found in palliative care settings: pain, 
breathlessness, sleep disturbance, urinary symptoms, intestinal 
symptoms and oral symptoms 
o Four psychological issues: anxiety, depression, feeling abandoned and 
difficulties in coping with the disease. 
o Two spiritual themes: the meaning of the lived experience of the disease 
and the help received from faith or religiousness 
o Two social issues: sense of social isolation and the perceived quality of 
the available services 
• For the informal carers: 
o Two social issues: sense of social isolation and the perceived quality of 
the available services 
o The burden of care 
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The QoL of the patients and the burden of care for the carers were identified as the 
main outcomes to be addressed, the others were considered as secondary outcomes. 
Side outcomes were other aspects such as the feasibility of such a study with very ill 
patients, the mortality rate, the attrition rate and other potential issues arising during the 
study. 
The sample size was not calculated “a priori” based on the statistical power of the study 
in view of the explorative nature of the study and a groups comparison without strict 
rules of sample size was chosen. Sample size was calculated based on the feasibility of 
the follow up process. This was assumed by considering that FARO foundation SPCS 
could care for a maximum of 50 patients in one year of time in addition to the routine 
case load represented by the cancer patients under the care of the service. The 
framework adopted to design and evaluate the service indicates the setting up of a 
definitive RCT at the following stage, called phase 3, that has as main outcome to 
“Compare a fully defined intervention with an appropriate alternative using a protocol 
that is theoretically defensible, reproducible, and adequately controlled in a study with 
appropriate statistical power”(Campbell et al. 2000). 
The methodology of the waiting list, also called the Fast Track versus Standard Track, 
was demonstrated to be feasible and reliable in the previous study conducted by the 
King’s College group (Higginson, I. J. et al. 2006c), and these features were used in the 
present research project.  
 
4.6.1 Sampling, recruitment, randomization and allocation 
 
The sample size adopted was very similar to the one used in the MS study (52 patients 
enrolled in that RCT versus 50 in the Ne-Pal RCT).  
The enrolment rate was very interesting because out of 52 patients who were referred to 
the study only 2 denied the consent and therefore 50 were enrolled. This low number of 
potential participants who refused to participate depends from the fact that they had 
previously been selected by their professionals (usually neurologists) who had been 
informed of  the inclusion and exclusion criteria of the study. For this reason no 
“urgent” patients were referred to the trial to avoid the risk that they might have been 
randomized in the ST group and would have had to wait for care to be provided. This 
was because being experimental, the service did not have an emergency policy. Thus 
there was no direct line for patients defined as urgent at the first evaluation leading to a 
direct care from the SPCS and this is a different approach to that of the King’s College 
MS study, where they excluded the potential participants if the referring staff and the 
screening deemed they had very urgent needs or were deteriorating rapidly. In this 
instance immediate referral to the service was offered, and the patient was withdrawn 
from the trial (required for 5/69 patients). 
 
In the present study, almost all the referred participants were very keen to participate to 
the development of an experimental new service potentially useful for them and for 
other people. For most of them this was the only chance to receive a service tailored on 
their unmet needs and so they declared to be happy even to wait 4 months, but to have 
the chance to be cared for by such a service. 
 
The randomization technique adopted with the coupling of two participants per week 
with similar features (e.g. diagnosis or disability level) allowed contact of potential 
participants closer to the first assessment and the subsequent randomization and 
allocation. This procedure was necessary because it was not possible to start the study 
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with all the sample at the same time. This would have led to a saturation of the service. 
If participants were to be contacted before the start of the study some would have had a 
period of several months before being assessed and randomized and this was not 
acceptable due to the advanced stage of their diseases and the risk of death. It must also 
be considered that 50% of them would have had a further 16 weeks of wait before 
receiving the SPCS, for those randomized in the ST group. 
The randomization procedure adopted was very simple and did not use specific 
randomization tools, such as computer based software or random numbers generators. 
As described in the methods it consisted of the random choice in blind of one of two 
anonymous and not recognizable folders containing the participants data, done by one 
of the FARO administrative employees. The first folder chosen was considered in the 
FT group and the remaining went into the ST one.   
Analyzing the results it appears that randomization was successful because the two 
study groups were homogeneous with an equal distribution of participants in terms of 
number of participants, gender, age groups, diagnostic groups and disability levels. 
4.6.2 Mortality, attrition and missing data 
 
Mortality rate in the 16 weeks of follow up was the same reported for the MS study as  
4 patients died during the follow up period: two had been allocated in the FT group and 
two in the ST, confirming that the input of the service did not increased the mortality 
rate of the participants. The patients who died during the study were two with 
ALS/MND and two with PDs.  
Attrition was also quiet low, just two participants voluntarily left the study before its 
natural conclusion - both were of the FT group. One patient had to decide whether to 
choose the FARO experimental service or a public service that was already receiving 
because the administrators of the latter did not want to collaborate with the study 
protocol, for this reason he preferred to stay with the public service fearing that the 
experimental service could be interrupted at the end of the period of follow up. The 
second patient, despite being severely disabled and totally dependent in the ADL, after 
12 weeks of service provision asked to be discharged from the service because he said 
he was not a terminally ill person and did not want to be cared for by a palliative care 
unit. 
Excluding the four who died and the two who withdrew from the study, 44/50 patients 
could be assessed at T1, after 16 weeks of service provision for those randomized in the 
FT or after 16 weeks of wait for those randomized in the ST group. For this reason at T1 
21 patients could be reassessed in the FT and 23 in the ST groups. 
Not all patients could complete all the tests used to assess the trial outcomes. Some 
tools, like the SEIQoL-DW required a longer interview and for this reason only 48/50 
(96%) patients at baseline could complete this test and only 41/44 (93.2%) at T1. Most 
patients were so disabled that could not write or keep a pencil in their hands so the 
researchers did it for them according to their vocal orders or through other way of non 
verbal communication (for instance the ALS/MND tracheostomized patients answered 
by electronic communicators or alpha numerical tables). This technique allowed to have 
100% of physical symptoms assessment at baseline (50/50) and at T1 (44/44). This 
means that all patients could correctly utilize the VAS or NRS for the physical 
symptoms assessment despite  being highly disabled. The remaining trial outcomes had 
lower response rate ranging between 45 – 49 (90-98%) out of 50 eligible at baseline and 
between 42-43 (95-97%) out of 44 eligible after the 16 weeks representing the duration 
of the study. The lowest response rate happened at baseline for the caregivers’ burden of 
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care (CBI) (90%) because five patients did not want that their carers (4 paid carers and 1 
family carer) to be involved in the research project. 
Overall the response rate was satisfactory allowing a good group comparison and few 
missing data. For these reasons we can conclude that the adopted tools to explore the 
trial outcomes were acceptable in terms of feasibility and allowed a good compliance in 
the participants even though they were severely disabled. 
4.6.3 Demographics and disability  
 
Analyzing the participants’ characteristics it results that there was a moderate 
prevalence of males (60%) and this can be explained because among the considered 
diseases it is known that ALS\MND tends to affect more males than females (Bendotti 
et al. 2005) and other studies on the QoL of patients with ALS/MND enrolled 2\3 of 
males in their sample (Clarke, S. et al. 2001), that even though MS affects more 
frequently women than men, the male gender is a negative prognostic factor and for this 
reason men are more likely to become severely disabled for MS (Ben-Zacharia and 
Lublin 2001), and finally some studies report that PDs are more prevalent in males (de 
Lau and Breteler 2006). 
The distribution of the three diagnostic groups (ALS/MND, MS and PDs) resulted 
homogeneous with respectively 16 patients with ALS/MND (32%), 16 patients with 
PDs (32%) and 18 with MS (36%). The same proportions were maintained in the two 
groups of the study after the randomization. This report indicates that even though 
participants were affected by different neurodegenerative disorders there was a good 
balance among the diagnostic groups and between the groups of the study. 
The results showed that the age groups involved were so distributed: about half of the 
sample was in the group of 65 years or over, 34% was in the middle age group and the 
remaining 16% in the group younger than 44. This data is consistent with the 
epidemiology of the considered diseases, in fact PDs tend to affect the elderly (Wenning 
et al. 2004, Poewe 2006, Litvan et al. 1996), in ALS/MND the association with 
increased age is clear and there is a steep rise in incidence after the age of 50 which 
continues to increase in age adjusted analysis (Shaw, C. 2006, p 7.), in MS, even though 
the incidence of the disease is higher in younger people becoming clinically apparent 
between the age of 20-40 years, high disability level appear in 80% of patients after 30 
years from the diagnosis (Goodin et al. 2002, Pugliatti et al. 2006). The youngest 
enrolled participants were MS patients whose disease progressed earlier than expected 
and ALS/MND patients with an early onset of the disease that chose to be 
tracheostomized. After randomization there was a small increase of participants in the 
45-64 group in the FT group versus a higher presence of patients in the under 44 years  
in the ST. In the group comparison using the Chi-square test for independence however 
no statistically significant difference appeared between the two groups. 
 
Analyzing the disability degrees of the overall sample at baseline it appears that the 
sample of patients involved in the present study was affected by a very high disability 
level. The aim declared in the methods section of enrolling patients severely affected by 
these neurodegenerative disorders has been achieved. Previous studies or reports about 
the palliative care involvement for the care of patients with these disorders reported 
similar or lower disability levels. The prospective RCT analyzing the impact of a SPCS 
for advanced MS patients reported an EDSS mean level in their sample of 7.7 versus the 
8.5 of this study sample (Higginson, I. J. et al. 2009). This result shows that in this 
study the mean disability level was higher and physical functioning of the participants 
was more impaired. 
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For the ALS/MND group in a descriptive study about the home care for patients with 
ALS/MND the mean ALS-FRS score of participants who were receiving the home care 
was of 13 (Krivickas, Shockley and Mitsumoto 1997), whereas in our study the mean 
score was 10.2 indicating higher dependency in the ADL of our participants. In other 
studies aiming at exploring different aspects of the QoL of severely ill patients and the 
impact on their informal carers, the mean score of ALS-FRS in the considered samples 
were 22, 22.5, 23.5 and 24.6 respectively (Adelman et al. 2004, Clarke, S. et al. 2001, 
Neudert, Wasner and Borasio 2004, Chio et al. 2005). Recently in a study evaluating 
the medical and supportive care among people with ALS/MND who were likely to die 
in few months for respiratory impairment the reported ALS-FRS-r mean of the patients 
who died over follow up was 22.3±8.1 and for those who chose tracheostomy 
21.3±7.0(Albert et al. 2009). We can conclude that also for ALS/MND patients the 
mean physical disability level was higher than what is present in the literature in studies 
set up to evaluate palliative care outcomes such as patients’ QoL or caregivers’ burden 
of care. 
 
For the PDs groups it is harder to make comparisons because studies showing the 
intervention of palliative care services are lacking. Lee’s papers discussing the 
prevalence of pain and the symptom load in idiopathic PD report a mean H&Y stage of 
3 among the assessed participants (Lee et al. 2007, Lee et al. 2006c).  Giles published a 
qualitative study in which 3 patients with a PD diagnosis were interviewed with their 
family carers and in that case the mean value of the H&Y disability scale was 4 (Giles 
and Miyasaki 2009). In the Parkinson’s disease model of care proposed by Bunting-
Perry the advanced stage of the PD disease coincides with 3.5 points of the H&Y scale 
(Bunting-Perry 2006) and in the paradigm for managing PD Thomas and MacMahon do 
not report a correlation with the H&Y stages, but identify the criteria to entry into the 
palliative stage of PD with the inability to tolerate adequate doses of dopaminergic 
drugs, unsuitability of surgery and advanced co-morbidity leading to a life threatening 
condition or high disability, conditions that can be considered close to the stage 4 of the 
H&Y scale (Thomas and MacMahon 2004a, Thomas and MacMahon 2004b). In this 
study sample the mean H&Y score was of 4.2 - very disabled patients, almost all 
wheelchair bound or bedridden. 
A further confirmation of the high disability of the sample can be detected by the a 
specific disability scales, the ADL-IADL and the Braden scale analyzing the risk of 
pressure ulcers due to immobility. ADL mean score was 1.08 out of 6 and IADL 0.98 
out of 8 (low values indicate high dependency) and the Braden scale mean value was 
15.8 indicating that participants were at risk of developing bed sores. 
4.6.4 The trial outcomes 
 
As declared in the methods section the trial outcomes of this pilot-explorative RCT 
were divided in:  
• 2 main outcomes: 
o The patients’ quality of life. 
o The burden of care for the caregivers. 
• 6 physical symptoms: 
o Pain (considering any painful chronic conditions that could be related or 
not to the neurodegenerative condition) 
o Breathlessness 
o Sleep disturbance  
o Urinary symptoms 
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o Intestinal symptoms 
o Oral symptoms  
• 4 psychological issues: 
o Anxiety 
o Depression 
o Feeling abandoned  
o Coping with the disease  
• 2 spiritual domains: 
o Finding a meaning in the experience of the disease 
o Help from religion 
• 2 social domains for the patients: 
o Social isolation 
o Satisfaction of the received services 
• 2 social domains for the caregivers: 
o Social isolation 
o Satisfaction of the received services 
For some of the listed domains it was possible to make comparisons with previously 
published studies for the various conditions, particularly for the main outcomes, 
symptoms and some psychological themes . For the others only qualitative studies exist 
and therefore a numerical comparison was not feasible. 
4.6.4.1 The Quality of life 
 
Focusing on the Quality of life of the patients, probably the main outcome of any 
palliative care intervention, the mean of the SEIQoL-DW at baseline for the overall 
sample was 62.8 with a Standard Deviation (SD) of 19.45. This data represent the mean 
of the SEIQoL-DW indexes of 48 out of 50 enrolled patients. Only two participants 
were not able to complete the SEIQoL-DW interview, even though most of them 
received help from the researchers to complete the assessment, mostly for difficulties 
related to the motor impairment which made it difficult for disabled patients to use the 
disc.. However the information obtained were accurate because it was up to the patients 
to indicate when the disk position fitted their exact will. 
 
The SEIQoL DW elicited cues represent the areas of individual quality of life chosen by 
the participants as the most representatives of their personal values. In the sample of this 
study all participants elicited the “family” as one of the five most important components 
of their individual QoL. The other more frequently chosen cues were “leisure and 
entertainment”, including television, sports and personal hobbies (ranging from 62% at 
baseline and 97% at T1). The health related problems and concerns (about half of the 
sample at T0 and at T1) were only in  third place, even though symptoms were kept 
separated in this analysis in order to see the comparison between the evolution of the 
cues and the symptom load and intensity measured with the VAS or NRS that are 
discussed below. If symptoms are summed to the health domain the percentage rises up 
to about 80% of participants. The fourth and the fifth most represented cues are 
occupied at baseline and after the intervention by “friends and relationships” ,“spiritual 
life”  and “ need of independence” all present in about the 50% of the interviews. Less 
prevalent cues were “financial-economic”, “social themes” and “information-
communication” that ranged from 10% to 1/3 of the interviewees. This finding confirms 
previous researches conducted in ALS patients in Germany (Neudert, Wasner and 
Borasio 2004) in which “family” was chosen by all patients as determinant of their 
QoL. Other cues elicited in that study were the friends and social life (54%), “health” ( 
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51%), profession (49%), finances and entertainment (both 22%) and the spiritual life 
(13%). Further  research about the QoL in PD patients living in the UK revealed the 
following cues elicited by the participants: family (87.8%), health (52.8%), leisure 
activities (36.6%), marriage (35%), and friends (30.9%)(Lee et al. 2006b). Clarke et al 
demonstrated that in ALS/MND a correlation exist between the type of domains chosen 
as important determinant of one’s own QoL and the physical impairment measured with 
the ALSFRS scale. In particular when the ALSFRS score is higher than the median, 
patients tend to elicit cues related to the disease or the health status, whereas when the 
ALSFRS score is low patients are more likely to chose psychosocial aspects of care 
(Clarke, S. et al. 2001). In our sample the mean disability level is very low and the most 
frequent cues elicited were in fact the family and entertainment confirming this data.  
 
The SEIQoL index represent the final output of the SEIQoL-DW test. It is a number 
included in  0-100 range with higher values indicating better QoL. It results from a 
formula which consider the five elicited areas representing the main aspects of the 
individual QoL and calculates the sum of the products of the satisfaction of each area 
(0-100) multiplied for the relative importance of that area (0-1) among the other four 
elicited. 
In the present study the mean SEIQoL-DW index at baseline for the overall sample 
(N=48) was 62.8 with a SD=19.45. In table 4.19 a comparison with other studies that 
used this tool in various samples of people in very different conditions is presented 
 
 
Table 4.19: comparison of the SEIQoL-DW index in different population studies 
Sample (n) Mean Index (SD) 
ALS/MND (21) (Clarke, S. et al. 2001) 57.8 (22.7) 
ALS/MND (21) (Neudert, Wasner and Borasio 2004) 72.3 (not reported) 
ALS/MND (80) (Chio et al. 2004a) 73.3 (22.8) 
ALS/MND (37) (Lo Coco et al. 2005) 45.56 (not reported) 
PD (123) (Lee et al. 2006a) Not reported 
MS (30) (Lintern et al. 2001) 60.99 (16.95) 
Palliative Care (62) (Waldron et al. 1999) 60.4 (17.5) 
Osteoarthritis (20) (O'Boyle, C. A. et al. 1992) 61.6 (18.8) 
Peptic ulcer disease (28) (McGee et al. 1991) 72.6 (10.7) 
Healthy adults (42) (McGee et al. 1991) 77.4 (9.5) 
Healthy elderly (56) (Browne et al. 1994) 82.1 (12.2) 
 
From this comparison we can conclude that the mean SEIQoL DW index in this study is 
in line with previously published papers. The SEIQoL-DW of the overall sample 
(N=41) after 16 weeks (T1) the mean was 66.41 (SD=21,10). 
 
Considering the SEIQoL-DW index in the 2 groups of the study we can see that at 
baseline the 25 patients who were randomized in the FT group had a mean score of 66.2 
(SD= 18.1) and the 23 of the ST who were able to complete the test had a mean score of 
59.2 (SD=20,6). This difference was due to chance and there was no statistically 
significant difference between the 2 groups for this domain (independent samples t-test, 
p.222). At T1 FT group (N=20) showed an improvement of the QoL measured with the 
SEIQoL index (mean=78.95; SD=11,76), whereas the control group (N=21) reported a 
worsening of the same domain (mean=54.47; SD=21,25). The difference between the 
groups was then statistically significant (p=.000). The analysis of covariance 
(ANCOVA) using the QoL index at T1 as dependent variable, the belonging to the two 
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groups as independent variable and the QoL index at baseline as covariate, confirmed 
this difference between the FT and the ST group (QoL (F1,38)=22.57, p=.000, partial 
eta square = .373).  
 
The difference between the means T0-T1 (baseline – after the intervention) for the 
SEIQoL- DW index between the FT and the ST groups was of 20,19 points representing 
an advantage for the treated group of the 20.2% (p=.001). This result with a higher than 
20% advantage was considered clinically significant. 
 
No other studies could be found that compared patients with these diagnoses with test-
retest methodology using this tool to assess the changes due to an intervention. One 
study hypothesised that patients with congenital heart diseases experiencing 
complications leading to a change in health status would not necessarily report a 
corresponding decrease in the Index. In line with this, the authors found that a 
deterioration in health status corresponded to an increase in the index score (Moons et 
al. 2004). Another study with patients with metastatic cancer evidenced improvement in 
the SEIQoL-DW index overtime (Sharpe et al. 2005) but both were not comparing the 
results of the sample with a control group. 
The tendency highlighted in this study shows how patients with neurodegenerative 
disorders in advanced stages tend to improve their individual QoL when are cared for by 
SPCS, whereas a group that is not receiving the service tend to have a worsening of the 
same domain. This difference is both statistically and clinically significant. The power 
of this pilot-explorative RCT, calculated at post-hoc, was very high, being 1-β=0.99. 
The sample size calculated “a posteriori” using the observed difference of the means for 
the QoL, resulted of 14 participants per arm. For this reason, even though the study was 
not aimed at being powerful enough to fulfil the criteria of  Phase 3 of the Framework 
for design and evaluation of complex interventions to improve health (Campbell et al. 
2000) for the QoL outcome it can be considered a phase 3 definitive randomized 
controlled study, that in that protocol should “Compare a fully defined intervention with 
an appropriate alternative using a protocol that is theoretically defensible, 
reproducible, and adequately controlled in a study with appropriate statistical power”. 
 
4.6.4.2 The caregivers burden of care 
 
The caregivers’ burden of care, assessed with the Caregiver Burden Inventory (Novak 
and Guest 1989) showed a mean of the total index at baseline for the overall sample of 
eligible caregivers (N=45) of 44.78 (SD=14,9). After the intervention the change in the 
overall sample was very small: (N=42) mean=41.90 (SD=16,38). Considering what 
happened in the two groups of the study at baseline the FT carers (N=24) scored a mean 
of 46.67 (SD=17,5) versus the ST carers (N=21) that scored a mean of 42.62  
(SD=11,3). No statistically significant difference between the two groups. After the 
intervention the FT carers’ mean score (N=21) decreased at 41.24 (SD=17,83) 
indicating a reduction of the burden of care of 5.1%, whereas the ST carers’(N=21) 
mean remained stable  at 42.57 (SD=15,22). 
It was observed a little reduction of the total caregivers’ burden of care in the FT group 
versus the ST, but this was so small to be considered not clinically nor statistically 
significant. For this reason the present study did not demonstrate a positive impact of 
the SPCS on the burden of care for the informal carers involved in the assistance of 
patients severely affected by neurodegenerative conditions. However the disability of 
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the patients in both groups was high and may have caused profound caring needs, for 
which there may be little relief. 
4.6.4.3 The physical symptoms 
 
The physical symptoms analyzed in this study were pain, breathlessness, sleep 
disturbance, urinary, intestinal and oral symptoms. These domains were chosen among 
the physical problems reported by the sample of patients who participated to the 
qualitative study and represent typical symptoms faced by traditional SPCS in cancer 
and non cancer care (Addington-Hall, J., Fakhoury and McCarthy 1998).  
Symptoms were measured with simple VAS (0-10 cm) or NRS (0-10 points) tools and 
both the prevalence (presence of the symptom) and the intensity were reported. 
For the overall sample at baseline it was possible to obtain the assessment of the 
symptoms in the whole sample (N=50) without missing data. The results are shown in 
the results chapter at the table 4.5. The most prevalent problem were the “oral 
symptoms” (84%), followed by the intestinal symptoms (80%), breathlessness (72%), 
pain and urinary symptoms (70%) and sleep disturbance (68%). In the literature review 
of the symptom prevalence among people affected by advanced and progressive 
neurological conditions (Saleem, Leigh and Higginson 2007) these problems were 
among those reported for the considered diagnostic groups (ALS/MND, MS, PD, MSA, 
PSP). In particular they were included among the 26 common symptoms present in 
these diseases. Bowel, urinary symptoms and swallowing (which may be seen as an oral 
symptom) were present in all 5 groups with a prevalence 50% or over. Pain was 
reported in all but the PSP group, but if spasms and stiffness were added, being painful 
conditions (Simmons 2005), they would have been present in all the groups with a 
prevalence higher than 50%. Breathlessness and sleep disturbance were less represented 
in that review even though they appeared in more than 80% and more than 60% 
respectively in the NeuNeeds qualitative analysis presented in this thesis. 
Considering the symptom intensity at baseline, the highest score was reported for the 
“bowel symptoms” (mean= 4.96, SD=3.46), the lowest for “breathlessness” (mean=3.24  
SD=2.71). 
 
After the randomization and the allocation in the 2 groups of the study no statistically 
significant difference between the means of the symptoms in the FT and ST group at 
baseline was found as shown in the table 4.11 of the results section. There was a small 
advantage in the mean intensity score in the FT group for pain, breathlessness, urinary, 
bowel and oral symptoms, whereas sleep disturbance was lower in the ST group. These 
difference were not statistically nor clinically significant. 
 
Conversely at T1 a statistically significant advantage was seen in the FT group for all 
the symptoms (see table 4.12 in the results chapter). This advantage was maintained 
after adjusting with the baseline results as shown with the ANCOVA test keeping the 
alpha value at <0.05. This analysis of covariance allows to compare the means of the 
symptoms between the groups at T1 adjusting the results for the means of the symptoms 
at baseline. With this procedure the differences that were present at baseline between 
the groups, even though not statistically significant, are considered as influencing the 
final comparison acting as covariates. 
 
Furthermore, because this comparison of means involved 7 variables (the physical 
symptoms) plus the QoL (the other statistically and clinically significant variable) an 
adjustment of the alpha value (that had been set at 0.05) was considered to avoid the 
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risk of a type 1 error (which is to refuse the null hypothesis when in fact it is true). 
When a Bonferroni adjustment is applied, considering the six symptoms and the QoL as 
the domains where a statistical significance was seen between the groups after the 
intervention (in total 7 variables for which a statistical significant improvement were 
seen in the FT group compared to the ST with a α set at 0.05), keeping the alpha value 
at 0.05\7= 0.007, the statistical advantage is maintained for pain, breathlessness, sleep 
disturbance and intestinal symptoms (and the QoL described above). 
In conclusion we can say that this study showed an improvement in the symptom 
severity (pain, breathlessness, sleep disturbance and intestinal symptoms) after a 16 
weeks SPCS provision for the treated group versus the standard care group. 
Clinically, if we consider as a moderate clinically significance an improvement of +10% 
of the scale used to measure the symptom and as a clinically relevant significance an 
improvement of +20% of the same scale we can say that this study demonstrated that 
the SPCS input caused a moderate clinically significant improvement in the treated 
group for oral and urinary symptoms and a clinically relevant improvement in pain, 
breathlessness, sleep disturbance and intestinal symptoms. The power of the study, 
calculated at post hoc was higher than 90% (1-β > 0.90) for pain, breathlessness and 
intestinal symptoms. The post hoc calculation of the sample size, using the observed 
difference in the means between the groups, allowed to say that for pain and 
breathlessness the sample was bigger than what it would have been expected to be 
conclusive.  
 
4.6.4.4 The psychological issues 
 
The assessed psychological issues for this study were anxiety, depression, felling 
abandoned and coping with the disease.  
Anxiety and depression are part of the disorders of the mood category that were 
described in the qualitative assessment (NeuNeeds). From the content analysis of that 
study results that in all the interviews to the patients and the caregivers some sentence 
related to mood disorders appeared. These symptoms are typically measured in clinical 
research settings and the tool used in this study, the Hospital Anxiety and Depression 
Scale (HADS)  is a very well experimented instrument used in patients with problems 
similar to this study sample (Marinus et al. 2002, Clarke, S. et al. 2001, Honarmand and 
Feinstein 2009). 
In this study sample the prevalence of probable or definitive anxiety and depression was 
of 37.5% for both symptoms. This data were calculating by subtracting from the total 
results those participants that scored  normal values defined as 7 or less in the HADS-A 
or HADS-D. 
Of the total scores obtained from the overall sample at baseline (N=48) thirty patients 
scored 7 or less for both anxiety and depression (62.5%) which correspond at the 
normal category.  Of the remaining patients nine (18.75%) scored between 8 and 10 for 
anxiety (borderline category) and the remaining nine (18.75%) scored 11 or more being 
in the caseness category. For depression, of the eighteen patients who scored more than 
7, eight (16.7%) were in the borderline category and 10 (20.8%) in the caseness 
category. 
Anxiety has been reported as affecting 30% of ALS/MND patients in their last month of 
life whereas depression was at 40% (Ganzini, Johnston and Silveira 2002). In another 
study the prevalence of depression at baseline for ALS/MND patients was of 19% 
including minor and major depression (Rabkin et al. 2005). In a study for the validation 
of the HADS for PD patients percentages for possible and probable depression were 
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21.5% and 16.9% and 50% showed signs of anxiety (Marinus et al. 2002).  In a survey 
with 495 patients severely affected by ALS/MND, MS, PD and Hungtington’s disease 
using the HADS to assess these symptoms an overall of 26% on anxiety and 22% of 
depression was found(Kristjanson, Aoun and Oldham 2006). These results are similar to 
the ones obtained in the present study. 
 
The mean scores of the HADS-A and HADS-D in the present study are displayed in 
table 4.20 and are compared with the findings of the same domains obtained in other 
studies involving patients with advanced neurodegenerative conditions. 
 
 
Samples (N=) HADS-A 
mean (SD) 
HADS-D 
mean (SD) references 
NePAL RCT (48) 6.98 (4.34) 6.75 (4.04)  
ALS/MND, MS, PD and 
Hungtinton’s disease 
(495) 
7.6 (4.64) 7.00 (4.35) (Kristjanson, Aoun and Oldham 2006) 
ALS/MND (26) 5.8 (3.63) 4.76 (2.8) (Clarke, S. et al. 2001) 
PD (176) 8.74 (4.09) 10.25 (4.38) (Marinus et al. 2002) 
MS (180) 6.69 (4.44) 5.26 (4.05) (Honarmand and Feinstein 2009) 
Table 4.20: mean HADS scores reported in other published studies  
 
The mean values for anxiety and depression in the overall sample at baseline in this 
study were both in the “normal” category indicating that on average the levels of these 
symptoms were not significant.  
After the randomization in the two groups of the study the mean scores for both anxiety 
and depression did not show statistically significant differences between the groups (see 
table 4.11 in the results section). This condition remained after the intervention when  
the mean score for anxiety in the overall sample raised at 7,63 (SD=4,1) and for 
depression to 7.67 (SD=4.3), but no difference were found between the groups. 
 
In conclusion it is possible to say that the anxiety and depression assessment in this 
study, measured with the HADS reported prevalence and intensity of both symptoms 
similar to other findings shown in studies involving patients with the same diseases. No 
differences were seen between the groups of this study therefore was no impact on these 
domains from the SPCS. 
 
Feeling abandoned and coping with the disease are two psychological themes that 
emerged from the qualitative part of the study.  
As reported in results section of the qualitative NeuNeeds assessment 95% of the 
interviewed patients talked about the personal unpleasant sensation of “feeling 
abandoned”, confused and of fear the future because of their neurological condition. 
 
 
In the RCT in exam this domain was measured with VAS (0-10cm) or NRS (0-10 
points). Lower scores indicated total abandonment whereas higher ones meant absence 
of this problem.  At baseline 49/50 patients completed this item and the mean reported 
score was 7.45 (SD=2.82). After the intervention (T1) the mean score in the overall 
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sample (N=43/44) was 7.67 (SD=2.74) so we can conclude that no difference appeared 
overtime for the overall sample. 
 
Considering the 2 groups of the study at baseline the results were almost identical: 
FT (N=25)  mean=7.44 (SD=3.07)  
ST (N=25)  mean=7.46  (SD=2.6) 
After the intervention no significant differences resulted for this test 
FT (N=20)  mean=8.00 (SD=2.36) 
ST (N=23)  mean=7.39  (SD=3.05) 
 
The difference between the means in the two groups (6.7%) is lower than 10% of the 
scale used to assess this domain (no clinical significance) and there is no statistically 
significant difference between the groups. This difference is positive for the group who 
has received the service and can reflect the tendency of an improvement of this domain 
in those who received the service, but the difference is too low to justify such claim. 
 
Similar consideration can be done for the “Coping with the disease” domain. 
Difficulties related to this issue appeared in 77% of the interviews conducted in the 
qualitative assessment and confirm what has widely reported in the literature about the 
difficulty to accept the continuous losses due to the progression of the neurological 
conditions s described for MS (Edmonds et al. 2007b, Wollin, Yates and Kristjanson 
2006), the importance of the mastery (Koplas et al. 1999) and the prevalence of the 
mental and psychosocial losses over the difficulties in the ADL’s  in determining  the 
QoL in PD patients (Abudi et al. 1997). The coping strategies and the relative impact on 
the QoL of ALS/MND patients (Hughes et al. 2005) as well as the shift of personal 
values observed from conservative values towards self-transcendence values may be 
related to coping processes of terminally ill patients (Fegg et al. 2005).  
 
In the present study at baseline 49/50 patients completed the VAS (0-10cm) or NRS (0-
10 points) used to assess this item. The higher score indicated that patients were coping 
perfectly with the disease and its consequences, lower scores meant difficulties in 
coping with the problems caused by their conditions. 
The mean score for the overall sample at baseline was of 5.02 (SD=3,16). No difference 
between the groups was found at baseline. After the follow up period the overall mean 
of the sample (N=43) was 5.60 (SD=3,56) and the results in the two groups indicated 
that patients who had received the service scored worse than the control group for this 
domain. The difference was of 0.92 points of the scales corresponding at 9.2% of 
difference . This difference is not statistically significant (p=.393) and is borderline for 
the clinical significance that was set at 10%.   
 
The assessment of the psychological domains in this study aimed to evaluate if a SPCS, 
that includes professionals specifically dedicated to the support care and the 
accompaniment of severely ill patients, could be helpful. The results indicate that no 
difference was found between the groups for the psychological domains, even though 
for coping with the disease it seemed there was a small advantage for patients who were 
not receiving the SPCS. One possible interpretation of this results (that might be due to 
chance because its not significant statistically nor clinically) is that patients affected by 
neurodegenerative disorders, although in far advanced stages, do not see themselves as 
terminally ill, but usually describe themselves as chronically ill. This vision of their 
condition can be negatively impacted by the care provided by a SPCS whose 
professionals are used to deal with dying persons and that tend to talk about death and 
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dying. This option can worsen the psychological status of patients who are experiencing 
anxiety and depression symptoms and difficulties in coping with the losses. It is harder 
to explain why patients did not have improvement in the “abandonment” item when it 
was clear that they were in charge of a specific service modelled to meet their needs. 
One explanation attempted by the researchers was that the negative sensation of feeling 
abandoned is a profound loss deep-rooted in patients who have a chronic illness and a 
16 weeks provision of a service, though with a positive impact on the individual QoL 
and on symptom control, represented a too short period of time to reverse this feeling. 
Analyzing the qualitative description of the abandonment it results that participants 
reported to have been abandoned by their relatives, friends and professional carers. The 
input of a new service could improve the feeling of being abandoned by the 
professionals (sensation worsened by the feeling of being abandoned because they are 
too ill and/or are felt to be incurable, whereas a SPCS should give the message that they 
will not be abandoned exactly because they are very ill and are incurable). The same 
SPCS may not necessarily improve the sensation of abandonment from the other family 
members and friends. 
The impact on this domain should probably be assessed in a longer period. Overall the 
impact on the psychological domains was lower than what could be expected “ a priori” 
and represent a critical point that should be rethought and considered in further research. 
 
4.6.4.5 The spiritual issues 
 
Spirituality is an important component of the total pain, as described by Dame Cicely 
Saunders (Clark 1999), and is also a determinant part of the QoL of people severely 
affected by neurodegenerative conditions (Murphy et al. 2000, Rabkin, Wagner and Del 
Bene 2000, Taylor and Herr 2004, Teno 1999).  
The two domains that were assessed in this study came out from the qualitative 
interviews and were the “meaning” of the lived experience represented by the disease 
and the help received by faith or religiousness.  
For the meaning issue what was observed in the qualitative part of the study was that 
participants seemed divided between those who found a partial or a complete meaning 
in what was happening to them and those who did not. The fact of having found a 
meaning could be related to a transcendent signification like a religious experience or 
because suffering is a normal part of life, or to a social meaning like the sense of justice 
that can be seen as having received many gifts in life whereas others did not and so 
falling ill can be a compensation for this. 
 
One of the tasks of a palliative care intervention is to help dying people to obtain a 
peaceful death and to achieve this result it is very important to help the patients to find 
some answers to what is happening to them. 
 
The other spiritual issues measured in this trial were the help from faith or religiousness. 
Even though the FARO SPCS is not a religious charity a number of professionals have 
religious backgrounds. Three nurses are nuns, one doctor and one nurse have 
undertaken a masters training in religious support and theology. In the SPCS team there 
is a Catholic priest that works as spiritual assistant. In the qualitative assessment 
appeared that faith can be both a positive resource enabling patients to face the losses 
caused by the neurological disorder and to accept deeply what is happening to them, but 
can also be an obstacle to the search of the peace when patients live their faith seeking  
miracles that often do not happen. This can lead to frustration, refusal of their beliefs 
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and eventually rage. For this reason it was decided to measure if the SPCS, having 
professionals skilled in spiritual support, could make a difference. 
 
The results, presented in the results session, showed that no statistically significant 
differences were found between the groups in these two items. This was particularly 
true for the “help from faith” item, whereas for the “meaning of the lived experience” it 
was observed an improvement of the 14.5% of the scale used for the assessment in the 
group who received the service versus the control one. This was reported as a moderate 
clinical improvement, although the lack of statistical significance could mean that the 
observed improvement could be due to chance. 
4.6.4.6 The social issues 
 
Social problems faced by people severely affected by neurodegenerative conditions 
affect both patients and their carers (Oliver and Gallagher 1998). The task of caring for 
terminally ill patients causes social difficulties to the carers independent of the 
diagnosis (Aoun and Kristjanson 2004). Patients may fell that they are a burden to their 
carers and this may be  related to their depressive status (Chio et al. 2005). There are 
differences among different diagnostic groups in the social needs and in the keenness to 
accept services focused on palliative care (Kristjanson, Aoun and Oldham 2006, Goy, 
Carter and Ganzini 2008). 
 
In this study, as part for the specific outcome represented by the caregivers’ burden 
described above, domains also considered included  the sense of social isolation, as this 
had been commonly described by both the patients and their carers in the qualitative 
study. The degree of satisfaction or not satisfaction of these services, of both the 
patients and their carers, was assessed using VAS (0-10cm) or NRS (0-10 points). 
For the social isolation domain “0” represented feeling totally isolated and “10” do not 
feeling isolated at all. For the service satisfaction “0” represented absolute absence of 
satisfaction, whereas  “10” a total satisfaction of the received services. On consideration 
of the social isolation item it appears that at baseline the mean scores for the overall 
sample were very similar between patients 5.27 (SD=3.23) and carers 5.76 (SD=2.98). 
After the follow up the scores, for the overall sample, remained quiet similar: 5.36 
(SD=3.39) for the patients and 5.98 (SD=3.47) for the carers. Considering the difference 
between the two groups of the study it results that both the patients and the carers 
showed an improvement of this domain in the FT group which were not statistically 
significant, but was clinically relevantly significant for the patients (23.9% of the scale). 
The carers’ sense of social isolation improved by about 7.8% therefore was considered 
as not clinically significant. 
 
The trend for social isolation, though not conclusive, appeared to be positive for the 
participants who received the service compared to the control group. 
Analyzing the satisfaction degree of the received services, assessed with VAS (0-10cm) 
or NRS (0-10 points) it seems  that both patients and carers showed a moderate 
improvement of this domain in the group of treatment respect the control one of about 
13%. These results are not conclusive because there is not a statistical significance, but 
they indicate a positive trend in this social issue.  
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4.6.5 Limitations of the study 
 
There are several limitations in the present study. 
• The sample was composed of patients severely affected by neurodegenerative 
disorders which have different illness trajectories, prognosis and characteristics, 
even though all are progressive and no cure is available. This was the first 
published experience of a trial exploring the impact of a SPCS on such 
heterogeneous group, even though it has been recognized that these patient 
groups share common palliative care problems (Saleem, Leigh and Higginson 
2007). 
• Recruitment: patients were referred to the service by specialist neurological 
services (tertiary clinics) therefore a selection bias could be present due to the 
exclusion of patients cared for by general neurological departments or too ill to 
attend the hospital services. A second limitation was due to the design of the 
study that did not allow to enrol patients with severe cognitive impairment 
because they had to be able to complete the outcome measures. For this reason 
patients with severe dementia or psychiatric problems were excluded even 
though they represent the most disabled and advanced stages of the considered 
neurodegenerative disorders. 
• The explorative nature of the phase 2 study would only allow to elicit a sample 
size that could be feasible for the new SPCS provided by FARO. For many 
items the results were not conclusive and therefore the null hypothesis had to be 
accepted probably because the sample size was not big enough. This does not 
seem true for the patients’ QoL and for pain and breathlessness where the 
observed difference in the means between the groups show that the sample size 
was large  enough to demonstrate the positive effect of the service provision.   
• Only one assessment was done after the intervention. This did not allow a 
comparison between the groups over time nor allowed a crossover between the 
groups to evaluate if the same positive effects seen in the treatment group 
appeared in the control group after a similar period of time of the received 
service. This is one of the main limitations and is one major area of difference 
in methodology compared to the other published phase 2 RCT for the MS 
patients (Higginson, I. J. et al. 2009).  
• The study was conducted in an area of the North West of Italy and all the social 
issues can be influenced by the local conditions bound to the regional health 
service . We can assume that the patients QoL and symptoms were not different 
from patients with the same pathological conditions living in different places, 
but the results are to be confirmed by wider and multicentre studies.  
4.6.6 Summary 
 
This phase 2 RCT was aimed at comparing two groups of patients severely affected by 
neurodegenerative conditions and their informal carers: one group received a 16 weeks 
provision of a new SPCS while the second was receiving the best standard care. From 
the groups comparison resulted that the SPCS group had significant improvement in 
QoL and symptom burden versus the control group. There was positive trend (although 
not significant) for the SPCS group in “social isolation” and “finding a meaning in the 
experience of the disease” for the patients and in the “service satisfaction” for both 
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patients and carers. No improvement could be detected in the SPCS for the 
psychological domains, on the contrary it seems that “coping with the disease” could be 
worsened by the SPCS provision. 
 
Overall from this study it appears that the studied population can have a favourable and 
significant improvement if cared for by a SPCS, above all for the QoL and some 
symptoms, for which the explorative trial showed a very high statistical power and can 
be considered conclusive. 
 
Psychosocial and spiritual issues were not conclusive and further research should be 
undertaken to explore these domains.  
Other observations were that the methodology of the waiting list procedure is feasible 
and reliable and can be used to assess palliative outcomes in palliative care settings for 
patients with an expected life span of months/years. Low attrition and relatively low 
missing data confirmed a good impact of the study on the participants that keenly 
adhered at the proposal of this study and remained in the protocol for the follow up with 
a very low attrition rate. 
Mortality was low, confirming the prognostic difficulties in neurodegenerative 
disorders, despite the high disability of the enrolled sample. This data could mean that 
disability alone is not a precise indicator of end of life stages in neurodegenerative 
conditions representing a confirmation of the difference existing in cancer palliative 
care. 
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5. Conclusions and Recommendations 
 
5.1 Conclusions 
In this section of the thesis the conclusions of the research project are presented.  
This chapter consists of a resume of all the previously presented components of the 
project, a description of the overall effect on the SPCS for neurological patients and 
some comments of the overall results. 
5.1.1 Aim of the study 
As stated in the “Idea for the research” chapter this research project was based on a 
research question composed by two parts:  
 
1. What are the palliative care needs of people severely affected by 
neurodegenerative conditions? 
2. How can a Specialist Palliative Care Service (SPCS) best meet their unmet 
needs?  
 
The objective of the project was to answer to the research question. 
A new SPCS for patients severely affected by ALS/MND, MS and PDs in Turin city 
and its province was designed, set up, assessed and evaluated. The results of this 
process were used to answer to the research question. 
5.1.2 Methods 
 
The design and the evaluation of the new SPCS for patients severely affected by 
neurodegenerative disorders was undertaken following the first three phases of the 
MRC framework for design and evaluation of complex interventions to improve health 
(Campbell et al. 2000). 
 
A literature review aimed at obtaining information about the state of the art of palliative 
care in neurology was performed. It focused on the characteristics of the considered 
disorders, specific palliative care needs in this population, previous experiences of 
palliative care provision or SPCS inputs. Published guidelines, recommendations or 
official positions from scientific societies, government agencies and research groups 
were also considered. This step is part of the “theory-preclinical” stage of the MRC 
framework. 
 
A qualitative study aimed at exploring the palliative care unmet needs of patients 
severely affected by ALS/MND, MS and PDs and their family carers, living in Turin’s 
area and cared for by neurologic services operating in two min hospital of the Turin’s 
province was undertaken. The methodology of this study was based on in-depth 
interviews with the patients and their carers and focus groups with the professionals 
involved in their care. This needs assessment study (called Neu-Needs) is part of the 
“Modelling-phase 1” stage of the MRC framework.  
 
A quantitative study aimed at evaluating the impact of the new SPCS on the PCO of 
people severely affected by neurodegenerative conditions concluded the research 
project. It was a pilot-explorative RCT using the waiting list procedure. The latter 
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allows a comparison of the effects of the intervention on a treated group compared with 
a control group receiving standard best practise care. After the follow up period (16 
weeks) all the enrolled participants can receive the service if desired. 
The tools used to assess the trial outcomes were in part validated tests already tested in 
this population (SEIQoL-DW, HADS, CBI), and other general tools, VAS or NRS, 
specifically created to assess the impact of the SPCS on the unmet needs reported by the 
participants of the qualitative needs assessment. 
The analysis of the outcomes was conducted with statistical tests to compare the groups 
(independent samples t-test, non-parametric tests and ANCOVA) and with a clinical 
judgement based on the clinical significance of the results. 
5.1.3 Results 
 
 
5.1.3.1 The literature 
 
5.1.3.1.1 Needs and problems 
 
The concepts of palliative care unmet needs and the description of the hierarchy of 
needs by Maslow were the basis of the literature search that looked at the needs and at 
the problems faced by both the patients severely affected by neurological conditions and 
their carers. The classic framework of the palliative care needs of the dying, that divides 
these needs into physical, psychological, social and spiritual, offers a clear definition, 
but does not provide an straight forward distinction between needs and problems. 
 
Needs and problems are by no means synonymous: 
 
Problems are defined in several dictionaries as - Perceived gap between the 
existing state and a desired state, or a deviation from a norm, standard, or status 
quo. Although most problems turn out to have several solutions (the means to 
close the gap or correct the deviation), difficulties arise where such means are 
either not obvious or are not immediately available -. 
 
Needs are better described as - A lack of something requisite, desirable, or 
useful;  
a physiological or psychological requirement for the well-being of an organism;  
a condition requiring supply or relief -. 
This difference can be transposed in the present thesis by analysing the number 
of problems and needs described in the published literature and compared with 
the findings of the qualitative and the quantitative studies of this research 
project. 
 
 
Problems can be seen as the physical impairment caused by the diseases, the loss of 
independence, the reduction of the life span, the changes in the roles inside the families 
and in the social environment. These situations are objective and can be detected easily 
by comparing what the expected functions of healthy people of the same age as those 
involved in the research. This can clearly show how the gap between the physical and  
social limitations of the impaired patients and the healthy control group and how this 
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gap is due to the progressive and relentlessly evolution of the disease, and therefore the 
“problems”. 
Needs are far more subjective. Participants could experience problems but not report 
them as unmet needs. For instance those participants who accept their disability (which 
is an objective problem) seem to cope better with the disease and do not see their 
incapability to be unmet need. On the other hand other situations that are not objective 
problems, such as the fear of choking to death when there is plenty of evidence that this 
condition do not happen at the end of life of neurodegenerative conditions and can be 
easily tackled by simple and well established plans of care, represent a clear unmet need 
of personal safety and can lead to a rise in the anxiety and in some case to undesired 
decisions like the wish for a hastened death. 
 
5.1.3.1.2 Palliative care and neurodegenerative disorders 
 
The literature review evidenced an increasing interest in the involvement on palliative 
care in neurological disorders in recent years. 
ALS/MND despite being the rarest condition among the considered, is the neurological 
disorders with the highest number of papers describing the palliative care involvement. 
Patients affected by this disease are commonly cared for by SPCS in many western 
countries. In Italy the hospice care for this population is still underrepresented and most 
of the care is provided by neurological services. 
MS is the only neurodegenerative disorders for which a SPCS prospective evaluation 
has been attempted (Higginson, I. J. et al. 2009). Due to the difficulties in predicting 
prognosis, people affected by this disorder are rarely considered as terminally ill and 
their palliative care needs tend to be unrecognized and unmet. Physical symptoms are 
reported in the literature, but little information is available about the end of life issues 
and the quality of death of people with end stage MS. 
PDs are a group of neurological disorders of which Parkinson’s disease is the most 
frequent and the best known, but including MSA and PSP, two movement disorders 
with a poorer  prognosis and less response to the available symptomatic therapies. 
Published studies report the palliative care needs explored qualitatively (including 
psychosocial issues) and quantitatively (mostly physical symptoms) for Parkinson’s 
disease only. For the atypical disorders the physiopathology and natural histories only 
are described. 
In the literature a number of articles describe people suffering for neurodegenerative 
conditions considered as a whole. The main reason to justify the inclusion as a unique 
group is that these patients are severely affected by neurological relentless progressive 
conditions for which no cure exist and that are likely to die for a direct cause of their 
illnesses. Furthermore recent systematic reviews evidenced how the physical needs of 
patients affected by the disease considered in this study are frequent, many are common 
among the diseases and are also similar to those experienced by advanced cancer 
patients or other non malignant conditions (Saleem, Leigh and Higginson 2007, Solano, 
Gomes and Higginson 2006). Official documents from health organizations suggest 
improvement of  the collaboration among neurology, rehabilitation and palliative care in 
order to find common pathways for the care of the patients and to exchange expertise 
(Turner-Stokes et al. 2007, Turner-Stokes, Sykes and Silber 2007).  
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5.1.3.2 The qualitative component of the study 
 
The needs assessment was conducted with 22 in-depth interviews (involving 22 patients 
and 21 family carers) and three focus groups with 11 professionals directly involved in 
the care of these patients. The adopted methodology allowed participants to talk freely 
about the main difficulties that they were experiencing, and how these had been 
managed. The interaction between patients and their family carers provided information 
about the lived experience of the family group and helped when patients were impaired 
in communication and their carer could describe the situation and patients could 
intervene with non verbal communication. The focus groups included discussions 
among professionals who were often involved in the care of a specific disease and 
allowed them to compare their experience with colleagues involved in the care of 
different conditions. Information about the existing services in the area and suggestions 
on the organization of the forthcoming SPCS were very helpful.  
The main findings of the content analysis of the transcript verbatim of the interviews 
and the focus groups were: 
• High prevalence of physical symptoms: 
o problems with mobility and oral symptoms, including swallowing 
difficulties, that affected 100% of the patients, 
o  pain and respiratory troubles (>80%), 
o  intestinal symptoms (>70%), 
o  urinary and sleep disorders (>60%) 
These results are consistent with those previously published in the literature. 
• High prevalence of psycho-social and spiritual unmet needs: 
o anxiety, depression, abandonment and coping issues (70-100%), 
o social isolation (100%), 
o difficulties in finding meanings in the experience of the disease and 
ambivalence related to faith, religiousness and spiritual support (50-
88%). 
They were generally dissatisfied with home care services, whereas the hospital based 
services were described as more efficient and helpful. 
Overall all participants (the potential users and the professionals) seemed positive about 
the forthcoming SPCS, above all for the potential help at home and the possibility of 
respite admissions into the hospice inpatients facility.  
The findings of the needs assessment, summarized above, highlight how both problems 
and needs were found during the interviews and the focus groups. Within the problems 
are the objective findings such as the high disability level of the sample of patients 
(described by the 100% of movement impairment), the lack of available service tailored 
on the needs of the participants, the absence of effective therapies to arrest or relent the 
evolution of the diseases. Unmet needs included the necessity of the participants to be 
considered and treated as human beings, to have the symptoms controlled, to find 
meaning in their lived experiences, to have their decisions (above all those related to the 
end of life decisions) respected. 
 
This classification was taken as a lead for the following quantitative assessment of the 
service. In fact a cohort of measurable domains was chosen from the multitude raised by 
the participants of the qualitative assessment. The adopted criteria were: 
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• the importance of the elicited domains was defined by the prevalence of the 
problems – needs as classified in the content analysis (the most frequently 
reported conditions were likely to be a reliable outcome measure) 
• the needs were considered to be more subjective and potentially reversible than 
the problems. In particular those unmet needs that usually a SPCS have to face 
when caring for very ill people (e.g. symptom control, psychosocial issues, 
spiritual concerns, support to the families etc) are potentially impacted in a 
positive manner, rather than objective problems like the closeness to death, the 
physical restrictions, the loss of job or the unrealistic expectations that 
unfortunately can not be changed and in fact are not considered as palliative care 
outcomes.   
 
5.1.3.3 The quantitative component of the study 
 
A phase 2 pilot explorative RCT, adopting the waiting list procedure, allowed an 
assessment of the impact of the new SPCS on the PCO of patients severely affected by 
neurodegenerative disorders and of their carers. 
50 patients and their informal carer were recruited and randomly allocated in the two 
groups of the study, one receiving the SPCS, the other having to wait 16 weeks before 
being cared for by the SPCS. At baseline no significant differences were found between 
the groups. Overall the sample revealed a very high disability level, an equal 
distribution for the different conditions and for the demographics. The study was 
feasible, well accepted by the participants, with low attrition, low mortality and little 
missing data. The groups who had received the service had the same number of 
deceased patients of the controls, confirming that palliative care does not increase 
mortality. 
Considering the trial outcomes the treated group compared with the control one 
reported: 
• A statistically and clinically significant improvement in the QoL and in the 
control of pain, breathlessness, sleep disturbance and intestinal symptoms 
• A clinically relevant improvement of the social isolation of the patients 
• A clinically moderate improvement of 
o the urinary and the oral symptoms 
o one spiritual theme “finding a meaning in the experience of the disease” 
o the satisfaction about the received services for both patients and carers 
All the other measured outcomes did not show significant changes between the groups. 
In particular one of the main outcomes of the trial was the caregivers’ burden of care. 
This aspect showed a very small improvement for those carers who were supported by 
the SPCS (5%) that is to be considered too small to be clinically significant and is not 
statistically significant. 
 
5.1.3.4 The role of the MRC framework 
 
The MRC framework for developing and assessing complex interventions, adopted as a 
general scheme for both the service development and the research project reported in 
this thesis, showed some positive aspects and some limits that will now be described. 
The most positive aspect of having such a structured programme to follow is that each 
step can be effectively thought, planned and put in action without incurring into the risk 
of bypassing some fundamental part. 
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1. The theory phase precedes the modelling of the service and in the present thesis 
involves all those processes that led: 
 
• from the initial awareness of the general problem – the perception that 
people severely affected by neurodegenerative conditions could receive help 
from palliative care, but the lack of experience worldwide in this field and 
the presence of sparse published evidences  
• to the formulation of the research question 
• to the choice of the mixed methods methodology to address the two different 
parts of the question 
• the literature review concluded this preliminary phase allowed a better 
understanding of the problem and led to the second step of the framework. 
 
 
2. The phase 1 (modelling) included: 
 
 
• The education process of the personnel of the SPCS, which was stimulated 
by the evidence from the literature and, later, from the qualitative 
assessment, of: 
a. the lack of knowledge of the professionals, expert in cancer care, of 
the specific clinical features of the neurodegenerative disorders 
b. the lack of experience of the management of the specific equipment 
used by these patients (e.g. mechanical ventilators, cough machines, 
augmentative-alternative communicators) 
c. the failure of other hospices in starting to care for neurological 
patients or their decision to stop their admissions in their programmes 
due to the difficulties that raised during the care and the lack of 
education in the care for this patient group  
d. the reports from the potential users (e.g. the participants of the 
interviews) that stated that they felt totally unsatisfied when they 
were seen by health professionals (e.g. GP’s, emergency services, 
general wards), who they felt were not prepared for the specific 
features of their disorders and, sometimes, were scared by the 
equipment used by the patients and often knew less than the informal 
caregivers about the correct management of the patient and his or her 
problems. 
 
 
• The needs assessment. By means of the interviews and of the focus groups 
much useful information was collected and consequently used to model the 
forthcoming specialist service. The aim was to design it tailored on the needs 
of the potential users, it was thus essential to ensure that the exploration of 
the needs of patients and their families living in the area where the SPCS 
was going to be set up, and collection the professionals’ point of view was 
undertaken. The methodology of the modelling phase was therefore a mix of 
the analysis of pre-existing experiences from other services, and published in 
the literature, and new data collected in the qualitative needs assessment of 
this research. 
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3. The experimental phase, reflecting the phase 2 of the MRC, represent the final 
outcome of this research project, but at the same time is just the start of the new 
service provided by FARO Foundation for people severely affected by 
neurodegenerative conditions. This is being continued and implemented and that 
will be better explained in the following paragraph. This phase was explorative 
by definition and aimed at finding a number of variables potentially modifiable 
by the input of the new service that are be measured overtime compared to an 
appropriate control group. In the present piece of research this phase provided 
the most important news, showing how the service was able to improve some 
important palliative care outcomes in this population and provide novel data 
never shown before in the published literature. In this phase a fully quantitative 
approach was adopted to assess the impact of the new service. A parallel 
qualitative approach aimed at understanding not only how much the variables 
changed between the group that received the service and the control group, but 
also why and how this process would have been very helpful and allowed a 
broader understanding of the effectiveness of the service. This had not been 
possible, due to time restraints but future research using this MRC approach 
would benefit from a qualitative approach in conjunction with the quantitative 
methodology.  
 
Among the limits of this framework what really makes it difficult the extend use of this 
tool is its length. It would be very difficult to have to repeat all the procedures if, for 
instance, FARO Foundation should decide to extend its SPCS to other categories of non 
cancer patients like those affected by cardiopulmonary advanced conditions, renal 
failures, or other untreatable disorders. Furthermore the different methodologies 
adopted in this research and described in this thesis should be conducted in parallel 
rather than in series. The use of a mixed methods approach with both quantitative and 
qualitative methods used together, rather than following each others, provide more 
information and, above all, explain the meaning of the findings in a more straight 
forward way. 
To conclude the iterative process of the MRC framework appears to be a positive 
pathway to follow to achieve a continuous improvement of the service.  The framework 
is certainly applicable to the palliative care setting, perhaps a little too long to be used in 
daily clinical settings, whereas it can be an optimal solution for experimental designs.   
 
5.1.3.5 Overall effect 
 
Since the beginnings of this research project the FARO new SPCS for people severely 
affected by neurodegenerative conditions has cared for 90 patients with a neurological 
diagnosis. The service is now fully operative for ALS/MND patients who do not have a  
tracheostomy and is still in a research phase for the other diagnoses and for the 
ALS/MND tracheostomized patients. The professionals working in the SPCS are 
satisfied with the new skills learnt during the education process that led to the 
establishment of the service. The professional network that resulted by the interaction of 
the new SPCS with the neurologists, rehabilitation specialists, lung specialists and other 
professionals has aided the development of a comprehensive service for the patients and 
their families throughout the various aspects of the care pathway. A new inpatients 
facility is under construction to satisfy the increased number of respite admissions for 
these people. 
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In conclusion this project is one of the few evaluations of specialist palliative care for 
patients with a diagnosis other than cancer. In particular it is the first study that assessed 
the impact of a SPCS on the palliative outcomes of patients severely affected by 
different neurodegenerative conditions and in their family carers.  
One important result reported in this study is that the involvement of a SPCS caused an 
improvement of the individual QoL of the patients and a better symptom control above 
all for pain, breathlessness, quality of sleep and intestinal symptoms. This is the first 
published study, at the author’s knowledge, to show such results in a palliative care 
setting for neurodegenerative conditions. As there are very few studies on the 
development of SPCS the study has also shown the effectiveness and importance of 
SPCS developments generally.  
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5.2 Recommendations  
 
From the analysis of the results of the overall research project summarized in the 
Conclusions section the following recommendations can be drawn: 
 
1. Specialist Palliative Care should be offered to patients severely affected by 
ALS/MND, MS and PDs because of the positive impact on the individual QoL 
and symptom control.  
2. Further studies should be done to evaluate if the positive impact, demonstrated 
by this study after 16 months of service provision, is maintained over time. 
3. Further studies are also needed to reassess the impact of SPCS on the caregivers’ 
burden of care and on the psycho-social and spiritual issues because this study 
was not conclusive for these aspects, perhaps it was too small to detect 
significant changes. 
4. Comprehensive assessment tools should be constructed and validated to assess 
the palliative care outcomes for advanced neurological conditions. These 
instruments should not be disease related, but should consider the common 
unmet needs of severely impaired neurologic patients independently from their 
specific diagnosis as it happens for the tools used for cancer patients that are not 
dependent on the type of cancer, but on the most common problems. 
5. Different modalities of service provisions should be experimented for the care of 
people suffering for long term neurological conditions based on the needs of 
both the patients and their carers. The positive effect of the input of the SPCS 
(demonstrated in this study) on the individual QoL and on the symptoms could 
be exploited not only for the terminal care, but as an “on demand service” to be 
offered in those occasions of particular sufferance experienced by the patients 
throughout the long term condition. This idea is similar to the simultaneous care 
for cancer patients receiving palliative care inputs when chemotherapy is 
continued and palliative care needs appear. 
6. When a palliative care team involved in cancer care decides to extend the 
service to patients with conditions other than cancer, a dedicated educational 
project must be set up to enable the professionals to acquire the necessary skills. 
Improving the knowledge of the specifics of the diseases (trajectories, 
symptoms, equipment, end of life issues, ethics issues) affect the outcomes of 
the service.   
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7. Appendix 1: abbreviations  
 
Table of abbreviations 
ADI Italian Public Primary Care Home Assistance 
AAN American Academy of Neurologists 
A&E Accident & Emergency Units 
ADL Activities of Daily Living 
ALS/MND Amyotrophic Lateral Sclerosis / Motor Neurone Disease 
AMTS Abbreviated Mental Test Score  
ALSFRS-R Amyotrophic lateral sclerosis functional rating scale revised  
ANCOVA Analysis of Covariance  
CBI Caregiver Burden Inventory  
CNS Central Nervous System  
COPD Chronic Obstructive Pulmonary Disease 
CPR Cardiopulmonary Resuscitation 
CRF Case Record Form 
DBS Deep Brain Stimulation 
DN District Nurse 
EoL End of life 
EAPC European Association for Palliative Care  
EC Ethics Committee  
EDSS Expanded Disability Status Scale 
FARO Foundation for Assistance and Research in Oncology 
FDA Federal Drug Administration  
FT – ST Fast Track – Standard Track 
FTD Fronto-Temporal Dementia 
GP General Practitioner  
H&Y Hoehn & Yahr Score (PDs disability scale) 
HADS Hospital Anxiety and Depression Scale 
HIV/AIDS Human Immunodeficiency Virus / Acquired Immunodeficiency 
Syndrome 
IADL Instrumental Activities of Daily Living 
IGF Insuline-Like Growth Factor 
IV Invasive Ventilation 
MMSE Mini-Mental State Examination 
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MS Multiple Sclerosis 
MSA Multiple System Atrophy 
NeuNeeds Neurological Needs (the qualitative study of this thesis) 
NePal Neurology and Palliative care (the quantiitative study of this thesis) 
NHS National Health Service  
NIV Non Invasive Ventilation 
NRS Numerical Rating Scales 
PCN Palliative care needs  
PCO Palliative Care Outcomes  
PD Parkinson’s Disease 
PDs Parkinson’s Disease and related disorders (Parkinson’s plus syndromes) 
PEG Percutaneous Endoscopic Gastrostomy 
PHT Physiotherapy  
PPMS Primary Progressive Multiple Sclerosis 
PRMS Progressive/Relapsing Multiple Sclerosis 
PSP Progressive Supranuclear Palsy 
QoL Quality of Life 
RCT Randomized Controlled Study 
RRMS Relapsing Remitting Multiple Sclerosis 
SEIQoL-DW Schedule For The Evaluation Of Individual QoL- Direct Weighting  
SLT Speech and Language Therapy  
SIN Italian Society of Neurologists  
SPCS Specialist Palliative Care Service 
SPMS Secondary Progressive Multiple Sclerosis 
VAS Visual Analogue Scales  
WHO World Health Organization 
WMA World Medical Association  
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8. Appendix 2: Study documentation 
The study documentation of both the qualitative and quantitative studies is provided in 
the exact form in which it was used in the research (Italian versions) followed by the 
English translation. 
8.1 Participants documents of the qualitative study 
 
8.1.1 Leaflet for the patients and the carers original Italian version: 
 
Allegato 2 
 
Foglietto illustrativo allegato al modulo di richiesta del consenso informato. 
 
Le chiediamo di leggere attentamente questo foglietto illustrativo. 
 
Esso è stato fatto per informarla riguardo ad un progetto di ricerca per il quale sarà 
richiesta la sua partecipazione. Le verrà richiesto di accettare o meno la partecipazione a 
tale ricerca, per cui leggendo con attenzione il contenuto del presente avrà la possibilità 
di conoscerne gli obiettivi, come esse sarà condotta, quali sono i suoi diritti di 
partecipante e come potrà revocare l’eventuale consenso in qualunque momento lei lo 
desideri. 
 
Lo studio ha per titolo: 
 
“Quali sono i bisogni di cure palliative specialistiche in pazienti affetti da patologie 
neurodegenerative in fase avanzata? Uno studio qualitativo.” 
 
Che obiettivi ha questa ricerca? 
 
Si tratta di una ricerca nella quale un gruppo di ricercatori che si occupano di Cure 
Palliative e di Neurologia cercheranno di capire quali sono i bisogni, i problemi, le 
preoccupazioni di malati gravemente affetti da patologie come la Sclerosi Laterale 
Amiotrofica, la Sclerosi Multipla, il morbo di Parkinson, l’Atrofia Multi-sistemica  e la 
Paralisi Sopranucleare Progressiva. 
Nella stessa ricerca verranno anche studiati i problemi che colpiscono i famigliari che si 
prendono cura di questi malati. 
 
Come si svolgerà la ricerca? 
 
Verranno effettuate delle interviste ai malati ed ai loro famigliari da parte di un gruppo 
di ricercatori. 
Le interviste verranno effettuate nel luogo preferito dai partecipanti, presumibilmente al 
loro domicilio. 
Le interviste saranno registrate, poi trascritte e studiate dai ricercatori. Le registrazioni 
saranno poi cancellate. 
Chapter 8. Appendix 2: Study documentation 
 277 
 
I dati che varranno utilizzati saranno completamente anonimi. Solo i ricercatori che 
avranno condotto le interviste conosceranno l’identità dei partecipanti e non li 
divulgheranno per nessun motivo. 
A chi parteciperà sarà chiesto di esprimere un consenso alla partecipazione. Sarà un 
modulo scritto dai ricercatori. Esso verrà letto e spiegato ai malati e famigliari 
interessati. Se verrà dato il consenso alla partecipazione verrà chiesto di firmare  il 
modulo, o comunque di esprimere chiaramente la propria volontà in presenza di un 
famigliare. 
 
 
 
 
Come vengono selezionati i partecipanti? 
 
I neurologi, che hanno in cura gli ammalati e ne conoscono le condizioni cliniche e le 
caratteristiche famigliari, segnaleranno ai ricercatori queste persone. Poi il gruppo di 
ricerca contatterà i possibili interessati e ne chiederà il consenso alla partecipazione.  
 
Chi acconsente alla partecipazione dovrà per forza completare le interviste? 
 
Assolutamente no! In qualsiasi momento il consenso potrà essere revocato. L’intervista 
si bloccherà ed il partecipante potrà acconsentire a che si utilizzi il materiale raccolto 
fino a quel momento oppure potrà chiedere l’immediata cancellazione delle 
registrazioni. 
 
A cosa servirà questa ricerca? 
 
• In primo luogo servirà per capire meglio le problematiche specifiche di 
ammalati e famigliari quando una grave malattia neurologica li colpisce. Siamo 
interessati a conoscere non solo i problemi fisici, ma anche le difficoltà 
psicologiche, relazionali, le difficoltà legate alla comunicazione in famiglia e 
con i medici. Vorremmo conoscere i problemi sociali che si manifestano in 
queste situazioni: i problemi sul lavoro, le difficoltà economiche, l’isolamento 
dagli altri, la burocrazia. 
Ci interessa anche conoscere come la spiritualità possa giocare un ruolo in 
queste fasi difficili della malattia. 
Tutti queste informazioni saranno raccolte e studiate.  
Cercheremo di pubblicare i risultati su riviste specifiche e li presenteremo nei 
congressi scientifici dedicati alle cure palliative e alla neurologia. 
Ci aspettiamo che la conoscenza chiara ed approfondita dei problemi delle 
persone possa essere da stimolo per migliorare l’assistenza. 
• L’obiettivo più prossimo ed interessante sarà però quello che cercheremo di 
attuare dall’autunno di quest’anno. Infatti verrà istituito un nuovo servizio di 
cure palliative che la fondazione FARO, che già da anni si occupa di assistere a 
casa ed in Hospice i malati terminali di cancro, fornirà anche ai malati affetti 
dalle patologie elencate sopra. Questo servizio sarà modellato il più possibile sui 
bisogni che saranno evidenziati dall’attuale ricerca. Ecco perché sarà importante 
la vostra partecipazione. Con i dati raccolti dalle interviste si cercherà di creare 
un nuovo servizio “cucito” addosso ai bisogni dei malati e delle loro famiglie. 
 
La partecipazione allo studio è dunque graditissima. 
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Non sarà riconosciuta nessuna forma di pagamento ai partecipanti. 
L’eventuale rifiuto alla partecipazione sarà ovviamente accettato serenamente dal 
gruppo di ricercatori.  
Chiaramente non ci sarà nessuna disparità di trattamento, in termini di qualità di cure e 
assistenza, tra chi darà il proprio consenso ad essere intervistato e chi non vorrà 
partecipare. 
 
Vi porgiamo i più cordiali saluti 
 
Il gruppo di ricerca: Simone Veronese, Gloria Gallo, Chiara Rivoiro 
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8.1.2 Leaflet for the patients and the carers English version 
 
Attachment 2 
 
Illustrative leaflet appended to the consent form for the participants.  
 
We kindly ask you to read carefully this leaflet. 
 
This document was prepared in order to inform you about a research project in which 
you have been asked to participate. You will be asked to accept or to decline your 
participation at the present study, for this reason reading this leaflet will inform you of 
the aims, how it will be conducted, what are your rights as participant and how you will 
be able to withdraw your consent at any time.  
 
The title of this study is: 
 
“What are the specialist palliative care needs of patients severely affected by 
neurodegenerative conditions in advanced stage? A qualitative study.” 
 
What are the aims of this research? 
 
This research project, set up by a group of researchers with an interest in palliative care 
and neurology, aims at exploring the unmet needs, the worries and the problems faced 
daily by people severely affected by Amyotrophic Lateral Sclerosis, Multiple Sclerosis, 
Parkinson’s disease, Multiple System Atrophy and Progressive Supranuclear Palsy. 
Family carers issues will be also considered in this project. 
 
How will be conducted the research? 
 
A group of researchers will interview you and your family. The interviews will be held 
in the participant’s preferred location, usually your own home.  
Interviews will be audio and video recorded, a transcript verbatim of the contents will 
be performed and analyzed by the researchers. The tapes will be then deleted. Data will 
be studied and used anonymously. Only the researchers conducting the interviews will 
know the participants identity and no-one else will have this information. Potential 
participants are asked to provide their consent to the participation. A specific form will 
be read and explained to the interested participants. If you consent to be involved you 
will be asked to sign the form, or to clearly express your consent if you cannot sign it.  
 
How are selected the participants? 
 
Potential participants will be referred to the researchers by the neurologists that take 
care of them in the hospital services. They are aware of the inclusion criteria for this 
study. The research group will them contact the potential participants. 
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If a consent is given, will the participants be bound to complete the interviews? 
 
Not at all! At any time the consent can be withdrawn. The interview will be stopped and 
then you may decide whether the material collected until that point could be used for the 
research, or ask the cancellation of the content. 
 
What will be this research used for? 
 
• First of all it will provide important information about the specific problems 
faced by the patients and by their families with a severe neurologic disorder. 
Researchers are interested in the physical problems, the psychological and the 
relational issues, the communication problems within the family and with the 
professional carers. Further specific points of interest are the social problems 
that appear in this situations: job related problems, economic difficulties, social 
isolation and bureaucracy. We also want to know about the role of spirituality in 
these difficult circumstances. All this information will be collected and studied. 
We will try to publish the findings in specialized journals and to present in 
scientific congresses of palliative care and neurology. 
• A more ambitious objective is what is going to be set up in Autumn of this year. 
A new specialist palliative care service provided by the FARO Foundation, an 
experienced charity that provides a well known similar service for people 
severely affected by cancer, will be designed and assessed for people severely 
affected by the disorders listed in this leaflet. This forthcoming new service will 
be modelled as much as possible on the needs that will emerge from this 
research project. This is why your participation is so important. Data collected 
from the interviews will be used to develop a new service tailored on the needs 
of the patients and of their families. 
 
Your participation is therefore very welcome.  
No payment will be provided for the participation. Researchers will accept your refusal 
if you do not wish to be involved and there will be no discrimination in terms of quality 
of care and assistance will be applied among who will accept and who will decline the 
consent to participate at this research. 
 
Yours faithfully, 
 
The research group:  
                           Simone Veronese, Gloria Gallo, Chiara Rivoiro 
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8.1.3 Leaflet for the patients’ General Practitioners Italian version 
 
Allegato 3. 
 
Protocollo di studio sui bisogni:  
• di pazienti affetti da patologie neurodegenerative in fase avanzata 
• dei loro famigliari (caregivers) 
 
LETTERA INFORMATIVA PER IL MEDICO DI MEDICINA GENERALE. 
 
Egregio Collega, 
 
desidero informarla che è stato proposto al suo paziente, sig. 
……………………………………. 
affetto da…………………………………………………….. ed il suo famigliare di 
riferimento  
sig……………………………………………… Entrambi hanno accettato di partecipare 
allo studio clinico  
 
“Quali sono i bisogni di cure palliative specialistiche in pazienti affetti da patologie 
neurodegenerative in fase avanzata? Uno studio qualitativo.” 
 
Tale progetto di ricerca viene condotto da un team di ricercatori formato da medici 
palliatori e neurologi ed ha l’obiettivo primario di valutare i bisogni di tipo fisico, 
psicologico, sociale e spirituale degli ammalati affetti da patologie neurodegenerative in 
fase avanzata (Sclerosi Laterale Amiotrofica,  Sclerosi Multipla, morbo di Parkinson, 
Atrofia Multi-sistemica  e la Paralisi Sopranucleare Progressiva). 
Anche i famigliari di riferimento (caregivers) saranno coinvolti per conoscere le loro 
problematiche legate alla gestione della malattia. 
I partecipanti saranno intervistati, con interviste semistrutturate ed approfondite, presso 
il loro domicilio, o comunque dove sarà loro più comodo. 
La partecipazione sarà libera, previo consenso informato che sarà comunque revocabile 
durante le interviste. 
I dati saranno trattati con riservatezza. I risultati saranno presentati in forma anonima. 
Il progetto nasce dalla collaborazione tra la fondazione F.A.R.O., che da anni si occupa 
di assistere a casa ed in Hospice i malati terminali di cancro, e le cliniche neurologiche 
dell’ospedale Molinette di Torino e dell’ospedale S.Luigi di Orbassano. 
I risultati dello studio saranno pubblicati su riviste specialistiche, presentati ai congressi 
dedicati alle cure palliative ed alla neurologia. 
Dall’analisi dettagliata di questi bisogni nascerà un nuovo servizio di cure palliative 
domiciliari, il più possibile modellato sulle reali necessità di queste persone. 
Tale servizio sarà fornito dalla fondazione F.A.R.O. a partire dall’autunno 2007, 
inizialmente in via sperimentale su casi selezionati per valutarne l’efficacia e 
l’appropriatezza, poi in futuro sarà a disposizione di tutti i pazienti affetti da patologie 
neurodegenerative le cui caratteristiche siano compatibili con la quelle previste dalla 
Delibera Regionale sulle Cure Palliative vigente: D.G.R. n. 15-7336 del 14.10.2002. 
 
RingraziandoLa anticipatamente per la sua attenzione rimango a sua disposizione per 
qualsiasi chiarimento in merito e per qualsiasi informazione che Lei ritenesse 
necessaria.  Cordiali saluti                                                                                                      
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8.1.4 Leaflet for the patients’ General Practitioners English version 
 
Attachment 3 
 
Study Protocol on the needs:  
• Of patients severely affected by neurodegenerative conditions 
• And their carers (caregivers) 
 
INFORMATION LETTER FOR THE GENERAL PRACTITIONERS 
 
 Dear Colleague, 
 
I want to inform you that it has been proposed to your patient, Mr…. affected by …… 
and to his or her family carer ………  Both accepted to participate at the clinical study 
called: 
 
“What are the specialist palliative care needs of patients severely affected by 
neurodegenerative conditions in advanced stage? A qualitative study.” 
 
This research project is conducted by a team of researchers formed by palliative care 
experts and neurologists and its the primary aims is to assess the physical, 
psychological, social and spiritual unmet needs of people severely affected by 
neurodegenerative conditions (Amyotrophic Lateral Sclerosis, Multiple Sclerosis, 
Parkinson’s disease, Multiple System Atrophy and Progressive Supranuclear Palsy). 
Family carers will be involved to collect their point of view about the problems caused 
by the diseases. Participants will be interviewed, with in-depth semi structured 
interviews,  in their homes or in other places of their choice. 
Participation is free, an informed consent will be obtained beforehand and will be 
possible to withdraw at any time. Data will be treated confidentially and the results will 
be presented in anonymous form.  
The project was born from the collaboration between FARO Foundation, which has 
been providing palliative care for cancer patients at home and in hospice for many 
years, and the neurological clinics of the Molinette Hospital of Turin, and San Luigi 
Gonzaga Hospital of Orbassano. 
Results will be submitted for publication to scientific journals and to specialist 
congresses. 
From the analysis of the unmet needs that will emerge in this study a new specialist 
palliative care service will be set up, modelled as much as possible on the real problems 
of this population. This service will be provided by FARO Foundation from Autumn 
2007, initially as an experimental phase on selected case to assess its efficacy and 
appropriateness, later will be available for all the patients with neurodegenerative 
conditions whose characteristics will be included in the Regional Resolution on 
Palliative Care in force: D.G.R. n. 15-7336 of the 14.10.2002. 
 
Thanking you in advance I will be available for any enquiry or information that you 
should need. 
 
The research group:  
                              Simone Veronese, Gloria Gallo, Chiara Rivoiro 
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8.1.5 Participant’s consent form Italian version 
 
Allegato 1 
 
MODELLO DI CONSENSO INFORMATO 
 
Io sottoscritto\a…………………………………………. attesto di essere stato informato 
da……………………… ………degli obiettivi dello studio: 
 
 “Quali sono i bisogni di cure palliative specialistiche in pazienti affetti da patologie 
neurodegenerative in fase avanzata? Uno studio qualitativo.” 
 
Ho letto il foglio informativo allegato a questo modulo. 
Se non ho potuto leggerlo il ricercatore………………. ………………………lo ha fatto 
per me.  
Ho compreso il contenuto del foglietto allegato. 
Se accetterò di partecipare a tale studio lo farò sapendo che il mio consenso potrà essere 
revocato in qualsiasi momento lo riterrò necessario. 
Nel caso in cui decida di negare il mio consenso durante lo svolgimento dello studio 
stesso potrò decidere se consentire ai ricercatori di utilizzare le informazioni già raccolte 
o se chiederne l’immediata distruzione. 
Sono consapevole dell’utilizzo che verrà fatto dei dati che fornirò ai ricercatori. 
Sono stato informato che le registrazioni delle interviste da me rilasciate verranno 
distrutte dopo essere state trascritte.  
Sono anche consapevole che queste trascrizioni saranno conservate dai ricercatori in 
modo sicuro e che saranno anonime, cioè non ci sarà traccia dei mie dati personali su di 
esse. 
Sono consapevole che la partecipazione o meno allo studio non influirà in alcun modo 
sulla qualità ed il tipo di cure che riceverò. 
 
In base a tutte queste informazioni da me ricevute e comprese (crociare la risposta 
precelta): 
 
      
                     ACCONSENTO                                          NON ACCONSENTO 
 
 
Alla partecipazione a questo studio. 
 
 
 
Data e luogo                                                               firma del partecipante 
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8.1.6 Participant’s consent form English version 
 
Attachment 1 
 
CONSENT FORM MODULE 
 
Mr/Mrs …. ….states that I have been informed by Dr Simone Veronese about the aims 
of the study:  
 
“What are the specialist palliative care needs of patients severely affected by 
neurodegenerative conditions in advanced stage? A qualitative study.” 
 
I have read the leaflet for the participants, in case I could not read it the researcher …. 
did it for me.  
I understand the content of the leaflet. If I accept to participate to the present study I will 
do it knowing that my consent can be withdrawn at any time if I decide to do so. 
If I will withdraw the consent during the interview I will decide whether consent or not 
to the researchers to use the data already collected or not. 
I am aware of the use that the researchers will do of the data I will provide. 
I am aware that the video and audio taped material will be made into a transcript and 
then deleted. 
I am aware that data will be treated anonymously and my personal information will not 
be given out to anyone else. 
I am aware that the decision to participate or not participate will not influence the 
quality of care and of assistance that I will receive in the future.  
 
According to these conditions I decide to  
 
               
 
 
                          ACCEPT                                              NOT ACCEPT 
 
 
To participate at the present  study 
 
 
 
Date, Place.                                                    Participant’s signature 
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8.2 Participants documents of the quantitative study 
 
8.2.1 Leaflet for the participants Italian version  
  
FOGLIO INFORMATIVO PER I PAZIENTI 
 
 STUDIO ESPLORATIVO PILOTA RANDOMIZZATO, CONTROLLATO 
SULLA VALUTAZIONE DELL’IMPATTO SUI PALLIATIVE CARE 
OUTCOMES (PCO) DA PARTE DI UN SERVIZIO SPECIALISTICO DI CURE 
PALLIATIVE (SPCS) IN PAZIENTI AFFETTI DA PATOLOGIE 
NEURODEGENERATIVE 
 
Introduzione: 
Questo studio è realizzato per verificare l’efficacia di un Servizio di Cure Palliative 
Specialistiche nell’aiuto a persone affette da malattie neurodegenerative a domicilio ed 
in Hospice. Si tratta di uno studio randomizzato controllato. Questo significa che alcuni 
partecipanti riceveranno il servizio, offerto gratuitamente dalla Fondazione F.A.R.O., 
per un periodo di quattro mesi. Gli altri invece dovranno attendere quattro mesi per 
poterlo ricevere. Tutti i pazienti riceveranno contemporaneamente i normali servizi che 
il servizio sanitario mette loro a disposizione (medico di famiglia, servizi ospedalieri e 
domiciliari come sempre). Il posizionamento nel gruppo che riceverà subito il servizio 
di cure palliative della F.A.R.O., oppure che si debba attendere quattro mesi è 
puramente casuale, avviene tramite un sorteggio. 
 
Qual è l’obiettivo dello studio? 
 L’obiettivo dello studio consiste nel determinare se il servizio di cure palliative 
domiciliare ed hospice della F.A.R.O. è in grado di migliorare alcune componenti della 
qualità della vita dei malati affetti da patologie neurodegenerative e nei loro famigliari. 
 
Come si eseguirà lo studio? 
Nel corso di 8 mesi verranno valutati alcuni ammalati di Sclerosi Laterale Amiotrofica, 
Sclerosi Multipla, malattia di Parkinson e parkinsonismi. Tutti saranno sottoposti ad una 
prima visita domiciliare da parte di personale specialistico della F.A.R.O. I pazienti che 
acconsentiranno alla partecipazione allo studio verranno valutati con dei test specifici 
per capire quali siano i loro principali problemi. Anche la persona che si prende cura di 
loro sarà sottoposta ad alcuni test. Dopo questa valutazione i partecipanti saranno divisi 
nei due gruppi in modo casuale. Un gruppo riceverà subito il servizio della F.A.R.O., 
l’altro (che chiameremo gruppo di controllo) continuerà a ricevere gli attuali servizi a 
sua disposizione. Dopo 4 mesi tutti i partecipanti saranno nuovamente sottoposti agli 
stessi test. Le analisi statistiche ci aiuteranno a capire se e quanto il servizio di cure 
palliative della F.A.R.O. possa essere stato utile nel migliorare la qualità della vita dei 
partecipanti. Al termine dei 4 mesi dello studio tutti coloro che hanno partecipato 
potranno usufruire del servizio della F.A.R.O., se lo vorranno,  gratuitamente. 
 
Contiamo di arruolare 50 malati residenti nella città di Torino e nelle aree della 
provincia dove è attualmente in funzione il servizio domiciliare della F.A.R.O. 
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Sono tenuto/a a partecipare? 
No. Sarà a Lei decidere se prendere parte o meno allo studio. Se decide di parteciparvi, 
Le daremo questo Foglio informativo da conservare e Le chiederemo di firmare un 
modulo di consenso. Tuttavia, Lei rimarrà libero/a di ritirarsi in qualsiasi momento, 
senza dover indicare alcun motivo. Se decide di ritirarsi dallo studio, oppure di non 
parteciparvi affatto, questo non ridurrà in alcun modo la qualità o lo standard di cura che 
Lei riceve o che può aspettarsi di ricevere. 
Al termine dello studio, Lei potrà scegliere se continuare a ricevere, o meno, il servizio 
della F.A.R.O., se già lo stava ricevendo, o di iniziare a riceverlo, se si era trovato nel 
gruppo che doveva attendere i 4 mesi – sempre che non si siano identificati problemi di 
sicurezza di rilievo e che Lei non abbia ritirato il Suo consenso a partecipare a questo 
studio. 
 
Cosa mi succederà se partecipo allo studio? 
Nel corso della prima visita valuteremo la sua storia di malattia, verrà visitato da un 
medico della nostra fondazione,  le descriveremo l’intento dello studio e le modalità del 
servizio. Se intenderà partecipare allo studio chiederemo una firma sui moduli del 
consenso. Se il malato non fosse in grado di firmare, ma riuscisse ad esprimere un 
chiaro consenso alla partecipazione, allora chiederemo al suo famigliare di firmare in 
sua vece ed in sua presenza. 
 
Se Lei risulta idoneo/a allo studio, La assegneremo a caso al trattamento. 
Quest’assegnazione casuale, chiamata randomizzazione, significa che Lei potrà ricevere 
il servizio della F.A.R.O. immediatamente oppure se dovrà attendere 4 mesi. 
Normalmente per la randomizzazione si utilizza uno speciale programma di computer, 
in modo che né Lei né il medico saprete in quale gruppo lei finirà. 
 
Se finirà nel gruppo che riceve subito il servizio le sarà assegnato un medico ed un 
infermiere della fondazione che verranno gratuitamente a visitarla a domicilio e le 
spiegheranno tutte le possibilità di intervento, finalizzate al miglioramento della qualità 
della vita, che saranno a sua disposizione. Se finirà nel gruppo di controllo continuerà a 
ricevere gli attuali servizi a sua disposizione ed alla fine dei 4 mesi sarà nuovamente 
sottoposto ai test della prima visita. Da quel momento le verrà proposto di ricevere 
gratuitamente tutti i servizi della nostra fondazione 
 
Se decide di interrompere lo studio, Le chiederemo di completare una valutazione 
quando decide di sospendere lo studio, oppure il più presto possibile dopo quella data. 
 
 
Quali sono le alternative di trattamento? 
 
Se decide di non partecipare allo studio, continuerà a ricevere tutti i servizi che ha 
ricevuto fino ad ora. 
 
Quali sono i rischi e gli effetti indesiderati del trattamento che riceverò durante la 
partecipazione a questo studio? 
 
Non sono previsti rischi specifici implicabili alla partecipazione allo studio. Ogni 
intervento, farmacologico e non, che le sarà eventualmente proposto sarà basato sulle 
più aggiornate linee guida ed indicazioni internazionali e verrà attentamente discusso 
con lei. 
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Quali sono i benefici della partecipazione? 
 
Ci auguriamo che il servizio potrà giovare alla Sua qualità di vita, tuttavia non ci è 
possibile offrire alcuna garanzia a questo riguardo. Le informazioni che ricaveremo 
dallo studio potrebbero aiutarci a prenderci cura di molti altri malati affetti da patologie 
neurodegenerative in futuro. 
 
Cosa succede se dovessero emergere nuove informazioni? 
Talvolta durante un progetto di ricerca emergono nuove informazioni sui servizi oggetto 
di studio. In questo caso, il medico della ricerca La informerà e discuterà insieme a Lei 
se continuare o meno lo studio. Se decide di ritirarsi, il medico prenderà tutte le misure 
necessarie per il proseguimento delle Sue cure. Se invece decide di continuare lo studio, 
Le chiederemo di firmare un modulo di consenso aggiornato. 
 
Cosa succede al termine dello studio? 
Dopo l’ultima visita (quando Lei avrà completato i 4 mesi di osservazione), potrà 
scegliere di ricevere , o continuare a ricevere, il servizio della F.A.R.O., se lo desidera.  
Se non desiderasse ricevere tale servizio le sarà sufficiente comunicarcelo. 
 
La mia partecipazione a questo studio riceverà un trattamento riservato? 
Questo studio non è sponsorizzato. Il servizio verrà fornito gratuitamente dalla 
Fondazione F.A.R.O. di Torino. I dettagli riguardo il Suo trattamento e altre 
informazioni mediche – ma non i Suoi particolari - saranno resi disponibili solo alle  
autorità regolamentatrici, per verificare la corretta esecuzione dello studio. Può inoltre 
darsi che altri enti statali ispezioneranno i Suoi dati, ma manterremo sempre la 
riservatezza. Tutte le informazioni rimarranno riservate. Potremo pubblicare i risultati di 
questo studio, ma senza identificarLa in alcun modo. Se Lei acconsente a partecipare 
allo studio, informeremo il Suo medico. Tuttavia, il Suo nome non verrà divulgato a 
nessuno al di fuori dell’ospedale/ambulatorio del medico. 
 
 
Chi posso contattare per avere ulteriori informazioni? 
Se Lei ha problemi, preoccupazioni o altre domande circa questo studio, contatti 
preferibilmente il dottor Simone Veronese presso la Fondazione F.A.R.O. ONLUS 
telefono 011 888.272 
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8.2.2 Leaflet for the participants English Version 
 
INFORMATION LEAFLET FOR THE PARTICIPANT 
 
EXPLORATIVE RANDOMIZED AND CONTROLLED STUDY TO 
EVALUATE THE IMPACT OF A SPECIALIST PALLIATIVE CARE SERVICE 
(SPCS) ON THE PALLIATIVE CARE OUTCOMES (PCO) FOR PATIENTS 
WITH NEURODEGENERATIVE CONDITIONS 
 
Introduction: 
This study was designed to assess the effects of a new SPCS in the help to people 
affected by neurodegenerative disorders at home and in the hospice. It is a randomized 
controlled study, this means that some participants will receive immediately the SPCS 
provided by FARO Foundation, free of charge immediately whereas others will have to 
wait for 16 weeks before receiving the service. All the participants will continue to 
receive the normal services available from the NHS (GP, hospital based services, public 
home care). The allocation in the group immediately receiving the service, or in the 
group that has a 16 weeks wait is due to chance and happen for drawing of lots. 
 
What is the aim of this study? 
The aim of this study is to determine if the SPCS provided by FARO can improve some 
components of the Quality of Life in patients affected by advanced neurodegenerative 
conditions and in their family carers.  
 
How will be conducted the study? 
Over aperiod of 8 months patients with diagnosis of ALS/MND, MS, PDs will be 
assessed. They will receive a first visit from FARO personnel. Those who will consent 
to participate will be assessed with specific tools to highlight their main unmet needs. 
Also the family carer that provides the daily care to the patient will be invited to 
participate and asked to complete some tests. After this first assessment patients will be 
randomly allocated in two groups: one group will immediately receive FARO service, 
and the other group (that we will call control) will continue to receive the standard 
available services. After 4 months all participants will be reassessed with the same 
battery of tests. Statistical analysis will help to determine in which aspects the 
intervention of the SPCS can make the difference to improve the participants’ Quality 
of Life. After 4 months all participants will receive the fullservice from FARO, if they 
desire it, free of charge. We aim at enrolling about 50 patients and their carers living in 
Turin city and its metropolitan area. 
 
Must I participate?  
No. it is up to you to decide if take part to this study or not. If you decide to be involved 
you will be given this information leaflet and we will ask you to sign this consent form. 
However you will remain free to withdraw at any time from the study. If you will leave 
the study, or you decide not to take part in it this will not affect the standard of quality 
of care that you are receiving or that you will receive in the future. At the end of the 
study you will choose if you will want to receive the FARO service for the future.  
 
What happens to me if I participate? 
During the first assessment you will be visited by a FARO doctor, the study will be 
explained to you in details and you will sign the consent form. If you are not be able to 
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sign your oral consent will be considered valid and a member of your family will sign 
the form for you.  
 
If you will be considered eligible you will be allocated randomly in the group that 
receive immediately the FARO service or in the control group that has a 16 weeks wait 
before receiving the service. 
If you will be allocated in the group immediately receiving the service you will be 
assigned to a mini team composed by a physician expert in palliative care and a nurse. 
Both will look after you at home or in the hospice. If the input of other professionals of 
the service will be required they will be organised by your mini team. 
If you will be allocated in the control group you will spend 16 weeks receiving the 
standard services available only. After 4 months you will be reassessed and from that 
moment you will receive the FARO service. 
If you decide to withdraw from the study you will be asked to fill and sign a form. 
 
What are the alternative to the treatment? 
If you do not want to receive the service from FARO you can continue to receive the 
traditional available services. 
 
What are the risks and the possible side effects that I can incur into during this 
trial? 
No risks or specific potential negative factors are foreseen for those who will receive the 
service.  
Any drug or not pharmacological treatment that you will be offered is based upon 
international published guidelines and you will be informed of any therapeutic option 
and rationale.  
 
What benefits can I expect from my participation? 
We sincerely wish that the service can have positive effects to your own Quality of Life, 
but this cannot be guaranteed. Information emerging from the study will be of help for 
the care of other patients in the future. 
 
What if new information emerge during the study development? 
Sometimes, during the development of experimental studies, new information may 
emerge that can alter the activities of the research project. In that case you will be 
informed by the researchers and you will be able to decide whether withdraw or 
continue in the study. If you withdraw the research team will provide for you the best 
therapeutic option available. If you will remain in the study a new up to date consent 
form will be provided to you. 
 
What happens at the end of the study? 
At the end of the assessment that you will receive after 16 weeks you will be asked if 
you want to receive the service or not. If you will be keen on being cared for by the 
servcie this will be continued or initiated free of charge. If you will not be interested in 
receiving the service you will just have to communicate this to us. 
 
What is the data policy of this study? 
This study is not sponsored by any private company. The service is offered by the 
FARO Foundation that will cover all the costs. Data of the participants will be 
controlled by the competent authorities to guarantee about the correct development of 
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the study. No personal sensible data will be spread. The results of the study will be 
published in specialist journals and ìn congresses.  
 
Who can I contact for further information? 
In case of further doubts or questions please contact Dr Simone Veronese at the FARO 
Foundation of Turin 
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8.2.3 Leaflet for the General Practitioners Italian version 
 
LETTERA INFORMATIVA PER IL MEDICO DI MEDICINA GENERALE. 
Egregio Collega, 
desidero informarla che è stato proposto al suo paziente, sig………………  
affetto da …………………………..  ed al suo famigliare di riferimento 
sig……………………………………………… di partecipare allo studio clinico  
 
 
 
 
 
 
Tale progetto di ricerca viene condotto da un team di ricercatori della Fondazione 
F.A.R.O. onlus formato da medici palliatori e neurologi ed ha l’obiettivo primario di 
verificare l’efficacia di un Servizio di Cure Palliative Specialistiche nell’aiuto a persone 
affette da malattie neurodegenerative in fase avanzata (Sclerosi Laterale Amiotrofica,  
Sclerosi Multipla, morbo di Parkinson, e parkinsonismi atipici) a domicilio ed in 
Hospice. 
Si tratta di uno studio randomizzato controllato. Questo significa che alcuni partecipanti 
riceveranno il servizio, offerto gratuitamente dalla Fondazione F.A.R.O., per un periodo 
di quattro mesi. Gli altri invece dovranno attendere quattro mesi per poterlo ricevere. 
Tutti i pazienti riceveranno contemporaneamente i normali servizi che il servizio 
sanitario mette loro a disposizione (medico di famiglia, servizi ospedalieri e domiciliari 
come sempre). Il posizionamento nel gruppo che riceverà subito il servizio di cure 
palliative della F.A.R.O., oppure che si debba attendere quattro mesi è puramente 
casuale, avviene tramite un sorteggio. 
La partecipazione sarà libera, previo consenso informato che sarà comunque revocabile 
durante lo studio. 
I dati saranno trattati con riservatezza. I risultati saranno presentati in forma anonima. 
Il progetto nasce dalla collaborazione tra la fondazione F.A.R.O., che da anni si occupa 
di assistere a casa ed in Hospice i malati terminali di cancro,  le cliniche neurologiche 
ed i servizi ospedalieri dedicati alla cura di questi ammalati dell’ospedale Molinette di 
Torino e dell’ospedale S.Luigi di Orbassano. 
I risultati dello studio saranno pubblicati su riviste specialistiche, presentati ai congressi 
dedicati alle cure palliative ed alla neurologia. 
Questa fase è necessaria per ultimare il percorso intrapreso dalla Fondazione F.A.R.O. 
finalizzato alla creazione di un nuovo servizio di cure palliative domiciliari ed hospice, 
il più possibile modellato sulle reali necessità di queste persone. 
Tale servizio sarà fornito dalla fondazione F.A.R.O. al termine dell’attuale studio 
clinico che viene fatto in via sperimentale su casi selezionati per valutarne l’efficacia e 
l’appropriatezza. In futuro quindi esso sarà a messo a disposizione di tutti i pazienti 
affetti da patologie neurodegenerative le cui caratteristiche siano compatibili con la 
quelle previste dalla Delibera Regionale sulle Cure Palliative vigente: D.G.R. n. 15-
7336 del 14.10.2002. 
RingraziandoLa anticipatamente per la sua attenzione rimango a sua disposizione per 
qualsiasi chiarimento in merito e per qualsiasi informazione che Lei ritenesse 
necessaria.  Cordiali saluti       
     DR SIMONE VERONESE                 FONDAZIONE F.A.R.O. onlus Torino, 
telefono 011.888.272 cellulare 335.588.19.96 
STUDIO ESPLORATIVO PILOTA RANDOMIZZATO, CONTROLLATO 
SULLA VALUTAZIONE DELL’IMPATTO SUI PALLIATIVE CARE 
OUTCOMES (PCO) DA PARTE DI UN SERVIZIO SPECIALISTICO DI 
CURE PALLIATIVE (SPCS) IN PAZIENTI AFFETTI DA PATOLOGIE 
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8.2.4 Leaflet for the General Practitioners English version 
 
INFORMATIVE LEAFLET FOR THE GENERAL PRACTITIONERS 
Dear Colleague, 
I want to inform you that your patient, MR/MRS…….. affected by ………. His or her 
family carer MR/MRS …………………. Have been proposed to participate to the 
following trial 
 
 
 
This research project is conducted by a team of researchers of the FARO Foundation 
composed by physicians experts in palliative care and neurologists and aims at 
assessing the impact of a new SPCS on the help to people severely affected by 
neurodegenerative conditions (ALS/MND, MS, PDs) at home and in the hospice. 
It is a randomized controlled study, this means that some participants will receive 
immediately the SPCS provided by FARO Foundation, free of charge immediately 
whereas others will have to wait for 16 weeks before receiving the service. All the 
participants will continue to receive the normal services available from the NHS (GP, 
hospital based services, public home care). The allocation in the group immediately 
receiving the service, or in the group that has a 16 weeks wait is due to chance and 
happen for drawing of lots. 
Participation is free, an informed consent will be asked to the participants and this can 
be withdrawn at any time if the participants will not want to stay into the study. 
Data will be managed safely and will be presented anonymously. 
The project is a collaboration between FARO Foundation and the neurologic clinics of 
the Molinette Hospital in Turin and San Luigi in Orbassano.  
The results of the study will be published in scientific journals and presented at 
international congresses of palliative care and neurology. 
This phase is necessary to complete the pathway started by FARO Foundation aimed at 
creating a new SPCS for people with neurodegenerative disorders modelled as much as 
possible on the users’ needs. 
This service will be provided by FARO Foundation from Autumn 2007, initially as an 
experimental phase on selected case to assess its efficacy and appropriateness, later will 
be available for all the patients with neurodegenerative conditions whose characteristics 
will be included in the Regional Resolution on Palliative Care in force: D.G.R. n. 15-
7336 of the 14.10.2002. 
 
Thanking you in advance I will be available for any enquiry or information that you 
should need. 
DR SIMONE VERONESE                 FONDAZIONE F.A.R.O. onlus Torino, telephone 
number 011.888.272 mobile 335.588.19.96 
 
EXPLORATIVE RANDOMIZED AND CONTROLLED STUDY TO 
EVALUATE THE IMPACT OF A SPECIALIST PALLIATIVE CARE 
SERVICE (SPCS) ON THE PALLIATIVE CARE OUTCOMES (PCO) FOR 
PATIENTS WITH NEURODEGENERATIVE CONDITIONS 
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8.2.5 Participant’s consent form Italian version 
 
MODULO DI CONSENSO INFORMATO 
Per i partecipanti 
 
STUDIO ESPLORATIVO PILOTA RANDOMIZZATO, CONTROLLATO 
SULLA VALUTAZIONE DELL’IMPATTO SUI PALLIATIVE CARE 
OUTCOMES (PCO) DA PARTE DI UN SERVIZIO SPECIALISTICO DI CURE 
PALLIATIVE (SPCS) IN PAZIENTI AFFETTI DA PATOLOGIE 
NEURODEGENERATIVE 
 
Medico sperimentatore:  DR VERONESE SIMONE 
 
Io 
sottoscritto\a………………………………………………………………………………
….    nato 
a………………..il……………..indirizzo………………………………………………
… telefono……………………………………. 
DICHIARO 
 
• Di partecipare volontariamente al presente studio avente lo scopo di verificare 
l’efficacia di un Servizio di Cure Palliative Specialistiche nell’aiuto a persone 
affette da malattie neurodegenerative a domicilio ed in Hospice.  
• Di avere ricevuto dal Dott…VERONESE  esaurienti spiegazioni in merito alla 
richiesta di partecipazione alla ricerca, in particolare sulle finalità e procedure. 
• Di avere avuto a disposizione tempo sufficiente per potere leggere attentamente, 
comprendere ed eventualmente farmi spiegare quanto contenuto nella scheda 
informativa allegata e da me sottoscritta per presa visione, e che conferma 
quanto mi è stato spiegato a voce, in particolare che la ricerca sarà condotta nel 
rispetto dei codici etici internazionali. 
• Di aver avuto la possibilità di porre domande e di avere avuto risposte 
soddisfacenti su tutta la ricerca. 
• Di essere stato informato sui disagi ragionevolmente prevedibili. 
• Di acconsentire \ non acconsentire che il medico responsabile informi il mio 
medico di famiglia. 
• Di essere consapevole che la partecipazione allo studio è volontaria, con 
l’assicurazione che il rifiuto a partecipare non influirà nel ricevere il trattamento 
più idoneo. 
• Di essere consapevole che la mia firma a questo Consenso Informato non 
costituisce una rinuncia ai miei diritti legali o liberagli sperimentatori dalle loro 
responsabilità legali e professionali. 
• Di essere stato rassicurato che: 
o Potrò interrompere la mia partecipazione allo studio in qualsiasi 
momento lo dovessi ritenere opportuno, senza l’obbligo da parte mia di 
motivarne la decisione. 
o Sarò informato di eventuali variazioni del protocollo che possano 
influenzare la mia partecipazione. 
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o E’ mio diritto accedere alla documentazione che mi riguarda e alla 
valutazione espressa dal Comitato Etico (Comitato Etico Fondazione 
F.A.R.O. onlus) cui potrò rivolgermi se lo riterrò opportuno. 
o Una copia del consenso informato e della documentazione di cui ho 
preso visione rimarrà in mio possesso. 
o Per ogni problema o per eventuali ulteriori informazioni potrò rivolgermi 
al Medico Sperimentatore Dott  VERONESE SIMONE 
Indirizzo di lavoro FONDAZIONE FARO ONLUS recapito telefonico 
011.888.272 
 
 
 
Pertanto, 
confermo di avere avuto risposte esaurienti a tutti i miei quesiti e, preso atto 
della situazione illustrata 
 
ACCONSENTO 
 
LIBERAMENTE, SPONTANEAMENTE E IN PIENA COSCIENZA ALLA 
RICERCA PROPOSTAMI. 
Dichiaro inoltre di essere a conoscenza della possibilità di revocare il presente 
consenso in qualsiasi momento prima dell’avvio dello studio. 
 
Data ……………….. 
 
 
………………………………                    ………………………….              
Nome e cognome del paziente                    firma del paziente                           
 
 
 
NON ACCONSENTO 
 
LIBERAMENTE, SPONTANEAMENTE E IN PIENA COSCIENZA ALLA 
RICERCA PROPOSTAMI. 
 
Data ……………….. 
 
 
………………………………                    ………………………….               
Nome e cognome del paziente                    firma del paziente                           
 
 
 
 
 
 
 
 
DICHIARAZIONE DELLA PERSONA CHE ASSISTE (se presente) 
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Io ho letto e capito tutte le informazioni disponibili sullo studio, sulle procedure 
che il paziente deve seguire e il mio contributo come persona che assiste. 
 
 
 
……………………………………..     ……………………………….         
……………….. 
Nome e cognome della persona             firma della persona che assiste         data 
che assiste il paziente                             il paziente 
 
DICHIARAZIONE DELLO SPERIMENTATORE: 
 
Io sottoscritto Dr VERONESE SIMONE.(nome dello sperimentatore) dichiaro: 
o Di avere ricevuto dal Comitato Etico del Centro l’autorizzazione ad effettuare, 
secondo la normativa attuale, questo studio nell’uomo. 
o Di avere ottenuto il presente consenso dopo avere esaurientemente spiegato il 
Consenso Informato in tutte le sue parti al paziente che parteciperà allo studio e 
di essermi assicurato che tali spiegazioni siano state comprese dal paziente. 
o Di avere consegnato copia del Consenso Informato, firmato e datato dal paziente 
e copia della lettera per il medico curante. 
o Che copia del Consenso Informato, firmato e datato, sarà conservata al Centro 
nella documentazione relativa a ciascuno persona partecipante allo studio. 
 
              SIMONE VERONESE                            ………………………………………. 
Nome e cognome dello sperimentatore                                 firma dello sperimentatore  
 
 
       18153                                                                           ……………………………..        
N° iscrizione all’ordine                                                                              data 
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8.2.6 Participant’s consent form English Version 
 
PARTICIPANTS’ CONSENT FORM MODULE 
 
 
 
Main researcher: DR VERONESE SIMONE 
 
I undersigned MR/MRS………..………born in………………………... 
date…………..address………………………………….Telephone 
number……………………… 
 
DECLARE 
 
• To participate voluntarily at the present study aimed at assessing the impact of a 
new SPCS for people severely affected by neurodegenerative conditions at home 
or in the hospice. 
• To have received by Dr Veronese exhaustive explanations about the request to 
participate, in particular about the aims and the methods of this study. 
• To have had enough time to read carefully the participants’ leaflet, understand it 
and ask about its content. I have been reassured that this research is conducted 
according to the International Ethics Guidelines on research. 
• To have had time to make questions and have received satisfactory answers 
about all the research project. 
• To have been informed about the potential inconvenient that might happen 
during the study. 
• To give my consent / to withhold my consent to inform my GP of my decision to 
participate at his study. 
• To be informed that my participation is voluntarily and that in case of non 
participation I will not be discriminated in the care and assistance. 
• To be conscious that signing this document I am not renouncing to my legal 
rights of patient and I am not liberating the researchers by their professional and 
legal responsibility. 
• To have be reassured that I can withdraw my consent at any time during the 
study and that I will not have the obligation to motivate this decision. 
• To have been informed that I will be informed of any variation of the study 
protocol. 
• To be aware that I can access to the FARO Fondation EC, and that I can access 
to my documentation whenever I decide to. 
• To have received a copy of the documents that I signed (consent form and 
participants leaflet) 
• To be aware that Dr Veronese is the responsible for this research and that I can 
contact him through the FARO Foundation at the telephone number 011.888.272 
 
 
 
EXPLORATIVE RANDOMIZED AND CONTROLLED STUDY TO 
EVALUATE THE IMPACT OF A SPECIALIST PALLIATIVE CARE 
SERVICE (SPCS) ON THE PALLIATIVE CARE OUTCOMES (PCO) FOR 
PATIENTS WITH NEURODEGENERATIVE CONDITIONS 
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For the previously listed reasons I: 
 
CONSENT 
 
LIBERALLY, SPONTANEOUSLY AND FULLY CONSCIOUSLY TO THIS 
RESEARCH PROJECT. 
My consent is valid now and can be withdrawn at any time before or during the study 
 
 
DATE………………….                                                  SIGNATURE…………… 
 
DO NOT CONSENT 
 
LIBERALLY, SPONTANEOUSLY AND FULLY CONSCIOUSLY TO THIS 
RESEARCH PROJECT. 
 
DATE………………….                                                  SIGNATURE…………… 
 
 
DECLARATION OF THE FAMILY CARER (if present) 
 
I read and understood all the available information of this study, its procedures and the 
role of my contribute 
 
……………………………………….                  ………………….. 
 
Name and Surname of the family carer                   Signature 
 
 
DECLARATION OF THE MAIN RESEARCHER  
 
I UNDERSIGNED Dr Simone Veronese declare: 
 
• To have obtained by the FARO EC the authorization to undertake, according to 
the normative law on force, this study on the humans.  
• To have obtained the present consent from the participants after having 
provided accurate information about the study and the consent form. 
• To have let a copy of the consent form to the participant with a letter for the 
GP. 
• To keep safe a copy of the documentation and of the consent form of all the 
participants.  
 
 
In faith, 
 
Dr Simone Veronese                                                
 
Turin’s Order of Physicians                                                                
Registration number: 
          18153 
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8.3 Evaluation tools 
The tools used to assess the outcome measures in the quantitative study are appended in 
the next pages. They are reported both in the Italian version, as used in the participants’ 
CRF, and then translated in English. 
 
8.3.1 The SEIQoL-DW Italian version 
FOGLIO DI DEFINIZIONE DELLE AREE (CUES) 
 
DESCRIZIONE DELL’AREA                                                                ETICHETTA 
 
 
1.____________________________________________ 
 _____________________________________________ 
 _____________________________________________ 
                                                                                                                    
______________ 
 
 
 
2. ____________________________________________ 
 _____________________________________________ 
 _____________________________________________ 
                                                                                                                    
______________ 
 
 
3. ____________________________________________ 
 _____________________________________________ 
 _____________________________________________ 
                                                                                                                    
______________ 
 
 
4. ____________________________________________ 
 _____________________________________________ 
 _____________________________________________ 
                                                                                                                    
______________ 
 
 
5. ____________________________________________ 
 _____________________________________________ 
 _____________________________________________ 
                                                                                                                    
______________ 
 
 
 
SPUNTARE OGNI ETICHETTA LEGGENDONE LA LISTA AL PARTECIPANTE 
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FOGLIO DI ESEMPIO DI RILEVAZIONE DEL LIVELLO DI SODDISFAZIONE 
 
 
 
Peggio possibile 
Molto male 
Male 
Né bene né male 
Bene 
Molto bene 
Meglio possibile 
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FOGLIO DI RILEVAZIONE DEI LIVELLI DI SODDISFAZIONE PER IL 
PAZIENTE 
Peggio possibile 
Meglio possibile 
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FOGLIO DI RILEVAZIONE DATI 
 
1. TEMPO RICHIESTO  ______________________ 
 
2. LIVELLO DI COMPRENSIONE DEL METODO 
 
• NON COMPRESO DEL TUTTO 
• SCARSO \ INCERTO 
• BEN COMPRESO 
 
 
3. AFFATICAMENTO \ ANNOIAMENTO 
• NESSUNO 
• UN PO’ 
• MOLTO 
 
 
4. LIVELLO GENERALE DI VALIDITA’ DELLE INFORMAZIONE (alla luce 
di 2. & 3.) 
• DECISAMENTE NON VALIDE 
• INCERTO 
• VALIDE 
 
 
5. PESI ASSEGNATI ALLE AREE: 
• AREA 1: PESO (%):_____________________ 
• AREA 2: PESO (%):_____________________ 
• AREA 3: PESO (%):_____________________ 
• AREA 4: PESO (%):_____________________ 
• AREA 5: PESO (%):_____________________ 
 
 
 
 
 
Chapter 8. Appendix 2: Study documentation 
 302 
 
8.3.2 The SEIQoL-DW English version 
 
CUE DEFINITIONS RECORD FORM 
 
DESCRIPTION OF CUE                                                  CUE LABEL 
 
 
 
1.____________________________________________ 
 _____________________________________________ 
 _____________________________________________ 
                                                                                                                    
______________ 
 
 
 
2. ____________________________________________ 
 _____________________________________________ 
 _____________________________________________ 
                                                                                                                    
______________ 
 
 
3. ____________________________________________ 
 _____________________________________________ 
 _____________________________________________ 
                                                                                                                    
______________ 
 
 
4. ____________________________________________ 
 _____________________________________________ 
 _____________________________________________ 
                                                                                                                    
______________ 
 
 
5. ____________________________________________ 
 _____________________________________________ 
 _____________________________________________ 
                                                                                                                    
______________ 
 
 
(Tick any cues elicited by reading list to person) 
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SAMPLE CUE LEVELS RECORD FORM 
 
 
 
WORST POSSIBLE 
 
VERY BAD 
BAD 
 
NEITHER GOOD NOR BAD 
 
GOOD 
 
VERY GOOD 
 
BEST POSSIBLE 
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CUE LEVELS RECORD FORM 
 
WORST POSSIBLE 
 
BEST POSSIBLE 
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INTERVIEW RECORD FORM 
 
 
 
1. TIME TAKEN ______________________ 
 
2. UNDERSTANDING OF METHOD 
 
• Not Understood 
 
• Poor/Uncertain Understanding 
 
• Understood 
 
 
3. FATIGUE/BOREDOM 
 
• None / 
 
• Some / 
 
• A Lot / 
 
 
4. OVERALL VALIDITY OF INFORMATION (in light of 2 & 3 above) 
 
• Definitely Invalid 
 
• Uncertain 
 
 
• Valid 
 
 
5. WEIGHTS ASSIGNED TO CUES 
• Cue 1: Weight (%)______________________ 
 
• Cue 2: Weight (%)______________________ 
 
• Cue 3: Weight (%)______________________ 
 
• Cue 4: Weight (%)______________________ 
 
• Cue 5: Weight (%)______________________ 
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8.3.3 The CBI Italian version 
 
 
 
                  
                   
                   
Assistente:___________________________ Paziente assistito:______________________________    
                   
Data:______________________         
 
                  
Mai 
 
0  1  2  3  4  Sempre 
    
 
                  
                
scelta 
 
                                     
1 La persona di cui mi prendo cura ha bisogno del mio aiuto per molte attività quotidiane    
  
                                   
* 
                                  
2 La persona di cui mi prendo cura dipende da me    
  
                                   
* 
                                  
3 Devo seguire costantemente la persona di cui mi prendo cura     
  
                                   
* 
                                  
4 Devo aiutare la persona di cui mi prendo cura in molte funzioni essenziali    
  
                                   
  
                                  
5 Non ho un minuto di pausa nelle mie attività di cura    
  
                                   
  
                                  
6 Mi sento tagliato fuori dalla vita        
  
                                   
* 
                     
7 Vorrei poter evadere da questa situazione    
  
                                   
  
                                  
8 La mia vita sociale ne ha risentito       
  
                      
  
                                  
9 Mi sento emotivamente prosciugato dalle cure che fornisco al mio caro    
  
                                   
  
                                  
10 Mi aspettavo che a questo punto della mia vita le cose sarebbero state diverse    
  
                                   
  
                                  
11 Non dormo abbastanza          
  
                                   
  
                                  
12 La mia salute ne ha risentito         
  
                                   
  
                     
13 Fornire queste cure mi ha debilitato fisicamente    
  
                                   
* 
                                  
14 Sono fisicamente esausto         
  
                                   
  
                                  
15 Non vado più d'accordo con i miei familiari come una volta    
caregiver burden inventory 
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16 Gli sforzi che faccio per seguire il mio caro non vengono apprezzati dagli altri familiari    
  
                                   
  
                                  
17 Ho avuto problemi con il mio matrimonio    
  
                                   
  
                                  
18 Non lavoro più bene come prima       
  
                                   
* 
                     
19 Mi sento risentito con gli altri familiari che mi potrebbero aiutare ma non lo fanno    
  in una volta                          
  
                                  
20 Mi sento imbarazzato per il comportamento della persona di cui mi prendo cura    
  
                                   
  
                                  
21 Mi vergogno della persona di cui mi occupo    
  
                                   
  
                                  
22 Ho motivi di risentimento nei confronti della persona di cui mi occupo    
  
                                   
  
                                  
23 Mi sento a disagio quando degli amici mi vengono a trovare    
  
                                   
  
                                  
24 I miei rapporti con la persona di cui mi prendo cura mi causano rabbia    
  
                                   
  
                     
                                     
                     
Fattore 1:  
 
  
 (Tempo)       
Fattore 2: 
 
  
 (Progresso vita)         
Fattore 3: 
 
  
 (Fatica fisica)       
Fattore 4: 
 
  
 (Fattori sociali)      
Fattore 5: 
 
  
 (Fattori emotivi)      
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8.3.4 The CBI English version  
 
 
 
 
                 
                  
                  
Assistant___________________________ 
Assisted 
patient:______________________________   
                  
Date:______________________        
 
                 
Never 
 
0  1  2  3  4  Always choice 
 
                 
                
 
                                    
1 My care-receiver needs my help to perform many daily tasks   
  
                                  
* 
                                 
2 My care-receiver is dependent on me     
  
                                  
* 
                                 
3 I have to watch my care receiver constantly    
  
                                  
* 
                                 
4 I have to help my care-receiver with many basic functions   
  
                                  
  
                                 
5 I don't have a minute's break from my caregiving chores   
  
                                  
  
                                 
6 I feel that I am missing out on life      
  
                                  
* 
                    
7 I wish I could escape from this situation   
  
                                  
  
                                 
8 My social life has suffered        
  
                     
  
                                 
9 I fell emotionally drained due to caring for my care-receiver   
  
                                  
  
                                 
10 I expected that things would be different at this point in my life   
  
                                  
  
                                 
11 I am not getting enough sleep       
  
                                  
  
                                 
12 My health has suffered          
  
                                  
  
                    
13 Caregiving has made me physically sick   
  
                                  
* 
                                 
14 I am physically tired          
  
                                  
  
                                 
caregiver burden inventory 
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15 I don't get along with other family members as well as I used to   
  
                                  
  
                                 
16 My caregiving efforts aren't appreciated by others in my family    
  
                                  
  
                                 
17 I've had problems with my marriage     
  
                                  
  
                                 
18 I don't do as good a job at work as I used to   
  
                                  
* 
                    
19 I feel resentful of other relatives who could but do not help   
  
                         
  
                                 
20 I feel embarrassed over my care-receiver's behaviour   
  
                                  
  
                                 
21 I feel ashamend of my care-receiver     
  
                                  
  
                                 
22 I resent my care-receiver         
  
                                  
  
                                 
23 I feel unconfortable when I have friends over   
  
                                  
  
                                 
24 I feel angry about my interactions with my care-receiver   
  
                                  
  
                    
                                    
                    
Factor 1:  
 
  
 (Time-dependence burden)   
Factor 2: 
 
  
 (Developmental burden)       
Factor 3: 
 
  
 (Physical burden)    
Factor 4: 
 
  
 (Social burden)     
Factor 5: 
 
  
 (Emotional burden)    
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8.3.5 The VAS – NRS used to assess physical symptoms, psychological, 
social and spiritual issues: the Italian version 
  
 
SINTOMI FISICI 
 
DOLORE: 
Domanda del ricercatore: 
Nell’ultima settimana dovendo definire il livello di dolore fisico da lei provato in 
un intervallo compreso tra 0= nessun dolore e 10= il massimo dolore 
immaginabile, come definirebbe il suo dolore? 
 
   
 
 
 
           0------1------2------3------4------5------6------7------8------9------10 
 
DISPNEA: 
Domanda del ricercatore: 
Nell’ultima settimana dovendo descrivere la sua respirazione nell’ultima 
settimana come la definirebbe in questo intervallo? 
 
 
 
 
 
 
           0------1------2------3------4------5------6------7------8------9------10 
 
 
 
QUALITA’ DEL SONNO 
Nell’ultima settimana come descriverebbe la qualità del suo sonno? 
 
 
 
 
 
           0------1------2------3------4------5------6------7------8------9------10 
 nessun dolore massimo dolore immaginabile 
 Non mi è mai mancato il fiato Mi sento sempre senza fiato 
 Ho dormito benissimo Non ho mai potuto riposare bene 
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DISTURBI URINARI 
Nell’ultima settimana come descriverebbe il controllo delle funzioni 
urinarie?(suggerimenti: incontinenza?difficoltà ad urinare?) 
 
 
 
 
 
            0------1------2------3------4------5------6------7------8------9------10 
 
 
 
 
 
DISTURBI INTESTINALI 
 
Nell’ultima settimana come descriverebbe il controllo delle funzioni 
intestinali?(suggerimenti: stitichezza? diarrea?) 
 
 
 
 
 
             0------1------2------3------4------5------6------7------8------9------10 
 
 
 
 
DISTURBI DEL CAVO ORALE 
 
Nell’ultima settimana come descriverebbe lo stato della sua bocca?( 
suggerimenti: bocca asciutta? Perdita di saliva?) 
 
 
 
 
                         0------1------2------3------4------5------6------7------8------9------10
 Non ho avuto problemi urinari Ho avuto intollerabili problemi  urinari 
 Non ho avuto problemi alla bocca Ho avuto problemi intollerabili alla bocca 
 Non ho avuto problemi  intestinali Ho avuto intollerabili problemi intestinali 
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ASPETTI PSICOLOGICI: 
 
 Livello di supporto psicologico: 
Come definirebbe il livello di supporto psicologico da lei ricevuto nell’ultima 
settimana? 
 
 
 
 
 
              0------1------2------3------4------5------6------7------8------9------10 
Capacità di affrontare la malattia (livello di “Coping”) 
Come le sembra di avere affrontato i problemi dovuti alla sua malattia? 
 
 
 
 
 
 
 
              0------1------2------3------4------5------6------7------8------9------10 
 
ASPETTI SPIRITUALI 
 
Esplorare il livello di “Significato” dell’esperienza di malattia: 
 
Se le chiedessi di indicare la sua valutazione rispetto al Significato che 
l’esperienza di malattia che lei sta vivendo ha rispetto alla sua vita, come la 
definirebbe? 
 
 
 
 
 
 
 
 
 
              0------1------2------3------4------5------6------7------8------9------10 
 
Valutare l’importanza della religiosità rispetto al “Significato” della malattia 
Se le chiedessi di indicare il livello di aiuto che lei riceve dalla religione 
nell’affrontare questa malattia, come la definirebbe? 
 
 
 
 
 
 
                         0------1------2------3------4------5------6------7------8------9------10 
 
 Non mi sono sentito supportato per nulla Mi sono sentito ottimamente supportato 
 Non sono riuscito ad accettare minimamente 
la malattia 
Sono riuscito perfettamente a convivere con la malattia 
 Non riesco a trovare alcun senso in questa 
malattia  
Ho trovato una giustificazione pienamente soddisfacente 
a questa esperienza di malattia 
 Non riesco a trovare alcun aiuto nella 
religione  
Ho trovato piena risposta nella religione 
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ASPETTI SOCIALI 
 
Valutare il livello di isolamento sociale percepito: 
           Si è sentito isolato a causa dei problemi dovuti alla sua malattia? 
 
 
 
 
 
 
 
 
              0------1------2------3------4------5------6------7------8------9------10 
 
 
Livello di soddisfazione generale dei servizi ricevuti 
 
Può indicare il suo grado si soddisfazione generale rispetto ai servizi che sta 
ricevendo? 
 
 
 
 
 
 
 
 
 
               0------1------2------3------4------5------6------7------8------9------10
 Sono assolutamente insoddisfatto Sono completamente soddisfatto 
 Mi sono sentito completamente isolato  Non mi sono sentito mai isolato 
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8.3.6 The VAS – NRS used to assess physical symptoms, psychological, 
social and spiritual issues: the English version 
 
PHYSICAL SYMPTOMS 
 
PAIN 
Question: 
How would you rate the intensity of your pain in the last week using a scale from 
0 (zero) to 10 (ten)?An intensity of 0 means no pain; an intensity of 10 means 
pain as bad as you can imagine. Please rate your pain by indicating the number 
that best describes your pain. 
 
   
 
 
 
           0------1------2------3------4------5------6------7------8------9------10 
 
DYSPNOEA 
Question: 
How would you rate the intensity of your shortness of breath (SOB) in the last 
week using a scale from 0 (zero) to 10 (ten)?An intensity of 0 means no SOB; an 
intensity of 10 means SOB as bad as you can imagine. Please rate your SOB by 
indicating the number that best describes your shortness of breath. 
 
 
 
 
 
 
           0------1------2------3------4------5------6------7------8------9------10 
 
 
 
QUALITY OF SLEEP 
 
How would you rate the quality of your sleep (QoS) in the last week using a 
scale from 0 (zero) to 10 (ten)? An intensity of 0 means perfect QoS; an intensity 
of 10 means absolute impossibility to sleep. Please rate your QoS by indicating 
the number that best describes your QoS 
 
 
 
 
 
           0------1------2------3------4------5------6------7------8------9------10 
 No Pain  Worst Possible Pain 
 No shortness of breath Worst Possible shortness of breath 
 I slept perfectly well  I could not sleep at all 
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URINARY PROBLEMS 
 
How would you rate your urinary problems in the last week using a scale from 0 
(zero) to 10 (ten)? An intensity of 0 means did not have any urinary problem; an 
intensity of 10 means urinary problems as bad as you can imagine. Please rate 
your urinary problems by indicating the number that best describes your urinary 
problems 
 
 
 
 
 
            0------1------2------3------4------5------6------7------8------9------10 
 
 
 
INTESTINAL PROBLEMS 
 
How would you rate your intestinal problems in the last week using a scale from 
0 (zero) to 10 (ten)? An intensity of 0 means did not have any intestinal problem; 
an intensity of 10 means intestinal problems as bad as you can imagine. Please 
rate your intestinal problems by indicating the number that best describes your 
intestinal problems 
 
 
 
 
 
             0------1------2------3------4------5------6------7------8------9------10 
 
 
 
 
ORAL PROBLEMS 
 
How would you rate your oral problems in the last week using a scale from 0 
(zero) to 10 (ten)? An intensity of 0 means did not have any problem with your 
mouth; an intensity of 10 means oral problems as bad as you can imagine. 
Please rate your oral problems by indicating the number that best describes 
your oral problems 
 
 
 
 
                         0------1------2------3------4------5------6------7------8------9------10
 No Urinary Problems At All Worst Possible Urinary Problems 
 No Oral Problems At All Worst Possible Oral Problems 
 No Intestinal Problems At All Worst Possible Intestinal Problems 
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PSYCHOLOGICAL ASPECTS 
 
FEELING ABANDONED 
How would you rate your feeling of being abandoned in the last week using a 
scale from 0 (zero) to 10 (ten)? An intensity of 0 means you felt completely 
abandoned; an intensity of 10 means that you did not feel abandoned at all. 
Please rate your feeling of being abandoned by indicating the number that best 
describes your condition 
 
 
 
 
              0------1------2------3------4------5------6------7------8------9------10 
 
COPING WITH THE DISEASE: 
How would you rate your difficulty of coping with your disease in the last week 
using a scale from 0 (zero) to 10 (ten)? An intensity of 0 means you could not 
cope at all with the problems caused by the disease; an intensity of 10 means 
that you coped perfectly with your disease. Please rate your difficulty to cope 
with your disease by indicating the number that best describes your condition 
 
 
 
 
 
 
 
              0------1------2------3------4------5------6------7------8------9------10 
 
SPIRITUAL ASPECTS 
 
EXPLORING THE MEANING 
 
How would you rate the meaning that you could find in the experience of your 
disease in the last week using a scale from 0 (zero) to 10 (ten)? An intensity of 0 
means you did not find any meaning in the experience of your disease; an 
intensity of 10 means that you found a fully satisfactory meaning in the 
experience of your disease. Please rate your difficulty find a meaning in the 
experience of your disease by indicating the number that best describes your 
condition 
 
 
 
 
 
 
 
             0------1------2------3------4------5------6------7------8------9------10 
 
 
 
 I Felt Completely Abandoned I Did Not Feel Abandoned At All 
I Could Not Cope At All With My Disease I Coped Perfectly With My Disease 
I can not find any meaning in the experience of 
my disease  
I found a fully satisfactory meaning in the experience of 
my disease 
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HELP FROM FAITH 
How would you rate help that you received from your faith, religiousness or 
spirituality in the last week using a scale from 0 (zero) to 10 (ten)? An intensity 
of 0 means you did not receive any from your faith, religiousness or spirituality; 
an intensity of 10 means that you received a fully satisfactory help from your 
faith, religiousness or spirituality. Please rate your help from your faith, 
religiousness or spirituality by indicating the number that best describes your 
condition 
 
 
 
 
 
 
                         0------1------2------3------4------5------6------7------8------9------10 
 
 
SOCIAL ASPECTS 
 
How would you rate your social relationships in the last week using a scale from 
0 (zero) to 10 (ten)? An intensity of 0 means you felt totally social isolated; an 
intensity of 10 means that you felt no social isolation at all. Please rate your 
social relationships by indicating the number that best describes your condition 
 
 
 
 
 
 
 
 
              0------1------2------3------4------5------6------7------8------9------10 
 
 
SERVICE SATISFACTION 
 
How would you rate your satisfaction about the services that you are receiving 
in the last week using a scale from 0 (zero) to 10 (ten)? An intensity of 0 means 
you are completely unsatisfied of the services that you are receiving; an intensity 
of 10 means that you fully satisfied by the services that you are receiving. Please 
rate your service satisfaction level by indicating the number that best describes 
your condition 
 
 
 
 
 
 
 
 
               0------1------2------3------4------5------6------7------8------9------10 
I can not find any help from  help from your 
faith, religiousness or spirituality 
I found  a fully satisfactory help from faith, 
religiousness or spirituality 
 I Am Completely Unsatisfied of the Services that 
I am receiving 
I Am fully Satisfied of the Services that I am receiving 
 
 I  Felt In Complete Social Isolation I Felt No Social Isolation At All 
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8.4 Ethics Commettees Approvals 
8.4.1 San Luigi di Orbassano Hospital Ethics Commettee approval 
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8.4.2 Molinette Hospital Ethics Commettee approval 
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8.4.3 FARO Foundation Ethics Committee approvals 
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 S. Veronese, DJ Oliver (2007) “Neuneeds: una valutazione qualitativa dei 
bisogni di cure palliative in pazienti affetti da patologie neurodegenerative e nei 
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 Gallo G. –Veronese S. –Valle A. – Oliver D.J. (2008) “I bisogni di cure 
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palliative care service for neurological patients is born: development and 
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(ME) 3-6/11/2008. 
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 S. Veronese, G. Gallo, C. Rivoiro, A. Valle. (2009) “Il servizio di cure palliative 
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